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Abstract
ABSTRACT
The bHLH transcription factor Handl is essential for placentation and cardiac 
morphogenesis in the developing embryo. However, how the activity of Handl is 
regulated in either lineage remains largely unknown. Here we demonstrate that 
Handl is anchored in the nucleolus and negatively-regulated by the murine 
orthologue of the human I-mfa domain-containing protein (HIC). Nucleolar 
sequestration controls Handl activity during the differentiation of rat 
choriocarcinoma-1 (Rcho-1) trophoblast cells. Handl is sequestered in the nucleoli of 
Rcho-1 stem cells but is released into the nucleoplasm at the onset of their 
differentiation into trophoblast giant cells.
Site-specific phosphorylation of Handl was previously shown to modulate the 
affinity of Handl for its nucleoplasmic E-factor binding partners. We demonstrate 
that Handl phosphorylation is required for its nucleolar release, as a pre-requisite for 
dimerisation and biological function. Moreover, the polo-like kinase Plk4 (Sak) is 
responsible for this phosphorylation event. Plk4 localises to the nucleolus of Rcho-1 
stem cells at phase G2 and interacts with Handl in vitro and in vivo to promote 
mitotic cell cycle exit and entry into the endocycle. We also demonstrate that the 
B568 subunit of the PP2A phosphatase, shown previously to target Handl for 
dephosphorylation, is exported from the nucleus during Rcho-1 differentiation.
In this thesis we present findings that describe a novel mode of Handl 
regulation that is a crucial step in trophoblast stem cell differentiation and 
placentation and support previous studies that implicate the nucleolus as a molecular 
‘sink’. We suggest that nucleolar sequestration is an important mode of protein 
regulation and this may impact on a broad range of transcription factors.
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GLOSSARY OF ABBREVIATIONS
o P -G al..............beta-galactosidase
o A ct-D ----------actinomycin-D
o S H F ............. secondary heart field
o A m ps-----------ammonium persulphate
o ANF/ A N P  Atrial natriuretic factor/ atrial natriuretic peptide
o A P ---------- anterior-to-posterior
o A p-2y---------Activating protein 2 gamma
o A P C /C ---------- anaphase-promoting complex/ cyclosome
o A T P ---------- adenosine 5’ triphosphate
o A V ---------- atrioventricular
o A V C ----------atrioventricular canal
o B A C  bacterial artificial chromosome
o b H L H ---------- basic helix-loop-helix
o B M P ----------Bone morphogenetic protein
o bp —  ■— base pair
o B SA ----------bovine serum albumin
o C B F ----------CREB-binding factor
o C d c l4 -------- Cell division cycle homologue 14
o C d c5 ----------Cell division cycle homologue 5
o C D K ----------Cyclin-dependent kinase
o cDNA---------complimentary deoxyribonucleic acid
o C H D ----------congenital heart disease
o C M --------- conditioned medium
o C M V --------- cytomegalovirus
o C N S ----------central nervous system
o C 0 CI2 ---------cobalt chloride
o C P C --------- cardiac precursor cell
o D a ---------- Daughterless
o D A P I---------4',6-diamidino-2-phenylindole
o D E P C  diethyl pyrocarbonate
o D E S ----------diethylstilbestrol
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o D F C ---------- dense fibrillar component
o (IH2O---------- distilled water
o D M E M -----------Dulbecco’s modified eagle medium
o D M SO ----------dimethyl sulphoxide
o D N A --------- deoxyribonucleic acid
o D O R V ----------- double outlet right ventricle
o d N T P  deoxyribonucleoside triphosphate
o D P X ----------dibutyl phthalate xylene
o D T T ------------dithiothreitol
o D V ----------- dorsal-to-ventral
o E  embryonic day
o E (Spl)-----------Enhancer of split
o E B ---------- embryoid body
o E C ----------embryonic carcinoma
o E C M  extracellular matrix
o E D T A ---------- ethylene diamine tetra-acetate
o E G F P -----------Enhanced green fluorescent protein
o EGTA -----------  ethyleneglycol-bis(p-aminoethyl ether)-N,N,N’,N’-tetra-acetic
acid
o E M SA  electrophoretic mobility shift assay
o E P C ----------ectoplacental cone
o ES (cells)...............embryonic stem (cells)
o E T -1----------- Endothelin-1
o E V T ----------extravillous trophoblast
o F A C S  fluorescence-activated cell sorting
o F A K ----------Focal adhesion kinase
o F B S -----------fetal bovine serum
o F C ---------- fibrillar component
o FEAR (network) Cdc fourteen early anaphase release (network)
o F G F  fibroblast growth factor
o F IT C ---------fluorescein isothiocyanate
o F L IP --------- fluorescence loss in photobleaching
o F R A P ..............fluorescence recovery after photobleaching
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Glossary of abbreviations
o F zr ----------- Fizzy-related
o GO--------- quiescent phase (of cell cycle)
o G 1 ----------- first gap phase (of cell cycle)
o G 2 --------- second gap phase (of cell cycle)
o GAPDH ----------- Glucose-6-phosphate dehydrogenase
o G C ---------granular compartment
o G FP ----------- Green fluorescent protein
o G lyT ---------- glycogen trophoblast
o G ST ----------- glutathione-S-transferase
o H ---------- hairy
o H a n d l----------- Heart and neural crest-derived 1
o H and2----------- Heart and neural crest-derived 2
o H A T -----------histone acetyltransferase
o HH (stage)----------- Hamburger and Hamilton (stage)
o HICp40/ 32 ---------  Human inhibitor of Myo-D domain-containing protein
(40kDa/ 32kDa)
o H IC sh R N A il---------- HIC short-hairpin RNA-interference construct 1
o H IC shRN Ai2---------- HIC short-hairpin RNA-interference construct 2
o H IF ----------Hypoxia inducible factor
o H IV ------------ human immunodeficiency virus
o H R P -----------horseradish peroxidase
o H R T  hairy-related transcription factor
o H S --------- horse serum
o H TLV ------------human T-cell leukemia virus
o IC M   —  inner cell mass
o I F ----------- immunofluorescence
o I-m fa---------- Inhibitor of Myo-D family A
o IS H   —  in situ hybridisation
o IU G R -----------intra-uterine growth retardation
o IV G -----------interventricular groove
o I V S ----------interventricular septum
o kb - kilobase
o kD a ----------kilo-Dalton
o L IF ----------Leukemia inhibitory factor
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Glossary of abbreviations
o L V ---------- left ventricle
o M   —  mitosis (of cell cycle)
o M ash-2-----------Mammalian achaete-scute homologue 2
o M C S -----------multi-cloning site
o M E M a   —  minimum essential medium a
o M E N ---------- mitotic exit network
o M lc2v ...............Myosin light chain 2 ventricular isoform
o M M P9-----------Matrix metalloproteinase-9
o M PF -----------mitosis-promoting factor
o m RNA ----------- messenger RNA
o N B ---------- nuclear body
o N D F .............. nucleolus-derived focus
o NFkB ---------- Nuclear factor-icB
o N L S ----------nuclear localisation signal
o N oLS  nucleolar localisation signal
o NO Pdb---------- nucleolar proteome database
o N O R -----------nucleolar organiser region
o N P-40----------nonidet P-40
o OD„---------- optical density (at n nm)
o O FT ---------- outflow tract
o O R F ---------- open reading frame
o O R C -----------origin recognition complex
o P B S ----------- phosphate buffered saline
o N C BI---------National Centre for Biotechnology Information
o PC A F----------p300/CBP-associated factor
o P C R ----------polymerase chain reaction
o PECAM ---------platelet endothelial cell adhesion molecule
o P H F ---------- primary heart field
o PI3K ---------- Phosphatidylinositol 3-kinase
o PK A --------- Protein kinase A
o PK C --------- Protein kinase C
o PL -1---------- Placental lactogen-1
o PL -2---------- Placental lactogen-2
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Glossary of abbreviations
o P lk4  Polo-like kinase 4
o P lk4shR N A il---------Plk4 short-hairpin RNA-interference construct 1
o Plk4shRNAi2---------Plk4 short-hairpin RNA-interference construct 2
o PLP-A  Prolactin-like protein A
o PML (bodies)-------- promyelocytic leukemia (bodies)
o PM SF  phenylmethylsulphonyl fluoride
o PN B -----------pre-nucleolar body
o P o ll------------RNA polymerase I
o PolII---------- RNA polymerase II
o snoRNP--------------- small nucleolar ribonucleoprotein
o SR P ---------- signal recognition particle
o PP2A  Protein phosphatase 2A
o P R L  Pituitary hormone prolactin
o R A ............. retinoic acid
o Rcho-1--------- rat choriocarcinoma-1
o R D A ---------- representational differential analysis
o rDNA ---------- ribosomal DNA
o RENT (complex) ----------  regulator of nucleolar silencing and telophase
(complex)
o R ISC -----------RNA-induced silencing complex
o R L U ---------- relative light units
o R N A ---------- ribonucleic acid
o R N A i---------- RNA-interference
o R N P -----------ribonucleoprotein
o rpm ---------- revolutions per minute
o rRNA ---------- ribosomal RNA
o RT-PCR   —  reverse transcriptase PCR
o R V ----------- right ventricle
o  S ----------- DNA synthesis phase (of cell cycle)
o  S109------ —  serine-109
o S ak ...........Snk/ Plk-akin kinase
o SDS(-PAGE) ------  sodium dodecyl sulphate(-polyacrylamide gel
electrophoresis) 
o SER 5---------- shared enhancer region 5
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Glossary of abbreviations
o shRNA ------- short hairpin RNA
o siR NA --------small interfering RNA
o SM C ---------- smooth muscle cell
o SpT --------- spongiotrophoblast (layer)
o S tra l3 -----------stimulated-by-retinoic-acid 13
o SynT ----------- syncytiotrophoblast (layer)
o T 107---------- threonine-107
o  T B S -----  —  tris-buffered saline
o TBST -----------TBS with Tween-20
o T E ---------- trophectoderm
o TEM ED  N, N, N ’, N ’-tetramethy 1-ethylene diamine
o T et----------tetracycline
o TG (cells)----------- trophoblast giant (cells)
o TG Fp-----------Transforming growth factor beta
o TRITC ----------- tetramethylrhodamine isothiocyanate
o tR N A ----------- transfer RNA
o TS (cells)------- trophoblast stem (cells)
o Tween-20 polyoxyethylenesorbitan monolaurate
o U V ----------ultraviolet light
o V H L ----  — von Hippel-Lindau
o V SD -----------ventricular septal defect
o X-G al-----------5-bromo-4-chloro-3-indoyl-p-D-galactopyranoside
o Y 2H -------- yeast two-hybrid
o Z PA ----- —  zone of polarizing activity
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1.1. Overview of the bHLH transcription factor, 
Handl
1.1.1. Handl structure and evolution
Handl, previously termed Thing7, eHand or Hxt, encodes the heart and neural 
crest-derived factor 1. The Handl gene was cloned independently more than ten 
years ago by three different groups (Cross et al., 1995; Hollenberg et al., 1995; 
Cserjesi et al., 1995). Handl is located on human chromosome 5q33 and mouse 
chromosome l ip ,  and in both mammals comprises two exons separated by a single 
1.5kb intron that generates a 1.9kb transcript (Figure 1.1a). The encoded Handl 
protein is 216 residues in length (Figure 1.1b).
Handl belongs to a large super-family of transcription factors that are 
characterised by a conserved, N-terminal basic helix-loop-helix (bHLH) DNA- 
binding/ dimerisation domain (reviewed by Massari and Murre, 2000). This domain 
consists of a basic region comprising a cluster of positively-charged amino acids, 
which precedes a HLH motif of two amphipathic a-helices linked by a loop of 
variable length. Transcription factors containing the bHLH domain play critical roles 
in cell lineage determination, for instance the founding myogenic members of the 
family, MyoD, Myogenin, Mrf4 and Myf5 (reviewed by Weintraub, 1993). Hand2 is 
the most closely-related bHLH family member to Handl and, in addition to Twist 1, 
Twist2, Dermol, Scleraxis and Tcfl5, the Hand factors belong to the Twist subfamily 
o f bHLH factors (Figure 1.2). Members of this bHLH factor subclass have roles in 
the development of tissues deriving from the mesoderm and neural crest. The latter 
cell population represents a transient and pluripotent population of migratory cells 
that emerge from the dorsal tip of the neural tube as a result of inductive interactions 
between the neural plate and the surface ectoderm.
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a.
0.9kb
Exon 1
b.
1.0kb
Handl 1.5kb
Intron
Exon 2
C od ing  region
N on -cod in g
region
bHLH d om ain
Handlm HLH
P oly-h ist id ine  stretch  
I | Alanine-rich stretch
B a s ic  dom ain  
H elix-loop-helix  dom ain
□  HAND dom ain
MNLVGSYAHHHI 
216 BUSHPPHPMLHEP  
FLFGPASRCHQER  
PYFQSWLLSPADAA  
PDFPAGGPPPTTAV  
AAAAYGPDARPSQ  
SPGRLEALGSRLPK  
RKGSGPKKERRRT  
ESINSAFAELRECIP  
NVPADTKLSKIKTL 
RLATSYIAYLMDVL 
AKDAQAGDPEAFK  
AELKKTDGGRESK  
RKRELPQQPESFPP  
ASGPGEKRIKGRT<3 
WPQQVWALELNQ
Figure 1.1. The structure of the murine H andl gene (a) and encoded protein (b).
Murine Handl comprises two exons o f 0.9kb and l.Okb in length, separated by a 1.5kb intron (see key 
for details; a). The encoded Handl protein, of 216 residues and whose sequence is listed, contains 
several motifs including the bHLH domain (shown in bold; see key for details; b).
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H d l  M N L V G S Y A B M B B s HPPHPM LHEPFLFG PA SR C -H Q ER PY FQ SW LLS-PA D A A PD FPA  5 8  
H d2  MSLVGGFPHHPVVHHEGYPFAAAAAAAAAAAASRCSHEENPYFHGWLIGHPEMSPPDYSM 6 0
T w l   MMQDVSSSPVSPADDSLSNSEEEPDRQQPASGKRGARKRRSSRRSAGGSAGPGGATG 5 7
T w 2  M E E G S S S P V S P V D -S L G T S E E E L E R Q P  KRFGRKRRYSKKSS-------------------------4 0
S e x  MSFAMLRSAPPPGRYLYPEVSPLSEDEDRGSESSGSDEKPCRVHAARCG-------------------------4 9
T 1 5  MAFALLR— PVGAHVLYPDVRLLSEDEENRSESDASDQS FGCCEG-------------------------4 3
H d l  GGP-PPTTAVAAAAYGPDARPSQ-------------------------------------S P G R - L E A L G - i
H d 2  ALSYSPEYASGAAGLDHSHYGGV---------------------------------
T w l  GGIGGGDEPGSPAQGKRGKKSAGGGGGGGAGGGGGGGGGSSSGGGSPQSYEELQT|QRVMA| 1 1 7
T w 2 ---------------- EDGSPTPGKRGKK---------------------------------------------------G S PS A Q S FE E L Q S |Q R JL a] 7 1
S e x ------------- LQGARRRAGGRRAAGS----------------------------------------------- GPGPGGRPGREPR|QRHTA] 8 3
T 1 5 ------------- LEAARRGPG— PGSGR----------------------------------------------- RASNGAGPVVVVR|QRQAA| 7 5
H d l  iK K E R R R T ESlN SA FA E L R EC IPN V PA D T K L SK IK T LR L A T SY IA Y L M D V LA K D lAQAGDP 1 5 9  
H d2  |NR K ERRR TQSINSAFAELRECIPNVPADTKLSKIKTLRLATSYIAYLM DLLAKD|DQNGEA 1 6 4  
T w l  iNVRERQR T Q S L N E A F A A L R K IIP T L P S D - K L S K I Q TLKLAARYIDFLYQVLQSDlELDSKM 1 7  6 
Tw2 jN V R ER QR TQSLN EA FAA LR K IIPTLPSD -K LSKIQTLKLAAR Y IDFLYQ VLQSD jEMDNKM 1 3 0  
S e x  jNARERDRTNSVNTAFTA LRTLIPTEPADRK LSKIETLRLASSYISHLG NVLLVG|EACGDG 1 4  3 
T 1 5  |NA R ER D RTQSVNTAFTALRTLIPTEPVDRKLSKIETLRLASSYIAHLANVLLLG[PAADDG 1 3 5  
* * ; * ; *  * * •  * *  * * _  *  *  * *  *
H d l  EAFKAELKKTDGGRESKRKR-------------------------------- E L P Q Q P E S F P P A S G P G E K R I ^ t f f |  2 0 4
H d 2  EAFKAEIKKTD-VK EEKRK K-------------------------------- ELN E I L K S T V S S N D K K T ^ ^ i  2 0 5
T w l  A S C SY  VAHERLSYAFSVWRMEGAWSMSAS 2 0 5
Tw2 T S C S Y  VAHERLSYAFSVWRMEGAWSMSAS 1 5 9
S e x  QPCHSGPA FFH SG R A G SPL PPPPPPPPL A R D G G E N T Q PK Q IC T FC L SN Q R K L SK D R D R K - 2 0 2  
T 1 5  Q P C F R  AAGGGKSAVP----------------- AADG R QPRSICTFCLSNQRKGGSRRDLGG 1 7  9
H d l   2 1 6
H d 2  p^QHVWALELKQ 2 1 7
T w l  H-------------------------------------2 0 6
Tw2 H-------------------------------------1 6 0
S e x ------------------T A I R S -------2 0 7
T 1 5  SCLKVRGVAPLRGPRR 1 9 5
Figure 1.2. H andl belongs to the Twist subfamily of bHLH transcription factors.
The mouse Handl protein sequence was aligned with Hand2 and selected members of the Twist 
subfamily o f bHLH transcription factors (Twistl, Twist2 (formerly known as Paraxis), Scleraxis (Sex) 
and Transcription Factor 15 (Tcfl5; formerly known as Dermo-1). Conservation, which is particularly 
striking in the bHLH domain (boxed), is as follows: * absolutely conserved between sequences, : 
conserved amino acid substitutions,. semi-conserved amino acid substitutions. Note the asparagine-to- 
proline substitution in the Handl basic domain (highlighted in red), the conserved serine and threonine 
residues in the bHLH domains o f all Twist subfamily members (highlighted in yellow) and that the 
closely-related Hand2 protein lacks the N-terminal poly-histidine stretch present in Handl (highlighted 
in blue). The C-terminal HAND domain, present in Handl and Hand2, is also indicated (highlighted in 
purple). These alignments were produced using the Clustal W program version 1.82 
(www.ebi.ac.uk/clustalw/L Hdl: Handl, Hd2: Hand2, Twl: Twistl, Tw2: Twist2, Sex: Scleraxis, 
T15: Tcfl5.
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The primary sequence of the Handl bHLH domain is 47% identical to that in 
Twistl and 87% identical to that in another Hand factor, Hand2 (reviewed by Firulli, 
2003). Handl has a low sequence identity outside of the bHLH domain, being most 
closely-related to the neurogenic bHLH factor Henl (Brown and Baer, 1994). Handl 
notably contains several other unique domains (Figure 1.1b), including a 7-residue 
poly-histidine stretch and regions rich in alanine and proline residues. These are in 
addition to the highly-conserved, hydrophobic ‘Hand domain’ at its C-terminus that it 
shares with Hand2. However the roles of these motifs are largely uncharacterised.
The structure of the Handl protein differs markedly between species (Figure 
1.3). The oldest definitive orthologue is in Drosophila, which possesses only a single 
Hand gene and which is equally divergent from murine Handl and Hand2. However, 
the Drosophila Hand gene differs in structure to the Hand genes of higher organisms 
in that it possesses 4 exons and has a highly-divergent N-terminus (Kolsch and 
Paululat, 2002). The N-terminus shows no amino acid identity with the equivalent 
region of vertebrate Handl or Hand2, and as such is unlikely to be crucial for 
biological function having been lost during evolution through genetic drift (reviewed 
by Firulli, 2003). Furthermore, Drosophila Hand, unlike mammalian Handl, neither 
encodes the N-terminal poly-histidine stretch nor the alanine-rich motif. This 
suggests that Handl has acquired novel function(s) since the divergence of 
invertebrates and vertebrates.
The single zebrafish Hand gene is most closely-related to mammalian Hand2 
(Angelo et al., 2000; Yelon et al., 2000). This suggests that Hand2 is the ancestral 
gene of the subclass from which Handl was derived. Indeed, Handl and Hand2 map 
to human chromosomes 5q33 and 4q33 respectively, regions that possess at least 13 
pairs of paralogous genes (reviewed by Lundin, 1993). This suggests that part of 5q 
containing Handl likely arose from the portion of 4q containing Hand2 in a 
tetraploidisation event (Knofler et al., 1998). This probably occurred some time 
between the divergence of fish and amphibians, since the latter possess two Hand 
genes. Notably, the cardiac phenotype of HandlK0IK0 (cardiac); Hand2KOIKO mice is 
less severe than that of the zebrafish hands o ff mutant (McFadden et al., 2005). This 
suggests that mammalian Hand genes have acquired further functions during the 
evolution of the four-chambered heart from the ancestral two-chambered fish heart.
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MmHdl
H s H d l
X t H d l
MmHd2
H s H d 2
D rH d 2
DmHd
MmHdl
H s H d l
X t H d l
MmHd2
H sH d 2
D rH d 2
DmHd
 MNLVGSYAHHHHHHHSHPPHPMLHEPFLFGPASRC-HQERPYFQSWLLSPADAAP-D 5 5
 MNLVGSYAHHHHHHHPHPAHPMLHEPFLFGPASRC-HQERPYFQSWLLSPADAAP-D 5 5
MQTMNLIGSYQHH------------------------ M M PD PFIFSPGSR C -H QER PYFQG W VLNPGEVSP-D 47
 MSLVGGFPHHPVVHHEGYPFAAAAAAAAAAAASRCSHEENPYFHGWLIGHPEMSPPD 57
 MSLVGGFPHHPVVHHEGYPFAAAAAAAAAAAASRCSHEENPYFHGWLIGHPEMSPPD 57
 MSLVGGFPHHPVMHHDGYSFAAA-------------------- SR C -H E E PP Y F H G W L IS H P E M SPP D  47
----------------------------------------------------------------MFKNSVALTC— EYSTMYYNSIYNTSNMFDMK 3 0
★  •
F  PAGGPPPTTAVAAAAYGPDARPSQSPGRLEALGSRLPK
F ----- PAGGPP PAAAAAATAYGPDARPGQS PGRLEALGGRLGR
F ----- PA Q PP---------------YSPEYGAVVGPSQTPGRMETLGGKLGR
YSMALSYSPEYASGAAGLDHSHYGGVPPGAGPPGLGGPRPVK 
YSMALSYSPEYASGAAGLDHSHYGGVPPGAGPPGLGGPRPVK 
YTMAPSYSPEYSTGAPGLDHSHYGGVP-GAGAVGMG-PRTVK 
H--------------------------------SESQVQQQIYNTSHLGYVPTSNTRIVK
R KG SGPKK ERRRTESINS
R KG SGPKK ER R R TESINS
R KG APPKK ER R R TESINS
RRGTANRKERRRTQSINS
RRGTANRKERRRTQSINS
RRPTAN RKERRRTQSIN S
KRNTANKKERRRTQSINN
112
112
98
1 1 7
1 1 7
1 0 5
7 6
* * * * * * . * * *
MmHdl a f a e l r e c i p n v p a d t k l s k i k t l r l a t s y i a y l m d v l a k d |^ QAGDPEAFKAELKKTDGG 1 7 2
H s H d l a f a e l r e c i p n v p a d t k l s k i k t l r l a t s y i a y l m d v l a k d |[a q s g d p e a f k a e l k k a d g g 1 7 2
X t H d l a f a e l r e c i p n v p a d t k l s k i k t l r l a t s y i g y l m d v l a k d |s e p g g t e g f k a e l k k v d g - 1 5 7
MmHd2 a f a e l r e c i p n v p a d t k l s k i k t l r l a t s y i a y l m d l l a k d |d q n g e a e a f k a e i k k t d v k 1 7 7
H s H d 2 AFAELRECIPNVPADTKLSKIKTLRLATSYIAYLMDLLAKD|dQNGEAEAFKAEIKKTDVK 1 7 7
D rH d 2 AFAELRECIPNVPADTKLSKIKTLRLATSYIAYLMDILDKDl^QNGETEAFKAEFKKTDAK 1 6 5
DmHd AFSYLREKIPNVPTDTKLSKIKTLKLAILYINYLVNVLDGDl LDPKG— G FR A E L K PV S R - 1 3 3
* * ;  * * *  * * * * * ; * * * * * * * * * * ; * *  * *  * * : : ; * * . * ; * * ; *
MmHdl R E S K R K R E L P Q Q P E S F P P A S G P G E K R l | |U W f l M ^ H i f @ £ i i H  2 1 6
H s H d l  RESKRKREL-QQHEGFPPALGPVEKRIKGRTGWPQQVWALELNQ  2 1 5
X t H d l   KRRREP-QPTEGYWGAAPTGEKKLKGRTGWPQQVWALELNP  1 9 7
MmHd2 -E E K R K K E L -----NEILKSTVSSNDKKTKGRTGWPQHVWALELKQ  2 1 7
H s H d 2  -E E K R K K E L -----N E I L K S T V S S N D K K T M H H H B B B B B I  2 1 7
D r H d 2  -EERRKKEM-----NDVLKSSGSSNDKKIKGRTGWPQHVWALELKQ 2 0 5
DmHd  K I C S E K -----K H C L K S E I Q N V P L S T B M f f l H B B g ^ g H R E H N  1 7 4
*  * * * * * * * *  * * *  * *
Figure 1.3. Hand protein sequence is conserved between diverse species.
Handl, Hand2 or Hand protein sequences from mouse, human, frog, zebrafish and fruit fly were 
aligned as in Figure 1.2. Conservation, which is particularly striking in the bHLH domain (boxed) as 
well as in the so-called C-terminal Hand domain (highlighted in purple), is as follows: * absolutely 
conserved between sequences, : conserved amino acid substitutions, . semi-conserved amino acid 
substitutions. The conserved serine and threonine residues in the bHLH domains o f all Hand factors 
are also highlighted, in yellow. Mm: Mas musculus, Hs: Homo sapiens, Xt: Xenopus tropicalis, Dr: 
Danio rerio, Dm: Drosophila melanogaster; Hdl: Handl, Hd2: Hand2; Hd: Hand.
1.1.2. Overview of H andl function
The first insights into Handl function were gained by over-expressing Handl 
in mouse blastomeres (Cross et al., 1995) and via antisense experiments in chicks
30
Chapter 1
(Srivastava et al., 1995). These respectively suggested an involvement of Handl in 
placentation (this chapter, section 1.2) and cardiac morphogenesis (section 1.3). More 
recent studies have also implicated a role for Handl in the adult heart (section 1.3.3) 
and in the development of other tissues, particularly those with a neural crest 
contribution (section 1.4).
1.1.3. Handl regulation
Despite the cloning of the Handl gene over a decade ago, the mechanisms 
that regulate its activity during embryogenesis remain largely unknown. Investigating 
how the developmental activity of Handl is regulated has proven difficult in vivo due 
to early embryonic lethality following loss-of-function (Riley et al., 1998; Firulli et 
al., 1998). In vitro analyses using cell lines in which Handl is endogenously 
expressed has also been difficult. Few cardiac cell lines exist and trophoblast stem 
(TS) cells are difficult to maintain and manipulate in culture (S. Tanaka, personal 
communication). A better understanding of the mechanisms of Handl regulation 
could nevertheless provide valuable insight into the underlying cellular causes of 
defective placentation and idiopathic congenital heart disease (CHD). Moreover, 
neither mutations in human Handl, nor chromosomal rearrangements involving the 
Handl gene, have been identified in a disease setting. This implicates Handl as an 
excellent candidate for mutations in cis-acting sequences or defects in its upstream 
regulation that could lead to placental failure or CHD in humans.
1.1.3.1. Transcriptional regulation of Handl
A region of the human HAND1 promoter, spanning 274bp of sequence 
upstream of the transcriptional start site, has been defined (Vasicek et al., 2003). This 
contains several cis-acting elements that convey both positive and negative 
transcriptional effects on the downstream gene. These include four GC-rich 
sequences, which are bound by members of the specificity protein (Sp) transcription 
factor family, a CCAAT box, bound by the alpha-CAAT binding factor (a-Cbf), and 
several CG-rich recognition sequences for Egr transcription factors. Interestingly, Sp 
family transcription factors have recently been implicated in controlling Handl
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expression in rodent trophoblast (Takeda et al., 2007). Alignment studies performed 
by another group have identified a highly-conserved 119bp enhancer element 63.7kb 
upstream of the HAND] start codon, termed the shared enhancer region 5 (SER5) (P. 
Riley, unpublished data). SER5 fused to GFP directed reporter gene expression 
predominantly in the zebrafish heart. This suggested that this enhancer may be bound 
by as-yet unidentified proteins to regulate the HAND1 gene during cardiac 
morphogenesis. This is reminiscent of a right ventricle- (RV-) specific enhancer 
upstream of Hand2, shown to be bound by Gata factors (McFadden et al., 2000), and 
of a branchial arch-specific Hand2 enhancer, which is responsive to Endothelin-1- 
dependent signalling (Charite et al., 2001).
Notably, unlike some other bHLH factors such as MyoD, HAND1 expression 
is thought to not be subject to auto-regulation, as HAND 1-binding sites are not 
present within the HAND1 promoter (Vasicek et al., 2003). As further confirmation 
of this, Handl promoter activity is not affected by disruption of the murine Handl 
coding region (Firulli et al., 1998; Riley et al., 2000). Namely, the expression of a 
lacZ or luciferase reporter gene, knocked into the Handl locus in a targeted ES cell 
line, recapitulates that of endogenous Handl.
Several studies suggest that signalling molecules modulate Handl expression 
in vivo. This presumably occurs via their ultimate activation of transcription factors 
whose target genes include Handl. One study used animal cap explants to show that 
the bone morphogenetic proteins 2 and 4 (Bmp2 and Bmp4) can induce Handl 
expression in the developing Xenopus heart (Sparrow et al., 1998). Importantly, this 
effect was blocked by the co-expression of a dominant-negative Bmp receptor. 
Related to this finding, ectopic Bmp4 signalling induced the expression of Handl in 
non-neural crest-derived cells in the chick oesophagus and gizzard (Wu and Howard,
2002). Furthermore, implantation of beads soaked in Bmp2 into the chick limb 
mesoderm up-regulated Handl (Fernandez-Teran et al., 2003). Thus Bmps, which 
generally act to ventralise tissue, may be general regulators of Handl expression.
In Xenopus embryos treated with a retinoic acid (RA) antagonist the domain 
of Handl expression is restricted, and may in part underlie the defective cardiac 
development of these embryos (Collop et al., 2006). Additionally, Et-1- (endothelin-
32
Chapter 1
7)-null embryos have fewer Handl transcripts in the neural crest-derived pharyngeal 
arch mesenchyme than wild-type embryos (Thomas et al., 1998a). Related to this, 
Ga.c/Gan-null embryos, which lack a pair of G-protein coupled receptors that 
transduce Endothelin-1 signalling, are similarly down-regulated for Handl in the 
pharyngeal arches (Ivey et al., 2003). Additionally, signalling cascades downstream 
of leukemia inhibitory factor (Lif) have been suggested to up-regulate genes whose 
products promote rodent trophoblast giant cell differentiation, including I-mfa and 
Handl (Takahashi et al., 2003). Finally, the study by Sparrow and colleagues also 
showed that high levels of Handl expression were detected in animal cap explants 
treated with high doses of the TGF-P family member, Activin A (Sparrow et al., 
1998).
It is also possible that Handl is regulated by Notch signalling. The expression 
of the three hairy-related bHLH transcription (Hrt) factors, also known as hairy and 
enhancer-of-split related with YRPW motif (Hey) factors, is dependent on Notch 
signalling (Steidl et al., 2000). Interestingly Hrtl, Hrt2 and Hrt3 share with Handl 
several structural and functional features, can interact with Handl and are co­
expressed with Handl in the developing heart (Firulli et al., 2000). Related to this, 
Handl interacts with the factor Mastermind-like 2 (Maml2), a trans-activator of the 
Notch signalling pathway (P. Riley, unpublished data). Maml2 associates with Notch 
ligands and functions to activate transcription of the genes encoding the Handl- 
related Hrt bHLH factors including Hrtl (Wu et al., 2002). However, the functional 
significance of Handl involvement in Notch signalling to date remains unknown.
No transcription factor has yet been shown to directly activate vertebrate 
Handl transcription, either in the heart or the other tissues in which it is expressed. 
The expression of the Drosophila Hand gene is regulated by three major transcription 
factors that control cardiogenesis and haematopoiesis, namely the Nkx-like factor 
Tinman and the Gata factors Pannier and Serpent (Han and Olson, 2005). 
Interestingly these act through a cardiac- and haematopoietic-specific enhancer 
upstream of the gene. The regulation of Drosophila Hand by Gata factors is 
reminiscent of the regulation of murine Hand2 in the developing mouse heart from a 
right ventricle-specific enhancer (McFadden et al., 2000). However, to date, Gata 
factors have not been implicated in the regulation of Handl.
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Circumstantial evidence suggests that the transcription factors Nkx2.5 and 
Mashl, and the co-activators Fog-2 and Clp-1, may directly or indirectly regulate the 
cardiac expression of Handl in vertebrates. In several cases Handl is down-regulated 
in its native tissues in mice lacking these factors and/ or these animals exhibit cardiac 
phenotypes and modified gene expression profiles reminiscent of those in tetraploid- 
rescued Handl-null mouse hearts (Biben and Harvey, 1997; Ma et al., 1997; Riley et 
al., 1998; Tanaka et al., 1999; Tevosian et al., 2000; Bruneau et al., 2001; Huang et 
al., 2004). Other transcription factors have also been inferred to regulate Handl 
expression. For example, ectopic expression of normally left ventricular-restricted 
Tbx5 in the right ventricle induces ectopic Handl expression in the right ventricle 
(Takeuchi et al., 2003).
The Nkx2.5-null mouse is a good example of a mutant whose cardiac 
phenotype and gene expression pattern bears similarity to those of the tetraploid- 
rescued Handl-nv\\ mouse (Lyons et al., 1995; Biben and Harvey, 1997; Tanaka et 
al., 1999). Mice lacking Nkx2.5 exhibit defective heart tube looping, impaired 
ventricular myocardial trabeculation and are down-regulated for Mlc2v expression in 
their hypoplastic left ventricle. Importantly, Handl transcripts are lacking on the left 
side of the primitive heart tube in these embryos, implicating Nkx2.5 in the regulation 
of Handl expression. As further evidence for a functional link between Nkx2.5 and 
Handl, mice lacking cardiac expression of both Handl and Hand2 exhibit severe 
cardiac deformities reminiscent of an Nkx2.5-/ Hand2-double knockout mouse 
(Yamagishi et al., 2001; McFadden et al., 2005). Interestingly, the expression of 
Nhc2.5 is repressed in response to Handl over-expression in vivo (McFadden et al., 
2005). In contrast, Handl-null embryoid bodies (EBs), three-dimensional aggregates 
of cardiomyocytes generated by differentiating embryonic stem (ES) cells in culture, 
have a significantly elevated level of Nkx2.5 transcripts (Riley et al., 2000). These 
observations suggest that, although Nkx2.5 expression precedes that of Handl in vivo 
and in differentiating EBs, Handl may regulate Nkx2.5 transcription in a feedback 
loop.
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1.1.3.2. Interaction of Handl with other factors
The activity of a transcription factor is commonly modulated by its interaction 
with other proteins and Handl is no exception. As a lineage-restricted (class B) 
bHLH transcription factor, Handl, at least in vitro, conforms to the classic bHLH 
transcription factor paradigm (Hollenberg et al., 1995; reviewed by Massari and 
Murre, 2000). This states that to become transcriptionally-competent, Handl must 
heterodimerise with a near-ubiquitous (class A) bHLH factor. These factors can be 
either the E-factor products of the E2A gene (E l2 and E47), or the ubiquitous 
proteins Alfl or Itf2. Indeed, Handl was originally cloned by way of a yeast two- 
hybrid (Y2H) assay in which the Drosophila Daughterless (Da) bHLH protein, the fly 
counterpart of mammalian E-proteins, was used as bait (Hollenberg et al., 1995). The 
bHLH heterodimerisation paradigm is reliant on an interaction between the HLH 
domains of Handl and its partner. This event juxtaposes the two adjacent basic 
domains to form a dimeric DNA-binding motif (Figure 1.4).
Handl does not wholly conform to the classic bHLH paradigm, however. In 
vitro a heterodimer of Handl and an E-factor can bind a so-called bipartite Thing 1- 
(Thl-) or D-box site (CGTCTG), upstream of its target genes (Hollenberg et al., 
1995; Knofler et al., 2002). Notably the Thingl-box consensus sequence is a 
degenerate version of the canonical E-box sequence (CANNTG), bound by most 
other class B-class A heterodimers and by E-factor homodimers (Chiaramello et al., 
1995; Hollenberg et al., 1995; Sigvardsson et al., 1997). The binding of Handl to a 
degenerate E-box may be due to two unusual features of the Handl DNA-binding 
domain. Firstly, the Handl basic domain is more positively-charged (contains more 
lysine (K) and arginine (R) residues) than those in other, even closely-related, bHLH 
proteins (for example in Handl, Ki0iKERRRi06, but in Twistl, V 119RERQR124). 
Secondly, the basic domain of Handl contains an atypical proline residue, which is 
an asparagine in most bHLH factors, including other members o f the Twist subfamily 
(Figure 1.2). This unusual feature has been associated with bHLH factors that 
similarly bind DNA through non-canonical E-boxes such as the N-box. For example, 
it is also present in the Drosophila bHLH factors enhancer-of-split (E(Spl)) and hairy 
(h) (Garrell and Campuzano, 1991) as well as the mammalian Scleraxis (Atchley and 
Fitch, 1997), Stral3 (Boudjelal et al., 1997), and hairy-related transcription (Hrt)
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factors (Ishibashi et al., 1993). Indeed, the substitution of a proline for the asparagine 
in the basic domain of MyoD disrupts its binding to E-boxes (Davis et al., 1990).
Most class B bHLH proteins, particularly those expressed in a single cell type 
such as the myogenic factors, are unable to homodimerise. These factors either 
heterodimerise with E-factors to enhance transcription (Massari and Murre, 2000) or 
form heterodimers with Id and Misti factors to repress transcription (Jen et al., 1997; 
Lemercier et al., 1998). However Handl is expressed in a broad range of tissues, 
with the potential for more complex, post-translational control mechanisms to 
determine its target genes in a given cell type. Consistent with this, Handl is known 
to interact with a wide range of class B bHLH factors (Table 1.1).
The interaction of Handl with partners beyond class A bHLH factors, in 
contrast to the classic bHLH factor paradigm, was first inferred over a decade ago. 
For example, whilst the Placental Lactogen-I (PL-1) promoter was activated by 
Handl over-expression in transfection assays in vitro, this effect was abolished upon 
Id-1 co-expression (Cross et al., 1995). Id-1, which encodes a HLH factor lacking the 
basic domain and which can therefore inactivate bHLH factors by forming a complex 
unable to bind DNA, is expressed at high levels in Rcho-1 stem cells but is down- 
regulated during TG cell differentiation (Cross et al., 1995; Takeda et al., 2007). 
Thus it is possible that Handl and Id-1 interact during the early stages of trophoblast 
differentiation and that this negatively-regulates Handl activity.
By conducting a yeast two-hybrid (Y2H) screen with Handl as bait, Firulli 
and colleagues confirmed that the Hand factors have ‘promiscuous’ dimerisation 
properties (Firulli et al., 2000). This and a later study by the same authors identified 
interactions between Handl and the Hrt (Hey) factors (Firulli et al., 2000) and the 
closely-related Twistl factor (Firulli et al., 2005). Handl also binds Mashl, forming 
a heterodimer that may exist in vivo as the two bHLH factors are co-expressed in the 
autonomic nervous system (Bounpheng et al., 2000). However, no functional effect 
was attributed to this interaction. Handl can also form a heterodimer with MyoD 
(Bounpheng et al., 2000; Firulli et al., 2000), although this is likely biologically- 
irrelevant as the factors are not co-expressed in vivo. The bHLH factors with which 
Handl has been shown to interact are summarised in Table 1.1a.
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Some studies suggest that Handl can also interact with non-bHLH factors in a 
tertiary fashion (Hill and Riley, 2004, Yamada et al., 2005). That is, such an 
interaction can occur concomitantly with the obligate binding of Handl to a bHLH 
partner. As such, tertiary interactions are likely to involve regions outside of the 
Handl HLH motif. Although the biological significances of most of these 
interactions are unclear, an exception is the interaction of Handl with the LIM 
domain-containing protein Fhl2. This factor has been shown to differentially regulate 
the trans-activational activity of Handl depending on its dimerisation status (Hill and 
Riley, 2004). Specifically, whilst Fhl2 represses Handl-E-factor-dependent 
transcriptional activity of a mock Handl target gene, it had no effect on Handl- 
Handl homodimer-induced transcription. However, the mechanism by which Fhl2 
interferes with Handl-E-factor activity is currently unclear as the factor did not 
impact on heterodimer formation or DNA binding (Hill and Riley, 2004). Non-bHLH 
factors with which Handl interacts are summarised in Table 1.1b.
The Y2H screen conducted by Firulli and colleagues also identified several 
Handl-interacting proteins with high sequence identity to Handl itself, suggesting 
that the transcription factor can function as a homodimer in vitro (Firulli et al., 2000). 
Handl homodimers were later shown to be transcriptionally-competent by co- 
immunoprecipitation and mammalian two-hybrid studies (Scott et al., 2000). 
However the DNA binding affinity of Handl homodimers was an order of magnitude 
lower than that of Handl-E-factor heterodimers. This suggests that these homodimers 
must be associated with other proteins in a higher-order complex to sufficiently 
enhance their DNA-binding affinity. Nevertheless, tethered Handl homodimers can 
drive the differentiation of trophoblast stem (TS) cells into trophoblast giant (TG) 
cells in culture to a degree similar to that of the Handl monomer (Hu et al., 2006). 
Furthermore, Handl homodimer knock-in mice develop normally until E l4.5, 
suggesting that Handl can act exclusively as a homodimer to regulate early 
developmental processes (Hu et al., 2006).
Based upon the high degree of amino acid identity between Handl and Hand2 
(87% amino acid identity between the bHLH regions), and the fact that Handl can 
homodimerise, it was not surprising to find that these factors can interact (Firulli et 
al., 2000). Handl-Hand2 heterodimers have been hypothesised to play a role in the
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formation o f  the interventricular septum (IVS) o f  the heart, based on their 
complementary expression domains in ventricular chambers that intersect at the 
interventricular groove (Firulli et al., 2001; reviewed by Firulli, 2003). Collectively, 
these findings reveal that Handl has a broad dimerisation profile. This may explain 
how this widely-expressed factor regulates discrete cohorts o f  genes in different 
tissues. For example, Handl may bind a trophoblast giant (TG) cell-specific bHLH 
factor during TG cell differentiation that directs Handl binding to the promoters o f  
TG cell-specific genes. Crucially, these genes would not be regulated by Handl in the 
other lineages in which it is expressed during embryogenesis, by virtue o f  their 
lacking expression o f the TG cell-specific factors to which Handl binds.
f \  L oop  
Helix
B a s ic  d o m a in
xxxxxx xxxxxx Lineage Specific  Gene
C G T C T G C A N N T G
Figure 1.4. The bHLH factor heterodimerisation paradigm.
As a lineage-restricted (class B) bHLH transcription factor, Handl conforms to the classic bHLH 
transcription factor heterodimerisation paradigm. This states that to become transcriptionally- 
competent, Handl (blue protein) must bind a near-ubiquitous (class A) bHLH factor (red protein). The 
paradigm is reliant on an interaction between the HLH domains o f Handl and its partner. This 
juxtaposes the two basic domains from each factor to form a dimeric DNA-binding motif, such that the 
E-factor recognises the E-box CANNTG and Handl the degenerate Thingl-box CGTCTG.
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Table 1.1. Factors known to interact with murine Handl. 
(a) bHLH factors
Factor Target genes/ function of complex Reference(s)
E-factors
(El 2/ E47/ALF1)
Unknown.
May activate the PL-1 promoter.
Cross et al., 1995. 
Hollenberg et a l,  1995.
Id-1 Handl repression. Cross et al., 1995.
MyoD Handl repression. Bounpheng et al., 2000. 
Firulli et a l, 2000.
Mashl Handl repression.
May regulate ANS development.
Bounpheng et al., 2000. 
Firulli et a l, 2000.
Hand2 Unknown.
May regulate IVS formation.
Firulli et aL, 2000. 
Reviewed by Firulli (2003).
HRT family (1-3) Unknown. Firulli et al., 2000.
Twistl Unknown. Firulli et al., 2005.
Handl Unknown.
May promote TG cell differentiation.
Firulli et al., 2000. 
Scott et al., 2000. 
Hu et al., 2006.
PL-l: Placental lactogen-1, ANS: autonomic nervous system, IVS: interventricular septum.
(b) Non-bHLH factors
Factor Target genes/ 
function of complex
Handl binding 
domain(s)
Reference(s)
I-rafa Unknown. Cysteine-rich I-mfa domain. Kraut et al., 1998.
Nkx2.5 Unknown. Unknown. Thattaliyath et al, 2002b.
B566* Handl dephosphorylation. Multiple regions. Firulli e ta l ,  2003.
Fhl2 Handl-El 2 repression. LIM domain. Hill and Riley, 2004.
Mef2, Gata Activate Nppa expression**. Unknown. Morin et al., 2005.
Soxl5 Unknown. HMG box domain. Yamada et al., 2006.
MamI2 Unknown. Unknown. P. Riley, unpublished data
*As part of the Protein Phosphatase 2A (PP2A) enzyme.
**Nppa encodes the Atrial Natriuretic Factor/ Peptide (Anf/ Anp).
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1.1.3.3. Post-translational modification of Handl
Covalent modification is a cellular mechanism that is widely-used to 
modulate the activity of transcription factors, including members of the bHLH super­
family. For example, homo-cysteine disulphide linkage of E-protein homodimers 
stabilises these complexes during haematopoiesis (Benezra, 1994; Markus and 
Benezra, 1999). However, by far the most prolific post-translational modification is 
phosphoryLation. Indeed, during myogenesis, phosphorylation of the basic domain of 
myogenic bHLH factors enhances their DNA binding affinity (Li et al., 1992; Zhou 
and Olson, 1994). Additionally, phosphorylation of MyoD facilitates its 
heterodimerisation with E l2 (Lenormand et al., 1997). It is likely that post- 
translational modification acts as a molecular ‘switch’ that dictates the target genes of 
a bHLH factor. That is, phosphorylation modulates the DNA recognition sequence of 
a bHLH factor either directly (modification of residues in the basic domain) or 
indirectly (modification of residues in the HLH domain, which ultimately affects its 
dimerisation choice).
Through Y2H and GST-pull down assays, Firulli and co-workers identified an 
interaction between Handl and the regulatory B568 subunit of protein phosphatase 
2 A (PP2A) (Firulli et al., 2003). The identification of this Handl interactor ultimately 
led to the discovery that Handl can be site-specifically phosphorylated and 
dephosphorylated at two residues in helix 1. These covalent modifications were 
furthermore shown to be biologically relevant. Handl phosphorylation at these two 
residues increases during the differentiation of rat choriocarcinoma-1 (Rcho-1) 
trophoblast stem cells into trophoblast giant cells, in part due to the down-regulation 
of B56Sexpression during this process. The authors subsequently showed that Handl 
mutants that could not be phosphorylated at these residues had different dimerisation 
affinities and biological activity to wild-type Handl (Firulli et al., 2003). Since 
phosphorylation of Handl in the HLH domain alters its dimerisation affinity, and this 
bipartite DNA sequence to which it binds, changing the binding partner of Handl 
may thus be an important step in the TG cell differentiation program. Of note, the two 
helix 1 residues phosphorylated in murine Handl (T107 and S I09) are conserved in 
murine Hand2 (T112 and SI 14) and murine Twistl (T125 and SI27; Figure 1.2). 
They are also targeted for dephosphorylation by PP2A complexes containing B56S
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(Firulli et al., 2005). Moreover, the same study showed that mutation of these 
residues in Twistl affects the affinity of the factor for Hand2 and this underlies some 
cases of Saethre-Chotzen syndrome, characterised by limb defects (Firulli et al., 
2005). Thus, control of bHLH activity by the modulation of phosphorylation is 
evolutionarily-conserved within the Twist subfamily of bHLH factors and may 
explain how they regulate different sets of target genes in distinct tissues.
1.1.4. Modes of Handl activity
As described, Handl can act as a transcriptional activator, for example when 
bound to the E-factors E12/ E47 (Hollenberg et al., 1995). However, Handl has also 
been shown to function as a repressor at both the transcriptional and post- 
translational levels in vitro (Hollenberg et al., 1995; Knofler et al., 2002). This 
repressive activity may in part be underpinned by the atypical proline residue in the 
Handl basic domain. As discussed, this unusual feature has been associated with 
bHLH factors such as Drosophila enhancer-of-split (E(Spl)) and hairy (h), and 
mammalian Scleraxis, Stral3, and hairy-related transcription (Hrt) factors, which 
have also been shown to repress transcription. In this regard Hand2, which has not to 
date been observed to repress gene transcription, possesses an asparagine in its basic 
domain (reviewed by Firulli, 2003; Figure 1.2). Whether Handl acts as a 
transcription activator or repressor is likely dependent on cell type and cofactor 
availability, bHLH protein partner and DNA-binding sequence.
1.1.4.1. Transcriptional repression by Handl
That Handl can repress transcription was first suggested by reporter assays in 
which a GAL4-Handl fusion protein repressed a reporter gene downstream of GAL4 
DNA-binding sites (Hollenberg et al., 1995). Other findings also support a role for 
Handl in negative gene control. Handl may repress Hand2 expression in the 
developing yolk sac (Bounpheng et al., 2000), and has been shown to repress Soxl5- 
dependent transcription during TG cell differentiation (Yamada et al., 2006). 
Furthermore, several genes are up-regulated in a Handl -null background, implicating 
Handl in their repression (Smart et al., 2002; Morikawa and Cserjesi, 2004).
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The domain(s) responsible for conferring a transcriptional repressive activity 
to Handl are under debate. The original report of Handl-dependent transcriptional 
repression suggested that the HLH dimerisation domain was responsible for 
repression of a reporter gene, suggesting that Handl may bind a factor, bHLH or 
possibly otherwise, that conveys repressive activity (Hollenberg et al., 1995). Morin 
and colleagues showed that deletion of the Handl N-terminus produced a hyperactive 
deletion mutant that activated a reporter gene to a greater extent than wild-type 
Handl (Morin et al., 2005). This supports the observation of Knofler and colleagues, 
who suggested the presence of a repressive domain in the Handl N-terminus (Knofler 
et al., 2002). The N-terminal poly-histidine stretch and/ or a nearby alanine-rich 
region may be candidates and indeed similar motifs are thought to confer repressive 
activities to other transcription factors (Licht et al., 1990; Shi et al., 1991; Han and 
Manley, 1993). Alternatively, Handl-mediated transcriptional repression may be a 
function of the C-terminal tryptophan-rich ‘Hand domain’. This has homology to 
hydrophobic domains in the highly-related Hrt factors that recruit the co-repressor 
protein Groucho (Fisher et al., 1996) and to motifs in hairy-related transcription 
factors that are known to confer a repressive activity (Steidl et al., 2000). Finally, the 
asparagine-to-proline substitution in the basic domain of Handl has been associated 
with transcriptional repression in the bHLH family. Notably Stral3, one o f the bHLH 
factors that share this characteristic, blocks the assembly of the basal transcription 
complex at gene promoters to achieve its repressive effect (Boudjelal et al., 1997). 
However, it is unclear at present whether Handl is able to act in this fashion to 
repress its target genes.
As a final consideration, bHLH factors closely related to Handl interact with 
and modulate the function of transcriptional modifiers. For example, Twistl inhibits 
chromatin remodelling and thus transcription by displacing histone acetyltransferases 
(HATs) such as p300 (Creb-binding protein, CBP) and p300/CBP-associated factor 
(PCAF) from promoters of its target genes (Hamamori et al., 1999). Furthermore, 
Hand2, as a component of a complex with Gata4, physically interacts with CBP to 
synergistically activate the Nppa promoter (Dai et al., 2002). It is thus plausible that 
Handl also recruits co-repressors to, or displaces co-activators from, the promoters of 
target genes. Indeed, such a function for Handl was proposed on the basis of its 
interaction with Mef2 in a transcriptional complex bound to DNA at Me£2 binding
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sites (Morin et al., 2005). In this regard, Hill and Riley proposed that the mechanism 
of action of the Fhl2 cofactor may be to displace histone acetyl-transferases from the 
Handl-E-factor heterodimer-DNA complex, but not the Handl-Handl homodimer 
transcriptional complex (Hill and Riley, 2004).
1.1.4.2. Post-translational repression by Handl
Handl can also repress the activity of other transcription factors at the protein 
level. This was first suggested by mammalian one-hybrid experiments in which 
Handl suppressed GAL4-E47-dependent transcription from consensus E-box 
sequences (Knofler et al., 2002). This post-translational repressive function of Handl 
is thought to occur via three mechanisms. Firstly, Handl can compete for the obligate 
class A bHLH binding partners of other class B bHLH factors, a mode of action not 
without precedent within the Twist bHLH factor subfamily (Spicer et al., 1996). For 
example, Handl sequesters E-factors from Mash2 during TG cell differentiation to 
repress Mash2-dependent trans-activation (Scott et al., 2000). Secondly, Handl may 
bind and inactivate other class B bHLH factors to alter the bHLH dimer pool in a 
similar way to the inhibitory Id and Misti factors during myogenesis (Jen et al., 
1997; Lemercier et al., 1998). For example, Handl inhibits the DNA binding of 
MyoD-E12 heterodimers (Bounpheng et al., 2000; Firulli et al., 2000) and Alfl 
homodimers (Bounpheng et al., 2000) in competition EMSAs and reporter assays. 
Handl achieves this by forming heterodimers with E l2, MyoD and ALF1. Finally, 
Handl can inhibit MyoD-E47 tethered heterodimers, stable complexes resistant to 
dimerisation competition from other bHLH factors or HLH factors such as the Id 
proteins (Bounpheng et al., 2000). This mechanism suggests that Handl-mediated 
repression does not require its interaction with another bHLH factor. Handl-mediated 
post-translational repression in this case may depend on competition for common 
target gene promoters or cofactors, possibly including those involved in chromatin 
remodelling, such as histone acetyl-transferases (HATs; Morin et al., 2005).
43
Chapter 1
1.1.4.3. Does Handl function as a component of a multi-subunit 
protein complex?
Studies employing Handl deletion mutants have revealed that the Handl 
basic domain, and thus the ability of Handl to bind DNA, is required for Handl 
function in Rcho-1 cells (Scott et al., 2000). However, some evidence suggests that 
Handl may activate its target genes as a component of a multi-subunit complex, often 
containing non-bHLH transcription factors.
The possibility of Handl belonging to a higher-order transcriptional complex 
was first inferred from the observation that the DNA binding affinity of Handl 
homodimers is significantly lower than that of Handl-E-factor heterodimers (Scott et 
al., 2000). This suggested that Handl associates with other proteins to enhance its 
DNA-binding and/ or trans-activational affinity. For example, the Handl-interactor 
Fhl2 is thought to act as a scaffold around which a multi-subunit complex can 
assemble to enhance downstream transcriptional events (Hill and Riley, 2004). Thus 
Handl may activate genes in a DNA binding-independent fashion. Indeed, the 
closely-related Hand2 has been shown to operate via such a mechanism with Gata 
factors and the isolated HLH domain of Handl can drive the formation o f ectopic 
digits in the developing limb bud (Dai et al., 2002; McFadden et al., 2002). This 
suggests that regions outside this protein-protein interaction domain are not required 
in some settings for Handl activity and that DNA-binding and trans-activation 
domains may be provided by other factors in a Handl-containing multi-protein 
complex.
Morin and colleagues later showed that, whilst wild-type Handl is able to up- 
regulate Nppa expression, neither a tethered Handl-Handl homodimer nor a tethered 
Handl-Itf2 heterodimer could do the same (Morin et al., 2005). Moreover, mutation 
o f a Mef2-responsive element in the Nppa promoter drastically reduced wild-type 
Handl-mediated activation (Morin et al., 2005). These observations suggest that a 
complex containing Handl and Mef2 may activate Nppa expression. This is 
particularly supported by the fact that the DNA-binding domain of Mef2 was 
sufficient for synergy with Handl at the Nppa promoter, suggesting that Handl can 
support transcriptional activation. It was further suggested that Handl may represent
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a stage-specific Mef2 cofactor. This was based on the observation that the Mef2 
binding site in the Nppa promoter contributes differentially to gene activity in 
embryonic and postnatal cardiomyocytes (Naya et al., 1999). Notably, the Handl- 
dependent activation of Nppa was similarly abrogated when a Gata element was 
mutated (Morin et al., 2005). Thus complex interactions between Handl and the non- 
bHLH transcription factors Mef2 and Gata may activate the Nppa promoter.
1.2. The role of Handl in extra-embryonic tissues
Handl plays a crucial role during the formation of the rodent placenta. The 
haemochorial placenta is the first organ to develop during embryogenesis and brings 
maternal and fetal vascular systems together to allow fetal intrauterine development. 
It is responsible for nutrient, oxygen and waste transport and also has endocrine 
functions.
Placental defects in humans give rise to a range of complications, including 
spontaneous abortion, intrauterine growth retardation (IUGR), choriocarcinoma and 
pre-eclampsia (reviewed in Redman and Sargeant, 2005; Sibai et al., 2005). Pre­
eclampsia occurs in up to 10% of all human pregnancies and is characterised by 
inadequate invasion of trophoblast, the fetal component of the placenta, into the 
maternal decidua. This in turn results in aberrant remodelling of the uterine spiral 
arterioles, which leads to IUGR and oedema in the fetus and hypertension and 
proteinuria in the mother. Investigating the role and regulation of Handl during 
placentation may thus shed some light on the molecular bases for these placental 
deficiencies. Additionally placental development is an attractive model system for 
investigating the molecular bases of stem cell maintenance and differentiation. This is 
in part because TS cells are extremely well-characterised in terms of stem cell 
potency and differentiation derivatives (Carney et al., 1993; reviewed by Rossant and 
Cross, 2001).
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1.2.1. Overview of rodent placentation
The following overview will focus on stages o f murine placentation unless 
otherwise stated. The haemochorial placenta of rodents and primates is evolutionarily 
the most advanced. The distance between the maternal and fetal blood spaces is very 
small (~ 100-3 OOprn) by virtue of the fact that the fetal trophoblast cells are in direct 
contact with the maternal blood.
The placenta in rodents is derived from two major cell lineages. The first, the 
cell lineage which contributes chiefly to the placenta, is the trophectoderm (TE). This 
is composed of pluripotent trophoblast stem (TS) cells and forms the epithelial 
portions of the placenta (Carney et al., 1993; reviewed by Rossant and Cross, 2001). 
The second cell lineage that contributes to the rodent placenta is the extra-embryonic 
mesoderm, derived from the ICM, which forms the yolk sac and related structures, 
and the blood vessels of the placenta. The emergence of the TE during mouse 
development occurs when cells of the morula separate into the inner cell mass (ICM) 
and the epithelial TE population at the point of blastocyst formation (at embryonic 
day (E) 3.5). This represents the first differentiation event in the pre-implantation 
mammalian embryo. Studies have suggested that the segregation of ICM and TE cells 
is dependent on the down-regulation of Oct-4 and Nanog in blastomeres destined to 
become the TE (Nichols et al., 1998; Mitsui et al., 2003; Hough et al., 2006).
By the time the murine blastocyst implants into the uterus at E4.5, two 
separate TE populations have formed. These are the mural and polar TE. TS cells of 
the mural TE, which surround the blastocoel cavity and lack contact with the ICM, 
form a limited number (approximately 50-60) of primary TG cells (PGCs). These are 
the first differentiated cell type to arise during development. PGCs surround the 
blastocyst and facilitate the initial implantation of the blastocyst into the uterine 
tissue. This establishes the interface for subsequent formation of a network of blood 
sinuses at the periphery of the embryo, which allows the growth o f the embryo prior 
to the formation of the definitive chorio-allantoic placenta. Meanwhile, TS cells of 
the polar TE, which overlie the ICM, continue to proliferate. This is likely in 
response to mitogenic fibroblast growth factors (Fgfs), particularly Fgf4, from the
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ICM-derived epiblast of the early post-implantation embryo (Gardner and 
Beddington, 1988; Tanaka et al., 1998; Zhong et al., 2006). Fgf-dependent paracrine 
signalling via Fgf2r on the surface of the polar TS cells promotes their proliferation 
and this forms the chorion, also called the extra-embryonic ectoderm (ExE; Arman et 
al., 1998). By E5.5, the chorion matures into the ectoplacental cone (EPC), also 
known as the implanting pole. The EPC subsequently flattens and expands by the 
primitive streak stage (E7.5) into the spongiotrophoblast (SpT) layer or ‘junctional 
zone’. Both the EPC and SpT are progress zones that serve as reservoirs of diploid 
cells which progressively lose their stem cell potential. These structures ultimately 
spawn secondary TG cells (SGCs) from their outer reaches (reviewed by Rossant and 
Cross, 2001). Thus, in an E7.5 conceptus, PGCs can be found lining the implantation 
chamber at the more distal anti-mesometrial region of the conceptus up to the level of 
the EPC. In contrast, SGCs are located at the more proximal mesometrial end o f the 
conceptus arising adjacent to the EPC.
SGCs are inherently invasive and phagocytic. These are characteristics that 
are underpinned by their secretion of proteases (Peters et al., 1999; Nie et al., 2005; 
Hassanein et al., 2007) and their up-regulation of certain extracellular matrix protein 
receptors such as Alpha-7 Integrin (Sutherland et al., 1993; Damsky et al., 1994; 
Klaffky et al., 2001). This facilitates the digestion of the extracellular matrix 
surrounding the uterine epithelial cells, so enabling SGCs to invade the maternal 
deciduum. The invasive capacity of SGCs has also been recapitulated in Matrigel, a 
uterine-like synthetic basement membrane matrix (Hemberger et al., 2004). The 
ultimate purpose of decidual invasion is to establish intimate contact with the 
maternal decidua cells and to contact maternal blood sinuses by displacing maternal 
endothelial cells from vessels in the implantation site. As such, SGCs secrete 
angiogenic, vasodilatory and anti-coagulatory factors to promote maternal blood flow 
into the implantation site (Jackson et al., 1994; Weiler-Guettler et al., 1996; Achen et 
al., 1997; Yotsumoto et al., 1998). Furthermore, these cells also have endocrine 
functions. They secrete leutotrophic and lactogenic hormones such as prolactins and 
placental lactogens, which promote local and systemic adaptations in the mother that 
are necessary for embryonic growth and survival. For example, SGCs secrete 
Placental lactogen-1 (PL-1), also known as Chorionic somatomammotrophin-1 (Csh- 
1), which targets the ovary to maintain the corpus luteum and stimulate progesterone
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production, and promotes mammary gland development and lactation (Nieder and 
Jennes, 1990; Faria and Soares, 1991; Hamlin et al., 1994). The process of SGC 
differentiation is described in more detail later in this chapter (section 1.2.2).
In parallel with the process of SGC invasion, formation of the 
syncytiotrophoblast (SynT), also known as the labyrinth, takes place. This layer 
consists of villi lined with a multinucleated syncytium and is bathed in maternal 
blood. The SynT arises at approximately E8.5-9.0 when the allantois (extra- 
embryonic mesoderm-derived) fuses with the chorion (TE-derived; the process of 
chorio-allantoic fusion; Anson-Cartwright et al., 2000). Molecular signals from the 
allantois may initiate the process, supported by the fact that isolated TS cells in 
culture, which readily differentiate into TG cells in culture after Fgf4 removal, very 
rarely differentiate into SynT (Hughes et al., 2004). Although the SynT component of 
the placenta secretes hormones such as the aromatase Cypl9 (Anson-Cartwright et 
al., 2000), it is folded and branched to provide a large surface area for nutrient, 
oxygen and waste exchange. As such, fetal blood vessels from the SynT layer occupy 
the spaces in the maternal decidua left by the invading TG cells (reviewed by 
Rinkenberger and Werb, 2000). Thus by E l0.5, the mature chorionic placenta has 
formed and this is composed of three layers. The outermost layer of the placenta, that 
is the layer closest to the deciduum, is composed of SGCs. The SynT represents the 
innermost layer of the placenta, namely that closest to the embryo. Between these 
layers resides the SpT. Figure 1.5 summarises the process of murine placentation.
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Figure 1.5. Overview of murine placentation.
At E4.5 the murine blastocyst, consisting o f the mural and polar trophectoderm (mTE and pTE) and 
inner cell mass (ICM), implants into the maternal decidua. By E5.5 the mTE has differentiated into a 
limited population o f primary trophoblast giant cells (PGCs), which facilitate implantation into the 
decidual wall. The pTE meanwhile proliferates to form the chorion. By E7.5 the ectoplacental cone 
(EPC) has formed from chorionic trophoblast and secondary trophoblast giant cells (SGCs) arise from 
this to invade the maternal decidua. By E l0.5 the mature three-layered placenta has formed. SGCs 
comprise the outer layer and represent an interface with the maternal tissue, and the EPC has flattened 
to form the spongiotrophoblast (SpT), a reserve o f diploid trophoblast destined to form SGCs. The 
innermost layer, the syncytiotrophoblast (SynT), arises when the chorionic trophoblast fuses with the 
allantois, and this establishes contacts with maternal blood vessels.
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Some data have, however, challenged this rather simple model of murine 
placentation. One study suggests the existence of a fourth trophoblast cell type, so- 
called glycogen trophoblast (GlyT) cells (Adamson et al., 2002). These comprise a 
specialised sub-type of SpT cell that arise after E l2.5, once the mature, three-layered 
placenta has arisen. These express specific prolactin genes and migrate deep into the 
interstitium of the decidua to line the lumen of the maternal spiral arteries to promote 
vasculature contacts between the mother and embryo. The molecular events that 
underlie GlyT differentiation are unknown, but their numbers increase in mice 
deleted for Igf2 and p57Kip (Takahashi et al., 2000). Additionally, a recent study has 
challenged the view that SGCs are a homogeneous cell population in the rodent 
placenta. As well as the previously-recognised SGC subtype that surrounds the 
implantation site and forms the interface with the maternal decidua, Simmons and 
colleagues identified at least three other SGC subtypes, which have distinct patterns 
of gene expression and developmental origins (Simmons et al., 2007). These 
comprise spiral artery-associated SGCs, maternal blood canal-associated SGCs and a 
SGC within the sinusoidal spaces of the SynT, as well as the previously-recognised 
sub-type, classified in this recent study as ‘parietal SGCs’.
1.2.2. Trophoblast giant cell differentiation
The differentiation of TS cells into TG cells, of both the PGC and SGC 
subclasses, coincides with marked changes in cell size and cytoskeletal organisation 
(this chapter, section 1.2.2.1), the onset of endoreduplication and changes to the cell 
cycle machinery (section 1.2.2.2) and the elimination of endoreduplication inhibitors 
(section 1.2.2.3). Furthermore, there is some evidence that the process of SGC 
differentiation is modified by oxygen tension (section 1.2.2.4).
1.2.2.1. Cytoskeletal re-organisation
TG cell differentiation is accompanied by a dramatic increase in cell size, 
cytoskeletal actin re-organisation, stabilisation of cell-cell interactions and changes in 
focal adhesion formation (Parast et al., 2001; Figure 1.6). These changes are thought 
to occur in three distinct stages. Firstly, an epithelial-mesenchymal transition gives
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rise to a proliferative population of cells with strong cell-cell contacts. This is 
followed by a re-epithelialisation stage, which forms an intermediate trophoblast cell 
population that have destabilised cell-cell and cell-matrix interactions and decreased 
motility. The final phase of TG cell differentiation involves a specialised type of re- 
epithelialisation. This stabilises the cell-cell contacts and reorganises the actin 
cytoskeleton, enabling TG cells to form anchoring contacts with the decidual matrix 
(Parast et al., 2001).
Studies by Parast and colleagues characterised in detail the cytoskeletal 
changes that occur during TG cell differentiation of rat choriocarcinoma-1 (Rcho-1) 
cells, a faithful model of TS cells in culture, and freshly-explanted E7.5 EPC-derived 
trophoblast (Parast et al., 2001). Rcho-1 stem cells are small, highly-motile cells with 
patches of filamentous actin at their periphery. They also possess few, small 
peripheral focal complexes of Vinculin responsible for cell-cell interactions. Rcho-1 
TG cells are larger, immotile cells with prominent actin stress fiber bundles and 
many, large internal focal Vinculin complexes (Figure 1.6). The reorganisation of the 
cytoskeleton correlates with changes in the activity of members of the Rho family of 
small GTPases including Rho A, Racl and Cdc42. Rcho-1 stem cells have low Rho A 
but high Racl and Cdc42 activity compared to TG cells. These GTPases are thought 
to regulate cytoskeletal re-organisation through phosphorylation of EphB2/EphrinB 
(Parast et al., 2001). These cytoskeletal changes also coincide with a decrease in 
focal adhesion kinase (Fak) activity. Fak enhances integrin- and growth factor- 
mediated cell migration by turning over focal adhesions between cells and mediates 
coincident changes in E-Cadherin and specific Connexin expression (Reuss et al., 
1996). Another study reveled that the p53/56lyn kinases, which regulate cytoskeletal 
re-organisation through a phosphatidylinositol-3-kinase (PI3-K)- and protein kinase 
B (PKB)-dependent signalling cascade, are up-regulated during TG cell 
differentiation (Kamei et a l , 1997; Kamei et al., 2002).
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Figure 1.6. Rcho-1 trophoblast stem and trophoblast giant cells differ 
dramatically in terms of size and cytoskeletal organisation.
Rcho-1 trophoblast stem (TS) cells have a diameter o f approximately 20pm and have patches o f  
filamentous actin at their periphery. Rcho-1 trophoblast giant (TG) cells are larger (> 100pm in 
diameter) and have prominent actin stress fiber bundles.
I.2.2.2. E ndoredup lication  and  associated changes to  the  cell cycle 
m achinery
Both PGCs and SGCs are polyploid, possessing DNA contents o f up to a 
thousand times the haploid content (Varmuza et al., 1988). This remarkable feature 
arises because progenitor TS cells exit the mitotic cell cycle and commence 
endoreduplication (enter the endocycle) at the point o f  committing to differentiate 
(reviewed by Rossant and Cross, 2001; Cross, 2002; Figure 1.7).
Post-mitotic endoreduplication in trophoblast, which also occurs in 
mammalian hepatocytes and megakaryocytes as well as in Drosophila salivary 
glands, consists o f  repeated rounds o f DNA synthesis in the absence o f  intervening
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mitoses. Such endoreduplication-based differentiation is initiated during the second 
gap phase (G2) of the final mitotic cell cycle (MacAuley et al., 1998), and is thus 
distinct from terminal differentiation and entry into the quiescent state (GO) that 
occurs during phase G l. The length of an individual endocycle in trophoblast giant 
cells in vivo has been estimated as fourteen hours by pulse-chase experiments 
(Nakayama et al., 1998). Furthermore [3H]-thymidine incorporation experiments 
show that the rate of DNA synthesis declines during differentiation to 25% of the rate 
in proliferating TS cells (Hamlin and Soares, 1995).
Endocycling, in which the chromosomes do not condensate, likely enables the 
bulk transcription of genes whose products are crucial for uterine invasion. It may 
also allow the growth of cells beyond the limit defined by the nuclear/ cytoplasmic 
ratio that normally restricts the size of diploid cells, so permitting substantial size 
increases (MacAuley et al., 1998). Furthermore endoreduplication in trophoblast is 
thought to prevent contacts of the TG cell genome with chromosomes o f the 
phagocytosed allogenic maternal tissue. This serves to prevent an adverse immune 
response during embryogenesis (reviewed by Zybina and Zybina, 2005).
Endoreduplication in trophoblast is underpinned by marked modifications to 
the cell cycle regulation machinery (MacAuley et al., 1998; Palazon et al., 1998). 
These serve to prevent the cell from entering mitosis and so shunt it into the 
endocycle. For a cell to enter mitosis, mitotic (B-type, B1 and B2) cyclins bind 
cyclin-dependent kinases such as Cdkl to form the mitotis-promoting factor (MPF; 
reviewed by Sullivan and Morgan, 2007). For a TS cell to exit the mitotic cell cycle, 
these mitotic cyclins must therefore be completely destroyed. This is a process which 
begins in phase G2 of the final mitotic cell cycle and is normally complete by the end 
of the first endocycle (MacAuley et al., 1998; Figure 1.7).
Mitotic cyclin destruction is mediated in rodent trophoblast by the anaphase- 
promoting complex/ cyclosome (APC/C), which possesses E3 ubiquitin ligase 
activity. This complex ubiquitinates the destruction (D)-box in mitotic cyclins to 
target them for proteasomal degradation (Sudakin et al., 1995). Other events also 
block the activity of the MPF. Palazon and coworkers showed that the onset of TG 
cell differentiation coincides with translational inhibition of Cyclin B 1, resulting in
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elimination of the protein, but not the transcript (Palazon et al., 1998). Furthermore, 
the activity of Cdkl, namely the most prominent cyclin B-associated kinase, is 
reduced at the onset TG cell differentiation (MacAuley et al., 1998). These 
observations may also explain why the trophoblast cell does not initiate mitosis 
during the first endocycle, despite the persistence of cyclin B protein. Additionally 
Rcho-1 TS cells switch cyclin D isoform expression from D3 to D1 during TG cell 
differentiation (MacAuley et al., 1998). However, the reason for this is currently 
unclear.
The existence of defined endocyle S phases separated by gap phases suggests 
that endoreduplication is as carefully regulated as progression through the mitotic cell 
cycle (Sauer et al., 1995). The initiation of, and progression through, endocyclic S- 
phases involves the synthesis, degradation and subcellular trafficking of cyclins E 
and A (Palazon et al., 1998; MacAuley et al., 1998). This was confirmed by the 
phenotype of cyclin E l c y c l i n  ET1' TS cells, which are unable to undergo multiple 
rounds of DNA synthesis during endoreduplication (Geng et al., 2003; Parisi et al.,
2003). In rodent trophoblast, the endocycle-specific cyclin A- and E-associated 
kinase inhibitor p57Kip2 was subsequently shown to halt DNA replication at the end of 
endocyclic S-phases as a pre-requisite for resetting origins of replication (Hattori et 
al., 2000). This is a function that has also been attributed to the transcription factor 
Dpi (Kohn et al., 2003).
Several checkpoints are also altered coincident with the onset of TG cell 
differentiation, which is likely a consequence of the cell cycle reprogramming. For 
example, TG cells acquire insensitivity to DNA-damaging agents and do not arrest at 
the Gl/S phase checkpoint upon DNA damage (MacAuley et al., 1998). This is in 
accordance with the observed down-regulation of p53 during TG cell differentiation 
(Soloveva et al., 2004). This is also consistent with the observation of increased 
numbers of TG cells in p53-null placentae (Komatsu et al., 2007) and the fact that 
loss o fp53 induces mammalian cells to endoreduplicate (Cross et al., 1995b; Peled et 
al., 1996). Furthermore, in Rcho-1 stem cells, but not Rcho-1-derived TG cells, the 
Gl-S phase transition is sensitive to the presence of growth factors. This likely 
underlies the ability of cultured TG cells to grow in the absence of serum (Hamlin et 
al., 1994; Cross et al., 1995; MacAuley et al., 1998).
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1.2.2.3. Elimination of endoreduplication inhibitors
To commence TG cell differentiation TS cells must inactivate so-called 
‘endoreduplication inhibitors’. These factors maintain TS cell proliferation and 
diploidy. They include Snail, previously called mSna (Nakayama et al., 1998), and 
Geminin (Gonzalez et al., 2006). However, how these endoreduplication inhibitors 
are inactivated at the onset of TG cell differentiation is currently unknown (Figure 
1.7).
One of the ways in which Geminin is thought to prevent hyper-amplification 
of DNA is by blocking the assembly of the pre-replication complex. Accordingly, 
genetic ablation of Geminin promotes endoreduplication in murine blastomeres prior 
to the establishment of the TE. This has the effect of committing all cells of the 
blastocyst to the TG cell lineage (Gonzalez et al., 2006). More is known about the 
activity and mechanism of action of Snail, the mammalian homologue of the 
Drosophila Snail family member Escargot. The loss of Escargot in Drosophila leads 
to abnormal development whereby ordinarily mitotic imaginal disc cells undergo 
endoreduplication (Hayashi et al., 1993; Roark et al., 1995). Conversely, ectopic 
expression of Escargot suppresses endoreduplication in Drosophila salivary glands 
(Fuse et al., 1994). Snail expression is restricted to the proliferating TG cell 
precursors within the core of the EPC and later the SpT layer, but down-regulated 
upon SGC differentiation (Nakayama et al., 1998). This was confirmed by 
transfection experiments in Rcho-1 cells. These showed that Snail over-expression 
blocked, whilst its antisense-mediated knock-down promoted, TG cell differentiation 
(Nakayama et al., 1998). Furthermore, stable Rcho-1 cell transfectants for Snail 
underwent TG cell differentiation at a markedly-reduced level (Nakayama et al., 
1998).
Snail is a zinc finger transcriptional repressor that is thought to directly 
repress transcription, perhaps of pro-endoreduplicative genes (Nakayama et al., 
1998). Indeed, Snail possesses an N-terminal seven-amino-acid SNAG domain, 
which likely recruits co-repressor complexes to the promoter of the gene(s) to be 
repressed (Grimes et al., 1996; Cano et al., 2000). Otherwise Snail may compete 
with and/ or displace pro-endoreduplicative bHLH factors from E-box DNA elements
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(Fuse et a l , 1994; Nakayama et al., 1998). Although it was suggested that Handl 
may be one of these bHLH factors (Nakayama et al., 1998), Handl is known to bind 
the degenerate E-box Thing-1 site in vivo (Hollenberg et al., 1995). Additionally, 
Snail also promotes the expression of mitotic cyclins, via an as-yet unidentified 
mechanism. Over-expression of Snail in Rcho-1 stem cells results in markedly- 
increased levels of cyclin A and cyclin B transcripts, which would be inferred to drive 
mitotic entry at G2 in preference to the initiation of endoreduplication (Nakayama et 
a l , 1998).
1.2.2.4. Modification of trophoblast giant cell differentiation by 
oxygen tension
Implantation o f the murine blastocyst at E4.5 occurs in hypoxic conditions (3- 
5% oxygen) because maternal blood flow to the implantation site is low. However, 
when the chorio-allantoic placenta develops and establishes connections with the 
maternal vasculature at E9.0-E10.0 in mice, the placental environment becomes 
relatively oxygen-rich (8.6% oxygen; Rodesch et a l , 1992).
Hypoxia is thought to promote the rapid proliferation of diploid trophoblast 
cells needed to amass the quantity of cells required for formation of the placenta, at 
least in humans (Genbacev et a l , 1997; Caniggia et a l , 2000). Ectopically increasing 
oxygen tension inhibits diploid trophoblast renewal and promotes precocious invasive 
trophoblast differentiation (Genbacev et a l , 1997; Caniggia et a l , 2000). 
Interestingly, the heterodimeric hypoxia-inducible factor (HIF), up-regulated by low 
oxygen tension, is a negative regulator of TG cell differentiation (reviewed by Fryer 
and Simon, 2006). Predictably, therefore, mice lacking HIF-1 subunits are embryonic 
lethal due to placental defects characterised by precocious TG cell differentiation at 
the expense of the formation of other placental layers (Kozak et a l , 1997; Adelman 
et a l , 2000; Cowden-Dahl et a l , 2005). These observations are in agreement with the 
hypothesis that Mash2, which encodes a bHLH factor required for TS cell 
maintenance, is up-regulated either directly or indirectly by HIF in vitro (Cowden- 
Dahl et a l , 2005). Interestingly, HIF-1 is thought to regulate genes that may play a 
role in the development of pre-eclampsia. These include the gene encoding TGF-p3,
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an inhibitor of TG cell invasion, whose expression persists beyond the first trimester 
in pre-eclampsia and may underlie the failure of TG cell invasion (Cannigia et al., 
2000).
Interestingly, aspects of invasive trophoblast differentiation are compromised 
in Rcho-1 cells and other trophoblast stem cell models induced to differentiate under 
low oxygen tension (Gultice et al., 2006; Lash et al., 2007; Takeda et al., 2007). 
Molecularly, Rcho-1 cells cultured under hypoxia maintained the TS cell-specific 
expression of Id-1 and Id-2, which are down-regulated during Rcho-1 TG cell 
differentiation in normoxic conditions (Cross et al., 1995). This is in agreement with 
a study that demonstrated that hypoxia prevents the down-regulation of ID-2 during 
human invasive trophoblast differentiation (Janatpour et al., 2000). The Id factors 
may thus persist to inhibit Handl or other bHLH factor activity, which may be 
responsible for a block to TG cell differentiation. Furthermore, despite retaining their 
characteristic gene expression profile, low oxygen correlated with reduced PL-I and 
Palladin protein production. The lack of Palladin, normally expressed at high levels 
in TG cells and which is required for the formation of focal adhesions, cell-cell 
junctions and stress fibres (Parast and Otey, 2000), resulted in cytoskeletal 
disorganisation.
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Figure 1.7. The molecular basis of trophoblast giant cell differentiation.
The commitment o f trophoblast stem (TS) cells to trophoblast giant (TG) cell differentiation occurs 
during phase G2 o f the final mitotic cell cycle. This is concomitant with cells initiating 
endoreduplication, the replication of genomic DNA in the absence o f intervening mitoses to produce 
polyploid cells. As a pre-requisite for endocycle entry, the anaphase-promoting complex/ cyclosome 
(APC/C) must target mitotic cyclins and possibly endoreduplication inhibitors such as Snail and 
Geminin for terminal destruction. Until now the G2-specific event(s) that promote TG cell 
differentiation have been unclear.
M: mitosis, Gl: first gap phase, G2: second gap phase, S: DNA synthesis phase.
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1.2.3. The molecular basis of rodent placentation
Expression of specific transcription factors in the trophoblast cells of the 
developing rodent placenta regulates the expression of downstream target genes. 
These control whether a TS cell continues to proliferate or commits to differentiate, 
and furthermore which fate it adopts. TG cell differentiation is considered to be the 
‘default’ differentiation pathway in the absence of factors that maintain TS cell 
proliferation. As such, several of the factors listed in Table 1.2 actively suppress TG 
cell differentiation and their withdrawal is sufficient for TG cell differentiation (see 
table for references). Nevertheless, several exogenous factors, for example, retinoic 
acid (RA; Yan et al., 2001), diethylstilbestrol (DES; Tremblay et al., 2001), 
parathyroid hormone-related protein (PTHrP; El-Hashash et al., 2005) and nerve 
growth factor (NGF; Kanai-Azuma et al., 1997), have been shown to actively 
promote TG cell differentiation in a paracrine fashion.
The combined expression patterns of many signaling molecules and 
transcription factors define distinct subpopulations of trophoblast cells in the placenta 
(reviewed by Cross, 2002). For example, Scott and colleagues identified three 
functionally-distinct trophoblast subpopulations in the E7.5-8.5 murine placenta 
based simply on the expression domains of Handl and Mash2. These are the TS cells 
of the chorion (Mash2 only), cells in the core of EPC or SpT (both Handl and 
Mash2) and the TG cells forming at the periphery of the EPC or SpT (Handl only) 
(Scott et a l , 2000). It is clear, however, that there are many more transcriptional 
domains in the developing murine placenta involving other factors and that there is 
considerable overlap between them. A selection of the molecules that control murine 
placentation are summarised in Table 1.2. The role of Handl in regulating SGC 
differentiation will be described in detail in the next section (1.2.4) of this chapter.
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Table 1.2. A selection of factors involved in murine placentation.
Factors required for TS cell renewal (a) are expressed at high levels in TS cells or promote TS cell proliferation in a paracrine fashion, but are down-regulated upon TG cell 
differentiation. If  the genes encoding these factors have been deleted in mice, placental defects characterised by precocious TG cell differentiation generally result. 
Conversely, factors required for TG cell differentiation (b) are absent from TS cells but are up-regulated during their differentiation into TG cells. I f  the genes encoding these 
factors have been deleted in mice, placental defects characterised by a lack o f  TG cells generally result. Factors required for SynT differentiation and for formation o f  extra- 
embryonic mesoderm are not listed.
Factor Function Reference(s)
(a) Factors required for trophoblast stem (TS) cell renewal
Fgf4, FgflS Act in a paracrine fashion through Fibroblast growth factor receptor-2 (Fgf2r) on 
the TS cell surface to activate Cdx2 and Eomes expression.
TGFp family members Act in a paracrine fashion to inhibit JunB but promote Mash2 and Snail 
(e.g. Nodal, Activin) expression.
Cdx2
Eomes
Errp
Controls trophoblast versus ICM cell fate. 
Controls polar versus mural trophectoderm fate. 
Unknown.
Arman et a l, 1998.
Tanaka et al.; 1998.
Zhong et al., 2006.
Ma et al., 2001. 
Guzman-Ayala et al., 2004.
Strumpf et al.t 2005.
Russ et al., 2000.
Luo et aL> 1997.
Tremblay et al., 2001.
Ap-2y
Elf5
Couples Fgf signalling to Cdx2 and Eomes expression. 
Controls chorionic versus EPC cell fate.
Auman et al., 2002. 
Donnison et al., 2005.
Factor Function Reference(s)
Spl Activates Id-1 expression. Takeda et al., 2007.
Foxd3 Unknown. Tompers et al., 2005.
Id-1 and Id-2 May inhibit Handl, Stra2 and Stral3 activity. Cross et al., 1995. 
Jen et al., 1997. 
Takeda et al., 2007.
Socs3 Suppresses Lif signalling. Takahashi et al., 2003. 
Isobe et al., 2006.
(b) Factors required for trophoblast giant (TG) cell differentiation
Handl Activates PL-I expression.
Promotes mitotic cell cycle exit at the onset of endoreduplication.
Cross et al., 1995. 
Hughes etal., 2004.
Ap-2y (Stra2) Activates PL-II and PTHrP expression.
Transduces retinoic acid (RA) secreted by the decidua, which promotes TG cell 
differentiation.
Yan et al., 2001. 
Auman et al., 2002. 
Ozturk et al., 2006.
Stral3 Promotes mitotic cell cycle exit at the onset of endoreduplication. 
Transduces RA secreted by the decidua.
Yan et al., 2001. 
Hughes et al., 2004.
Gata2/3 Activates PL-I expression.
Restricts the expression of PLP-A to secondary, rather than primary, TG cells.
Ng et al., 1994.
Ma and Linzer, 2000.
c-Jun Activates expression of PL-I and the matrix metalloproteinase genes Mmp2 and 
Mmp9.
Bamberger et al., 2004.
JunB Unknown. Schorpp-Kistner et al., 1999.
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Factor Function  Reference(s)
I-mfa Inhibits Mash2 activity in diploid TG cell precursors. Kraut et al., 1998.
Soxl5 Enhances H andl-dependent transcription. Yamada et al., 2006.
Ets family Activate genes encoding various members of the placental lactogen family. Yamamoto et al., 1998. 
Sun and Duckworth, 1999.
Ngf Unknown. Kanai-Azuma et al., 1997.
PTHrP Maternal PTHrP stimulates PGC differentiation.
PTHrP-dependent signalling in SGCs promotes entry into the endocycle. 
Up-regulates Stra2 and Stral3 but down-regulates Mash2 and Snail expression.
El-Hashash et al., 2005. 
El-Hashash and Kimber, 
2006.
Ppar|3 Up-regulates I-mfa expression but down-regulates Id-2 expression. Nadra et al., 2006.
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1.2.4. Handl is required for rodent placentation
The expression of murine Handl in trophoblast was first demonstrated by 
injecting a Handl -encoding plasmid into an individual blastomere of a morula (Cross 
et al., 1995). After culturing this morula to later stages and allowing for blastocyst 
outgrowth, whole-mount RNA in situ hybridisation analyses were performed to map 
Handl expression. This revealed an absence of Handl transcripts in TS cells of the 
chorion layer, an up-regulation of Handl in the EPC, particularly in the more 
differentiated cells at its periphery, and the strongest expression in the TG cell layer 
surrounding the implanted conceptus. Weaker and more transient Handl expression 
was observed in the extra-embryonic mesoderm cells that form the developing yolk 
sac, amnion and allantois (Cross et al., 1995).
This Handl expression pattern was subsequently confirmed by in vivo studies. 
In one study, Handl was targeted in ES cells via the insertion of a LacZ (J3- 
galactosidase) expression cassette to create a loss-of-function Handl allele (Firulli et 
al., 1998). In E7.5 mouse embryos heterozygous for this allele, p-galactosidase 
staining revealed Handl promoter activity in the trophectoderm of the EPC and 
extra-embryonic mesodermal components of the primitive placenta, namely the 
amnion, allantois and yolk sac, as well as in the extra-embryonic mesoderm-derived 
umbilical and vitelline vessels. Whilst the previous in situ hybridisation study failed 
to show Handl expression in the chorion (Cross et al., 1995), chorionic LacZ 
expression was detectable in these embryos (Firulli et al., 1998). This implies that 
Handl is either very weakly expressed or its transcript is unstable in chorionic TS 
cells.
1.2.4.1, Handl is required for trophectoderm specification
Handl mRNA was detected at the two-cell embryo prior to blastocyst 
formation, suggesting a role in early lineage specification (Cross et al., 1995). Indeed, 
Handl over-expression in mouse blastomeres promotes their differentiation into 
trophectoderm whilst in ES cells ectopic Handl activity arrests cell proliferation 
(Cross et al., 1995). The bias of blastomeres towards the trophectoderm lineage at the
63
Chapter 1
expense of ICM formation resulted in blastocysts with fewer cells than wild-type 
blastocysts due to premature TG cell differentiation. Occasionally ‘trophoblastic 
vesicles’ arose, which resembled blastocysts but which lacked an ICM (Cross et al., 
1995). These observations implicate Handl in the specification of trophoblast cell 
fate at the morula-to-blastocyst transition.
I.2.4.2. Handl is required for trophoblast giant cell differentiation
Reporter assays using the Rcho-1 cell line, a faithful model of TS cells, 
revealed that endogenous Handl expression is up-regulated coincident with TG cell 
differentiation following serum withdrawal (Cross et al., 1995). Furthermore, ectopic 
expression of Handl drives precocious TG cell differentiation in Rcho-1 cells (Cross 
et al., 1995). Later experiments showed that the suppression of Rcho-1 TG cell 
differentiation by dimethyl sulphoxide (DMSO) correlates with a down-regulation of 
Handl expression (Sahgal et al., 2005). Another group later generated H andl-null 
TS cells from Handl-null blastocysts (Hemberger et al., 2004). Such cells 
appropriately have an impaired ability to undergo TG cell differentiation, as indicated 
by the down-regulation of the TG cell marker Placental lactogen-1 (.PL-1), upon the 
withdrawal of proliferation-inducing molecules such as Fgf4, its cofactor Heparin and 
those secreted by feeder cells. These cells also exhibit an approximately 50% 
decrease in invasion rates in comparison with Handl -heterozygous TS cells, as 
assessed by Matrigel assays (Hemberger et al., 2004). These and other studies (Kraut 
et al., 1998; Scott et al., 2000) imply that Handl is both necessary and sufficient for 
TG cell differentiation of Rcho-1 and trophoblast stem cells.
Two research groups independently generated a knock-out mouse model for 
Handl by gene targeting to analyse Handl function in vivo (Riley et al., 1998; Firulli 
et al., 1998). Mice heterozygous for Handl had no apparent phenotypic defects and 
were fertile. However, Handl-null mice arrested at E7.5 and were embryonic lethal at 
E8.0-E9.0. This was primarily due to combined failure of EPC cells, which are 
reduced in number, to properly differentiate into SGCs (Riley et al., 1998), and as a 
result o f defects of the extra-embryonic mesoderm, which ultimately resulted in a 
hemorrhaging of the yolk sac (Firulli et al., 1998). The reduced number of SGCs
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resulted in a smaller implantation chamber and a failure to invade the maternal 
decidua to establish a maternal-fetal interface (Riley et al., 1998; Figure 1.8). Indeed, 
the number of TG cells surrounding Handl-null implantation sites at E8.5 (-80) was 
not significantly different from the number of mural trophectoderm cells present at 
the blastocyst (E3.5) stage in wild-type concepti.
These studies collectively implied that Handl regulates cell commitment to 
the trophoblast lineage and subsequent SGC differentiation in rodents. Notably the 
number of SGC precursors in the EPC or its derivative SpT layer is not increased in 
Handl -null embryos, as might be expected in the absence of their differentiation, but 
is in fact reduced. This suggests that TS cells are able to exit the mitotic cell cycle 
normally in the absence of Handl and that the absence o f Handl prevents their 
subsequent differentiation. Nevertheless, if Handl-null TS cells, induced to 
differentiate by withdrawal of Fgf4, are transfected with a Handl expression 
construct, their rate of differentiation is not further increased (Hughes et al., 2004). 
Indeed, in the same study, Handl over-expression was shown to promote exit from 
the mitotic cell cycle in TS cells concomitant with TG cell differentiation. This 
occurred even in culture conditions that normally maintain TS cell proliferation 
(Hughes et al., 2004). This dominant effect of Handl and its ability to override 
factors that maintain TS cell diploidy suggests that Handl activity is sufficient for 
mitotic cell cycle exit and the onset of endoreduplication, albeit via an 
uncharacterised mechanism.
It is also of note that Handl-null mutant blastocysts were able to implant, 
hatch and outgrow normally into maternal decidua (Riley et al., 1998). This suggests 
that Handl-null PGCs, responsible for blastocyst implantation, form and function 
normally. Despite the similarity in morphology of PGCs and SGCs, several 
molecules have been identified in either one or the other (Rebstock et al., 1993; Ma 
and Linzer, 2000). This suggests that the molecular events underlying their formation 
probably differ and that PGC differentiation may not require Handl. Nevertheless, 
maternal Handl transcripts have been identified in the oocyte and cleavage-stage 
embryos (Cross et al., 1995), which could support PGC formation in Handl -null 
embryos. However, this is unlikely to feature at later stages (E7.5-8.0) coincident 
with SGC differentiation.
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Figure 1.8. Handl is essential for secondary trophoblast giant cell differentiation 
in vivo.
In wild-type embryos, TS cells o f the ectoplacental cone differentiate into secondary giant cells 
(SGCs) that invade the maternal decidua to generate a maternal-fetal interface (a; enlarged section 
shows SGCs in (c)). However, Handl-nn\\ mice arrest at E7.5 due to a failure o f SGC differentiation 
and SGC invasion o f the maternal decidua (b). Adapted from Scott et al., 2000.
The exact mechanism by which Handl drives SGC differentiation is poorly 
understood. A possible mechanism was suggested based on the findings o f RNA in 
situ hybridisation experiments on E8.5 mouse embryos (Scott et al., 2000). These 
showed that Handl and Mash2 expression domains overlap in the EPC and its 
derivative SpT layer. Mash2 is the predominant bHLH transcription factor in diploid 
trophoblast but is absent in SGCs. Mash2 deficiency in mice causes embryonic 
lethality at E l0.5 due to excessive and precocious TG cell differentiation and a
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resultant absence of the SpT layer (Guillemot et al., 1994). Over-expression of 
Mash2 in Rcho-1 cells blocks TG cell differentiation (Scott et al., 2000). Similarly, 
Mas/z2-transfected TS cells continue to divide for longer after withdrawal of Fgf4, 
which ordinarily results in TG cell differentiation by default (Hughes et al., 2004). 
Collectively these studies implicate Mash2 in the maintenance of diploid trophoblast.
Whilst Mash2 expression is chorionic and that of Handl is highest in the SGC 
population, their expression domains overlap in the EPC and its derivative SpT layer. 
Scott and colleagues used co-immunoprecipitation, EMSA and reporter competition 
assays to show that the increasing levels of Handl in SGC precursors in these regions 
reduces Mash2 activity (Scott et al., 2000). Mechanistically this was due to Handl 
binding the E-protein partners of Mash2, and/ or Handl occupying Mash2 binding 
sites in the promoters of Mash2 target genes (Bounpheng et al., 2000; Scott et al., 
2000). A positive-feedback loop thus likely ensues. SGC differentiation, initiated in 
part by Handl expression, is accompanied by a progressive inhibition of Mash2 
activity (Scott et al., 2000). Ultimately the antagonistic relationship between Handl 
and Mash2 diminishes Mash2-induced expression of genes whose products are likely 
required for TS cell renewal, with the net and default effect being SGC 
differentiation. Whether heterodimers of Handl and E-factors in diploid trophoblast 
activate genes whose products promote TG cell differentiation, or otherwise, is 
presently unknown.
However, a wholly passive role for Handl during TG differentiation is 
disputed by the results of functional studies analysing Handl deletion mutants (Scott 
et al., 2000). Over-expression of a Handl deletion mutant lacking the basic domain, 
which is thus unable to bind DNA but can still compete for the E-factor binding 
partners of Mash2, had no significant effect on TG cell differentiation. This suggests 
that Handl has a more active role during TG differentiation, namely that it regulates 
its own target genes. The fact that Handl-null placental defects are retained in a 
H andl/ Mash2 double-null mutant mouse further supports this idea (Scott et al., 
2000). Thus Handl function is not restricted to inhibiting Mash2-dependent 
transcription and moreover the phenotype of Handl-null embryos is not simply due 
to ectopic Mash2 activity.
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E-factors are down-regulated during differentiation in several cell types and 
indeed are detectable neither in SGCs (Cross et al., 1995; Scott et al., 2000) nor 
cardiomyocytes (Riley et al., 2000). Thus, although Handl likely titrates E-factors 
from Mash2 during SGC differentiation, Handl must itself bind different bHLH 
partners during later stages of this process. Possible bHLH binding partners of Handl 
in SGCs include Handl itself, Stral3, and/ or the Hrt (Hey) factors (Firulli et al., 
2000; Hughes et al., 2004; Hu et al., 2006). Interestingly the bHLH factors 
NEUROD1 and D2 are expressed during human extravillous trophoblast invasion, 
although it is currently unknown whether this is the case in rodents and whether 
Handl interacts with these (Westerman et al., 2002). Recent studies argue against the 
possibility of Stral3 being a Handl binding partner, however. An interaction between 
Handl and Stral3 was neither detected in mammalian two-hybrid nor in co­
transfection experiments and Stral3 and Handl did not synergistically promote SGC 
differentiation (Hughes et al., 2004). The Hrt factors are particularly strong 
candidates for Handl interaction in both trophoblast and cardiomyocytes; Hrt I '1'/ 
HrtT1’ double knockout mice are embryonic lethal due to cardiac and placental 
defects (M. Gessler, personal communication). Notably, tethered Handl homodimers 
can drive TG cell differentiation in cultured TS cells to a degree similar to that of the 
Handl monomer (Hu et al., 2006). This suggests that Handl may act as a homodimer 
to actively promote TG cell differentiation, but would require further investigation to 
corroborate.
Handl activity in TG cells may depend also on tertiary interactions, namely 
with non-bHLH factors. Handl interacts with the non-bHLH, HMG-box transcription 
factor Soxl5 in SGCs cells (Yamada et al., 2006). Soxl5 is up-regulated during TG 
cell differentiation in vivo and ectopic expression of Sox 15 promotes precocious 
Rcho-1 TG cell differentiation in a Handl-dependent fashion. Whilst Sox 15 
interaction with Handl enhanced Handl-dependent transcription in reporter assays, 
the Handl-Sox 15 interaction had the opposite effect at Sox 15-dependent promoters 
(Yamada et al., 2006). However, the biological relevance of these observations in 
vivo is currently unclear.
Handl, in combination with as-yet unidentified factors, likely activates genes 
whose products contribute to the process of SGC differentiation. Otherwise, Handl
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may repress genes whose products maintain the proliferative trophoblast population. 
However, few Handl target genes in the trophoblast lineage have been identified. 
This may be because Handl heterodimerisation partners are largely unknown and 
possibly since Handl activity, like that of Hand2, may not require the basic domain 
and is independent of DNA binding (McFadden et al., 2002). Handl, in combination 
with Gata2/3 and Ap-1 (Shida et al., 1993; Ng et al., 1994), regulates the gene 
encoding the hormone Placental Lactogen-1 (PL-1) (Cross et al., 1995). This gene is 
down-regulated in trophoblast of Handl -null mice (Riley et al., 1998; Firulli et al., 
1998). Appropriately the mouse PL-1 promoter contains a Thing 1-box (CTGCTG) 
which conforms to the consensus site to which Handl-E47 heterodimers bind 
(Hollenberg et al., 1995). Deletion of an 86bp region of the promoter (between -274 
and -188 relative to the Handl transcription start site) that encompasses this element 
furthermore results in diminished PL-I promoter activity in Rcho-1 cells co­
transfected with Handl (Cross et al., 1995; Scott et al., 2000). Notably Smart and co­
workers identified Wnt2 as a putative target gene of Handl, albeit in a cardiac cell 
model (Smart et al., 2002). Specifically, Wnt2 is up-regulated in a Handl-null 
background, implicating Handl in its repression. This is particularly interesting in 
light of the fact that deletion of the Wnt2 gene in mice is associated with defective 
placentation characterised by ectopic TG cells (Monkley et al., 1996). Notably, the 
expression domain of Handl in the developing mouse heart overlaps with that of the 
transcriptional co-activator Cited 1, and its expression is down-regulated in the hearts 
of conditional Handl-null embryos (Dunwoodie et al., 1998; McFadden et al., 2005). 
Cited 1 expression is furthermore required for proper placentation (Rodriguez et al.,
2004), suggestive of its regulation by Handl in trophoblast. Finally, Hughes and 
colleagues demonstrated that Stral3 was co-expressed in a subset of Handl-positive 
TG cells (Hughes et al., 2004). This implies that Handl may activate Stral3 
expression during TG cell differentiation.
1.2.4.3. Handl is required for formation of the yolk sac vasculature
During murine placentation, the yolk sac does not develop from TE (TS 
cells). Instead, the yolk sac is formed from two populations of cells derived from the 
ICM in two stages (reviewed by Rossant and Cross, 2001). Firstly, just after
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blastocyst implantation, endoderm cells migrate onto the basal surface of the PGC 
layer and form the parietal yolk sac. This absorbs nutrients from the maternal blood 
via capillaries in the decidua. It is not known whether Handl is required for this 
process. Subsequently, by E8.0, extra-embryonic mesoderm cells migrate to the inner 
surface of the parietal yolk sac. This generates the visceral yolk sac, composed of 
primitive vitelline vessels and haematopoietic cells, which facilitate more efficient 
exchange of materials between embryo and mother until formation of the definitive 
chorio-allantoic placenta. Handl is specifically expressed in this mesodermal yolk 
sac component (Firulli et al., 1998).
Handl -null embryos do not display reduced numbers of extra-embryonic 
mesodermal cells, suggesting that the gene is not required for their differentiation. 
However, such embryos have a visceral yolk sac that is rough and disorganised in 
appearance, particularly in the area in contact with the EPC (Firulli et al., 1998). In 
addition, their yolk sac vasculature is abnormal, which results in extensive leakage of 
haematopoietic cells into the space between the yolk sac and the amnion (yolk sac 
hemorrhaging; Firulli et al., 1998; Riley et al., 1998). Many of the features of Handl - 
null embryos, such as a failure to undergo turning and the formation of a crooked 
neural tube, may in this respect be consequences of a defective extra-embryonic 
blood supply.
A recent study cast some light on the function of Handl in the visceral yolk 
sac vasculature (Morikawa and Cserjesi, 2004). This reported that Handl is required 
for the remodelling and maturation of the visceral yolk sac blood vessels, including 
the recruitment of smooth muscle cells (SMCs) to the endothelial network. 
Endothelial cells exist in the Handl-null visceral yolk sac, as indicated by 
immunofluorescence for platelet endothelial cell adhesion molecule (PECAM). Thus 
early vasculogenesis, namely the formation and clustering of endothelial cells, is not 
dependent on Handl. However, the PEC AM-positive endothelial cells of Handl- null 
visceral yolk sacs were distributed in a honeycomb-like structure. This was 
characteristic of an immature vascular plexus, similar to the yolk sac phenotype of 
mice deleted for angiogenic genes such as Tiel, Tie2 and Vegf (Sato et al., 1995; 
Carmeliet et al., 1996). Recruitment of SMCs to the endothelial network was also 
defective in H andl-null visceral yolk sacs. This was demonstrated by reduced
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immunofluorescence for the early SMC marker smooth muscle alpha-actin (SMaA). 
Loss of smooth muscle support results in vessels that lack the strength to carry blood 
under pressure, and moreover may underlie the leakage of haematopoietic cells from 
the visceral yolk sac into the yolk sac-amniotic space. Thus vasculogenesis, the 
process by which angioblasts differentiate into endothelial cells to form the vascular 
primordium, occurs in Handl-null visceral yolk sacs. However, Handl is required for 
angiogenesis, namely the maturation of the primitive endothelial plexus to refine into 
a functional vascular system.
In the same study, several angiogenic genes were shown by RT-PCR analysis 
to be up-regulated in Handl-null extra-embryonic membranes, implicating Handl in 
their repression. The mis-expression of these genes may account for the observed 
visceral yolk sac vasculature defects. These genes include the signalling molecules 
vascular endothelial growth factor (Vegf), angiopoetin 1 (Angl) and the ephrin B 
ligand Efnh2. Furthermore, the expression of genes encoding the Vegf receptors 
Flkl, Fltl and Nrpl, and that encoding the Angl receptor Tiel, are all up-regulated in 
Handl -null yolk sacs. Additionally, Notchl/4 expression, also implicated in 
vasculogenesis, is enhanced in Handl-null yolk sacs. This occurs together with an 
up-regulation of the Notch-dependent gene Heyl (Morikawa and Cserjesi, 2004). 
This implies a direct role for Handl in Notch signaling, which attaches functional 
significance to our observed interaction of Handl with the placenta-expressed Notch 
regulator Maml2 (P. Riley, unpublished data; Appendix 8).
1.2.5. Human placentation and the role of HAND1 in human 
extra-embryonic tissues
The process of human placentation is markedly different to that in rodents 
(reviewed by Georgiades et al., 2002; Malassine et al., 2003). This is perhaps 
explained by the fact that the placenta is a relatively young organ in evolutionary 
terms. In humans, proliferation and differentiation of pluripotent, trophectodermal 
cytotrophoblasts, the equivalent cell population to rodent TS cells, gives rise to three 
placental layers. These are the syncytial chorionic villi (equivalent to the rodent 
SynT), cytotrophoblast cell columns (also called anchoring villi; equivalent to the
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rodent SpT) and the extravillous cytotrophoblast (EVT; equivalent to the outermost 
rodent SGC layer). These layers are thought to be in place by the third week of 
pregnancy (reviewed by Loregger et al., 2003), which is much earlier, relative to the 
length of gestation, than the time taken for the three-layered murine placenta to form 
(E10.5).
Reminiscent of the emergence of TG cells from the periphery of the rodent 
EPC, cytotrophoblast cell columns, bound to the uterine wall, give rise to EVT cells. 
EVT cells are known to up-regulate MMP9, which facilitates digestion of the uterine 
matrix (Librach et al., 1991), and have evolved mechanisms, such as the secretion of 
immuno-suppressors, to evade maternal immune responses (Roth et al., 1996). The 
EVT cells therefore invade the uterine endometrium to attain contacts with the 
maternal spiral blood vessels and also serve an endocrine function by secreting 
hormones such as human chorionic gonadotrophin (hCG) and human placental 
lactogen (hPL) (reviewed by Loregger et al., 2003). However, unlike the process of 
rodent TG cell differentiation and invasion, little is known about the mechanisms of 
EVT formation. Strikingly, human EVT cells do not undergo endoreduplication, but 
may instead fuse to produce multinucleate cells (al-Lamki et al., 1999). Notably, 
based on patterns of gene expression, it has been suggested that human EVT cells are 
more analogous to murine glycogen trophoblast (GlyT) cells (Giorgiades et al., 
2002).
Despite the morphological differences between rodent and human 
placentation, several factors that function in rodent placentation are also expressed in 
the developing human placenta. For example, the human MASH2 (HASH2), STRA13 
and I-MFA genes are expressed, in varying degrees, in both isolated cytotrophoblasts 
and the EVT invading the maternal decidua (Janatpour et al., 1999; Meinhardt et al.,
2005). Moreover, HASH2 is down-regulated during EVT differentiation, but STRA13 
and I-MFA are up-regulated, which is reminiscent of the molecular changes during 
rodent placentation (Table 1.2). Additionally, a later study by the same authors 
showed that ID-2, expressed at high levels in cytotrophoblast stem cells, is down- 
regulated during EVT differentiation. Moreover, ID-2 over-expression inhibits EVT 
differentiation and trophoblast invasion of a Matrigel matrix substance in vitro 
(Janatpour et al., 2000).
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However, most importantly for our study, a role for human HAND1 in 
placentation has yet to be demonstrated. Neither RT-PCR, RNase protection assays 
nor RNA in situ hybridisation could detect HAND1 expression in human 
cytotrophoblasts or the invasive EVT layer (Russell et al., 1997; Knofler et al., 1998; 
Janatpour et al., 1999; Meinhardt et al., 2005). HAND1 mRNA and protein are, 
however, abundantly expressed in the JEG-3 and BeWo human choriocarcinoma cell 
lines (Knofler et al., 2002). Furthermore, RT-PCR analysis and immuno- 
histochemical staining of blastocysts has revealed HAND1 mRNA and protein within 
the trophectodermal cell layer of the blastocyst (Knofler et al., 2002). These findings 
suggest that the transcription factor could be required for early trophoblast 
specification and/ or differentiation (Knofler et al., 2002). Moreover, HAND1 
expression is detectable in the mesodermal components of the human placenta, for 
example purified amnion cells {in vitro) and amniotic epithelium {in vivo; Knofler et 
al., 2002) at different stages of gestation. This suggests that HAND1 may be required 
for differentiation and/ or function of the early amnion during human placentation.
1.3. The role of Handl in the developing heart
Handl has been shown to play a crucial role during the formation of the 
rodent heart. The heart is the first organ to develop and function in the vertebrate 
embryo proper. The complexity of cardiac morphogenesis is underlined by the fact 
that congenital heart disease (CHD), the physical manifestation of defects in this 
process, occurs in 8 of 1000 (-1%) of live births in humans. The importance of 
normal cardiac morphogenesis is also underlined by the multitude of lethal 
phenotypes in animal models carrying null mutations in genes critical for 
cardiovascular development. CHD is also the most prevalent cause of miscarriage 
(Hoffman, 1995). CHDs tend to affect segments of the heart, rather than the whole 
organ, reflecting the modular fashion of heart development (reviewed by Fishman 
and Olson, 1997).
Several genes have been shown to play a role in cardiac morphogenesis in the 
mouse and have been linked to specific CHDs in humans. Their encoded transcription
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factors belong to a wide range of families. These include basic helix-loop-helix 
(bHLH), homeobox, T-box, zinc finger and MADS domain classes (reviewed by 
Harvey, 1999; Risebro and Riley, 2006). Handl has a crucial role in cardiac 
morphogenesis, as discussed below, but no mutations in this gene have been 
identified in human patients to date. Nevertheless, delineating how Handl is involved 
in heart development may provide valuable insight into the underlying molecular and 
cellular causes of a subset of patients with idiopathic CHD.
1.3.1. Overview of cardiac morphogenesis
1.3.1.1. Formation of the linear heart tube
The following overview will focus on stages o f murine cardiac 
morphogenesis unless otherwise stated. The heart is the first organ to form and 
function in the vertebrate embryo proper. Heart morphogenesis initiates soon after 
gastrulation, at around E7.0 in the developing mouse embryo. The process begins 
with the specification of cardiac precursor cells (CPCs) in the anterior portion of the 
lateral plate mesoderm, partly in response to molecular signals from the underlying 
endoderm (reviewed by Chen and Fishman, 2000). This region is termed the pre­
cardiac mesoderm, cardiac crescent, cardiac primordia or primary heart field (PHF) 
(reviewed by Harvey, 1999). PHF CPCs are arranged in two bilaterally-symmetrical 
populations located in the anterior region of the primitive streak on either side of the 
embryonic midline. Subsequently, several cardiac transcription factors are induced in 
these cells. These include the homeobox factor Nkx2.5, the earliest known marker of 
the cardiomyocyte lineage (Lints et al., 1993).
At E7.5 in the mouse, the paired CPC populations that comprise the PHF 
migrate medially to the anterior of the embryo and by E8.0 fuse at the ventral 
embryonic midline to form the so-called linear heart tube. This structure is composed 
of an inner endocardium and an outer myocardial layer, which are separated by an 
extracellular matrix called ‘cardiac jelly’. This is attached to the body wall by the 
dorsal mesocardium and begins to pump blood rhythmically through its posterior end 
by E8.5 in the mouse, 29 hours in the chick and by day 23 in humans (reviewed by
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Risebro and Riley, 2006). The formation of the linear heart tube is summarised in 
Figure 1.9.
Recently, data have emerged that suggest that the heart is actually formed 
from two distinct CPC populations. In addition to the PHF, a more anterior and dorsal 
population of CPCs arise in the so-called second lineage, or secondary (anterior) 
heart field (SHF; Kelly and Buckingham, 2002; Zafffan et al., 2004). This is located 
in the splanchnic mesoderm and may be specified by the transcription factor Islet 1 
(Isll). This population is therefore distinct from the PHF that contributes to the linear 
heart tube. Between E8.5 and E l0.5, namely during cardiac looping, CPCs of the 
SHF contribute to the arterial pole myocardium of the developing outflow tract 
(OFT), as well as to the myocardium of the right ventricle (RV). In addition, CPCs of 
the SHF contribute to the endothelium of the aortic arch arteries (Kelly and 
Buckingham, 2002; Zaffran et al., 2004).
Lineage tracing analyses of the Islet-1 factor and retrospective clonal analyses 
were recently used to show that the PHF and the SHF are both derived from an 
ancestral population of cardiac progenitors, formed at around E6.5 (Meilhac et al., 
2004). This has been interpreted that the two heart fields actually represent a single 
heart-forming region (van den Hoff et al., 2004). Moreover, whilst this study agreed 
with the model that two separate cardiac lineages contribute to heart formation, it 
revealed that each contributes slightly differently to the developing heart than the 
previously-defined PHF and SHF. Namely, the left ventricle (LV) was derived 
entirely from the PHF and the OFT from the SHF, yet both lineages were shown to 
contribute to all other regions of the heart (Meilhac et al., 2004).
1.3.1.2. Heart tube looping and the ballooning model
At E8.0-8.5 during mouse development, the linear heart tube undergoes a 
morphological transition. This is termed rightward (dextral) cardiac looping 
(reviewed by Harvey, 1999). During this process, which is conserved among all 
vertebrates, the original anterior-posterior polarity of the linear heart tube is 
converted into a left-right asymmetry, the first manifestation of this in the developing
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embryo. This ensures that the presumptive chambers are aligned with the 
presumptive great vessels of the heart. During looping, the linear heart tube detaches 
from the dorsal mesocardium and substantially elongates via the contribution of cells 
from the SHF (Kelly and Buckingham, 2002; Zaffran et al., 2004). The process of 
murine heart tube looping is summarised in Figure 1.9.
Cardiac looping may be driven by asymmetric expression of extracellular 
matrix (ECM) molecules, for example Flectin, that differentially modulate the rate of 
cardiomyocyte migration (Tsuda et al., 1996; Linask et al., 2002). Otherwise the 
process may rely on shear forces of blood flow (Hove et al., 2003), and/ or the 
external forces of surface tension imposed by other embryonic or extra-embryonic 
structures (Voronov, 2004). Ultimately, the looping process creates a structure with a 
single ventricle, which has an inflow and an outflow region that connect to a single 
atrium via the atrioventricular canal (AVC) and the outflow tract respectively. 
Abnormalities in cardiac looping can cause defective OFT alignment, resulting in the 
aorta and the pulmonary artery arising from the right ventricle (double outlet right 
ventricle (DORV); reviewed by Risebro and Riley, 2006).
Early cell fate analyses in the mouse suggested that the linear and early- 
looping heart tube is patterned molecularly along the anterior-to-posterior (A/P) axis 
into the presumptive segments of the heart (Yutzey et al., 1995). However, the recent 
discovery of the SHF has led to the conclusion that the linear heart tube mainly 
contributes to the LV (Kelly and Buckingham, 2002; Zaffran et al., 2004). Moreover, 
this early model has been succeeded by the ‘ballooning model’ of chamber 
development (Christoffels et al., 2000). This is based on extensive gene expression 
studies and proposes that chamber formation occurs in two steps. The first step 
involves the formation of the linear heart tube, composed of ‘primary’ myocardium. 
This has molecular polarity along the anterior-to-posterior and dorsal-to-ventral axes. 
This is followed by the specification of ‘secondary’ (working, chamber) myocardium 
at the ventral surface of the heart tube, which has a distinct molecular profile to that 
o f the primary myocardium. As the heart tube loops, cells of the outer curvature of 
the primitive chambers proliferate and so ‘balloon’ out from the heart tube to 
generate the four chambers of the heart. Genes are activated in the outer curvature 
demarcating the future working myocardium of the atria and ventricles including
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Nppa, Chisel and Connexin 40 (Cx40). The myocardium o f the inner curvature, 
inflow tract, atrioventricular canal and OFT retains the gene expression profile it 
exhibited in the linear heart tube and thus remains as primary myocardium 
(Christoffels et al., 2000).
Notably, the myocardium o f the OFT, derived from the SHF, also receives a 
significant contribution from the cardiac neural crest during cardiac looping. This is 
also true o f the aortic arch arteries and the interventricular septum. The cardiac neural 
crest population arises from rhombomeres 6-8, and migrates through pharyngeal 
arches 3, 4 and 6 (reviewed by Kirby and Waldo, 1995; Srivastava et al., 1997; 
Waldo et al., 1999; Waldo et al., 2005). As such, ablating the cardiac neural crest in 
chicks causes cardiac defects, particularly affecting the OFT, as well as aortic arch 
anomalies (Kirby and Waldo, 1995).
El 2.5
Figure 1.9. Overview of murine cardiac morphogenesis.
Vertebrate cardiac morphogenesis begins when the primary heart field (PHF) progenitors are specified 
in the lateral plate mesoderm at E7.5, in the so-called cardiac crescent (purple). The second cardiac 
lineage (blue) is located in the splanchnic mesoderm, in the so-called secondary heart field (SHF) (a). 
The PHF progenitors migrate and fuse at the ventral midline o f the embryo, forming the linear heart 
tube at E8.0 (b). Between E8.5-10.5 the linear heart tube undergoes rightward cardiac looping and the 
SHF progenitors migrate to this structure and contribute to the arterial and venous poles (c). All 
regions o f the heart tube are colonised by progenitors from both fields with the exceptions o f the LV 
(derived entirely from PHF) and the OFT (derived entirely from SHF). Following cardiac looping, the 
heart undergoes maturation and the chambers septate, forming the mature four-chambered organ by 
E12.5 (d; adapted from Risebro and Riley, 2006).
LA: left atrium, RA: right atrium, LV: left ventricle, RV: right ventricle, OFT: outflow tract, A: atria.
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Following murine heart tube looping and the expansion of the chambers, 
namely beyond E l2.5, there is a requirement for heart remodeling and separation of 
the chambers to ensure uni-directional blood flow. The murine heart assumes its four- 
chambered structure coincident with the formation of endocardial cushions, the 
precursors of the cardiac valves and the membranous septae (reviewed by Eisenberg 
and Markwald, 1995). This occurs at two regions of the heart tube, namely at the 
position of the atrioventricular canal (AVC) and outflow tract (OFT). In parallel with 
endocardial cushion formation, the ventricular myocardium grows out from the 
ventral surface of the heart tube. This results in the formation of finger-like 
projections of myocardium surrounded by endocardium, called trabeculae. These are 
thought to provide contractive force to the beating heart during murine 
embryogenesis (reviewed by Harvey, 1999). Thus the primitive ventricles exhibit 
dorso-ventral (DV) asymmetry: trabeculae only form at the outer curvature, the inner 
curvature remaining smooth-walled (Christoffels et al., 2000). Once chamber 
septation and valve formation commences, specialised cardiomyocytes congregate to 
form the nodes, the site of initiation of the electrical impulse for contraction, and the 
conduction system (reviewed by Olson and Srivastava, 1996). Table 1.3 summaries a 
selection of factors that regulate the process of murine cardiac morphogenesis.
1.3.1.3. Overview of human heart development
Heart development in humans is similar to that described in the mouse, both 
in terms of morphological changes and the relative time-points during development at 
which they occur (reviewed by Harvey, 1999). During human embryogenesis, the 
cardiogenic plate, the equivalent progenitor population to the murine PHF at E7.5, is 
specified at day 15. This population gives rise to two endocardial tubes on either side 
of the embryo. These fuse at the midline and form a linear, contractile heart tube by 
day 21 (equivalent to the E8.0 linear heart tube in mice). Next, the heart tube loops at 
around day 28 (E8.5-E9.5 in mice), and the atria separate before the ventricles, 
resulting temporarily in a three-chambered heart, similar to that observed in the frog. 
By day 50 the four chambers and the OFT have completely septated, and the valves 
and conduction system have been established. Despite the subtle differences during 
cardiac morphogenesis between the mouse and human, the transcription factors that 
regulate this process are largely comparable.
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Table 1.3. A selection of factors involved in murine cardiac morphogenesis.
Note that Handl is involved in multiple processes during murine cardiac morphogenesis. The factors listed are not exhaustive. Adapted from the 
review by Risebro and Riley (2006); references therein.
E Stage of cardiac morphogenesis__________________________ Factors
7.0 Specification of the PHF CPCs Bmp ligands, Fgf ligands, Wnt 11, Mesp 1
7.5-8.0 Migration and fusion of PHF CPCs at the embryonic midline to form 
the linear heart tube
Nkx2.5, Gata factors, Mef2, Myocardin, Tbx20, Foxp4
8.0-10.5 Cardiac looping Handl, Nodal, Pitx2
8.0-10.5 Specification of the SHF CPCs and their migration to the looping heart 
tube
Isll, Mef2c, Tbxl, FoxHl, Bmp ligands, Fgf8, FgflO
10.5-12.5 Ventricular chamber formation and expansion
LV formation and expansion Handl, Tbx5, Irx4
RV formation and expansion Hand2, Irx4
13.5 Septation Handl, Cited2
14.5 Valvulogenesis Handl, Smad6, TGFp, Notch
E: embryonic day, PHF: primary heart field, SHF: secondary heart field, LV: left ventricle, RV: right ventricle, CPC: cardiac precursor cell.
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1.3.2. Handl is essential for cardiac morphogenesis
A significant proportion of the murine cardiovascular system is derived from 
lateral plate mesoderm and cardiac neural crest, and Handl is strongly expressed in 
both lineages. The Hand proteins of all species play highly-conserved roles in cardiac 
morphogenesis, with an emphasis on regulating differentiation of CPC into 
cardiomyocytes rather than the initial specification of CPCs (reviewed by Firulli, 
2003).
I.3.2.I. Hand/ Handl cardiac expression and role(s) in non- 
mammalian cardiac morphogenesis
Invertebrates and fish possess only a single Hand gene. C. elegans has a gene 
with homology to Handl, hnd-1, which is initially broadly expressed in the 
mesodermal precursors that generate striated muscles, but subsequently becomes 
restricted to the somatic gonadal precursor (SGP) cells (Mathies et al., 2003). Thus 
hnd-1 may have roles in both myogenesis and gonadogenesis. Ciona intestinalis is 
also thought to possess a Hand gene, which is expressed in its primitive heart, but its 
precise roles during development are unknown (Davidson and Levine, 2003).
The oldest definitive version of a Hand gene is present in Drosophila. 
Drosophila Hand, which is equally divergent from mammalian Handl and Hand2, is 
expressed in both cardioblast and pericardial cells of the developing dorsal vessel, the 
fly equivalent of the vertebrate heart (Kolsch and Paululat, 2002; Han et al., 2006). 
This is unusual as all other cardiac-specific transcription factors in Drosophila are 
expressed in only one of these cell types. This suggests that Drosophila Hand may be 
a master regulator of heart-specific genes (Kolsch and Paululat, 2002). However, 
expression of Drosophila Hand is initiated after that of the early regulators Tinman 
and Bagpipe (Yelon et al., 2000), which implicates Drosophila Hand in the 
subsequent differentiation of dorsal vessel cell types rather than in their initial 
specification. A more recent study suggested that Drosophila Hand is also involved 
in haematopoiesis, as disruption of Hand by homologous recombination results in a 
deficiency o f pericardial and lymph gland haematopoietic cells (Han et al., 2006).
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This phenotype is accompanied by profound cardiac defects, including hypoplastic 
myocardium, a deficiency of pericardial cells and abnormal cardiac morphology.
In zebrafish, which possess a primitive heart composed of a single atrium and 
a single ventricle, mutation of the single Hand gene (han) results in the formation of 
the hands o ff mutant (Angelo et al., 2000; Yelon et al., 2000). In addition to 
deformations of the pectoral fin, the hands o ff phenotype is characterised by an 
ablation of the single ventricular chamber. This is caused by impaired CPC 
specification and an inability to form a linear heart tube. Moreover, there is a marked 
lack of ventricular myosin heavy chain and tbx5 expression in these mutants, which 
results in the primitive heart tissue being molecularly of atrial identity (Angelo et al., 
2000; Yelon et al., 2000). Thus pre-cardiac, Nkx2.5-expressing lateral plate 
mesoderm is specified to the cardiac lineage but continued differentiation and 
development is impaired. Notably the primordial han gene in zebrafish is most 
closely-related to higher vertebrate Hand2, suggesting that there is no Handl gene in 
fish and that Hand2 is the ancestral member of the Hand gene family (reviewed by 
Firulli, 2003).
In Xenopus, which possesses a three-chambered heart with two atria and a 
single ventricle, both Handl and Hand2 exist. However, there has until recently been 
some controversy regarding the cardiac expression pattern of Xenopus Handl. 
Sparrow and colleagues concluded that Handl expression in the primitive heart tube 
is asymmetric, at least in the lateral plate mesoderm, exhibiting randomness as to its 
expression on the left or right side (Sparrow et al., 1998). In the myocardium and 
pericardium, transcripts are also asymmetrically distributed, but in these tissues they 
are specifically restricted to the left side. Moreover, the authors could not detect 
Handl expression in the neural crest-derived pharyngeal (branchial) arches. 
However, a later study showed a uniformly-symmetric expression of H andl, that is, 
without left-right asymmetry, throughout all tissues of the developing heart (Angelo 
et al., 2000). Furthermore, these authors were able to detect Handl transcripts in the 
pharyngeal arches.
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A subsequent study employed three-dimensional reconstruction techniques to 
derive accurate models from digital images of serial histological sections to analyse 
the morphological changes that accompany heart formation in Xenopus in more detail 
(Mohun et al., 2000). These revealed that Handl expression is dynamic in the 
Xenopus myocardium during cardiac morphogenesis. Specifically, Handl transcripts 
are initially restricted to the left side of the linear heart tube myocardium but become 
more symmetrical just before the onset of heart tube looping. After the onset of 
looping, Handl expression localises to the ventral portion of the myocardium that
will develop into the single Xenopus ventricle (Mohun et al., 2000). To date,
however, functional insight into the Xenopus Hand proteins in the developing heart is 
lacking.
Chick Handl is co-expressed with Hand2 throughout the heart tube
(Srivastava et al., 1995; Srivastava et al., 1997). Handl transcripts in the chick are 
first detected at HH stage 8 in the cardiac crescent, and in the paired heart primordia 
as they fuse at HH stage 9. Handl is expressed throughout the cardiac tube and the 
inflow region at HH stage 10. At HH stage 15, after cardiac looping, Handl is 
expressed in the atria, the future LV, bulbus cordis, truncus arteriosus and throughout 
the branchial arches (Srivastava et al., 1995; Srivastava et al., 1997).
Antisense experiments first implied a role for Handl in chick heart
development (Srivastava et al., 1995). Hamburger and Hamilton (HH) stage 8 chick 
embryos were treated with antisense oligonucleotides specific to Handl and Hand2 
transcripts, both singly and in combination, to knock-down their expression during 
development. Applied alone, the antisense oligonucleotides had no effect on cardiac 
development. However, in combination they arrested cardiac morphogenesis at the 
cardiac looping stage (stage 11-12). This has led to speculation that the Hand genes 
may be functionally-redundant, as discussed further in this chapter (section 1.5). Like 
frog Handl, however, little is known at present regarding the function of chick Handl 
during cardiac morphogenesis.
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1.3.2.2. Handl cardiac expression and role(s) in mammalian cardiac 
morphogenesis
Handl expression and function during mammalian cardiac morphogenesis has 
been chiefly studied in the mouse (Figure 1.10). Cardiac expression of murine Handl 
is first detected throughout the PHF at E7.0 (Firulli et al., 1998; Riley et al., 1998). 
Previous studies suggested that, at the onset of heart tube looping, Handl is 
expressed at the anterior and posterior termini of the linear heart tube (Yutzey et al., 
1995; Biben and Harvey, 1997; Srivastava et al., 1999). Early studies also reported 
symmetrical Handl expression along the left-right axis of the heart tube during 
looping (Thomas et al., 1998b). However, both conclusions are now considered 
incorrect.
More detailed analyses have revealed that by E9.5 and after cardiac looping, 
Handl expression is actually confined to the left side of the linear heart tube 
myocardium (Biben and Harvey, 1997). Subsequently, after cardiac looping, Handl 
transcripts are distributed heterogeneously along the dorso-ventral (DV) axis. Handl 
is expressed strongly in the outer (ventral) curvature of the LV, and weakly in the 
outer curvature of the RV and the cardiac neural crest cells-derived of the developing 
OFT (Riley et al., 2000; Figure 1.10a). Handl expression is, however, absent from 
the atria and the inner (dorsal) curvature of all structures. Thus Handl is uniquely 
expressed in derivatives of both the PHF (LV) and the SHF (OFT). During 
subsequent cardiac morphogenesis, Handl expression remains high in these regions 
of the developing heart until E l0.5, after which it declines. At El 1.5 Handl is still 
expressed in the OFT and by E l3.5 expression becomes restricted to the sites of the 
developing valves (Cserjesi et al., 1995).
The generation of mice lacking Handl identified a role for the transcription 
factor in the formation of extra-embryonic structures (Firulli et al., 1998; Riley et al., 
1998). However, the early embryonic lethality of these embryos originally precluded 
analysis of Handl function in the embryo proper. Thus to prove that the early 
developmental arrest of Handl-null mutants was caused by abnormal placentation,
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and to investigate embryonic roles for Handl, tetraploid-rescue was performed (Riley 
et al., 1998). Aggregation chimeras were generated from Handl mutant and 
tetraploid morulae. This meant that the resulting embryo was derived from diploid 
Handl mutant cells, whilst the extra-embryonic tissues were derived from wild-type 
tetraploid cells. Thus, if early lethality was primarily due to extra-embryonic defects, 
the embryo would be rescued and would develop further, allowing analysis of Handl 
function in the embryo proper.
Tetraploid-rescued Handl-null mouse embryos arrest at around E l0.0 and are 
embryonic lethal by E10.5 (Riley et al., 1998). Specifically, the Handl-null embryo 
possesses an un-looped, un-segmented heart tube and a malformed OFT and LV 
(Figure 1.10b). These phenotypes suggest that Handl may have a crucial role in the 
regulation of cardiac looping. This model is supported by the observation that Handl 
is expressed in the outer curvature of the LV, the leading edge of the looping heart 
tube (Biben and Harvey, 1997; Sparrow et al., 1998) and by the fact that Handl is 
down-regulated in Nkx2.5-null embryos, which also fail to undergo rightward looping 
(Biben and Harvey, 1997; Tanaka et al., 1999).
However a putative role for Handl in the regulation of cardiac looping cannot 
account for the fact that cardiac looping is initiated, albeit not completed, in 
tetraploid-rescued Handl -null mice (Riley et al., 1998). Furthermore it is not wholly 
compatible with the phenotype of situs inversus (inv/inv) mice, whose left-right heart 
asymmetry is reversed due to an atypical leftward looping. In these mice, expression 
of Handl persists in the LV and that of Hand2 in the RV, albeit in reversed 
anatomical locations (Thomas et al., 1998b). This suggests that Handl expression is 
chamber- rather than side-specific. Moreover it indicates that the Hand genes are 
involved in the development of segments of the heart tube, rather than controlling the 
direction of cardiac looping. Indeed, Handl-mx\\ embryos undergo defective LV 
morphogenesis, manifesting as a LV with a thin LV wall and a lack of myocardial 
trabeculation (Riley et al., 1998), whilst Hand2-null embryos have a hypoplastic RV 
(Srivastava et al., 1997). Thus debate has surrounded whether Handl is involved in 
regulating cardiac looping as a primary function that affects ventricular
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morphogenesis, or whether the role o f Handl is restricted to ventricle specification 
and maturation coincident with looping.
a.
Figure 1.10. Handl is expressed in the developing mouse heart and is essential for 
murine cardiac morphogenesis.
At E9.5, subsequent to cardiac looping, Handl expression in the developing mouse heart becomes 
restricted to the outer curvature o f the left ventricle (Iv) and the outflow tract (oft). At this stage, 
Handl is also expressed in the lateral plate mesoderm (1pm) and at the midline region o f the first 
branchial (pharyngeal) arch (ba) (a; Handl in situ hybridisation of E9.5 wild-type embryo courtesy of 
C. Risebro). Tetraploid-rescued Handl-null embryos are embryonic lethal at E l0.5 due to defects in 
cardiac looping and left ventricular morphogenesis (b; adapted from Riley et al., 1998).
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Despite the apparent defects in left ventricular myocardium in Handl-null 
hearts, cardiomyocyte commitment and differentiation can occur in the absence of 
Handl. The expression of cardiomyocyte marker genes, for example Nkx2.5, are 
normal in homozygous Handl mutant mice (Riley et al., 1998). Furthermore Handl - 
null embryonic stem cells are able to differentiate normally into cardiomyocytes that 
express cardiac-specific transcripts in vitro even after the time point (approximately 
day 6) at which Handl is normally activated (Riley et al., 2000; Smart et al., 2002; 
Risebro et al., 2006). However, it was noted that Handl -null ES cells generated more 
cardiomyocytes than the wild-type R1 ES cell line, suggesting that Handl may 
modulate the rate of cardiomyocyte differentiation (Riley et al., 2000).
Notably, at least one gene, myosin light chain-2 ventricular isoform (.Mlc2v), 
was shown by in situ hybridisation to be down-regulated in the LV myocardium of 
Handl -null embryos (Riley et al., 1998). Mlc2v encodes a protein required for 
ventricular cardiomyocyte differentiation and its putative regulation by Handl 
implicates the transcription factor in the specification and/ or differentiation of left 
ventricular myocardium. Despite this, cardiomyocytes derived from Handl-null ES 
cells form normally and express Mlc2v, albeit at reduced levels (Riley et al., 2000). 
Thus the thin ventricular wall and down-regulation of Mlc2v in the tetraploid-rescued 
Handl-null embryos may be secondary effects and Handl may not be required for 
specification of the LV.
To gain further insight into the role of Handl during heart development, Riley 
and co-workers generated chimeric embryos by aggregating Handl-null ES cells with 
ROSA26 embryos (Riley et aL, 2000). ROSA26 embryos ubiquitously express lacZ 
and so can be visualised by staining for p-galactosidase to assess cell contribution. 
Low-contribution chimeras, composed of 50% Handl-null ES cells or less, were able 
to develop normally. However, in E8.0 chimeras derived from >50% Handl -null ES 
cells, a non-random distribution of cells in the developing heart was observed. 
Specifically, Handl -null cells were under-represented in the caudal region of the 
linear heart tube, fated to become the LV. This may occur because Handl-null cells 
that initially colonised these regions failed to proliferate or underwent apoptosis. By
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E9.5, after cardiac looping, mutant cells were under-represented in the outer 
curvature of the myocardium of the LV and the OFT. Accordingly such embryos at 
E l0.5 were smaller than their littermates and their heart tubes were abnormal, 
possessing a thin, transparent wall. These chimera studies thus collectively indicate a 
cell-autonomous requirement for Handl in the expansion of the outer curvature of the 
LV during cardiac looping (Riley et al., 2000). The described studies have implicated 
Handl in LV specification and outer curvature expansion coincident with cardiac 
looping. More recent functional studies have revealed a role for Handl in the 
formation of the interventricular septum (IVS), the atrioventricular (AV) valves and 
the outflow tract (OFT).
In a study by Togi and colleagues, the Handl cDNA was targeted to the 
Mlc2v locus to force its constitutive expression in both its native left ventricular 
myocardium, but also the right ventricular myocardium (Togi et al., 2004). Handl 
over-expression was also detected in the intervening region that forms the 
interventricular septum (IVS). The outer curvatures of the LV and RV, known as the 
interventricular boundary region or interventricular groove (IVG), does not expand 
during the formation of the muscular I VS during normal cardiac morphogenesis. In 
contrast, over-expression of Handl throughout the ventricular myocardium and in 
septal cardiomyocytes resulted in hyper-expansion of the outer curvatures of both 
ventricles. This generated a single, expanded ventricle and was associated with an 
absence of the IVS, resulting in embryonic lethality between El 2.5 and E l 4.5.
In order to exclude the possibility that the septal defect was a secondary or 
non-specific effect, the same authors also generated transgenic embryos that over­
expressed Handl in the ventricles alone (Togi et al., 2004). This ensured that Handl 
expression was absent from the boundary region between the ventricles. In these 
transgenic embryos, the IVS formed normally. These results thus suggested that 
Handl plays an important role in defining the ventricular boundary and that an 
absence of Handl expression in the IVG may be critical for the proper positioning 
and formation of the IVS. This is interesting in light of the finding that over­
expression of the Tbx5 transcription factor in both ventricles, which promotes ectopic
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Handl expression in the RV and IVG, results in failed IVS morphogenesis (Takeuchi 
et al., 2003).
McFadden and colleagues more recently generated conditional, heart-specific 
Handl-null (Handl cardiacK0/K0) embryos. The authors generated mice harbouring a 
Handl allele flanked by Cre recombinase loxP recognition sites. They then crossed 
these with mice harbouring Cre recombinase downstream of a cardiac-specific alpha- 
myosin heavy chain (ccMHC) promoter or Nkx2.5 enhancer. The embryos thus 
specifically lacked Handl expression in cardiac tissues. Although viable until birth, 
these embryos exhibited a spectrum of heart defects. These included left ventricular 
hypoplasia, abnormally-thickened atrioventricular (AV) valves, and ventricular septal 
defects (VSDs). Of particular note, these mice had a disorganised but thickened 
ventricular septum at all stages of development. This supports the findings of Togi 
and colleagues, who suggested that the absence of Handl in the IVG is a pre-requisite 
for normal growth and/ or positioning of the IVS. Thus whilst over-expression of 
Handl abolishes septum formation (Togi et al., 2004), cardiac deletion of Handl 
causes an expansion of the septum (McFadden et al., 2005). These studies also 
support previous findings that implicate Handl in (left) ventricular expansion (Riley 
et al., 1998; Riley et al., 2000).
The AV valve malformations of conditional, cardiac Handl-null mutant mice 
are interesting because the alpha-MHC.Cre transgene does not direct Cre expression 
in endocardial cushions or their valve derivatives. This suggests that Handl may 
regulate an unidentified myocardium-derived signal that regulates endocardial 
cushion morphogenesis. However, early myocardial function has been shown to 
affect endocardial cushion development (Bartman et al., 2004), and therefore 
abnormal myocardial differentiation in these embryos could have an effect on 
endocardial cushion development. Previous studies have also shown that regions of 
the AV endocardial cushions contribute to both the atrial and ventricular septa 
(Bartram et al., 2001). This in interesting in light of the VSDs in Handl-mill hearts, 
present in 90% of the embryos (McFadden et al., 2005). However, comparison of cell 
proliferation rates and apoptosis levels between wild-type and mutant endocardial
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cushions revealed no significant differences.
OFT defects were observed in some of the conditional Handl knock-out mice 
at postnatal day 1-2 (McFadden et al., 2005). In this regard, a role for Handl in OFT 
morphogenesis has been implied by the findings of a more recent study (Risebro et 
al., 2006). Using homologous recombination in ES cells, Risebro and colleagues 
inserted the Tet-Off trans-activator (tTA), responsive to the antibiotic tetracycline 
(Tet), into the Handl locus, under the control of the Handl promoter and regulatory 
regions. Mice derived from these cells, the tTA knock-in strain, were termed 
‘drivers’, and these were crossed with ‘responder’ mice. In the responder mice, a 
tetracycline-responsive region was placed upstream of a full-length Handl cDNA 
and randomly inserted into ES cells to establish mice harbouring a Tet-responsive 
Handl transgene. Manipulation of Handl expression during gestation with the Tet 
derivative doxycyline allowed the authors to force over-expression of Handl in its 
‘native’ (Handl-expressing) tissues during embryogenesis.
In embryos over-expressing Handl, the heart tube was significantly extended 
and underwent extraneous rightward looping. The ultimate effect of this was that the 
distal OFT became significantly expanded in length (Risebro et al., 2006). The 
observed OFT expansion was not due to an enhanced migration of CPCs from the 
SHF, indicated by the normal expression of the SHF markers Isll, Mef2c and Hand2 
in Handl -over-expressing embryos. However, RT-PCR and in situ hybridisation data 
demonstrated down-regulation of several markers of cardiomyocyte differentiation in 
the OFT. These included Nppa, W ntll, Chisel, Nkx2.5 and Gata4. This was 
accompanied by an enhanced rate of cell proliferation, as assessed by enhanced levels 
o f phospho-histone H3. Additionally, markers of cardiomyocyte differentiation were 
also down-regulated in the left ventricular myocardium of Handl gain-of-function 
embryos. This was accompanied in many embryos by defective expansion of the 
developing LV. The authors suggested on the basis of this cardiac phenotype that 
Handl has a cell-autonomous role in promoting CPC proliferation during heart 
development.
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In light of the findings of this study, it is likely that Handl promotes SHF 
CPC proliferation prior to their commitment to differentiate into cardiomyocytes at 
the site of the developing OFT. Thus in Handl -over-expressing hearts, CPCs are 
unable to differentiate into cardiomyocytes at the time that Handl would normally be 
down-regulated, resulting in significant CPC hyperplasia in the distal OFT 
myocardium. The thin-walled LV in Handl-over-expressing embryos may similarly 
be explained by CPC hyperplasia. Hyper-proliferation of CPCs may prevent the outer 
curvature of the LV from expanding and ballooning ventrally as secondary 
myocardium in accordance with the ballooning model to produce the LV chamber 
(Christoffels et al., 2000). This is supported by the fact that the LV myocardium of 
Handl-over-expressing hearts is down-regulated for markers of secondary 
myocardium, for example Nppa and Chisel, which is suggestive of failed secondary 
myocardium differentiation (Risebro et al., 2006). These findings agree with the 
Handl loss-of-function studies. They are consistent with the left ventricular 
hypoplasia and a shortening of the OFT observed in the conditional, heart-specific 
Handl mutant embryos (McFadden et al., 2005), and may suggest that the 
hypoplastic OFT and a thin-walled LV of Handl -null tetraploid-rescued embryos are 
underpinned by deficiencies in CPC proliferation (Riley et al., 1998).
Whilst Handl over-expression in the developing heart promotes CPC 
proliferation, it is unclear how Handl regulates this activity per se. One possibility is 
via transcriptional modulation of the genes encoding the cell cycle regulators Cyclin 
D2 and Cdk4, suggested by their up-regulation in the gain-of-function embryos and 
embryoid bodies, but their down-regulation in Handl-null embryoid bodies (Risebro 
et al., 2006). Although it is unclear whether Handl directly activates the Cyclin D2 
and Cdk4 genes, adult transgenic mice over-expressing Cyclin D2 in the myocardium 
show enhanced cardiomyocyte proliferation (Pasumarthi and Field, 2002) and Cyclin 
D2 represses cell hypertrophy by enhancing proliferation (Busk et al., 2005).
Further insights into the role of Handl during murine cardiac morphogenesis 
have been made possible by the identification of some of its target genes. An isolated 
study suggested that Handl, in combination with Hand2, regulates cardiac expression 
of the gene encoding the striated muscle-specific metabolic enzyme adenylosuccinate
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synthetase 1 (Adssl) (Lewis et al., 1999). Handl is also thought to activate the Nppa 
gene, which encodes the Atrial Natriuretic Factor/ Peptide (ANF/ ANP). Cardiac- 
specific Handl -null mice have a reduced level of Nppa transcripts in the LV 
(McFadden et al., 2005), whilst ectopic expression of Handl in the RV was sufficient 
to mis-express Nppa expression in this region (Togi et al., 2004). Furthermore, 
Handl regulates the expression of Nppa in transfection assays in vitro, likely through 
a mechanism reliant on its interaction with other cardiac-specific transcription factors 
such as Mef2 (Morin et al., 2005).
As described, Handl has been implicated in the migration of cardiomyocyte 
and neural crest populations during cardiac looping and OFT morphogenesis (Riley et 
al., 2000). Another study employing representational differential analysis (RDA), 
which compared RNA species from in vzYro-differentiated wild-type and Handl -null 
ES cells, appropriately implicated cohorts of Handl target genes in cell movement 
and migration (Smart et al., 2002). In Handl-null EBs, Thymosin {14 (T/34), which 
encodes a protein involved in actin-based cell motility (Smart et al., 2007), was 
significantly down-regulated. Conversely, Cystatin C, which encodes a cysteine 
protease inhibitor involved in ECM degradation and remodelling (Afonso et al., 
1997) was up-regulated. This was also true of a-cardiac actin, which encodes a 
component of the cardiomyocyte cytoskeleton (Arber et al., 1997). Using whole- 
mount in situ hybridisation, all three analysed genes were moreover shown to be 
temporally- and spatially-co-expressed with Handl in the LV and OFT of wild-type 
embryos and mis-expressed in Handl-null mutant hearts. Additionally Wave3, a 
member of the WASP family that functions downstream of the Rac GTPase during 
cell migration, is up-regulated in a Handl -null background (P. Riley, unpublished 
data). In addition to the genes involved in cell migration, the RDA screen identified 
various others, including several involved in cell cycle regulation (a selection of these 
genes is listed in Table 1.4). Nevertheless it remains to be determined whether Handl 
directly or indirectly regulates these genes.
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Table 1.4. A selection of putative cardiac target genes of Handl, up-regulated (a) 
or down-regulated (b) in a H andl-null background. Adapted from Smart et al., 
2002; references therein.
Gene Function of Encoded Protein
(a) Genes up-regulated in a Handl-null background
Cystatin C Cysteine protease inhibitor/ECM remodelling
Cyclin D2 G1 phase cyclin
Wnt2 Placentation
a-cardiac actin Component of cardiac sarcomere
HMGP2 Oct2 interactor
(b) Genes down-regulated in a Handl-null background
Thymosin P4 Regulates actin polymerisation/ cell motility
Fibronectin Extracellular matrix (ECM) component
Lim kinase 1 Actin assembly
Wave3 Negative regulator of Ras neuroblast proliferation/ cell cycle control
TifI3 Transcriptional co-repressor
Circumstantial evidence also implicates other genes as Handl targets. The 
expression domain of Handl in the developing mouse heart overlaps with that of the 
transcriptional co-activator Citedl and its expression is down-regulated in the hearts 
of conditional Handl-null embryos (Dunwoodie et al., 1998; McFadden et al., 2005). 
Additionally, the myocardial marker Chisel is up-regulated upon Handl over­
expression in the ventricular myocardium (Togi et al., 2004). This is also true of 
Cx40, whose expression is also reduced in Handl cardiacKO/KO embryos (McFadden 
et al., 2005). Another putative Handl target is endothelin-1 (ET-1) (Morin et al.,
2005), which has also been implicated in the regulation of Handl expression (Ivey et 
al., 2003), suggesting that these factors operate in an auto-regulatory feedback loop. 
Notably, despite the up-regulation of Hand2 in a Handl-null background (Morikawa
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and Cserjesi, 2004), and its down-regulation upon Handl over-expression in the RV 
(Togi et al., 2004), it is unlikely that Handl and Hand2 regulate each other’s activity, 
consistent with their non-overlapping respective domains of expression (Cserjesi et 
al., 1995; Srivastava et al., 1995).
1.3.3. Roles of Handl in the adult heart
Handl expression was previously undetected in the adult mouse heart 
(Cserjesi et al., 1995; Srivastava et al., 1995). However, more recent studies 
identified Handl transcripts in adult rodent and human ventricles, but not the atria 
(Natarajan et al., 2001; Thattaliyath et al., 2002). Moreover experiments in adult 
rodent hearts showed that following cardiac hypertrophy induced by pharmacological 
(phenylephrine treatment) and surgical (aortic constriction) manipulation, Handl and 
Hand2 expression were down-regulated in the LV and RV respectively (Thattaliyath 
et al., 2002). This is in agreement with a previous study, which demonstrated a down- 
regulation of HAND1, but not HAND2, in the hearts of human patients suffering 
pathological ischemic or dilated cardiomyopathy (Natarajan et al., 2001).
Supporting these observations, mouse hearts lacking cardiac lineage protein-1 
(Clp-1), which exhibit a fetal form of cardiac hypertrophy characterised by a reduced 
left ventricular chamber with thickened myocardial walls, are down-regulated for 
Handl (Huang et al., 2004). Furthermore, Irx4-null mice, which have reduced Handl 
expression in the developing LV, are prone to adult-onset, left ventricular 
hypertrophy (Bruneau et al., 2001). Finally, some evidence implicates the Handl 
interactor Fhl2 in modulating the hypertrophic response in the heart (Kong et al., 
2001). Thus Handl appears to inhibit cardiac hypertrophy in both the adult human 
and rodent hearts. As such, the down-regulation of Handl expression in rodent 
hypertrophy and human cardiomyopathy may allow cardiomyocytes to reinitiate the 
fetal gene program and thus promote physiological changes that allow the heart to 
respond to genetic insult or environmental stresses by undergoing hypertrophy.
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1.4. The role of Handl in other developing tissues
Handl is expressed during the development of murine lineages that receive a 
significant contribution from the neural crest population. Notably Handl transcripts 
are not detectable in the developing or migrating neural crest cells, arguing against a 
role for the transcription factor in the formation or migration of these cells. However, 
Handl expression is up-regulated by the time such cells have populated the 
pharyngeal arches and aortic arch arteries, suggesting a role in neural crest cell 
differentiation (Firulli et al., 1998; Thomas et al., 1998b).
At E l0.5 Handl transcripts and/ or promoter activity are detectable in the 
precursors of the sympathetic trunk ganglia, whilst by El 1.5 expression is up- 
regulated in lateral mesoderm derivatives, namely the first pharyngeal arch and the 
developing mid- and hindgut (Cserjesi et al., 1995; Firulli et al., 1998). At mid­
gestation Handl is also expressed in the forebrain, the septal region of the tongue bud 
and the mandible (Cserjesi et al., 1995; Hollenberg et al., 1995). Riley and colleagues 
confirmed these findings by identifying regions of the embryo, in addition to the left 
ventricular myocardium, from which Handl -null ES cells are excluded (Riley et al., 
2000). This study identified a requirement for Handl in the branchial arches and 
dorsal root ganglia, both of which are in part neural crest-derived, and in several 
mesoderm-derived structures such as the limb bud and gut.
1.4.1. Handl is required for limb morphogenesis
Whilst Hand2 activates Sonic hedgehog (Shh) as an essential step during the 
formation of the zone of polarising activity (ZPA) (Charite et al., 2000), little is 
known about the precise role of Handl during limb morphogenesis. Early studies 
demonstrated low Handl levels in the mouse limb buds at E l0.5 (Cserjesi et al., 
1995). Thattaliyath and colleagues showed later that mis-expression of either Handl 
or Hand2 in the developing limb bud in transgenic mice induces ectopic digits, and 
that this activity is dependent exclusively on the HLH region (Thattaliyath et al., 
2002).
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Fernandez-Teran and co-workers more recently demonstrated that Handl 
expression, initially detectable in the ventral mesoderm of the developing chick limb 
(Hamilton and Hamburger stages 17-20), becomes restricted to a more antero-ventral 
population of mesoderm cells and later to the ventral portions of the digits 
(Fernandez-Teran et al., 2003). Importantly, a re-specification of the anterior 
mesoderm in the developing chick limb, in response to Shh or retinoic acid 
application, leads to a down-regulation of Handl expression. Conversely, over­
expression of Handl in a low percentage of cases results in duplications of digit 2. 
The pattern of Handl expression in two chick mutants further supports its association 
with the anterior identity of the mesoderm (Fernandez-Teran et al., 2003). The limbs 
of the talpid-2 (ta2) mutant, which have a constitutively-active Shh pathway that 
results in all the limb mesoderm being posteriorised, do not express detectable levels 
of Handl. Conversely, the oligozeugodactyly (ozd) chick mutant, which lacks limb- 
specific Shh activity, is accordingly up-regulated for Handl. However, at present, the 
precise function(s) of Handl during limb development are unclear.
1.4.2. Handl is involved in gut formation
The expression of Handl in the gut is conserved between organisms, although 
the specific cells in which it is expressed varies. The Drosophila Hand gene is 
expressed in circular visceral midgut muscle progenitors (Kolsch and Paululat, 2002), 
whilst in the chick transcripts encoding Handl are observed only within the cells 
forming the epithelial lining of the small intestine and colon (Wu and Howard, 2002). 
This is the first description of Hand gene expression in an endoderm-derived tissue.
In the mouse, Handl expression is restricted to smooth muscle cells of the 
embryonic gut and persists in the adult mouse intestine (Cserjesi et al., 1995; 
Hollenberg et al., 1995). A later study suggested that different lineages of cells in the 
developing mouse gut express Handl and Hand2. Whilst Hand2 is required for the 
neuronal differentiation of neural crest cells, Handl expression is limited to 
mesodermal gut derivatives (D’Autreaux et al., 2007). To date, neither the role of 
Handl during gut morphogenesis, nor in the adult gut, is understood.
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1.4.3. Handl is required for the formation of the autonomic 
nervous system
Drosophila Hand is expressed in the developing central nervous system, but 
its role during this process is largely unknown (Kolsch and Paululat, 2002). In the 
chick, Handl plays a role in the development of the autonomic nervous system. 
Antisense knock-down of Handl transcripts revealed Handl involvement in the 
differentiation of avian neural crest-derived cells into sympathetic, catecholaminergic 
neurones in culture (Howard et al., 1999). This may be dependent on an interaction 
between Handl and the neurogenic bHLH factor Mashl (Bounpheng et al., 2000). 
The same factors also activate the catecholaminergic differentiation program in vivo 
and in cultured chick neural crest cells (Howard et al., 1999). However, the precise 
function(s) of Handl during the formation of the autonomic nervous system, and 
whether this role is conserved in mammals, are currently unclear.
1.4.4. Handl is required for craniofacial and tooth 
development
Barbosa and colleagues recently identified a role for Handl, in co-operation 
with Hand2, in the regulation of distal midline mesenchyme development (Barbosa et 
al., 2007). Handl is expressed in the distal (ventral) zone of the branchial arches 
(arches 1 and 2), an expression domain that partly overlaps with that of Hand2 and 
whose derivatives include the inter-dental mesenchyme and the distal symphysis of 
Meckel’s cartilage. The authors generated mice with neural crest-specific deletion of 
H andl, using Cre recombinase controlled by the neural crest cell-specific Wntl 
promoter, in combination with various Hand2 mutant alleles. Whilst the loss of 
Handl activity in neural crest cells had no phenotypic effect, concurrent Hand2 
deletion led to impaired growth of the distal midline mesenchyme of the first 
branchial arch. Secondary to the loss of distal midline mesenchyme, both the terminal 
differentiation of chondrocytes in Meckel’s cartilage symphysis and the membranous 
ossification of the mandible is aberrant, leading to impaired growth of the lower 
incisors. Interestingly, expression of the genes Msx2, Pax9 and Prx2 was down- 
regulated in the distal mesenchyme, implicating the Hand factors in their regulation.
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1.5. Functional redundancy of Hand genes
Several studies have suggested the existence of functional redundancy 
between the Hand factors, that is, an ability to compensate for each other. Functional 
redundancy was first inferred when knock-down of Handl and Hand2 using 
antisense oligonucleotides in combination, but not in isolation, was shown to disrupt 
heart development at the cardiac looping stage in chick embryos (Srivastava et al., 
1995). These antisense experiments suggested that the Hand factors play redundant 
roles in avian cardiac development.
However, uniform overlapping expression of the Hand genes applies only to 
the chick. The distinct and only partially-overlapping expression patterns of Handl 
and Hand2 in mice, and the complementary phenotypes of Handl-null and Hand2- 
null mice, suggest that the Hand factors have separate and independent roles in 
murine ventricular morphogenesis (Firulli et al., 1998; Riley et al., 1998). For 
example, Handl -null mice are characterised, in part, by defective LV morphogenesis, 
whilst loss of Hand2 results in the formation of a hypoplastic RV (Srivastava et al., 
1997). Related to this, Hand2 and Nkx2.5 synergistically regulate expression of Nppa 
in the RV, but this is not true of Handl and Nkx2.5, despite their ability to physically 
interact (Thattaliyath et al., 2002b). Other data also support the idea that Handl and 
Hand2 have non-overlapping roles during embryogenesis. For example, whilst Hand2 
is up-regulated in Handl-null yolk sacs, this attempted compensatory mechanism is 
ultimately insufficient as yolk sac defects persist (Morikawa and Cserjesi, 2004). In 
agreement with this, the yolk sac vasculature defects in Hand2-null mice are distinct 
from those seen in Handl -null mice (Srivastava et al., 1997; Firulli et al., 1998).
Nevertheless, evidence does exist to support the idea that Hand factors have 
overlapping functions in mice. The lethality of Drosophila Hand mutants can be 
rescued by the cardiac expression of a single human HAND gene (Han et al., 2006). 
The zebrafish hands o ff cardiac phenotype is caused by the loss of the han gene, 
which bears most similarity to mammalian Hand2. The hands o ff fish have cardia 
bifida, which is a is much more severe than the Hand2-null cardiac phenotype in the 
mouse (Srivastava et al., 1997; Angelo et al., 2000; Yelon et al., 2000). This suggests
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that in Hand2-null mutant mice, in which Handl and Hand2 cardiac expression 
domains partially overlap, Handl may somewhat compensate for the loss of Hand2. 
Since zebrafish possess only one Hand gene, no such compensation can occur, and 
the resultant phenotype is more severe (Yelon et al., 2000).
Studies in mouse models have also suggested the existence of functional 
redundancy between the Hand factors. For example, over-expression of the HLH 
domain of either Handl or Hand2 in the developing limb bud induces polydactyly 
(McFadden et al., 2002). Additionally, a more recent study showed that when Handl 
cardiac-specific knockout mice, which die of mild cardiac abnormalities at birth, are 
crossed into a //a«<72-heterozygous background, the resulting mutants have a more 
severe embryonic lethal phenotype (McFadden et al., 2005). Such mice are 
embryonic lethal at E l0.5 due to a thin and poorly-trabeculated left ventricular 
myocardium. Similarly, the removal of one Handl allele significantly exacerbated 
the Hand2-mi\\ phenotype, resulting in an earlier embryonic lethality. Furthermore, 
embryos lacking both Hand genes (HandlKO/KO (cardiac); Hand2KO/KO) displayed the 
most severe cardiac phenotype, an ablation of both ventricles, and were embryonic 
lethal at E9.0. The authors proposed that the absence of both Hand genes results in a 
loss of CPC specification at an early stage of cardiogenesis, similar in mechanism to 
that that is thought to underlie the lack of cardiomyocytes and failure of ventricular 
morphogenesis in the hands o ff zebrafish mutant, deficient for the sole Hand gene 
(Angelo et al., 2000; Yelon et al., 2000). Finally, a recent study showed that distal 
midline mesenchyme development was only impaired when both Handl and Hand2 
were deleted in the neural crest lineage (Barbosa et al., 2007). Given the Handl 
domain is completely included in the Hand2 domain in the branchial arches, this 
suggests that Hand2 activity compensates for the loss of Handl and that the Hand 
factors redundantly regulate the same sets of target genes in the pharyngeal arches.
In conclusion, in species with more than one Hand gene, the encoded Hand 
factors may function in a redundant fashion, but only to a degree. Some of their 
observed functional overlap may be due to their dimerisation with a common partner 
that confers a dominant function regardless of the Hand protein to which it is bound. 
Knock-in studies in which either Hand gene is replaced by the other and vice versa 
are required to confirm Hand factor functional redundancy in vivo.
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1.6. The rat choriocarcinoma-1 (Rcho-1) cell line
Gain- and loss-of-function studies have provided only limited insight into the 
specific role(s) of Handl during development. A better understanding of the 
mechanisms of Handl function and regulation could nevertheless provide insight into 
the underlying cellular causes of defective placentation and idiopathic CHD. Indeed, 
no mutations in the human Handl gene have been identified. This implicates Handl 
as an excellent candidate for mutations in cz's-acting sequences or defects in its 
upstream regulation that could lead to congenital heart or placental failure in humans.
Mechanisms regulating the developmental activity of Handl remain elusive 
and have been difficult to discern both in vitro and in vivo. In terms of cell culture 
experiments, there are no faithful models of cardiomyocytes. With respect to the in 
vivo lineages in which Handl is expressed, for example cardiomyocytes and primary 
TS cells, they are often difficult to maintain and manipulate in culture (S. Tanaka, 
personal communication). ES cells have previously been employed to investigate 
aspects of Handl regulation and function in vivo (Riley et al., 2000; Smart et al., 
2002; Risebro et al., 2006). Several studies suggest that the process of ES cell 
differentiation into EBs faithfully models cardiomyocyte differentiation in the 
developing heart (Maltsev et al., 1993; Doevendans et al., 2000; Fijnvandraat et al., 
2003). However, the percentage of ES cells that give rise to Handl -expressing 
cardiomyocytes can be very low and this can rule out their use in certain assays 
(reviewed by Boheler et al., 2002).
For these reasons, we employed a trophoblast cell model, the rat 
choriocarcinoma-1 (Rcho-1) cell line, to investigate the mechanistic bases of Handl 
post-translational regulation in vivo. These cells are easy to culture and faithfully 
mimic many aspects of primary TS cells in vitro, including an ability to undergo 
trophoblast giant (TG) cell differentiation (Hamlin et al., 1994; Sahgal et al., 2006). 
Most importantly for our study, Handl appears to be both necessary and sufficient 
for the process of Rcho-1 TG cell differentiation (Cross et al., 1995; Scott et al.,
2000). This made the use of the Rcho-1 trophoblast model highly attractive for 
interrogating key aspects of Handl cellular function.
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1.6.1. Overview
Rcho-l cells were derived from a transplantable rat choriocarcinoma (Rcho), 
a highly-malignant trophoblast tumour, 25 years ago (Teshima et al., 1983). 
Asynchronous Rcho-l stem cells have a large nuclear-to-cytoplasmic ratio and 
comprise a morphogenetically-heterogeneous population. They consist of either 
mitotic, rounded cells with circularly-distributed peripheral actin, or slightly-spread, 
highly-motile interphase cells possessing patches of actin at the periphery (Faria and 
Soares, 1991; Figure 1.6). After differentiation, Rcho-l TG cells resemble their in 
vivo counterparts by virtue of a dramatic increase in cytoskeletal complexity and 
immotility. Rcho-l stem cells moreover mimic TS cells in that their differentiation 
into TG cells is dependent on mitotic cell cycle exit and entry into the endocycle 
(MacAuley et al., 1998).
Importantly, the molecular mechanisms underlying Rcho-l TG cell 
differentiation are largely conserved. Rcho-l-derived TG cells faithfully recapitulate 
the incremental changes in gene expression typical of bona fide  TG cell 
differentiation. For example, they up-regulate members of the placental prolactin 
family related to the pituitary hormone prolactin (PRL) (Hamlin et al., 1994). The 
changes to the cell cycle machinery that coincide with mitotic cell cycle exit and the 
onset of endoreduplication in Rcho-l cells also faithfully copy those that occur in 
rodent trophoblast in vivo (MacAuley et al., 1998). In this regard, numerous analyses 
have effectively employed Rcho-l cells as a model system in which to investigate 
changes in gene expression pattern during TG cell differentiation (Yamamoto et al., 
1994; Grummer et al., 1996; Oda et al., 2001; Mehta et al., 2002; Hayashi et al., 
2004; Morris-Buus and Boockfor, 2004; Novak et al., 2004; Xu et al., 2005; 
Hassanein et al., 2007; Minekawa et al., 2007). These are in addition to studies that 
have successfully used the Rcho-l cell line as a tool to investigate the role of Hand 1 
during TG cell differentiation (Cross et al., 1995; Scott et al., 2000; Firulli et al., 
2003).
Cultured Rcho-l stem cells can be induced to undergo TG cell differentiation 
by numerous methods. These include increasing the plating density, applying ectopic 
factors such as retinoic acid, the anti-retroviral drug PMEA or diethylstilbestrol
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(DES), or simply by replacing mitogen-rich fetal bovine serum (FBS) with horse 
serum (HS) (Cross et al., 1995; Hatse et al., 1998; Yan et al., 2001; Tremblay et al.,
2001). Rcho-l TG cells can subsequently be separated from Rcho-l stem cells by 
virtue of their increased adherence and accompanying insensitivity to trypsin (Parast 
et al., 2001). The spontaneous differentiation rate of Rcho-l stem cells is 5.9±0.5% 
per 24 hours, which represents the percentage of Rcho-l cells cultured in FBS- 
supplemented medium that initiate TG cell differentiation over a 24 hour period 
(Nakayama et al., 1998; Scott et al., 2000). Consistency in cell culture practices is 
vital, since variations in culture densities and passaging ratios influence cell 
phenotype (Cross et al., 1995).
Rcho-l TG cells are specifically a model of SGCs. The ontogeny of 
expression of members of the PRL gene family during Rcho-l differentiation 
resembles that of cells originating from the periphery of the EPC (Hamlin et al., 
1994). This is supported by the observation that a monoclonal antibody directed to 
Rcho-l stem cells specifically recognises proliferative TG cell precursors at the 
periphery of the EPC (Verstuyf et al., 1992). Furthermore, recent data has likened 
Rcho-l cells to SGCs by virtue of their cytoskeletal organisation and gene expression 
profile (Parast et al., 2001; Gultice et al., 2006). In light o f the recent findings by 
Simmons and co-workers, it is encouraging also that the only subtype of SGC that 
expresses PL-1, in common with Rcho-l TG cells, is the so-called ‘parietal SGC’ 
(Simmons et al., 2007). This is the cell type that forms the interface with the maternal 
decidua and which has traditionally been refereed to as the ‘SGC’.
1.6.2. Differences between TS cells and Rcho-l cells
The Rcho-l cell model is not, however, perfect. These cells do differ from 
their in vivo counterparts due to phenotypic drift in culture. By flow cytometry, Rcho- 
1 stem cells were shown to possess up to eight times the haploid content, in contrast 
to diploid TS cells (MacAuley et al., 1998). The underlying reason for this difference 
is unknown. Furthermore, pulse-chase experiments revealed that the length of an 
Rcho-l endocycle is between 40-50 hours (MacAuley et al., 1998), significantly 
longer than the 14-hour endocycle of TS cells (Nakayama et al., 1998). Moreover
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Rcho-l stem cells are a transformed cell line and unlike cultured TS cells they can 
grow in an Fgf4-independent, un-regulated manner, without the additional factor(s) 
provided by conditioned medium (CM) or embryonic fibroblast feeder cells 
necessary for TS cell maintenance (Tanaka et al., 1998; Hughes et al., 2004). This 
may, in part, be due to the specific, as-yet unidentified, mutations that occurred 
during the transformation of TS cells into the choriocarcinoma cells from which 
Rcho-l cells were originally derived.
Although generally conserved, certain aspects of the gene expression profile 
of Rcho-l TS and TG cells differs to that of their counterparts in vivo. For example, 
Rcho-l TG cells do not express the TS cell-specific bHLH factor Mash2 and, unlike 
TS cells, cannot differentiate into syncytiotrophoblast upon Gcml over-expression 
(Scott et al., 2000; Hughes et al., 2004). Rcho-l stem cells express low levels of 
Handl, whilst TS cells only initiate Handl expression when they are positioned at 
the outer reaches of the EPC (Cross et al., 1995; Hughes et al., 2004; Gultice et al.,
2006). Additionally Sox 15 expression increases during TG cell differentiation in vivo, 
but is not expressed during Rcho-l differentiation (Yamada et al., 2006). 
Furthermore, PL-1 is only transiently expressed in SGCs in vivo, and yet its 
expression persists during Rcho-l cell differentiation in vitro (Nieder and Jennes, 
1990; Faria and Soares, 1991; Hamlin et al., 1994). Finally, whilst Rcho-l cells 
express increasing levels of Mmp9 through 13 days of culture, in vivo trophoblast 
cells reduce Mmp9 expression at an earlier time during differentiation (Peters et al., 
2000). However, these differences are subtle and do not preclude the use of Rcho-l 
cells as a relatively faithful model of in vivo TS cells to investigate the mechanisms 
underlying Handl regulation during TG cell differentiation.
1.7. Aims of these PhD studies
A subject of long-standing interest in developmental biology centers on how 
the differentiation of stem cells is temporally controlled. Several studies have shown 
that specific transcription factors, including those of the basic helix-loop-helix 
(bHLH) super-family, play a major role in the commitment of certain stem cell
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populations to differentiation. For example, it has been known for nearly a decade 
that the bHLH factor Handl is involved in determining trophoblast stem (TS) cell 
fate during rodent placentation and has been implicated in regulating cardiomyocyte 
differentiation during cardiac morphogenesis (Riley et al., 1998; Firulli et al., 1998). 
However, how Handl biological activity is regulated in either lineage remains largely 
unknown.
Handl protein-protein interactions are clearly very important for modulating 
Handl activity (Table 1.1). However, to date, Handl has only been shown to 
functionally interact with other bHLH factors in vivo. Given the promiscuous 
dimerisation properties of Handl, we hypothesised that the transcription factor may 
interact with non-bHLH factors, which may play a role in regulating Handl function 
and biological activity. In this regard, we carried out a yeast two-hybrid screen to 
identify Handl interactors and isolated the murine orthologue of the nucleolar factor 
HICp40.
The following PhD studies examined the functional significance of the 
Handl -HICp40 interaction in a model of TS cells and progressed to uncover a novel, 
potentially more widespread, mechanism of controlling the developmental activity of 
a transcription factor via its nucleolar sequestration and subsequent release. Later in 
the thesis we evaluate these findings in terms of the known functions of the nucleolus 
and of Handl, and describe ongoing studies and areas of potential future work. A 
better understanding of Handl regulation and function during invasive trophoblast 
differentiation may provide insight into the underlying molecular and cellular defects 
resulting in common placental defects such as pre-eclampsia. This is a very common 
disease that occurs in up to 15-10% of all human pregnancies and is characterised by 
inadequate invasion of trophoblast into the maternal decidua and deficient 
remodelling of the uterine spiral arterioles (reviewed by Redman and Sargeant, 2005; 
Sibai et al., 2005). Additionally, delineating the cellular mechanisms that control 
Handl activity during cardiomyocyte differentiation may suggest how signalling 
cascades involving the transcription factor become aberrant during a subset of 
idiopathic congenital heart disease.
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Chapter 2
Materials and methods
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Described below are the materials and methods used during the course of this 
work. Reagents, PCR primers, PCR programs, antibodies and in situ hybridisation 
riboprobes employed are listed in Appendices 1-7. The yeast two-hybrid analysis 
(this chapter, section 2.3), characterisation of the Handl-HICp40 interaction (section 
2.4) and whole-mount RNA in situ hybridisation of HICp40 (section 2.5) were 
carried out by Maria del mar Franco Viseras. The northern blot analysis (section 2.8) 
was carried out by Catherine Risebro.
2.1. Construction of plasmids
Several constructs used during the course of this study either existed in house 
or were obtained from outside sources. These included those used for:
• Yeast two-hybrid assay: pGBDU-Hand 1 (provided by Stanley Hollenberg).
• In vitro transcription assay: pcDNA3-Handl and pcDNA3-E12 (existed in- 
house), pcDNA3-HICp40, pcDNA3-HICp32 and pcDNA3-HICAC (provided by 
Sabine Thebault).
• Immunofluorescence: pCEP4.1-B568 (provided by Anthony Firulli), pEGFP- 
HICp40 and pEGFP-HICp32 (provided by Sabine Thebault), pGFP-Plk4 
(provided by Frank Sicheri) and pEGFP-MyoD (provided by Vivek Mittal).
• Co-immunoprecipitation: pFLAG-Handl (existed in-house), pHIS-HICp40 and 
pHIS-HICp32 (provided by Sabine Thebault) and pFLAG-Plk4 (wild-type) and 
pFLAG-Plk4 (T170D) (provided by Carol Swallow and James Dennis).
• Various other assays: pHand2-Neo, pFLAG-Hand 1 (T107;S109A) and pFLAG- 
Handl (T107;S109D) (provided by Anthony Firulli).
The following constructs were generated for specific use in this project.
• The pHandl-EGFP construct was produced by inserting the full-length Handl 
cDNA, generated by PCR amplification of the pcDN A3-Handl template, 
including the ATG start codon but minus the stop codon, into the pEGFP-Nl 
vector downstream and in frame with the EGFP cDNA (Clontech).
• The pHand 1 (T107;S 109A)-EGFP and pHandl(T107;S109D)-EGFP constructs
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were generated in a similar way, but by PCR amplification of the relevant point- 
mutated, full-length Handl cDNAs from the pFLAG-Handl(T107;S109A) and 
pFLAG-Handl(T107;S109D) templates, and their insertion in-frame with the 
EGFP cDNA in the pEGFP-N 1 vector.
• The pHandl-EGFP fragments (pbHLHHandi-EGFP and pHandlHis-EGFP; 
Appendix 4) were generated in a similar way, but by PCR amplification of the 
relevant stretch of Handl cDNA from the pEGFP-Handl template and their 
insertion in-frame with the EGFP cDNA in the pEGFP-N 1 vector.
• The pHand2-EGFP construct was generated in a similar way, but by PCR 
amplification of the full-length Hand2 cDNA from the pHand2-Neo vector 
template and its insertion in-frame with the EGFP cDNA in the pEGFP-N 1 
vector.
• The pGST-Handl construct was generated by PCR amplification of the full- 
length Handl cDNA from the pFLAG-Hand 1 template and its insertion in-frame 
with the GST cDNA in the pGEX4.1 (Promega) vector.
• The pKS+-MICp40 and pcDNA3-MICp40 constructs were generated by PCR 
amplification of the MICp32 cDNA using a specific IMAGE clone as a template 
(#12645-K05). This cDNA, inserted into the pKS+ vector, was then extended by 
the upstream ligation of a PCR product amplified from a template consisting of a 
BAC containing mouse genomic sequence (#RP24-350N23). This generated 
pKS+-MICp40. pcDNA3-MICp40 was produced by simply excising the full- 
length MICp40 cDNA from pKS+-MICp40 and inserting it into the pcDNA3 
vector.
• The RNAi constructs (.HICshRNAil, HICshRNAi2, PM shRN Ail and 
Plk4shRNAi2) were generated by inserting annealed 21 bp or 22bp sense and 
antisense HICp40 and Plk4 oligonucleotides downstream of the HI RNA 
polymerase III promoter in a modified pcDNA3 vector (Kunath et al., 2003). The 
oligonucleotide design is predicted to generate a transcript with a hairpin structure 
containing a 9 base-pair loop. The sequences were designed in accordance with 
published guidelines (Cui et al., 2004; www.bioit.dbi.udel.edu/mai/). This 
involved employing sequences of the form 5,-AA(Ni7.i9)TT-3’ or 5’-AA(Ni9-2i), 
where N is any nucleotide, starting at least 100 nucleotides downstream from the 
start codon. This pattern is optimal because siRNAs with 3’ overhanging UU
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dinucleotides are the most effective. Sequences with GC content below 30% or 
above 79% were also excluded due to considerations relating to thermo-stability 
and the formation of secondary structure. Sequences containing AAAA or TTTT 
were also excluded since they are inappropriate for siRNA generation via RNA 
polymerase Ill-mediated promoters due to the tendency of RNA polymerase III 
transcription to terminate at these sequences. In addition, sequences containing 
CCCC or GGGG are excluded from consideration as they are known to form a 
nucleotide quartet and may affect RNAi function. The annealing reaction was 
carried out in a total volume of 1 Opl with 1 x annealing buffer and was left to 
proceed at an initial temperature of 95 °C that gradually cooled to room 
temperature.
With the exception of the RNAi constructs, these constructs were generated as 
follows. Pfu DNA polymerase-based PCR was used to amplify the relevant cDNA 
from lOng plasmid or lOOng BAC template. Each of the primers used for the PCR 
contained recognition sites for specific restriction enzymes at their 5’ end (see 
below), such that the generated PCR products could be cut and ligated into the 
relevant vector, generally within the polylinker region (multi-cloning site (MCS)). 
Notably, each primer contained a recognition site for a different restriction enzyme, 
to exclude the possibility of incorrect orientation of the insert in the vector plasmid 
after ligation. After the PCR, the reaction mix was supplemented with l/6th of its 
volume of gel loading solution, loaded onto a 1% agarose gel (in lxTBE) and run 
through the gel for 90 minutes at 100V. The amplified DNA was visualised by way 
of an ultra-violet illuminometer and excised from the gel using a scalpel. It was then 
purified by way of the QIAquick™ Gel Extraction Kit (Qiagen) according to the 
manufacturer’s protocol. Each end of the amplified PCR product was subsequently 
digested using the relevant restriction enzymes (New England Biosciences). The 
digestions were performed separately for each enzyme at 37°C, in a total volume of 
lOjal for the first digest and then 20pl for the second, with lx  reaction buffer and lOx 
BSA. Between the two digests, the first enzyme was denatured by heating the mixture 
to 65°C for ten minutes. Concurrently, lpg  of each vector into which the cDNAs 
were to be inserted were also cut with the same enzymes. The enzymes used to cut 
the various DNAs were as follows:
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• Wild-type and mutant Handl cDNAs, Handl cDNA fragments and Hand2 
cDNA, were restricted with iscoRI (5’ end) and BamRl (3’ end) for insertion into 
pEGFP-N 1.
• MICp32 cDNA was restricted with Dr all (5’ end) and BamHl (3’ end) for 
insertion into pKS+. A 51 Obp region of the mouse BAC upstream of the MICp32 
start codon was inserted upstream of MICp32 using the Kpnl (5’) and Drall (3’) 
enzymes.
• The annealed 21 bp or 22bp oligonucleotides were designed such that their 
overhangs were complementary to the Asp718 (5’ end) and Xbal (3’ end) sites 
downstream of the HI RNA polymerase III promoter in the modified pcDNA3 
vector.
After another round of agarose gel electrophoresis and gel purification to 
purify restricted insert and linearised vector DNA, DNA ligation was carried out. An 
appropriate amount of insert and vector, estimated by assessing the relative molar 
ratios of the two species by agarose gel electrophoresis, were mixed in the presence 
of 2pi ligase buffer and 1U T4 DNA Ligase (both from Promega) in a total volume 
of 20pl. Generally, insert was incubated at a three-fold molar excess with vector. The 
reaction was left to proceed overnight at an initial temperature of 30°C that gradually 
cooled to 4°C. In control ligations, vector and insert were incubated individually and 
a mix lacking T4 DNA ligase was also included. The following day, 5 pi of the 
ligation mixture was added to 50pl of DH5a subcloning efficiency competent E. coli 
cells (Invitrogen), which were subsequently incubated on ice for 20 minutes to 
promote plasmid uptake. Cells were then incubated at 42°C for one minute (‘heat 
shock’), which induced expression of the antibiotic resistance marker on the 
transformed construct, and returned to ice for another five minutes. Next, 1ml of 
antibiotic-free Luria broth (LB) was added to the cells, which were then incubated at 
37°C for 60-90 minutes to allow for expression of the gene whose encoded enzyme 
confers antibiotic resistance. After centrifugation and re-suspension of the cells in a 
smaller volume of LB, the cells were then plated on LB-agar plates containing the 
appropriate antibiotic, using a flamed, glass spreader, carried out in such a way as to 
ensure single colony growth. Plates were then incubated at 37°C overnight to select 
for transformants.
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The following day, colonies were picked from these plates and grown in 2- 
3 ml LB containing the appropriate antibiotic over 8 hours in a shaking incubator at 
37°C. 1.5ml of each culture was then centrifuged at 12,000rpm for 2 minutes and the 
supernatant discarded. Next, 200 j l x 1 TELT solution A was added to the pellet, which 
was then vortexed and placed on ice for 20 minutes to lyse the cells. Subsequently, 
protein was removed from the preparation by extraction in 200pi 
phenol:chloroform:isoamyl alcohol (24:24:1). The mixture was vortexed before 
spinning at 12,000rpm for 2 minutes. The upper, aqueous phase was removed and 
added to 200pl isopropanol, and this mixture was then placed on a rotating platform 
for one hour at room temperature to precipitate DNA. After centrifugation for 30 
minutes at 12,000rpm and removing the supernatant, the remaining DNA pellet was 
washed with 70% ethanol and re-suspended in TE (pH8.0) supplemented with 
RNAse A. An aliquot of this DNA (5 pi) was then digested with the appropriate 
enzymes as before, and the size of the respective fragments ascertained by agarose 
gel electrophoresis in the presence of a Hindlll/A, DNA size ladder. In the case of the 
RNAi constructs, whose oligonucleotide insert was too small to resolve by agarose 
gel electrophoresis, the presence of the correct insert was determined by colony PCR. 
This was carried out using one primer specific to the insert and one to the vector 
backbone and involved transferring a sample of the colony grown in LB to the PCR 
reaction tube using a lOpl pipette tip. If the DNA was correct, lOng was re­
transformed into competent cells, and the Qiagen Maxiprep Kit™ was used to 
generate sizeable quantities of the DNA from a larger bacterial culture according to 
the manufacturer’s instructions. After suspending the DNA in TE (pH8.0), its 
concentration was assessed using a spectrophotometer set at OD2 6 0 -
2.2. Cell culture
Rcho-l cells were a kind gift from Michael Soares, trophoblast stem cells 
were obtained from Satoshi Tanaka, P19-CL6 embryonic carcinoma (EC) cells were 
generously provided by John Pizzey and the transgenic embryonic stem (ES) cell line 
was a kind gift from Sean Wu. The H9c2 and NIH-3T3 cell lines existed in house and 
their ATCC catalogue numbers are CRL-1446 and CRL-1658 respectively.
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Cells were cultured in 75cm3 flasks containing 15ml of relevant medium in a 
humidity-controlled chamber at 37°C and 5% CO2 . Cells were passaged by washing 
with 10ml of sterile PBS, applying 1ml of pre-warmed 0.05% trypsin/ 0.02% EDTA 
for 5 minutes at 37°C until the cells were lifted off the plate, spinning down the cells 
at 7,000rpm for 10 minutes and plating down 10-30% of the flask contents in fresh 
15ml of appropriate medium. This was carried out at each 48 hour period, which was 
particularly necessary in the case of NIH-3T3, P I9, P19-CL6 and Rcho-l cells, which 
divide particularly rapidly and can reach confluence in a short period of time.
Certain cell lines and assays required specific culturing conditions. Prior to 
seeding ES cells, plates were coated with 0.1% gelatin to ensure proper cell adhesion. 
To culture trophoblast stem (TS) cells, a ‘feeder’ layer of primary mouse embryonic 
fibroblast (MEF) cells, pre-treated with the antibiotic mitomycin-C, were first grown 
to 70% confluence. At this point, TS cells were plated on top and the conditions 
changed to TS cell-specific medium. Synchronising cells at the G2/M phase 
checkpoint was achieved by application of 400ng/ml nocodazole, a drug that 
promotes Tubulin depolymerisation and which therefore blocks mitosis. Culturing 
cells in hypoxic conditions was carried out by one of two methods. The first method 
involved culturing cells in a humidified, normoxic (ambient air, supplemented with 
5% carbon dioxide/ 21% oxygen) chamber at 37°C in medium supplemented with 
250pM cobalt chloride, which has previously been shown, in cell types including 
Rcho-l cells, to initiate intracellular signalling cascades triggered ordinarily by low 
oxygen (Hayashi et al., 2004). Otherwise, cells were incubated in a humidified, 
hypoxic chamber {Coy Laboratory Products), maintained at 1% oxygen/ 5% carbon 
dioxide/ 94% nitrogen at 37°C. In order to decrease cellular exposure to oxygen, 
reagents used in hypoxic experiments were pre-equilibrated in the chamber for a 
minimum of 30 minutes prior to use. In both cases, an appropriate cellular response 
to hypoxic conditions was assessed by western blot analysis to assess an up- 
regulation of the hypoxic inducible factor-1 alpha (H IFla) subunit.
Several cell lines were induced to undergo differentiation in vitro by 
modifying culture conditions. To induce Rcho-l trophoblast giant (TG) cell 
differentiation, freshly-passaged Rcho-l stem cells were washed with 10ml PBS and
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then treated with 15ml differentiation-inducing medium. The medium was 
completely replaced at 48 hour intervals throughout the differentiation process. By 
48-72 hours after the initiation of differentiation, trophoblast giant cells were 
observed in the cultures. Of note, a relatively homogeneous population of Rcho-l 
stem cells could be obtained, in common with previous studies (Cross et al., 1995; 
MacAuley et al., 1998), by trypsinising freshly-plated Rcho-l cells, by virtue of the 
fact that TG cells are trypsin-resistant. To induce P19-CL6 embryonic carcinoma 
(EC) cell differentiation into cardiomyocytes, cells were grown to confluence and re­
suspended in bacteriological-grade dishes in medium supplemented with 0.8% 
DMSO. After two days of incubation, medium was replenished with fresh DMSO- 
containing medium, and after 4 days in suspension aggregates were plated in medium 
lacking DMSO. By 5-6 days after the initiation of aggregate formation, rhythmically- 
contracting cardiomyocytes were observed in the cultures. To induce transgenic 
embryonic stem (ES) cell differentiation into cardiomyocytes, cells were trypsinised 
at approximately 80% confluency and were re-suspended in ES medium minus 
ESGRO. Cells were transferred to 10cm non-gelatin coated bacteriological dishes at 
low density. Cells were maintained in floating culture for 14 days and their medium 
partially replaced daily, with care taken not to remove the embryoid bodies (EBs). By 
10-14 days after the initiation of differentiation, rhythmically-contracting, fluorescent 
cardiomyocytes (within the EBs) were observed in the cultures.
Although most cell types used in this study could be transfected at a high 
efficiency with Effectene™ (Qiagen), we found that the transfection efficiency of 
Rcho-l and trophoblast stem cells transfected with Lipofectamine™ 2000 
(Invitrogen) was significantly higher. Transfection with Effectene™ was carried out 
as per the manufacturer’s instructions. Briefly, cells were plated 16 hours before 
transfection into 6-well plates such that they had reached approximately 70% 
confluency by the time of transfection. 100 pi DNA condensation buffer (EC buffer) 
and 8pi Enhancer were added to 1-1.5pg total plasmid DNA, and mixed by vortexing 
for 1 second. The total amount of transfected DNA per well was kept constant by 
adding an appropriate amount of empty expression vector or pcDNA3. The DNA- 
Enhancer mix was incubated at room temperature for 5 minutes to allow 
condensation of the DNA. 15 pi Effectene™ was then added to this mix and vortexed
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for 10 seconds. The samples were then incubated at room temperature to allow 
Effectene™-DNA complex formation. During this incubation time, cells were 
washed with sterile PBS and 1.2ml fresh medium was added to each well. 800pl fresh 
medium was then added to the transfection complexes, mixed by pipetting up and 
down, and added drop-wise to the cells. Swirling the dish gently attained uniform 
distribution of the complexes. The cells were then incubated for 48 hours in normal 
culture conditions, although the medium was changed completely 24 hours post­
transfection. Transfection with Lipofectamine 2000™ was carried out again as per 
the manufacturer’s instructions. Briefly, cells were plated 16 hours before 
transfection into 6-well plates such that they had reached approximately 80% 
confluency by the time of transfection. In two separate tubes, 2-2.5pg total plasmid 
DNA was added to lOOpl serum- and antibiotic-free medium, and 5 pi of 
Lipofectamine™ 2000 was added to another lOOpl of such medium. The two 
mixtures were mixed thoroughly by pipetting up and down, and were subsequently 
incubated at room temperature for 30 minutes to allow for complex formation. 
During this time, cells were washed with sterile PBS and 1.8ml fresh, serum- and 
antibiotic-free medium was added to each well. The mixture (about 200pl) was then 
added to each well in a drop-wise fashion, and the plates were then swirled to attain a 
uniform distribution of complex. Cells were then incubated at 37°C for 5-8 hours in 
normal culture conditions. After this time, cells were washed with PBS and treated 
with normal, serum- and antibiotic-added medium and incubated for 48 hours in 
normal culture conditions.
For the generation of Handl-dsRed knock-in ES cells, transgenic ES cells 
(generously provided by Sean Wu) were co-transfected with the Handl-dsRed 
construct and a pTK-Neo selection plasmid (Clontech) using Effectene™ (Qiagen). 
Initially, a killing curve was determined with concentrations of neomycin (G418; 
from 50-200pg/ml), applied 48 hours post-transfection, to determine the optimum 
concentration of antibiotic. After 14 days’ culture at the optimum concentration of 
neomycin, resistant clones were picked into 96-well plates and the cultures expanded 
in media containing a maintenance concentration of neomycin (50pg/ml). Once the 
stable clones had expanded sufficiently, samples were taken for DNA extraction and 
aliquots were frozen down. For genomic DNA extraction from selected cells, cells
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were lysed, using 0.5% SDS and 0.25jag/jLxl proteinase K, at 55°C for three hours. The 
DNA was extracted in one volume of 1:1 phenol:chloroform on a nutator, for a 
minimum of 30 minutes. The extraction mix was centrifuged at 12,000rpm for 10 
minutes at 4°C and the upper, aqueous phase then transferred to a fresh Eppendorf. 
The DNA was then precipitated with 0.6 volumes of isopropanol, on a nutator, for a 
minimum of 30 minutes. The mixture was then spun down at 12,000rpm for 10 
minutes at 4°C and the remaining pellet washed in 70% ethanol and re-suspended in 
50|iil of TE (pH8.0). This DNA was then used as a template in a PCR reaction with 
relevant primers to genotype for stable Handl-dsRed expression.
For RNA and protein extraction, cells were harvested in all cases by washing 
twice with 10ml ice-cold PBS, scraping with an elongated rubber spatula and 
spinning down the resultant mixture in 10ml ice-cold PBS at 7,000rpm for 10 
minutes. Supernatant PBS was then removed using an aspirator. Cell pellets were 
then lysed by one of the following methods.
• To lyse cells for the luciferase and (3-Gal assays, the cell pellet was re-suspended 
in 450pl lx  reporter lysis buffer (RLB; Promega) and vortexed for 10 seconds. 
The resultant mixture was then frozen and thawed rapidly twice between -70°C 
and 37°C to ensure complete cell lysis. Cell debris was then removed by 
centrifugation at 12,000rpm for 2 minutes at 4°C and the supernatant was 
transferred to a fresh Eppendorf.
• To lyse cells for mRNA extraction, the cell pellet was re-suspended in 1ml 
Micro-FastTrack™ 2.0 lysis buffer (.Invitrogen) and was incubated at 45°C for 20 
minutes to allow the complete digestion of proteins and ribonucleases. The lysate 
was then passed through a 21-gauge needle 4 times to shear any remaining DNA. 
Finally, the NaCl concentration of the samples was adjusted to a final 
concentration of 0.5M to attain optimum salt concentration for mRNA 
purification.
• To lyse cells for western blotting and anti-FLAG co-immunoprecipitation, the cell 
pellet was treated with 800pl FLAG IP kit lysis buffer, to which 8pi of a protease 
inhibitor cocktail had been added. The mixture was vortexed and incubated at 4°C 
on a spinning wheel for 30 minutes, before being centrifuged to remove cell
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debris for 10 minutes at 12,000rpm. The supernatant was then transferred to a 
fresh tube.
• A previously-described method was used to generate whole-cell lysates 
subtracted for the nucleolar fraction (Kurki et al., 2004). Briefly, the cell pellet 
was treated with lOOpl so-called ‘NP-40 lysis buffer’, the constituents of which 
are listed in Appendix 1, and was vortexed vigorously for 30 seconds before 
being incubated on ice for 20 minutes. After centrifugation for 10 minutes at 
12,000rpm the supernatant was removed, and this represents the whole-cell lysate 
subtracted for the nucleolar fraction.
• To lyse cells for co-immunoprecipitation, the cell pellet was treated with 0.5ml 
ice-cold RIPA buffer, to which lOpl of a protease inhibitor cocktail had been 
added. The mixture was vortexed and incubated at 4°C on a spinning wheel for 30 
minutes, before being centrifuged to remove cell debris for 10 minutes at 
12,000rpm. The supernatant was then removed.
Cells to be immunostained were seeded onto glass cover slips (13mm 
diameter), which had been incubated for 5 minutes in 0.1% gelatin, and which were 
themselves placed into wells of a 6-well plate. After cells had adhered and/ or been 
transfected, they were washed twice with 2ml PBS. Cells were fixed with either 4% 
paraformaldehyde in PBS (if they were to be probed with anti-C23) or ice-cold 100% 
methanol (used in all other cases) and incubated for 10 minutes at room temperature. 
Cells were then washed twice with PBS and then permeabilised with 0.5% Triton X- 
100 in PBS and incubated for a further 5 minutes. Cells were then washed once more 
with PBS, and then blocked with 1% Bovine Serum Albumin (BSA) in PBS for 2 
hours at 4°C. Next, cover slips were removed from the plates, attached to glass slides 
using DPX cover mount and encircled with a ring of wax using an Immedge Pen. The 
slides were housed in a dark (aluminum foil-covered), humidity-controlled chamber. 
Cells were then washed twice with 1% BSA in PBS by applying drop-wise and 
aspirating the liquid. The relevant primary antibody, diluted in 1% BSA-PBS, was 
then added drop-wise to the cells, which were then incubated overnight. A secondary 
antibody-only coverslip was included as a control and was left overnight in 1% BSA- 
PBS alone.
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The following morning, after washing cells three times for 5 minutes with 
PBS, the relevant fluorescin isothiocyanate (FITC)- or tetramethyl rhodamine 
isocyanate (TRITC)-labelled secondary antibody, diluted in 1% BSA-PBS, was 
applied to cells and incubated for 1 hour. Cells were then washed with PBS twice, 
and 5pg/ml of the DNA stain bis-benzamide (Hoechst 33342) was applied in PBS for 
10 minutes at room temperature. Cells were again washed twice with PBS, and were 
mounted with cover-slips secured in 50% glycerol-PBS.
Fluorescent images were obtained, and cell counts conducted, using a Zeiss 
Axio Imager M l fluorescent microscope with lOx, 20x and 40x Zeiss Plan-Neofluar 
objectives and FITC, TRITC and DAPI filters. Images were captured with a Zeiss 
Axiocam CCD-videocamera followed by image processing and multiplayer analysis 
using AxioVision™ 3.0. Time-lapse movies were recorded using a Zeiss Axiovert 135 
fluorescent microscope with the program Openlab™ 4.0.
For long-term storage, cells were frozen to -70°C in medium containing 45% 
DMEM, MEMa or NCTC-135 (as appropriate), 45% serum and 10% DMSO. This 
was carried out in an isopropanol bath (Coy Laboratory Products; isopropanol added 
fresh) to ensure gradual cooling. After 72 hours cells were transferred to liquid 
nitrogen.
2.3. Yeast two hybrid assay
The Y2H screen was carried out as described previously using a mouse 
E9.5/10.5 library (Hollenberg et al., 1995). Bait (Handl) was cloned into the DNA- 
binding domain vector (pGBDU-C3), which was expressed as a fusion protein to 
amino acids 1-147 of the yeast Gal4 protein. The cDNA library was cloned into the 
activation domain vector, which was expressed as a fusion protein to amino acids 
768-881 of Gal4. pGBDU-C3 contains the URA-3 (Uracil) selectable marker.
One litre of the yeast strain PJ69-4A* was transformed with 500jug of a 
mixture of the mouse embryo library and lOmg of salmon sperm carrier DNA by the 
lithium acetate method with 10% DMSO. Briefly, this involved preparing a carrier
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mix of sheared salmon sperm carrier DNA (lOmg/ml) by boiling 5 pi of carrier mix 
for 5 minutes, followed by rapid chilling on ice. lOOng of DNA was then added to the 
carrier mix. lOOpl of competent yeast cells was also added, together with 300pl of 
1 xlithium acetate/ 1 xTE/ 40% PEG, and the cell/ DNA mixture incubated at 30°C for 
30 minutes. 70pl o f DMSO was added to the cell/ DNA mixture, and this was 
followed by a heat shock at 42°C for 15 minutes. Cells were harvested (10,000rpm, 
10 seconds at room temperature), re-suspended in 500pl o f dEEO and plated onto 
minimal media plates with the appropriate selection (histidine-deficiency) and 
incubated at 30°C for 2-3 days. Histidine-synthesising clones were lysed in liquid 
nitrogen and assayed for P-Gal activity on filters. Library DNA from colonies which 
were positive with pGBDU-Handl was sequenced, and the sequences were tested 
against the National Centre for Biotechnology Information (NCBI) database using the 
BLAST search program.
* The genotype of the yeast strain PJ69-4A is gal4, gal80, his3-200, trpl-901, 
ura3-52, leu2-3, 112, + GAL2->ADE2, LYS2::GAL1-*HIS3, met2::GAL7->LacZ.
2.4.In  wYro-translation and GST-pull down assay
The pGEX4.1-Handl, pcDNA3-HICp40, pcDNA3-HICp32 and pcDNA3- 
HICAC plasmids were processed for in vitro transcription and translation using a 
TNT™ kit (Pr omega), as per the manufacturer’s instructions. Briefly, lp g  of 
supercoiled DNA was combined with 25 pi TNT rabbit reticulocyte lysate, 2pi 
reaction buffer and lp l amino acid mixture (minus methionine). 3pi S-methionine 
(Amersham Pharmacia), 1U of RNAsin (RNAse inhibitor) and 1U of RNA 
polymerase (T7) was added and the volume made up to 50pl with dH20. The reaction 
was incubated for 60-120 minutes at 30°C.
For the GST pull-down assay, 2pg GST-Handi was captured on glutathione- 
Sepharose beads and 0.5pg radio-labelled HICp40, HICp32 and HICAC were then 
added. Binding was performed in 150ml binding buffer overnight on a rotating wheel 
at 4°C. The next morning, the beads were washed four times with binding buffer. The
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beads were eluted in 20pl of 2x Laemmli buffer (+5% beta-mercaptoethanol) and 
boiled for ten minutes. Protein interactions were then analysed by SDS-PAGE, 
followed by western blot, with 5% of the input crude extract being used for the 
determination of protein expression levels (see section 2.9).
2.5. Whole-mount in situ hybridisation
The whole-mount in situ protocol was carried out in RNAse-free conditions. 
Thus, prior to use, all equipment was rinsed once with RNAseZap (Ambion) and twice 
with dFEO to remove RNAse activity. Embryos were extracted and fixed in 4% 
paraformaldehyde (in PBS) overnight at room temperature, then transferred to 100% 
methanol. Embryos were then re-hydrated through 75%, 50% and 25% methanol in 
PBS for five minutes each, and then washed twice in PBS for 10 minutes each. The 
embryos were then digested with lOpg/ml proteinase-K in PBS for 15 minutes at 
room temperature, rinsed once in PBS and post-fixed for 30 minutes in 4% 
formaldehyde in PBS and 0.1% gluteraledhyde. Following post-fixing, the embryos 
were washed twice in PBS, for five minutes, and then pre-hybridised in hybridisation 
solution overnight at 68°C in a humidity-controlled chamber.
The riboprobe was denatured at 95 °C for three minutes and cooled 
immediately on ice. The following day, the riboprobe was applied to the embryos at 
an approximate concentration of 400ng/ml in fresh hybridisation solution, and this 
was left to incubate overnight at 68°C. After hybridisation with the riboprobe, the 
embryos were rinsed twice for five minutes, and washed three times for 30 minutes in 
hybridisation solution at 68°C. Next, the embryos were washed three times for 30 
minutes in TBST at room temperature on a nutator. The embryos were subsequently 
blocked in TBST with 10% sheep serum and 1% BSA for a minimum of three hours 
at room temperature on a nutator.
The antisense RNA probe was labeled with digoxigenin {Roche), and this was 
then incubated with the samples at a concentration of 1:2000 on a nutator at 4°C 
overnight. Following this, the embryos were washed at room temperature on a nutator 
three times for one hour in TBST and washed twice for 10 minutes in PBS. After
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washing, the embryos were developed in Nitro Blue Tetrazolium and 5-bromo-4- 
chloro-3-indolyl-phosphate (NBT/BCIP) solution (one tablet in 10ml dl-hO; 
Amersham Pharmacia) in the dark (aluminum foil-covered) at room temperature on a 
nutator. Once the signal strength was sufficient, the embryos were washed in PBS 
with 0.1% Triton X-100 to stop the reaction and were fixed overnight at room 
temperature in 4% paraformaldehyde in PBS. To reduce background, embryos were 
cleared in 1 0 0 % methanol for 1 0  minutes on a nutator and re-hydrated through a 
methanol-PBS gradient. Embryos were then imaged using a Nikon SMZ-U 
microscope, and photographed using a FujiFilm FinePix S2 Pro digital camera and 
Hyper-Utility Software HS-S2.
2.6. Luciferase assay
1 0 0 pl of luciferase assay buffer (Promega) was added to 2 0 pl of cell lysate 
(transfected with appropriate vector(s) and the pCMV-figal plasmid 48 hours before) 
in a Turner Designs TD-20/20 illuminometer. Luminescence was measured at room 
temperature for 10 seconds. A concurrent P-Gal assay was performed by adding 50pl 
lx  Reporter Lysis Buffer (Promega) and 150jnl 2xp-Gal assay buffer to lOOpl cell 
lysate. The mixture was vortexed and incubated at 37°C until the reaction turned 
yellow (indicating the presence of O-nitrophenyl, which was usually between 30 
minutes and 2 hours). To stop the reaction, 300pl of 1M Na2 CC>3 was added and the 
samples vortexed. The A4 2 0  was measured for each sample and was in the linear 
range between 0 . 2  and 0 .8 .
2.7. RNA extraction and RT-PCR analysis
Cells were lysed as described earlier, and mRNA was extracted using 
lnvitrogeri’s Micro FastTrack™ 2.0 kit, as per the manufacturer’s instructions. 
Briefly, the cell lysate was added to an oligo(dT) cellulose column and placed on a 
nutator at room temperature for an hour. The oligo(dT) cellulose was then pelleted by 
centrifugation at 6000rpm for 2 minutes and then washed 3 times in Binding Buffer. 
Next, the oligo(dT) cellulose was re-suspended in Binding Buffer and transferred to a
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spin column. The spin column was subsequently washed 3 times with Binding 
Buffer, and a further 2 times with Low Salt Wash Buffer. The mRNA was eluted 
from the spin column with Elution Buffer. 20pl glycogen carrier, 70mM (pH5.2) 
sodium acetate and 100% ethanol were then added to this solution, and the mixture 
was frozen on dry ice to precipitate the mRNA as a pellet. The mRNA pellet was then 
re-suspended in 1 Opl of Elution Buffer, assessed for concentration using a nanodrop 
spectrophotometer, and stored at -70°C.
Prior to the RT-PCR reaction, lOOng purified RNA was incubated with lx 
RQ1 RNase-free DNase (Promega) in lx  RQ1 RNase-free DNase reaction buffer in 
dELO at a final volume of lOpl for 30 minutes at 37°C. After this time, lp l of RQ1 
DNase Stop Solution was added to the mixture to terminate the reaction, and this total 
mixture was then incubated at 65°C for 10 minutes to inactivate DNase activity. The 
mixture (11 pi) was then split into two tubes of 5.5pl each, which each contained 
ImM dNTP mix in dLLO, 300ng random primers and were made up to lOpl with 
dLLO. These mixtures were then incubated at 65°C for five minutes.
The reverse transcription reaction was then carried out. Each tube was treated 
with a mixture containing lx  first strand buffer (Invitrogen), 5mM MgCL, 0.01M 
DTT and 40 units RNAsin (Promega), but only one set were also treated with 50 
units o f Superscript II RT (Invitrogen). This meant that one set of tubes acted as a 
control for genomic DNA contamination. Both sets o f tubes were then subject to a 
pre-programmed RT-PCR reaction to produce first-strand cDNA (using a PE Applied 
Biosystems GeneAmp® PCR System 9700 PCR machine). PCR was then performed 
using the first-strand cDNA as a template and Taq polymerase-containing Ready-To- 
Go™ beads (Amersham Biosciences). The PCR mix was then supplemented with 
l/6 th o f its volume of gel loading solution, loaded onto a 1% agarose gel (in lx  TBE) 
and run for an hour at 100V. DNA was then visualised by way o f an ultra-violet 
illuminometer and photographed.
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2.8. Northern blot analysis
Northern blot analysis was carried out in RNAse-free conditions. Thus, prior 
to use, all glassware and electrophoresis equipment was rinsed once with RNAseZap 
(Ambion) and twice with dH20 to remove RNAse activity. Northern blots were 
carried out using the NorthernMax™  formaldehyde-based system {Ambion). Briefly, 
2pg o f sample RNA, extracted from cells as described earlier, was mixed with 3 
volumes of formaldehyde/ ethidium bromide (provided in the kit) to a final 
concentration of lOpg/ml. The samples were denatured for 15 minutes at 65°C in a 
dry heat block, pulsed, and loaded into a 1% agarose, lx  denaturing gel buffer 
(RNase-free) gel (included with the kit). The gel was run in lx  MOPS gel running 
buffer at 5V/cm (distance between the two electrodes) until the bromophenol dye 
front reached the bottom of the gel. The mRNA on the gel was then visualised by 
way o f UV light, photographed and transferred to a positively-charged nylon 
membrane (Hybond™-N+; Amersham) by the downward-capillary method for 2 
hours in MOPS gel transfer buffer (included with the kit). Following transfer, the 
membrane was rinsed in lxMOPS gel running buffer and the mRNA was cross- 
linked by baking at 80°C for 20 minutes. Next, the membrane was pre-hybridised at 
42°C for 1 hour in ULTRAhyb™ {Ambion) in a bottle rotator hybridisation oven. The 
RNA probe was radio-labeled by the random primer labeling method and was then 
denatured and added immediately to the pre-hybridised blot. Hybridisation was 
carried out overnight at 42°C. The membrane was then washed twice at room 
temperature with agitation using low-stringency wash solution, followed by two 
washes at 42°C in the hybridisation oven using high-stringency wash solution. The 
blot was then wrapped in cling film and exposed to Kodak BioMax autoradiography 
film for 15 minutes to overnight, depending on the relative signal strength as 
determined by Geiger counter measurement.
2.9. SDS-PAGE and western blot analysis
Western blotting was performed using the Bio-Rad Mini-Protean® III 
apparatus {Ambion). Briefly, lysate samples were mixed with an equal volume o f 2x 
Laemmli buffer (+5% beta-mercaptoethanol) and denatured for 10 minutes at 100°C.
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The samples were loaded on an SDS-PAGE gel (approximate dimensions 
65x85x1.5mm). Electrophoresis was performed in lx  TGS running buffer at a 
constant current of 30mA until the dye front reached the bottom of the gel. 
Importantly, the samples were run in parallel with lOpl of the Rainbow (full-range) 
protein molecular weight marker (.Amersham), to indicate the molecular weight of 
sample proteins. The separated proteins were then transferred to a Hybond™-C 
nitrocellulose membrane (.Amersham) by a ‘wet transfer’ method using an 
electroblotter (Biometra). Briefly, this involved placing the nitrocellulose membrane 
on top o f the gel and closest to the anode, and inserting a small sheet of Whatman 
paper and a thin sheet of sponge on either side. A constant current of 200mA was 
then applied to this entire assembly, which was submerged in lx  TGS transfer buffer, 
for 2 hours at 4°C. Proteins on the membrane were then visualised by staining in 
0.2% Ponceau S. Next, the membrane was then rinsed in lx  TBS and blocked in 
blocking buffer for 2 hours at room temperature on a nutator, and was then briefly 
rinsed with TBST. The primary antibody was then diluted in blocking buffer to the 
required concentration, added to the membrane in a sealed polythene bag and 
incubated overnight at 4°C on a nutator. The next morning, the membrane was 
washed 6 times for 10 minutes with wash buffer on a nutator. The secondary 
antibody, conjugated to horseradish peroxidase (HRP), was subsequently diluted to 
the required concentration in blocking buffer and incubated with the membrane in a 
sealed polythene bag on a nutator for 1 hour. The membrane was then washed again 6 
times for 10 minutes with wash buffer. A further two, 5-minute washes were then 
carried out in lx  TBS. Subsequently, the membrane was developed using ECL™ 
Western blotting detection reagents {Amersham). A 1:1 mix o f the ECL™ 
components was freshly made and 0.123ml/cm2 was added to the membrane for one 
minute. The blot was then wrapped in cling film and exposed to autoradiography film 
for 5 seconds to 30 minutes, depending on the signal strength.
2.10. Co-immunoprecipitation
To purify the FLAG-Plk4 proteins for use in the kinase assay, Rcho-l cells 
were transfected with either pFLAG-Plk4 or pFLAG-Plk4;T170D (gain-of-function, 
activating mutant). After 48 hours cells, were lysed using FLAG IP kit lysis buffer as
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described, and the resultant lysates were immuno-precipitated using a a-FLAG M2 
antibody Kit (Sigma) as per the manufacturer’s protocol. Briefly, 40pl of the supplied 
Anti-FLAG M2 affinity gel was washed three times with 0.5ml 1 x Wash Buffer and 
once with 0.5ml lx  Elution Buffer. 1ml of cell lysate was added to this pre-washed 
Anti-FLAG M2 affinity gel and incubated overnight at 4°C on a rotating wheel. The 
next morning, the resin, now bound to the FLAG-tagged fusion protein to be purified, 
was centrifuged for 30 seconds and washed again three times with 0.5ml lx  Wash 
Buffer. 3x FLAG Elution Buffer was prepared by adding 3 jul o f the provided 3x 
FLAG peptide solution to lOOpl kinase buffer. This was then added to the washed 
affinity gel, incubated on a rotating wheel for 30 minutes at 4°C and subsequently 
centrifuged. The supernatant, containing the eluted FLAG fusion protein, was then 
transferred to a fresh tube. An equal volume of 2x Laemmli buffer (+5% beta- 
mercaptoethanol) was then added to the precipitates. Protein interactions were then 
analysed by SDS-PAGE followed by autoradiography, and 5% percent of the input 
crude extract was used for determining protein expression levels by western blot 
analysis (see section 2.9).
To purify Handl-Plk4 complexes formed in vivo, Rcho-l cells were treated 
for 1 hour with medium supplemented with 10% horse serum to induce a 
commitment towards differentiation and then lysed in RIPA buffer as described. The 
control cell population was untreated, asynchronous Rcho-l stem cells. 250pl protein 
sepharose A/G beads (Amersham Pharmacia) were pre-blocked by incubation in an 
equal volume of 1% BSA in PBS on a rotating wheel for one hour at 4°C. After brief 
centrifugation at 6,000rpm to collect the resin and after washing once with PBS, 3- 
4pg o f a-Plk4 antibody was conjugated to the resin in the same volume of fresh 1% 
BSA in PBS for 2 hours under the same conditions. After centrifugation to remove 
the supernatant, cell lysates were added to these antibody-conjugated beads and the 
mixture was incubated at 4°C on a rotating wheel overnight to allow for immuno- 
precipitation. The following morning, the beads, to which endogenous Plk4 was now 
bound, were centrifuged at 6,000rpm for 1 minute and washed five times (between 
similar centrifugations) with ice-cold PBS. After all traces of supernatant were 
removed using a fine pipette, an equal volume of 1% BSA in PBS was then added to 
the beads. An equal volume of 2x Laemmli buffer (+5% beta-mercaptoethanol) was
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then added to the precipitates. Protein interactions were then analysed by SDS-PAGE 
followed by autoradiography, and 5% percent of the input crude extract was used for 
determining protein expression levels by western blot analysis (see section 2.9).
2.11. In vitro phosphorylation (kinase) assay
FLAG-Plk4 (wt) and FLAG-Plk4 (T170D) were in v/vo-translated in 
transfected Rcho-l cells and purified as described (see section 2.10). The eluates 
were incubated with 30pg of GST-Handi or lysates from wild-type Handl-EGFP or 
Handl-EGFP T107;S109A/D-transfected Rcho-l cells and 2juCi of 30 CimM'1 32P 
ydATP (Amersham) for 30 minutes at 37°C in kinase buffer in a total volume of 30pl. 
In separate, parallel reactions, 2pg of a-Casein was used as a positive control, as 
described previously (Swallow et al., 2005), and 30pg GST and 30jag BBS2-GST 
were used as negative controls. After the reaction, radio-labelled protein was boiled 
in 2x Laemmli buffer (+5% beta-mercaptoethanol) and then analysed by SDS-PAGE 
(western blot analysis; see section 2.9). The gel was then washed in TBS and dried on 
Whatman paper before exposure to Kodak BioMax autoradiography film.
2.12. /YA:4-null embryo analysis
Genotyping o f embryos by nested PCR was carried out on tissue taken from 
wax-embedded sections. E7.5 Plk4-null concepti were fixed with 4% 
paraformaldehyde (in PBS) for a minimum of 4 hours, but preferably overnight 
(especially for whole embryos). Thereafter, embryos were either dehydrated and 
wax-embedded or cryo-embedded.
Wax embedding was carried out by dehydrating the embryos through a graded 
ethanol series, two hours in each 50%, 70%, 80%, 90% and 96% ethanol/ dH20, 
followed by two one-hour incubations in 100% ethanol. The embryos were then 
cleared in 100% butanol overnight at room temperature. Next, the embryos were 
transferred to a 1:1 mix of butanol:molten pastillated fibrowax (BDH) for 30 minutes 
at 60°C. The embryos were then incubated in 100% molten fibrowax at 60°C for 24
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hours, with three changes of wax during this period. The embryos were then placed in 
individual moulds, orientated with a warm needle, and left to set. The embedded 
embryos were stored at 4°C until sectioning. Sections were cut at 10pm thickness in a 
Micro HM 330 microtome (Microm), and gently guided in series onto TESPA-coated 
slides. The embryo sections were dried on a flat bed dryer (R.A. Lamb) for 30-60 
minutes at 50°C and stored in a dry, dust-free box at room-temperature until analysis.
Cryo-embedding was carried out using established protocols. Firstly, the 
embryos were cryo-protected by incubating at 4°C in 30% sucrose (in PBS) 
overnight, or until the samples sunk to the bottom of the vessel. Then, embryos were 
infiltrated by applying a 1:1 mixture of sucrose in PBS:OCT embedding medium 
(Miles Inc.) for 30 minutes. The embryos were then transferred to an embedding 
mould, which was filled with fresh OCT. The embryos were then oriented with a 
pipette tip, frozen on dry ice until solid, wrapped in aluminum foil and then stored at 
-70°C until ready for sectioning. Sections were cut at 10pm thickness in a Cryo-2000 
cryostat (Sakura), and gently guided in series onto Superfrost™ glass slides (LSL) 
and allowed to dry at room temperature. Slides were carefully wrapped in aluminum 
foil and then stored at -70°C until analysis.
Sections were processed prior to analysis. Wax sections were de-waxed and 
re-hydrated, by applying 100% of the de-parafinising agent Histoclear (R.A. Lamb) 
for five minutes, carrying out serial ethanol dilutions applying 100% ethanol twice, 
then 95%, 80%, 70% and 50% once each, and then carrying out two 5-minute washes 
in dE^O. Cryosections were simply thawed to room temperature and washed twice in 
PBS. For histology, sections were stained with haematoxylin and eosin. This was 
carried out by application of 0.5% eosin (aqueous) for one minute and then by 
washing in dE^O. Meyer’s haematoxylin solution was then applied for 5 minutes and 
slides were washed twice in df^O. The slides were then visualised on an Olympus 
SZ4045TR microscope. For immunostaining, sections were firstly boiled in 0.1M 
citric acid (pH6.0) for five minutes (antigen retrieval), circled with an ImmEdge pen 
and permeabilised with 0.5% Triton X-l00/PBS for five minutes. They were then 
blocked in 1% BSA in PBS for 30 minutes. The slides were then incubated with 
primary antibodies against Handl (Abeam), Nucleostemin (NS; R&D Systems) or
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Plk4 (Abeam; to confirm the PCR genotyping of Plk.4-null embryos) overnight in a 
humidity-controlled chamber at 4°C. A secondary antibody-only coverslip was 
included as a control, and was left overnight in block. The embryos were then washed 
three times in block solution and the relevant, fluorophore-conjugated secondary 
antibody was applied to samples in a humidity-controlled chamber at room 
temperature for one to three hours. The samples were then counterstained with the 
nuclear marker bis-benzamide (Hoechst 33342) at a concentration of 5pg/ml in PBS 
for 10 minutes. Slides were mounted with coverslips using a 1:1 mixture of PBS and 
glycerol and wrapped in foil until imaging.
2.13. Embryoid body (EB) dissociation
Individual cardiomyocytes were isolated from in v/7ro-differentiated embryoid 
bodies (EBs) using collagenase-B according to a previously-published protocol 
(Maltsev et al., 1993). Briefly, 5-10 fluorescent, beating EBs were manually isolated 
using a pipette tip, and placed into an Eppendorf containing 1ml low calcium 
medium. The isolated cells were then spun down and re-suspended in 1ml enzyme 
medium (supplemented with 1 mg/ml collagenase-B) for 30 minutes at 37°C in order 
to dissociate the individual cells. The cells were then incubated in 1ml KB medium 
with gentle shaking at room temperature for one hour to complete their dissociation. 
The dissociated cells were then completely re-suspended in an appropriate volume o f 
normal ES culture medium and incubated overnight in 0.1% gelatin-treated flasks at 
37°C under normal cell culture conditions.
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Chapter 3
Nucleolar interaction with HICp40 
negatively-regulates Handl activity
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3.1. INTRODUCTION
Handl is essential for placentation and appropriate genesis of the heart. 
However, how its activity is regulated during these embryologically-distinct 
processes is largely unknown. Protein-protein interactions commonly regulate the 
activity of transcription factors and indeed numerous bHLH factors, and some non- 
bHLH factors, have been shown to bind to and modulate the activity of Handl 
(Chapter 1, Table 1.1). The promiscuous dimerisation properties of Handl led us to 
speculate that a wider range of non-bHLH factors may also bind the transcription 
factor to achieve functional effects. We thus conducted a yeast two-hybrid (Y2H) 
screen to identify novel Handl cofactors.
3.2. RESULTS
3.2.1. H andl interacts with the murine orthologue of 
HICp40
In order to identify proteins that interact with Handl and that may modulate 
its activity, we conducted a yeast two-hybrid (Y2H) screen using Handl as bait. This 
identified numerous Handl-interacting factors from a murine E9.5/ El 0.5 cDNA 
library (Hollenberg et aL, 1995; Appendix 8). The assay was validated by the 
identification of an interaction between Handl and A lfl, the murine orthologue of 
human E47, a class A bHLH factor previously shown to bind Handl (Hollenberg et 
a l , 1995).
Sequence analysis of one particular Handl interactor (identified by two 
independent clones in the Y2H screen) revealed an 89% nucleotide identity and 95% 
amino acid identity with the murine orthologue of the human inhibitor of MyoD 
family (I-mfa) domain containing protein (HIC). HIC is otherwise known as the 
MyoD family inhibitor containing protein (Mdfic) or as the protein derived from the
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kidney-derived transcript-1 (K dtl). HIC consists o f  two isoforms o f  molecular 
weights 32kDa and 40kDa, denoted HICp32 (o f 246 amino acid residues) and 
HICp40 (o f 355 amino acid residues), respectively. These arise from different 
translational initiator codons (GTGo for HICp40 and ATG591 for HlCp32; Thebault et 
al., 2000a). The structure o f HIC is shown in Figure 3.1.
GTG (109) 259 325
45 63 273 355
Figure 3.1. The structure of HIC, a novel H andl interactor identified in a yeast 
two-hybrid (Y2H) assay using H andl as bait.
HICp40, translated from an unusual GTG start codon, possesses two so-called nucleolar localisation 
signals (NoLS) at its N-terminus o f the form R/K-R/K.-X-R/K (shown in green). These are lacked by 
the HICp32 isoform, which is translated from a downstream ATG start codon. At the C-terminus o f  
both HIC isoforms there is a cysteine-rich I-mfa domain (shown in red), which has significant 
homology to the sequence o f the I-mfa domain in the ancestral I-mfa protein. The location of the 
Handl-interacting clones identified by Y2H in the HIC protein sequence, which overlap with the I-mfa 
domain, are shown in yellow.
Our Y2H clones represent the mouse orthologue o f  HIC, which we term 
murine I-mfa domain containing protein (MIC). This cDNA is represented in the EST 
database (GenBank accession number BB222360) and includes a coding region with 
81% amino acid identity to that o f HICp32. The full-length MIC gene can be located 
in ENSEMBL (NM _175088), where transcript information predicts an exon/ intron 
structure and further 5 ’ coding sequence with homology to the longer human isoform 
HICp40. Full-length HICp40 homologues in the monkey, chicken and various other 
species are also listed in ENSEMBL. We cloned the full-length MICp40 cDNA by 
extending the MICp32 cDNA (from an IMAGE clone) using a BAC sequence. By in 
vitro translation (IVT) we subsequently demonstrated that, like HICp40, MICp40 
encodes two proteins, o f  molecular weights 40kDa and 32kDa (data not shown).
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We then sought to corroborate the Handl-HICp40 interaction in vitro (Figure
3.2). This interaction was initially demonstrated by a pull-down assay using a GST- 
Handi fusion protein and in v//ro-translated HICp40 (Figure 3.2a). Furthermore, a 
HIS-HICp40 fusion protein could be co-immunoprecipitated using a FLAG-Handl 
antibody in transfected NIH-3T3 cells (Figure 3.2b). These results therefore 
collectively confirm that Handl interacts with the HIC protein in vitro.
4 5 -
2 9 -
5% IVT
GST-Hand1
G ST alone
control
5% input
FLAG-Hand1
-< H IS-H ICp40
Figure 3.2. Confirmation of the H andl-H IC  interaction by GST pull-down and 
co-immunoprecipitation assays.
A GST pull-down assay using a GST-Handi fusion protein and in v/7ro-translated HICp40 confirmed 
the ability o f Handl to interact with HICp40 (a). Co-immunoprecipitation o f  FLAG-Handl with HIS- 
HICp40 in transfected NIH-3T3 cells with polyclonal a-HIS antibody further corroborated the Handl- 
HICp40 interaction (b).
3.2.2. HICp40 sequesters H andl in the nucleolus
By virtue o f  their translation via alternative initiator codons, the two HIC 
isoforms have a common C-terminal I-mfa domain but their N-termini significantly 
differ. This has implications for the sub-cellular localisations o f the two isoforms. 
The N-terminus o f HICp40 contains two highly-basic, so-called nucleolar localisation 
signals (NoLS) between residues 45 and 63 in its extended (I09aa) N-terminus (o f  
the form R/K-R/K-X-R/K, specifically RKRR and RRRR), which are lacking in 
HICp32 (Figure 3.1). The use o f  a secondary, upstream codon has been reported 
previously to generate a longer isoform o f a protein that contains a NoLS, for 
example, in the case o f  PTHrP (Lam et al., 2000). Thus, whilst HICp40 localises to 
nucleoli, with additional cytoplasmic fluorescence, HICp32 assumes a granular
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cytoplasmic distribution with only weak nuclear staining (Thebault et al., 2000a; 
Thebault et al., 2000b).
In light of the differences in subcellular location of the HIC isoforms, we next 
sought to investigate whether interaction of Handl with these proteins occurs in 
discrete subcellular compartments. A Handl-EGFP fusion protein was generally 
nuclear-wide in transfected NIH-3T3 cells 24 hours post-transfection. However, a 
small percentage of cells (15.0%+1.55) exhibited nucleolar fluorescence 
(mean±S.E.M.; n (the number of cells counted) =240; p<0.01; Figure 3.3). This is in 
contrast with transfected H9c2 cells, a rat DB1X heart myoblast (ventricular) cell 
line, of which 98.6%±2.70 exhibited nucleolar Handl-EGFP 24 hours post­
transfection (mean± S.E.M.; n=250; p<0.01). However, co-transfection of NIH-3T3 
cells with Handl-EGFP and an expression construct encoding HICp40 resulted in the 
restriction of the largely nuclear-wide fluorescent fusion protein almost exclusively to 
the nucleolar compartment (85.4%±1.24 of co-transfected cells exhibited nucleolar 
EGFP fluorescence 24 hours post-transfection (mean±S.E.M.; n=210; p<0.01; Figure
3.3). Handl-EGFP localisation to nucleoli was independent of fixation method and 
was confirmed by immunostaining to illustrate co-localisation with the nucleolar 
protein C23 (Nucleolin), a factor involved in ribosomal biogenesis. Interestingly, co­
transfection of NIH-3T3 cells with Handl-EGFP and an expression construct 
encoding HICp32 did not result in the restriction of the largely nuclear-wide 
fluorescent fusion protein to the cytoplasm. In conclusion, these results demonstrate 
that the interaction of Handl with HICp40 results in the nucleolar sequestration of 
Handl.
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H
Figure 3.3. HICp40 sequesters H andl-EG FP in the nucleolus.
Handl-EGFP is predominantly localised throughout the nucleus in transfected N1H-3T3 cells with a 
small percentage (~15%) exhibiting weak staining in the nucleolus as confirmed by immunostaining 
for the nucleolar protein Nucleolin (C23; top row). However, upon ectopic expression o f HICp40, 
>85% of cells exhibit nucleolar-localised Handl-EGFP (bottom row). See text for statistical 
significance.
3.2.3. Nucleolar sequestration of H andl negatively-regulates 
its transcriptional activity
In light o f  previously-described roles for the HIC isoforms as negative 
regulators o f  specific developmental pathways (discussed later in this chapter (section 
3.3.1)), we then investigated the functional consequences o f  their interaction with 
Handl. To this end, we carried out transient transfection assays in NIH-3T3 cells 
(Figure 3.4). HICp40 repressed the ability o f a Hand 1-E-factor (E l2) heterodimer to 
trans-activate a ‘mock’ Handl target gene. This comprised six high affinity Thing 1 
box (Thl) sequences upstream o f a minimal a-cardiac actin promoter and a 
luciferase cassette (Hill and Riley, 2004). This result revealed that HICp40 
negatively-regulates Handl activity in vitro.
Notably, HICp32, which lacks the N-terminal nucleolar localisation signals 
present in HICp40, was unable to abrogate Handl transcriptional activity to the 
extent o f  full-length HICp40 in the described reporter assay (Figure 3.4). Thus the 
HICp40 N-terminal nucleolar localisation signal is necessary for optimal Handl
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repression. Moreover, a HICp40 deletion mutant lacking the C-terminal I-mfa 
domain (HICAC) could not significantly repress Handl-E12-mediated reporter gene 
activity (Figure 3.4). Thus the C-terminal I-mfa domain of HICp40 is necessary for 
its interaction with and repression of Handl. The fact that the HICAC protein could 
not significantly sequester Handl-EGFP to the nucleoli o f NIH-3T3 cells in a similar 
assay to that described in Figure 3.3 adds weight to this conclusion (data not shown).
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Figure 3.4. HICp40 negatively regulates Handl activity.
In a transient transfection reporter assay in NIH-3T3 cells, the Handl-El 2 heterodimer can activate 
expression of a ‘mock’ Handl target gene comprising six high-affinity Handl-binding sites (Thingl 
boxes) upstream of a minimal a-cardiac actin promoter and a luciferase cassette (dotted-bar). 
However, HICp40 significantly represses Handl-El2 activity in this assay (diagonal lined-bar). 
HICAC, a HICp40 deletion mutant lacking the C-terminal I-mfa domain, cannot significantly repress 
Handl-El2 heterodimer activity (horizontal-lined bar). HICp32, which lacks the N-terminal nucleolar 
localisation signals present in the N-terminus of HICp40, can only modestly repress Handl-El2 
heterodimer activity (vertical-lined bar). Measurements are mean±S.E.M.; n=3; *** indicates p<0.001.
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We also investigated the regions o f  Handl required for its functional 
interaction with HICp40 (Figure 3.5). An EGFP fusion with the isolated Handl 
bHLH domain (b H L H Handi-EGFP) does not localise to the nucleolus (Figure 3.5a). 
Furthermore an EGFP fusion with a fragment o f Handl containing its poly-histidine 
stretch and flanking sequence (HandlHiS-EGFP), is nuclear-wide (Figure 3.5b). In 
both cases, this is true even upon HICp40 over-expression (data not shown). Both 
fusion proteins were expressed at detectable levels in transfected cells, as assessed by 
western blot analysis using an anti-EGFP antibody. In conclusion, neither the Handl 
bHLH domain nor the Handl poly-histidine stretch are sufficient for interaction with 
HICp40.
a.
U/T
►  -
b .
U/T
► --------
b H L H ^ -E G F P
H andl^-EG FP
m mIvIgjS
Figure 3.5. Neither the H andl basic domain, nor the H andl poly-histidine 
stretch, is sufficient for nucleolar interaction with HICp40.
An EGFP fusion with the isolated bHLH domain o f Handl (bH LH Handi-EGFP) cannot localise to the 
nucleoli o f transfected NIH-3T3 cells (a). An EGFP fusion with a fragment o f Handl containing the 
N-terminal histidine-rich domain, HandlHiS-EGFP, is also nuclear-wide (b). Presented also are western 
blot analyses using an anti-EGFP antibody to illustrate expression o f the EGFP fusion proteins in 
transfected cells. U/T: untransfected.
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3.2.4. HICp40 is co-expressed with Handl in several tissues 
during development
We next investigated whether the Handl-HICp40 interaction is likely to occur 
in vivo (Figures 3.6 and 3.7). In Rcho-1 cells, a rat cell line which was discussed in 
Chapter 1 (section 1.6), HICp40-EGFP is nucleolar (Figure 3.6a). Furthermore, the 
rat orthologue o f HICp40, ‘RlCp40\ is endogenously expressed in both Rcho-1 stem 
cells and Rcho-1 cells induced to differentiate over an eight-day time-course into 
trophoblast giant cells, as determined by RT-PCR (Figure 3.6b).
a.
HICp40-EGFP ct-C23
Diff e re ntia tion /da ys
RICp40’
Tubulin
Figure 3.6. HICp40-EGFP localises to Rcho-1 stem cell nucleoli and the rat 
orthologue o f HICp40 is endogenously expressed in Rcho-1 cells during their 
differentiation.
HICp40-EGFP is predominantly nucleolar, but with some cytoplasmic fluorescence, in Rcho-1 
trophoblast stem cells (a). Rcho-1 trophoblast stem cells endogenously express weak but detectable 
levels o f transcripts o f the rat orthologue of HICp40, ‘RICp40’, as assessed by RT-PCR, and its 
expression is maintained during their differentiation into trophoblast giant cells over an eight-day time- 
course (b).
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We then determined the endogenous expression pattern o f MICp40 (Figure 
3.7). Whole mount in situ hybridisation was performed on E9.5 wild-type embryos 
using a probe for full length HICp40. This showed that endogenous MICp40 is 
expressed in the LV and OFT o f the developing heart, and as such is co-expressed 
with Handl during embryogenesis (as reviewed in Chapter 1, section 1.3.2.2). 
Collectively, these findings strongly suggest that the Handl-HICp40 interaction, 
resulting in Handl nucleolar sequestration, may regulate Handl activity in vivo.
Figure 3.7. H IC p40  is co-expressed with H a n d l  in the developing heart.
Whole-mount in situ hybridisation using a probe for full length HICp40 shows that the murine 
orthologue o f HICp40, MICp40, is expressed in the left ventricle (lv) and outflow tract (ot) o f the 
developing heart, as well as in the first branchial (pharyngeal) arch (ba), aortic arch arteries (aa) and 
the tail bud (tb).
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3.2.5. Members of the bHLH family closely-related to 
H andl do not localise to the nucleolus
We finally investigated whether bHLH transcription factors closely-related to 
Handl localise to the nucleolus (Figure 3.8). EGFP fusions with both the closely- 
related bHLH factors Hand2 (Figure 3.8a) and MyoD (Figure 3.8b) are nuclear-wide 
in transfected NIH-3T3 cells. This suggests that nucleolar localisation, at least among 
closely-related members, is specific to Handl within the bHLH family.
Hand2-EGFP a-C23 Merge
MyoD-EGFP a-C23 Merge
Figure 3.8. Nucleolar localisation o f H andl-EG FP is not observed with EGFP  
fusions of the related bHLH factors Hand2 and MyoD.
The related bHLH transcription factor-EGFP fusion proteins, Hand2-EGFP (a) and MyoD-EGFP (b), 
are nuclear-wide in transfected Rcho-1 stem cells.
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3.3. DISCUSSION
Using a Y2H screen with Handl as bait, we identified a negative regulator of 
H andl, the murine orthologue of the human I-mfa domain-containing protein (HIC). 
HIC comprises two isoforms, HICp40 and HICp32. The data presented in this chapter 
strongly suggest that the interaction of Handl with either factor, but particularly with 
HICp40, results in the negative-regulation of Handl transcriptional activity. HICp40 
achieves this by sequestering Handl in the nucleolus. However, the mechanism 
underlying HICp32-dependent repression of Handl is, as-yet, unclear, but does not 
seem to rely on Handl cytoplasmic sequestration. The co-expression and co­
localisation of Handl with the murine orthologue of HIC in rodent trophoblast and 
during cardiac morphogenesis moreover suggests that this mechanism may control 
Handl activity in vivo.
3.3.1. HIC isoforms negatively-regulate Handl activity
In our Y2H screen, the region of HIC that interacted with Handl and which 
was indispensable for its repression of Handl mapped to a portion o f its cysteine- 
rich, C-terminal I-mfa-domain. The I-mfa domain of HIC has a high degree of 
homology to the corresponding I-mfa domain of the ancestral I-mfa protein (77% 
identity and 81% similarity; Thebault et al., 2000a). Indeed, the two proteins, which 
are found in all vertebrates, are thought to have arisen by duplication, supported by 
their similar intron-exon structures and homologous flanking genes (Wang et al., 
2007). Without exception, the determined roles of both I-mfa and HIC depend 
absolutely on the presence of the I-mfa domain, reflecting its importance in protein- 
protein interactions.
During somitogenesis in the mouse, the I-mfa protein is confined to cells of 
the ventral somite, the sclerotome, and here it inhibits the potent myogenic bHLH 
factors MyoD, Myf5, Mrf4 and Myogenin to prevent myogenesis (Chen et al., 1996). 
I-mfa is also thought to interact with and negatively-regulate the chondrogenic bHLH 
factor Scleraxis, and as such I-mfa-mx\\ embryos exhibit delayed caudal neural tube
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closure and skeletal patterning defects (Kraut et al., 1998). The I-mfa protein also has 
a crucial role during placentation. During this process it inhibits Mash2, a bHLH 
factor required for TS cell maintenance (reviewed in Chapter 1, section 1.2.4.2), by 
sequestering it in the cytoplasm. This contributes to the process of TG cell 
differentiation. Appropriately, I-mfa is strongly-expressed in cells at the periphery of 
the EPC and in SGCs, and an J-mfa-nu\\ mouse is embryonic lethal at E9.5 due to a 
significantly-reduced number of SGCs (Kraut et al., 1998). Furthermore I-mfa over­
expression induces precocious TG cell differentiation in the Rcho-1 trophoblast stem 
cell model, whilst conversely an I-mfa-null trophoblast stem cell line cannot undergo 
TG cell differentiation in culture (Kraut et al., 1998).
Most importantly for our study, an interaction between I-mfa and Handl, 
which is dependent on the I-mfa domain, has previously been reported in trophoblast 
cells (Kraut et al., 1998). However, the functional significance of this interaction 
remains unknown. Thus our results are in agreement with previous studies that report 
a role for I-mfa-domain-containing proteins in the negative regulation of factors 
involved in rodent placentation. Whilst no functional consequence was previously 
attributed to the interaction of the I-mfa protein with Handl, we show that the 
interaction of Handl with I-mfa domain-containing iso forms negatively-regulates the 
bHLH factor.
Similarly, the HIC proteins also play crucial roles in post-transcriptional 
repression of developmental factors. Reminiscent of I-mfa, every reported function of 
HIC is absolutely dependent on its interaction with other proteins via its C-terminal I- 
mfa domain. As such, deletion mutants lacking this portion are unable to mimic the 
full-length protein in relevant assays (Chen et al., 1996; Kraut et al., 1998). The HIC 
isoforms were first identified by Thebault and colleagues on the basis of their 
differential regulation of human retroviral promoters in the presence of viral 
transcriptional activators (Thebault et al., 2000a). Specifically, the HIC proteins 
enhance transcription from the Human T-Cell Leukemia Virus-1 (HTLV-1) long 
terminal repeat (LTR) promoter in the presence of the HTLV-1 trans-activator Tax, 
but down-regulate Human Immunodeficiency Virus-1 (HIV-1) pro viral transcription 
in the presence o f the HIV-1 trans-activator Tat (Thebault et al., 2000a).
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Later studies implicated the Xenopus orthologues of the HIC proteins, 
XICp40 and XICp32, in embryonic axis specification (Kusano and Raab-Traub, 
2002; Snider et al., 2001; Snider and Tapscott, 2005). Specifically, the XIC proteins 
bind to and mask the DNA-binding domain of the ventralising, HMG-box 
transcription factor Tcf3 to repress Wnt-dependent signalling. This blocks Tcf3- 
dependent expression of Wnt target genes a pre-requisite for the activation of the 
dorsalising homeodomain transcription factor Siamois and formation of the dorsal 
(Spemann) organiser (Snider et al., 2001; Snider and Tapscott, 2005). Embryos 
injected with a morpholino to XIC  mRNA thus lacked head structures, a neural tube 
and paraxial mesoderm, and were down-regulated for several dorsal organiser factors 
such as goosecoid and Cerberus (Snider and Tapscott, 2005). Conversely, another 
study revealed that the XIC proteins have a stimulatory effect on Wnt signalling, 
namely by binding the glycogen synthase kinase-3 p-binding site on Axin and 
preventing Axin-mediated phosphorylation of P-Catenin as a pre-requisite for its 
degradation. p-Catenin is then able to translocate to the nucleus and activate T-cell 
factors (Tcf) and lymphocyte enhancer factors (Lefs), which activate their Wnt target 
genes (Kusano and Raab-Traub, 2002). This study also showed that XIC binds Axin 
to prevent its interaction with Mekkl, so blocking downstream c-Jun N-terminal 
kinase (Jnk) signaling in the nucleus. However, the functional significance o f these 
interactions and effects are currently unknown. Overall, our results are in agreement 
with previous studies that have reported a role for I-mfa domain-containing proteins 
in the negative regulation of developmental factors, including members of the bHLH 
transcriptional factor super-family.
In conclusion, the HIC proteins can repress the transcriptional activity of 
Handl in vitro. Importantly, the C-terminal I-mfa domain o f HIC, a portion of which 
interacted with Handl in our Y2H assay and which is present in both HIC iso forms, 
was necessary for this effect. This is in agreement with previously-determined roles 
for HIC and the ancestral I-mfa protein in the negative regulation o f developmental 
factors. In many cases these targets, like Handl, are members of the bHLH family 
and have roles in determining cell fate.
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3.3.2. HICp40 sequesters Handl in the nucleolus
Our results demonstrate that HICp40 sequesters Handl in the nucleolus and 
that this is specific to Handl amongst closely-related bHLH family members. We 
show that the consequence of Handl nucleolar sequestration is its transcriptional 
repression. The nucleolar sequestration of a target factor by HICp40 may not be 
without precedent. HICp40 activates HTLV-1 pro viral transcription from the LTR 
promoter by blocking bHLH transcription factor activity (Thebault et al., 2000a). 
This occurs because the HTLV-1 trans-activator Tax activates pro viral transcription 
by binding co-activators such as CBP, which are also bound to by certain bHLH 
factors such as c-Myb (Colgin and Nyborg, 1998). HICp40 may repress bHLH 
factors by sequestering them in the nucleolus, supported by our findings regarding 
Handl presented in this chapter. Conversely, the repression of HIV-1 pro viral 
transcription from the LTR promoter by HICp40 (Thebault et al., 2000a) is thought to 
be underpinned by the nucleolar sequestration of the HIV-1 trans-activator Tat in the 
nucleolus (Young et al., 2003). Of note, HICp40 also binds and inhibits, perhaps via 
nucleolar sequestration, the Cyclin T1 component of the positive transcription 
elongation factor b (pTEFb) complex (Young et al., 2003). This may block pTEFb- 
dependent phosphorylation of the C-terminal domain of RNA Pol II, which is 
required for the transcriptional elongation of HIV-1 transcripts (Zhu et al., 1997). 
Thus our findings are in agreement with several of the established roles for HICp40 
in the repression o f factors, often via nucleolar sequestration.
Handl nucleolar sequestration may occur either via active transport into the 
organelle in complex with HICp40, which may shuttle between the nuclear and 
nucleolar compartments, or via passive diffusion followed by HICp40-dependent 
nucleolar retention. With respect to the latter possibility, the nucleolus lacks a 
membrane and so any soluble protein should be able to diffuse in and out of the 
organelle. By the ‘hit and run’ model, passive diffusion of nucleoplasmic proteins 
into the nucleolus is thought to be followed by non-specific retention of only those 
proteins which possess a nucleolar localisation signal (NoLS) (van Eenennaam et al., 
2001; Misteli, 2000; Olson, 2002). In contrast, active transport of proteins into the 
nucleolus is generally considered unlikely. Although a consensus sequence has not 
been identified, several viral proteins, for example HIV-I Rev and Tat, contain
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sequences with homology to cellular NoLS motifs and depend on these to localise to 
the nucleolus and hijack the host ribosome biogenesis machinery and/ or as a pre­
requisite for proviral replication (reviewed by Hiscox, 2007; Sirri et al., 2008). The 
NoLS is usually highly-basic, containing mainly arginine and lysine residues 
(reviewed by Thebault and Mesnard, 2001). As such, the motif is thought to form 
electrostatic interactions with negatively-charged nucleic acids or acidic components 
of the ribosome biogenesis machinery. For example, the nucleolar factors Ubf and 
C23 bind rDNA (Maeda et al., 1992; Heine et al., 1993; Schmidt-Zachmann and 
Nigg, 1993) and pRB binds the B23 factor, which has roles in ribosomal biogenesis 
(Takemura et al., 2002). A ribosome biogenesis machinery-attached scaffold of 
protein anchors, which include HICp40, is thus formed, and these possess high- 
affinity binding sites for specific nucleoplasmic proteins, which have neither a NoLS 
nor an obvious nucleolar role. Currently, the mechanisms underlying nucleolar 
release are largely unknown, but, in light o f the consensus view of nucleolar 
retention, are likely to require energy and/ or post-translational modification.
Our data thus suggest that binding of HICp40 to Handl is necessary and 
sufficient for Handl nucleolar sequestration. Our observation that a higher proportion 
of transfected H9c2 cells exhibit nucleolar-localised Handl-EGFP than transfected 
NIH-3T3 cells may in this regard be due to the presence or absence of HICp40 
cofactors or other proteins involved in nucleolar translocation of Handl, or otherwise 
due to variations in the abundance of HICp40 between cell lines. Further work is 
required to investigate these possibilities, but it is interesting that a recent study 
indicated a variation in the abundance of HIC mRNA between several cell lines 
(Wang et al., 2007). At present, the differences in Handl-EGFP sub-cellular 
localisation between cell lines are unclear.
Importantly, our data rule out the putative, albeit degenerate, NoLS of the 
form R/K-R/K-X-R/K in the Handl basic domain (RKGSGPKKERRR) as being 
sufficient for Handl nucleolar localisation. A possible involvement of this sequence 
in the nucleolar localisation of Handl was suggested by two observations. Analogous 
sequences in the related zebrafish bHLH factor Myf5 are required for nucleolar 
localisation (Wang et al., 2005) and Handl-EGFP remains nucleolar in the HICp40- 
deficient cell line, human breast epithelial MCF-7 cells (Wang et al., 2007; data not
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shown). However, two pieces of data argue against HICp40-independent Handl 
nucleolar localisation. An EGFP fusion with Hand2, which also possesses a similar, 
putative NoLS motif in its basic domain, does not localise to the nucleolus. 
Furthermore, the highly-related bHLH family member Twistl has been localised 
throughout the nucleus of several cell types (A. Firulli, personal communication). 
This suggests that HICp40 probably binds Handl specifically amongst members of 
the bHLH family. Additionally, the isolated Handl bHLH domain is unable to traffic 
to nucleoli when fused to EGFP. Nevertheless, the localisation of Handl-EGFP to the 
nucleolus in a HICp40-deficient background gives some insight into the mechanistic 
basis o f Handl nucleolar sequestration. Specifically, this suggests that HICp40 is not 
required for the active transport of Handl into the nucleolus. Thus Handl is likely to 
enter the nucleolus either in complex with other protein(s) or passively by diffusion 
and the role of HICp40 may be restricted to the subsequent retention of Handl in the 
organelle.
Despite these findings, the sequestration of some factors in the nucleolus is 
reliant on the nucleolar sequesteror unmasking a ‘cryptic’ NoLS in the nucleoplasmic 
target protein. This is thought to reinforce the negative regulatory mechanism. For 
example, Mdm2 possesses a ‘quiescent’ NoLS that is only activated by its binding to 
its nucleolar anchor, p ^ ^ * "  (Lohrum et al., 2000). Thus it cannot be ruled out that 
binding o f HICp40 to Handl may unmask a cryptic NoLS in Handl, possibly the 
putative signal in its basic domain. Nevertheless, contrary to this hypothesis is the 
fact that an EGFP fusion with the isolated Handl bHLH domain is unable to localise 
to the nucleolus. Thus, at present, it is unclear as to whether HICp40 is sufficient for 
Handl localisation to the nucleolus. Indeed, the fact that our Y2H screen identified an 
interaction between Handl and another nucleolar component (Fibrillarin-2; Appendix 
8) hints that other proteins may be involved in the nucleolar sequestration and/ or 
retention of the transcription factor.
Our data suggest that the C-terminal I-mfa domain o f HICp40 is necessary for 
its interaction with Handl. However, only by carrying out assays employing the 
isolated I-mfa domain would we be able to investigate whether this domain is 
sufficient to bind Handl, or whether Handl also binds other regions of HICp40. 
Furthermore it is currently unknown which domain(s) of Handl bind HICp40.
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Preliminary assays show that the bHLH domain of Handl is not sufficient, since an 
EGFP fusion with this domain failed to localise to the nucleolus, even upon HICp40 
over-expression. We hypothesised that the Handl-HICp40 interaction could be 
underpinned, in part, by contacts between the poly-histidine stretch in the N-terminus 
o f Handl and cysteine residues in the HIC I-mfa domain. HIC and I-mfa bind 
histidine-rich regions in gonadotrophin-inducible transcription factor 1 (Giotl) and in 
the Cyclin T1 subunit of the pTEFb complex (Mizutani et al., 2001; Young et al., 
2003; Wang et al., 2007). These interactions are dependent upon the cysteine-rich I- 
mfa domain coordinating bivalent metal ions in combination with histidine residues 
in the target protein. Importantly the N-terminal poly-histidine stretch is absent in the 
closely-related, but non-nucleolar, Hand2 factor. However, despite these precedents, 
our data suggest that the Handl poly-histidine stretch is not sufficient for HICp40 
interaction and Handl nucleolar localisation. Nevertheless, despite these findings, the 
bHLH domain and the poly-histidine stretch may still be involved in binding HICp40, 
that is, they may be necessary for the interaction. This could be assessed by 
determining whether EGFP fusions with Handl mutants lacking these domains 
localise to the nucleolus. Ultimately, GST-pull down and co-immunoprecipitation 
assays (as conducted to generate the data presented in Figure 3.2) employing Handl 
deletion fragments would need to be carried out to definitively map interaction 
domains.
Notably, the cytoplasmic HICp32 isoform is still able to moderately abrogate 
Handl activity. HICp32 is cytoplasmic, so we investigated whether it was able to 
restrict Handl to this subcellular compartment in a method similar to the negative 
regulation, mediated by cytoplasmic sequestration, of the Mash2 and myogenic 
bHLH factors by I-mfa (Chen et al., 1996; Kraut et al., 1998). However, this was not 
the case, suggesting that HICp32 may instead interfere with the DNA binding activity 
o f Handl, another mechanism by which I-mfa represses the activity of its bHLH 
targets (Chen et al., 1996; Kraut et al., 1998). Further investigation will, of course, be 
required to confirm this hypothesis, but it is interesting that I-mfa, as described, 
interacts with Handl but does not repress its activity in vitro (Kraut et al., 1998). This 
implies that sequences outside of the I-mfa domain of HICp32 are required for the 
repression of Handl. Despite this, it is clear that nucleolar sequestration, reliant upon 
the HICp40 N-terminal NoLS motifs, is required for maximal, possibly biologically-
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relevant, Handl repression. In this regard it can be inferred that HICp32-dependent 
repression of Handl, unlike its confinement to the nucleolus, cannot completely 
block its biological activity. It is also interesting in light of the modest negative 
regulation of Handl by HICp32 that several other nucleolar anchors also have a 
secondary, nucleolus-independent mode of regulating their target factor. For 
example, although p l9 ARF sequesters the p53 agonist Mdm2 in the nucleolus to 
enhance p53 stability (Tao and Levine, 1999; Weber et al., 1999) and p l9 ARF 
isoforms lacking the signals required for nucleolar localisation are thought to bind to 
and stabilise p53 to enhance its activity independent of effects on Mdm2 subcellular 
localisation (Llanos et al., 2001). Additionally, whilst Cfil (Netl) primarily 
sequesters the Cdcl4 phosphatase in the nucleolus to prevent it dephosphorylating its 
nuclear targets and promoting exit from mitosis (Shou et al., 1999; Visintin et al., 
1999), cells co-transfected with Cdcl4 and Cfil exhibit a Cdcl4 loss-of-function 
phenotype despite Cdcl4 being nucleoplasmic. This suggests that Cfil directly 
affects the catalytic activity of Cdcl4 independently of nucleolar sequestration 
(Visintin et al., 1999). In conclusion, the underlying molecular basis of HICp32- 
dependent repression o f Handl transcriptional activity is unknown and requires 
further investigation.
In conclusion, HICp40 is required for Handl nucleolar localisation and this 
has the effect of repressing Handl transcriptional activity. On the basis of these data, 
we can conclude that HIC and I-mfa repress their target transcription factors in a 
similar way. Both factors interact with all o f their target proteins via their I-mfa 
domains and furthermore negatively-regulate them via subcellular confinement, 
either to the nucleolus by HICp40 or to the cytoplasm by I-mfa (Chen et al., 1996; 
Kraut et al., 1998; Thebault et al., 2000a; reviewed by Thebault and Mesnard, 2001; 
Snider et al., 2001; Kusano and Raab-Traub, 2002; Snider and Tapscott, 2005; data 
presented in this study). This may restrict the access of these target factors to their 
binding partners and/ or target genes and so limit their biological activity. At present, 
however, it is unclear which regions of Handl are required for HICp40 interaction 
and this is a subject of ongoing studies.
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3.3.3. Summary and concluding remarks
The nucleolus has been traditionally viewed as a ‘ribosome biogenesis 
factory’ (reviewed by Perry, 1966). However, more recently, proteomic studies have 
demonstrated the nucleolar localisation of transcription factors, cell cycle regulators 
and tumour suppressors that are unlikely to play any part in the traditional roles of 
this organelle (Scherl et al., 2002; Andersen et al., 2002; Andersen et al., 2005). This 
has led to the suggestion that the nucleolus also acts as a molecular ‘safe’ or ‘sink’ to 
retain and negatively regulate proteins, preventing them from interacting with their 
downstream protein partners or target genes until a specific cell cycle stage or 
metabolic state. Indeed, this is a mechanism not without precedent among 
transcription factors. For example, the activity of p53 is modulated by p l9 ARF- 
dependent nucleolar sequestration of its negative regulator, Mdm2 (Tao and Levine, 
1999; Weber et al., 1999). Other examples include the inhibition of c-Myc-induced 
progression through the cell cycle by the sequestration of the transcription factor in 
the nucleolus by p lO ^ 1" (Datta et al., 2004) and the modulation of cell proliferation 
by NoBP-dependent nucleolar sequestration of Fgf3 (Reimers et al., 2001).
In agreement with these previous studies, we have identified an interaction 
between Handl and HICp40, a factor known to negatively-regulate several 
developmental factors in a post-translational fashion. The functional basis of this is 
the sequestration of Handl in the nucleolar compartment. This may occur during 
development to prevent Handl from binding its nucleoplasmic protein partners and 
activating its target genes until a specific cell cycle stage or metabolic state. 
Moreover, since the nucleolus lacks a membrane, this stockpile o f pre-existing Handl 
could be instantaneously released to permit a rapid response to molecular and/ or 
cellular cues, which could occur without the need for transcriptional up-regulation or 
even nuclear import.
Importantly, HICp40-dependent nucleolar sequestration is likely to regulate 
the activity o f Handl in vivo. Although HIC is chiefly expressed in lymphoid tissues, 
Thebault and colleagues localised embryonic murine HIC mRNA to organs in which 
Handl is expressed, including the developing small intestine (Thebault et al., 2000a). 
Nevertheless, their northern blot analysis was restricted to a limited number of tissues
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and there was no information on HIC expression in the heart. We have, however, 
demonstrated a co-localisation of Handl and the murine orthologue of HICp40 in the 
developing mouse heart by in situ hybridisation experiments. Moreover, the two 
mRNA species particularly overlapped in the left ventricular myocardium and 
outflow tract (OFT). Furthermore, we have demonstrated nucleolar localisation and 
endogenous expression of the rat orthologue of HICp40 in Rcho-1 trophoblast stem 
cells and their TG cell derivatives, coincident with Handl.
Since Handl is involved in the terminal differentiation o f trophoblast and 
cardiomyocyte cells (Riley et al., 2000; Hughes et al., 2004; reviewed in Chapter 1, 
sections 1.2.4 and 1.3.2), its nucleolar sequestration and negative-regulation by 
HICp40 may contribute to determining cell fate. For example, nucleolar localisation 
and inactivation of Handl may correlate with a trophoblast stem cell or cardiac 
precursor cell decision to proliferate. Upon Handl activation through its release into 
the nucleoplasm, these cells could then be committed to differentiation. Thus to 
assess the physiological significance of the findings of this chapter in vivo, we next 
investigated the biological relevance of Handl nucleolar anchorage in an appropriate 
cell model and our findings are presented in the following chapter.
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Chapter 4
Nucleolar sequestration and release 
regulates Handl activity in rodent
trophoblast
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4.1. INTRODUCTION
Handl plays an essential role in the differentiation of rodent trophoblast, the 
first lineage to arise in the developing embryo (reviewed in Chapter 1, section 1.2.4). 
Study of the regulation and function of Handl in this lineage is difficult, however, 
since trophoblast stem (TS) cells are difficult to maintain and manipulate in culture 
(S. Tanaka, personal communication). Thus we employed the rat choriocarcinoma-1 
(Rcho-1) TS cell line (reviewed in Chapter 1, section 1.6), to investigate the 
biological significance of Handl nucleolar sequestration in vivo.
Rcho-1 cells represent a faithful model of TS cells. They can be induced to 
exit the mitotic cell cycle and undergo endoreduplication concomitant with 
differentiation into so-called trophoblast giant (TG) cells (Kraut et al., 1998; Scott et 
al., 2000; Hughes et al., 2004; Sahgal et al., 2006). Importantly for our study, Rcho-1 
cells endogenously express Handl and its expression is necessary and sufficient for 
TG cell differentiation (Cross et al., 1995; Kraut et al., 1998; Scott et al., 2000). 
However, the precise role of Handl and how its activity is regulated during this 
process are unknown. Handl expression is detectable in Rcho-1 TS cells, albeit at a 
lower level compared to differentiated Rcho-1 TG cells (Cross et al., 1995), so the 
activity of Handl in this lineage may be post-translationally regulated. In this 
chapter, we show that the activity of Handl is regulated during Rcho-1 differentiation 
by its nucleolar sequestration and release, and discuss the implications o f this finding.
4.2. RESULTS
4.2.1 Nucleolar Handl-EGFP relocates to the nucleoplasm  
during TG cell differentiation
In order to investigate whether Handl nucleolar localisation plays a role in its 
regulation in rodent trophoblast, we ectopically expressed a Handl-EGFP fusion 
protein in Rcho-1 stem cells cultured in conditions favouring Rcho-1 stem cell
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maintenance (20% FBS-supplemented medium). We then tracked the subcellular 
localisation o f Handl-EGFP over a 72 hour period post-transfection (Figure 4.1).
In proliferating Rcho-1 stem cells 24 hours post-transfection, Handl-EGFP 
was almost exclusively localised to nucleoli. However, after 48 and 72 hours post­
transfection, Handl-EGFP gradually dispersed from nucleoli to assume a nuclear- 
wide distribution. This was coincident with the differentiation o f  the transfected 
Rcho-1 stem cells to TG cell differentiation (Figure 4.1). Additionally, the kinetics o f  
the change in Handl-EGFP localisation were recorded using time-lapse video­
microscopy. This revealed Handl-EGFP release from the nucleolus over a 12-hour 
period as individual transfected cells began to differentiate, which was coincident 
with decreased motility and an increase in cell size (Movie 4.1, Appendix 10).
Handl-EGFP
Figure 4.1. Release o f nucleolar H andl-EG FP coincides with Rcho-1 stem cell 
comm itm ent to a trophoblast giant cell fate.
In Rcho-1 stem cells, Handl-EGFP localises exclusively to the nucleoli. However, nucleolar Handl- 
EGFP becomes nuclear-wide as these cells undergo trophoblast giant cell differentiation over a 72 
hour period post-transfection.
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Quantitatively, the relative proportions o f transfected cells with nucleolar 
versus nuclear-wide EGFP fluorescence and the number o f  fluorescent TG cells were 
determined at each time point (Figure 4.2). These cell counts revealed that the nuclear 
dispersal o f  Hand 1-EGFP during the 72-hour time course o f the experiment was 
statistically significant (Figure 4.2a). Moreover, the number o f fluorescent TG cells at 
the 72-hour point was significantly higher than the number o f  fluorescent TG cells 24 
hours after transfection and statistically greater than the number o f Rcho-1 stem cells 
at the time-point (Figure 4.2b). This confirmed that nucleolar release o f  Hand 1-EGFP 
correlates with TG cell differentiation.
a. b.
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Figure 4.2. The relocation of H andl-EG FP that coincides with Rcho-1 stem cell 
commitment to differentiation is statistically-significant and correlates with the 
differentiation process.
Cell counts o f Handl-EGFP-expressing Rcho-1 cells reveal a significant reduction in nucleolar fusion 
protein with a corresponding elevation in nuclear-wide localisation over a 72 hour period post­
transfection (a). Cell counts o f the same populations reveal an increasing number o f fluorescent Rcho- 
1 giant cells during the course o f the experiment (b). Measurements are mean±S.E.M.; n (the number 
o f cells counted per treatment at each time point) = 450; * indicates p<0.05; ** indicates p<0.01; *** 
indicates pO.OOl.
Importantly, these figures were corrected for spontaneous Rcho-1 
differentiation in medium that ordinarily maintains Rcho-1 stem cell proliferation 
(5.9% per 24-hour period; Nakayama et al., 1998; Scott et al., 2000), and for an 
observed increase in differentiation rate due to the transfection with a construct
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encoding EGFP alone (10.3% per 24-hour period; mean±S.E.M.; n=250; PO.Ol). 
This applies to all cell counts in this thesis.
We next undertook experiments to confirm that Hand 1-EGFP, upon its release 
from the nucleolus, promotes normal TG cell differentiation. TG cells derived from 
Rcho-1 stem cells by a change in serum conditions (20% FBS to 10% horse serum) 
dramatically up-regulate the TG cell marker PL-1 and undergo cytoskeletal 
rearrangement, as assessed by phalloidin staining for F-actin (Figure 4.3a). 
Importantly, Rcho-1 stem cells induced to differentiate by ectopic Hand 1-EGFP 
expression in conditions favouring Rcho-1 stem cell maintenance produce TG cells 
with equivalent PL-1 up-regulation and cytoskeletal rearrangement (Figure 4.3b). 
These data confirm that the TG cells derived from Rcho-1 stem cells transfected with 
Hand 1-EGFP were bona fide. In conclusion, these results collectively demonstrate 
that nucleolar Hand 1-EGFP is released and becomes nuclear-wide during the 
differentiation of transfected Rcho-1 stem cells into bona fide TG cells.
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Figure 4.3. H andl-EGFP-induced differentiation of Rcho-1 cells produces bona  
f id e  trophoblast giant cells.
Rcho-1 giant cells induced by a change in serum conditions (20% FBS to 10% HS) undergo a dramatic 
up-regulation in the TG cell-specific marker PL-1 and complex cytoskeletal rearrangement as 
visualised by phalloidin staining for F-actin (a). Rcho-1 cells induced to differentiate by over­
expression o f ectopic Hand 1-EGFP (in medium supplemented with 20% FBS) produce giant cells with 
equivalent PL-1 up-regulation and cytoskeletal rearrangement (b).
152
Chapter 4
4.2.2. N ucleolar-endogenous H andl relocates to the 
nucleoplasm  during TG cell differentiation
We next sought to investigate whether the observed changes in the subcellular 
localisation o f Handl-EGFP during Rcho-1 TG cell differentiation applies also to 
endogenous Handl. Immunostaining for Handl and C23 revealed that endogenous 
Handl is restricted to the nucleoli o f  proliferating Rcho-1 stem cells (Figure 4.4). 
However, upon a change in serum conditions to promote TG cell differentiation, 
nucleolar-endogenous Handl is released and assumes a nuclear-wide localisation 
over a 72-hour period (Figure 4.4). In addition to the nuclear-wide localisation o f  
endogenous Handl in TG cells, a cohort (<5% o f  total cells) exhibited peri-nuclear, 
endogenous Handl (Figure 4.5a) or retained nucleolar-endogenous Handl (Figure 
4.5b). However, in both cases, a fraction o f total Handl was also localised in the 
nucleoplasm, suggesting that any amount o f endogenous Hand 1 translocation may be 
sufficient to drive TG cell differentiation.
a - H a n d 1 a - C 2 3 M e rge DNA
m
mSSm
Figure 4.4. Release of nucleolar-endogenous H andl coincides with Rcho-1 stem  
cell commitment to a trophoblast giant cell fate.
Immunostaining for a-Handl and a-C23 over a 72 hour time-course o f Rcho-1 differentiation reveals 
that endogenous Handl is predominantly localised to nucleoli in Rcho-1 stem cells (indicated as 24h). 
However, nucleolar-endogenous Handl is released to assume a nuclear-wide localisation coincident 
with a commitment o f Rcho-1 stem cells to differentiate over a 72-hour period.
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Figure 4.5. Endogenous Handl can occupy different subcellular localisations in 
trophoblast giant cells.
Endogenous Handl is localised to the peri-nuclear region (a) or occasionally retained in the nucleolus 
(b) in <5% of TG cells (induced by a change in serum conditions and differentiated for 72 hours). 
However, a proportion of Handl in both instances is nuclear-wide and induces TG cell differentiation.
Release o f endogenous Handl from the nucleoli o f  Rcho-1 stem cells during 
their differentiation was further confirmed by western blot analysis on whole-cell 
Rcho-1 lysates subtracted for the nucleolar fraction (Figure 4.6a,b). Levels o f  non- 
nucleolar Handl protein were analysed over an 8-day time-course o f  Rcho-1 
differentiation induced by a change in serum conditions (Figure 4.6a). The western 
blot data confirm the absence o f nuclear-wide Handl in Rcho-1 stem cells. 
Interestingly, nucleolar release o f Handl becomes evident 3 hours (‘day O’) after 
serum withdrawal. Furthermore, a more detailed western blot time-course revealed 
that endogenous Handl relocates from the nucleolar to the nucleoplasmic 
compartment just 1.5-2 hours after serum conditions are modified to promote Rcho-1 
differentiation (Figure 4.6b). Importantly, the elevated levels o f  non-nucleolar Handl 
protein at the onset o f differentiation are not accompanied by an up-regulation o f  
Handl transcription, as revealed by a northern blot analysis on mRNA extracted from 
Rcho-1 cells differentiated over a similar time-course (Figure 4.7). Several studies 
have reported that p-Tubulin transcription is down-regulated during Rcho-1 
differentiation (Faria and Soares, 1991; Hamlin et al., 1994). This explains our 
preference for the GAPDH probe and antibody in these analyses. In addition, 
GAPDH protein was shown to localise to the nucleolus in recent nucleolar proteomic 
analyses, further validating its use here as a loading control (Andersen et al., 2002).
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Figure 4.6. Redistribution of nucleolar-endogenous H andl during Rcho-1 
differentiation is confirmed by western blot analysis.
Western blot analysis using whole-cell lysates of Rcho-1 cells (subtracted for the nucleolar fraction) 
induced to differentiate over an 8-day time course reveal that nucleolar-endogenous Handl becomes 
nuclear-wide just 3 hours (‘day O’) after a change in serum conditions (20% FBS to 10% HS) (a). A 
more detailed time-course reveals that this nucleolar-to-nuclear relocation of endogenous Handl is 
initiated just 1.5 hours after this change in serum conditions (b).
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Figure 4.7. H a n d l transcription is not up-regulated during Rcho-1 trophoblast 
giant cell differentiation.
Northern blot analysis reveals that Handl transcription is not up-regulated at the onset o f TG cell 
differentiation in Rcho-1 cells induced to differentiate by a change in serum (20% FBS to 10% HS).
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In conclusion, these results demonstrate that during the early stages o f  Rcho-1 
TG cell differentiation, endogenous Handl is released from the nucleolus and 
becomes nuclear-wide. Importantly, this up-regulation in nuclear-wide Handl protein 
levels is caused by a change in Handl protein subcellular localisation and not an up- 
regulation o f Handl transcription.
4.2.3. H a n d l-E G F P  is localised to the nucleoli o f p r im ary  
m u rin e  trophob las t stem cells
We next demonstrated that Handl-EGFP is localised to the nucleoli o f  
primary murine trophoblast stem (TS) cells (Figure 4.8). This confirms that our 
observations in Rcho-1 cells are not cell line-dependent and also further supports the 
authenticity o f the Rcho-1 model with respect to trophoblast in vivo.
Handl-EGFP Merge
Figure 4.8. Handl-EGFP is localised to the nucleoli of transfected primary 
trophoblast stem cells.
Primary trophoblast stem cells transfected with Handl-EGFP exhibit nucleolar EGFP fluorescence.
4.2.4. In Rcho-1 stem cells, H IC p40  sequesters  and  
negatively-regulates endogenous H a n d l  in the nucleolus
To investigate the functional significance o f  Handl nucleolar sequestration by 
HlCp40 in vivo, we next conducted over-expression (gain-of-function) and RNA- 
interference (RNAi)-mediated knock-down (loss-of-function) assays involving
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HICp40 in Rcho-1 stem cells (Figure 4.9). Over-expression of HICp40 as an EGFP 
fusion protein (HICp40-EGFP) significantly blocked the differentiation of Rcho-1 
stem cells cultured in differentiation-inducing conditions, compared to untransfected 
Rcho-1 cells cultured in the same conditions (Figure 4.9a). Only transfected cells 
were counted, and these were identified by virtue of EGFP fluorescence.
We conversely used RNAi to knock-down endogenous HICp40. RNAi is a 
multi-step process involving the generation of a large double-stranded RNA 
(dsRNA), which is cleaved into small interfering RNAs (siRNAs) in vivo by an 
RNase III endonuclease. These siRNAs down-regulate target gene expression by 
forming an RNA-induced silencing complex (RISC) with cellular proteins. RISC then 
promotes the degradation of mRNAs containing sequences similar to the siRNA 
component and also may silence the target gene by recruitment of chromatin 
remodelling complexes (reviewed by Hannon, 2002). RNAi-mediated knock-down of 
endogenous HICp40, using two independent RNAi sequences (HICshRNAil and 
HICshRNAil), significantly promoted the differentiation o f Rcho-1 stem cells 
cultured in non-differentiating conditions (Figure 4.9b; sequence of RNAi 
oligonucleotides and their position within HICp40 are shown in Appendix 3). 
Endogenous HICp40 knock-down was confirmed in this study by western blot 
analysis using an anti-HIC antibody, a kind gift from J.-M. Mesnard (Figure 4.9c). Of 
note, these RNAi constructs would be predicted to also knock-down endogenous 
HICp32 as they contain sequences common to both HIC cDNAs. However, nucleolar 
localisation of endogenous Handl was a functional read-out that applied exclusively 
to HICp40-dependent sequestration.
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Figure 4.9. HICp40 gain- and loss-of function assays reveal that HICp40 
sequesters H andl into the nucleolus and negatively-regulates its activity in vivo.
Over-expression of HICp40-EGFP in Rcho-1 stem cells cultured in differentiation-inducing conditions 
(shown as HS) significantly inhibits TG cell differentiation (a). In comparison, knock-down of  
endogenous HICp40 in Rcho-1 stem cells cultured in non-differentiating conditions (shown as FBS), 
using two independent RNAi sequences o f HICp40 (HICshRNAil (i) and HICshRNAi2 (ii)), 
significantly promotes TG cell differentiation (b). HICp40 knock-down was demonstrated in this assay 
by western blot analysis using an anti-HIC antibody and then comparing HIC levels between un­
transfected (control, Co) and transfected cells by scanning densitometry (c). Measurements are 
mean±S.E.M.; n=350; ** indicates p<0.01; *** indicates p<0.001. o/e: over-expression.
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We next investigated the effect of HICp40 gain- and loss-of-function on 
Handl subcellular localisation in vivo. Gain in HICp40 function by HICp40-EGFP 
over-expression, which was associated with elevated numbers of Rcho-1 stem cells, 
resulted in a significant increase in nucleolar-endogenous Handl, as assessed by 
counts o f transfected cells. The percentage of control cells with nucleolar-endogenous 
Handl localisation was 43.9±1.87 (meantS.E.M.; n=210), whilst the percentage of 
HICp40-over-expressing cells with nucleolar-endogenous Handl localisation 72 
hours after transfection was 77.6+2.67 (meantS.E.M.; n=240) (p=<0.001). These 
data therefore suggest that gain of HICp40 function leads to reduced nuclear-wide- 
endogenous Handl and an associated block to TG cell differentiation.
Conversely, knock-down of endogenous HICp40y which was associated with 
elevated numbers of TG cells, resulted in increased nuclear-wide-endogenous Handl. 
The percentage of cells with nuclear-wide-endogenous Handl localisation in control 
cells was 28.6±2.08 (meantS.E.M.; n=210), whilst the percentage of cells 72 hours 
after transfection with HICshRNAil was 4 7 .lil.9 3  (meantS.E.M.; n=280), and those 
72 hours after transfection with HICshRNAi2 was 46.4i2.39 (meantS.E.M.; n=280) 
(p=<0.001). These data therefore indicate that loss of HICp40 function leads to 
increased nuclear-wide-endogenous Handl and associated TG cell differentiation.
4.2.5. Hypoxia neither affects Handl nucleolar release nor 
its nuclear activity
Previous studies have revealed that hypoxia blocks the proper differentiation of 
Rcho-1 stem cells and other trophoblast stem cell models in vitro (Gultice et al., 
2006; Lash et al., 2007; Takeda et al., 2007). Therefore, we sought to determine 
whether culture of Rcho-1 cells under hypoxic conditions has an effect on Handl 
nucleolar release. Hypoxic conditions were attained by either supplementing the 
medium with 250pM cobalt chloride, which has previously been shown, in cell lines 
including Rcho-1 cells, to initiate intracellular hypoxic signalling cascades (Hayashi 
et al., 2004), or by culturing cells in a hypoxic chamber (1% oxygen, 5% carbon 
dioxide, 94% nitrogen). Cells cultured under hypoxic conditions were shown by
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western blot analysis to have increased levels o f the alpha subunit o f the hypoxia 
inducible factor (HIF), a heterodimeric transcription factor activated by low oxygen 
(reviewed by Cannigia, 2000). This is consistent with an appropriate cellular response 
to low oxygen tension (Figure 4.10).
HxC CoCI
HIF1a
GAPDH
CoCI
Figure 4.10. Rcho-1 cells cultured under conditions that induce a hypoxic 
cellular response up-regulate the hypoxia-inducible factor-1 alpha subunit.
Culture of Rcho-1 cells in a hypoxic chamber (HxC) or in medium supplemented with 250pM cobalt 
chloride (CoCl2) induces HIF la  up-regulation. This was assessed by western blot analysis using an 
anti-HIFla antibody and then comparing HIF la  levels between control (cultured in normoxic 
conditions; Co) and cells exhibiting a hypoxic response by scanning densitometry.
Culture o f  Rcho-1 stem cells in differentiation-inducing (10% HS- 
supplemented medium) conditions in either medium supplemented with cobalt 
chloride or in a hypoxic cell culture chamber resulted in a significant suppression o f  
TG cell differentiation over 72 hour period in conditions that favour their 
differentiation (Figure 4.11). This is compared with Rcho-1 cells differentiated in 
normoxic, differentiation-inducing conditions and was assessed by PL-1 expression 
and changes in cytoskeletal organisation by staining for F-actin, as carried out by a 
previous study (Gultice et al., 2006). However, the percentage o f Rcho-1 stem cells 
cultured in normoxic, differentiation-inducing conditions for 72 hours that exhibit 
nucleolar-endogenous Handl localisation (43.9+1.87 (mean±S.E.M.; n=210)) was 
not significantly different to the percentage o f Rcho-1 stem cells cultured in hypoxic- 
response-inducing, differentiation-inducing conditions for the same time period with 
nucleolar-endogenous Handl (44.6±2.01 (mean±S.E.M.; n=220) for cells cultured in 
a hypoxic chamber, and 45.6+1.51 (mean±S.E.M.; n=220) for cells cultured in 
medium supplemented with 250juM C0 CI2). Furthermore, hypoxia had no effect on
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the ability o f  Handl-EGFP to drive Rcho-1 differentiation over a 72 hour period post­
transfection (Figure 4.12). These data therefore suggest that oxygen tension 
influences the process o f TG cell differentiation, but achieves this neither by affecting 
the release o f  Handl from the nucleolus, nor Handl-EGFP activity in the nucleus.
C o HxC CoCI2
Figure 4.11. Hypoxia significantly blocks Rcho-1 TG cell differentiation.
Cell counts o f Rcho-1 cells 72 hours after serum conditions were changed to promote their 
differentiation (20% FBS to 10% HS) revealed that cells cultured in hypoxic-response-inducing 
conditions (either in a hypoxic cell culture chamber (HxC) or in the presence o f 250pM CoCl2) have a 
reduced rate o f TG cell differentiation, indicated by a reduced number of giant cells and an increased 
number of stem cells, than control cells cultured in normoxic conditions (Co). TG cells were identified 
by PL-I up-regulation and cytoskeletal re-organisation. Measurements are meantS.E.M.; n=270; * 
indicates p<0.05; ** indicates p<0.01.
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Figure 4.12. Hypoxia does not modify Handl activity during Rcho-1 trophoblast 
giant cell differentiation.
Cell counts of Rcho-1 stem versus giant cells at 24, 48 and 72 hours post-transfection reveal that 
Rcho-1 cells transfected with Handl-EGFP and then cultured under conditions that induce a hypoxic 
response (either in a hypoxic cell culture chamber (HxC) or in the presence o f 250pM CoCl2) do not 
have a significantly different rate of differentiation to control cells transfected with Handl-EGFP and 
then cultured under normoxic conditions (Co). All cells were cultured under differentiation-inducing 
conditions (10% HS-supplemented medium). TG cells were identified by PL-I up-regulation and 
cytoskeletal reorganisation. Measurements are mean+S.E.M.; n=250.
4.3. DISCUSSION
4.3.1. The activity of H a n d l  is regu la ted  by nucleo lar  
sequestra tion  and  release in roden t tro p h o b las t
We have demonstrated that a Handl-EGFP fusion protein, nucleolar in Rcho- 
1 stem cells, gradually disperses throughout the nucleus over a time course o f 72 
hours as these cells undergo TG cell differentiation. TG cells exhibiting nuclear-wide 
Handl-EGFP are importantly bona fide , as determined by a characteristic up- 
regulation o f  PL-1 and associated changes in actin cytoskeleton and cell motility 
(Faria et al., 1991; Parast et al., 2001). The Handl-EGFP immuno-localisation
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studies in Rcho-1 cells were further supported by quantitative data, which revealed 
that the gradual nucleolar release of Handl-EGFP over the time-course of the 
experiment was statistically significant. The number of fluorescent TG cells in 
transfected cultures was significantly higher than the number of Rcho-1 TS cells at 
any given time point, and moreover the number of TG cells at the 48 and 72 hour 
points was higher than the number at the 24 hour point. This suggests that nuclear- 
wide, but not nucleolar-sequestered, Handl-EGFP is able to promote Rcho-1 TG cell 
differentiation. Importantly, the nucleolar localisation of Handl-EGFP was also 
observed in primary TS cells. This supports the authenticity of the Rcho-1 model 
with respect to the trophoblast lineage in vivo and excludes the possibility of any cell 
line-dependent effects. However, primary TS cells were precluded from any further 
use in these studies due to well-characterised problems with the maintenance of 
primary TS cells in an undifferentiated state in culture and very low transfection 
efficiency (S. Tanaka, personal communication).
Immunostaining for endogenous Handl using an anti-Hand 1 antibody 
revealed a similar relocation of the protein during Rcho-1 differentiation. This result 
was confirmed by western analysis using the same antibody on whole cell lysates, 
subtracted for nucleolar content, taken over a time course o f Rcho-1 differentiation 
induced by serum withdrawal. Notably, nucleoplasmic levels of Handl protein were 
significantly elevated only 1.5-3 hours after a change in serum conditions to promote 
differentiation. This suggests that the release of nucleolar Handl into the 
nucleoplasm is required for the earliest stages of TG cell differentiation. This event 
may even be responsible for the commitment of Rcho-1 stem cells to a TG cell fate. 
Crucially, this rapid increase in nuclear Handl protein level does not appear to be due 
to an up-regulation of Handl transcription. Northern analysis on the equivalent time- 
course revealed neither a change in Handl mRNA levels at the onset of Rcho-1 
differentiation nor during long-term differentiation. This observation of a constant 
level of Handl transcription during differentiation, although entirely reproducible, is 
at odds with previous studies (Cross et al., 1995; Firulli et al., 2003). The reason(s) 
for this discrepancy remains unclear.
It is worth here speculating on the underlying basis for the protocol used in 
this chapter to generate sub-cellular lysates. The study by Kurki and colleagues does
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not explain how the protocol operates at the molecular level (Kurki et al., 2004). 
Nonetheless immunostaining for nucleolar and non-nucleolar proteins revealed 
appropriate enrichment in the two subcellular fractions (data not shown), which 
suggested that the lysis protocol successfully separates the two cell compartments. 
We presume that the lysis buffer used in our current study, sufficient to lyse the cell 
and nuclear membranes, cannot break up the nucleoli. As will be discussed in 
Chapter 6 (section 6.4.1), nucleoli are membrane-less. Nonetheless they are robust 
structures whose architecture is held together by the rDNA and ribosome biogenesis 
machinery. When mammalian nuclei are physically disrupted, nucleoli remain intact 
even under conditions that disintegrate most other subnuclear bodies. Crucially, 
HICp40 and Handl would remain in the nucleolar fraction as many proteins that 
localise to the nucleolus are thought to bind the negatively-charged rDNA and acidic 
nucleolar proteins. So perhaps the inherently compact, dense structure of the 
nucleolus is resistant to (insoluble in) the NP-40 lysis buffer and can be separated in 
pellet form from the remainder of the cell lysate by ultra-centrifugation. NP-40 lysis 
buffer may be a more 'gentle' reagent than, for example, RIPA buffer in this regard. 
Only upon boiling the pellet in Laemelli buffer can the nucleolar proteins be 
denatured and suspended in solution. Possibly, this fraction also contains other 
organelles, meaning that the 'nucleolar' fraction is impure. However a 'dirty' method 
such as this was sufficient to illustrate the bulk translocation of Handl from the 
nucleolar to the nuclear fraction for the purposes o f our study. Further confirmation 
of the nucleolar sequestration and release of Handl could be attained by employing 
the more precise nucleolar isolation protocol of Angus Lamond’s group (listed at 
www.lamondlab.com/pdfnoprotocol). This involves centrifugation of sonicated 
nuclei through sucrose solutions of graded concentration.
We have also demonstrated a functional relationship between HICp40 and 
Handl, important for the control of TS cell fate, which involves the nucleolar 
sequestration and inactivation of Handl in Rcho-1 stem cells. Over-expression of 
HICp40 as an EGFP fusion protein in differentiation-inducing conditions 
significantly reduced Rcho-1 differentiation compared to untransfected Rcho-1 cells 
cultured in the same conditions. Conversely, RNAi-mediated knock-down of HICp40 
significantly enhanced the differentiation of Rcho-1 stem cells cultured under 
conditions that ordinarily maintain a proliferative Rcho-1 stem cell population.
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Furthermore, this gain- or loss-of-function of HICp40 correlated with a bias towards 
Handl nucleolar- or nuclear-localisation respectively, as assessed by cell counts. This 
confirms that the effects of HICp40 gain- and loss-of-function on TG cell 
differentiation are mediated through changing Handl subcellular localisation.
According to our data, the level of Handl-EGFP nuclear translocation does 
not seem to correlate precisely with the increase in Rcho-1 TG cell differentiation. 
Similarly, although cohorts (<5%) of TG cells exhibited peri-nuclear- or nucleolar- 
endogenous Handl, in both cases some fluorescence was also nuclear-localised. 
Although the spontaneous rate of Rcho-1 differentiation was taken into account 
during our quantitative analyses, the exact figure may have varied between 
transfected populations. Furthermore, Handl is clearly not the only factor that 
promotes TG cell differentiation and other factors that modulate this process may 
have affected the cell counts. For example, Ap-2y is another transcription factor 
required for TG cell differentiation (Auman et al., 2002) and its activity may have 
varied between transfected populations in our assays. Overall, however, our data 
indicate that the release of any amount of nucleolar Handl-EGFP, or nucleolar- 
endogenous Handl, may be sufficient to drive Rcho-1 TG cell differentiation. In 
summary, the data presented in this chapter are consistent with a role for HICp40- 
mediated nucleolar sequestration of Handl in governing TS cell fate.
4.3.2. Hypoxia inhibits Rcho-1 differentiation but not by 
modulating Handl nucleolar release
Mounting evidence suggests a link between protein nucleolar sequestration 
and the cellular response to hypoxia. Nucleolar confinement of both the alpha subunit 
o f HIF-1 (Fatyol and Szalay, 2001) and its negative regulator, the von Hippel-Lindau 
(VHL) tumour suppressor (Mekhail et al., 2004), modulate HIF-1 activity. 
Additionally, human STRA13, a bHLH factor whose mouse orthologue has been 
proposed to interact with Handl in TG cells (Hughes et al., 2004), is up-regulated by 
hypoxia (Ivanova et al., 2001). Interestingly, Stral3 also associates with Msp58, a 
protein that localises to the nucleolus (Lin and Shih, 1998). We thus hypothesised 
that Handl may be released from nucleolar confinement only under normoxic
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conditions. Indeed, previous studies have demonstrated that aspects of Rcho-1 TG 
ceil and other trophoblast stem cell model differentiation are blocked by low oxygen 
concentration (Gultice et al., 2006; Lash et al., 2007; Takeda et al., 2007; reviewed in 
Chapter 1, section 1.2.2.4). A model whereby Handl is only released from the 
nucleolus under normoxic conditions would be biologically-relevant in that TG cell 
differentiation would be blocked until the placenta makes contacts with the maternal 
blood supply and cellular oxygen concentration increases. This post-translational 
mechanism would furthermore explain why, in the study by Gultice and colleagues, 
Handl mRNA and protein levels were normal in Rcho-1 cells undergoing 
differentiation under hypoxic conditions (Gultice et al., 2006).
Consistent with the previous studies, we indeed showed that hypoxia 
suppressed the ability of Rcho-1 cells to differentiate over a 72-hour period. This was 
assessed by a block to PL-1 up-regulation and impaired cytoskeletal development. 
However, this block to differentiation was not due to an inability of Handl to escape 
from the nucleolus. There was no significant difference between the relative 
proportions of nucleolar- versus nuclear-wide-endogenous Handl in TG cells 
cultured under normoxic or hypoxic conditions for 72 hours after the culture 
conditions were modified to induce a hypoxic response. Thus, if impaired TG cell 
differentiation in hypoxic conditions is due to a deficiency o f Handl activity, these 
data suggest that the factor may be negatively-regulated after its nucleolar release. 
However, a further assay revealed that the ability of Handl-EGFP to drive Rcho-1 
differentiation is not modified by hypoxia. On first consideration, these data suggest 
that the nuclear activity of Handl is not modified by oxygen tension. However, 
Handl was over-expressed in this experiment, and as such any mechanism that 
ordinarily negatively-regulates endogenous Handl in trophoblast cultured under 
hypoxic conditions may have been squelched by ectopic Handl-EGFP. In any case, 
this result serves to reiterate the fact that Handl is not the only factor that promotes 
TG cell differentiation (Chapter 1, Table 1.2b). Hypoxia may thus modify the activity 
o f any one of a number of these TG cell differentiation-inducing factors. At present, 
just how hypoxia modifies the process of TG cell differentiation, through effects on 
Handl or otherwise, is unknown. What is clear, however, is that oxygen 
concentration does not appear to modify the nucleolar release of Handl during TG 
cell differentiation.
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4.3.3. Summary and concluding remarks
In this chapter we have demonstrated that the previously-described elevation 
of Handl activity during Rcho-1 TG cell differentiation is primarily due to a 
relocation of pre-existing Handl protein rather than an up-regulation of Handl 
expression. Handl is sequestered in an inactive state in the nucleoli of proliferating 
Rcho-1 stem cells by the rat orthologue of HICp40. However, upon commitment of 
these cells to a TG cell fate, Handl is released into the nucleoplasm, where it can 
drive Rcho-1 differentiation. However, we provide data that rules out the possibility 
that hypoxia, previously shown to impair proper Rcho-1 TG cell differentiation, 
modulates Handl nucleolar release.
Protein redistribution may be a more efficient method of regulating TG cell 
differentiation. Handl protein release into the nucleoplasm enables a rapid, likely 
almost instantaneous, commitment of Rcho-1 stem cells to a TG cell fate. This 
mechanism is probably more suited to govern TS cell fate than the relatively slow 
alternative of inducing an up-regulation of the Handl gene, followed by protein 
translation, in response to serum withdrawal. In this regard, our findings support 
previous studies that implicate the nucleolus as a molecular ‘safe’ or ‘sink’ that 
temporarily stores factors in an inactive state until a specific cell cycle stage or 
metabolic state (Tao and Levine, 1999; Weber et al., 1999; Datta et al., 2004).
Our RT-PCR data, presented in Figure 3.6b, indicate a persistence o f the rat 
orthologue of HICp40 in differentiated Rcho-1 TG cells. Thus it is likely that HICp40 
and/ or Handl are post-translationally modified to abrogate their interaction and 
permit Handl nucleolar release. In this regard, we next investigated the mechanism 
underlying Handl nucleolar release at the point of Rcho-1 stem cell commitment to 
differentiate and our findings are presented in the following chapter.
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Chapter 5
Phosphorylation of Handl underlies its 
release from the nucleolus
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5.1. INTRODUCTION
We next investigated the molecular mechanism that underlies the release of 
Handl from the nucleolus. Post-translational modification is a quick and reversible 
way of modulating the activity of a transcription factor. For example, 
phosphorylation of residues within the basic domain of myogenic bHLH transcription 
factors enhances their DNA-binding efficiency (Li et al., 1992; Zhou and Olson, 
1994). Additionally, phosphorylation of MyoD encourages its heterodimerisation 
with E l 2 (Lenormand et al., 1997). A wide range of post-translational modifications 
and ligands have been implicated in the nucleolar-nucleoplasmic or nucleolar- 
cytoplasmic shuttling of factors (Table 5.1). Despite this, phosphorylation is by far 
the most widely-used mechanism that underpins the nucleolar release of factors and 
several protein kinases and phosphatases have been localised to this organelle 
(Andersen et al., 2005). The best-characterised example of this is the phosphorylation 
of the budding yeast protein phosphatase Cdcl4 by the polo-like kinase Cdc5. This 
event promotes Cdcl4 nucleolar release as an essential step towards exit from mitosis 
(Shou et al., 1999; 2002; Visintin et al., 1999; 2003; Yoshida and Toh-e, 2002).
Handl is phosphorylated at the helix 1 residues T107 and S I09 during Rcho-1 
TG cell differentiation (Firulli et al., 2003). These residues are highly-conserved 
between bHLH factors of the Twist subfamily (Figure 1.1b). This process is 
enhanced by a down-regulation of the protein phosphatase 2A (PP2A) regulatory 
subunit B568, which targets Handl for dephosphorylation. The protein kinases PKC 
and PKA were suggested to site-specifically phosphorylate Handl during Rcho-1 
differentiation. The resultant net increase in Handl phosphorylation at these two 
residues was shown to enhance the affinity of the transcription factor for its E-factor 
binding partners as an important step in the TG cell differentiation program (Firulli et 
al., 2003). We hypothesised, therefore, that phosphorylation of Handl at these helix 1 
residues underlies its nucleolar release, as a pre-requisite for its E-factor binding and 
biological activity in the nucleus.
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Table 5.1. Post-translational modifications that underlie the nucleolar- 
nucleoplasmic/ cytoplasmic shuttling of factors.
Post-translational Factor Reference(s)
Modification
Asymmetric bFGF Xu et ah, 2003.
dimethylation of arginine
residues
Poly(ADP-ribosyl)ation CTCF Torrano et al., 2006.
Hydrogen ion binding VHL Mekhail et a l 2004.
GTP binding B23 Finch et al., 1995.
Nucleostemin Tsai and McKay, 2005.
Rrp22 Elam et al., 2005.
Gnl31 Rao et al., 2006.
Calcium ion binding Calmodulin Thorogate and Torok, 2007.
Phosphorylation Nucleolin Schwab and Dreyer, 1997.
Ki-67 Endl and Gerdes, 2000.
Cdcl4 Shou et al., 2002.
pRB Takemura et al., 2002.
TIF-IA Mayer et al., 2005.
Limk2 Goyal et al., 2006.
B23 Negi and Olson, 2006.
5.2. RESULTS
5.2.1. Phosphorylation of nucleoplasmic Handl increases 
during Rcho-1 differentiation
We first sought to investigate whether the nucleolar release of Handl 
coincides with increased Handl phosphorylation. To this end, we conducted western 
blot analysis using an anti-phosphoserine antibody on whole-cell Rcho-1 lysates 
subtracted for the nucleolar fraction over a time course of differentiation induced by a 
change in serum conditions (from 20% fetal bovine serum (FBS) to 10% horse serum 
(HS); stem, 0-8 days; Figure 5.1). This assay revealed that phosphorylation of non-
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nucleolar-endogenous Handl increased during this time-course, particularly between 
the stem cell stage and ‘day O’ (3 hours after a commitment to differentiate), relative 
to total cellular-endogenous (i.e. including nucleolar) Handl. This suggests that 
Hand 1 is phosphorylated coincident with its release from the nucleolus.
Nuclear lysates Total cell lysates
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Figure 5.1. Non-nucleolar, endogenous H andl is phosphorylated during Rcho-1 
differentiation.
Phosphoserine western (lysates subtracted for the nucleolar fraction and total cell, including nucleolar) 
on Rcho-1 cells over a time-course o f differentiation in 10% horse serum (HS; stem, 0-8 days). 
Elevated non-nucleolar-endogenous, phosphorylated Handl at the onset o f differentiation (‘day O’; 3 
hours’ exposure to HS) suggests nucleolar-to-nuclear re-distribution o f phosphorylated Handl.
5.2.2. A H a n d l  m u ta n t  th a t  canno t be phosphory la ted  
can n o t escape from  the nucleolus, w hilst a H a n d l  
phosphory la tion  mimic is nuclear-w ide
We next investigated whether the phosphorylation o f  Handl is required for its 
nucleolar release and moreover which residues are phosphorylated. To this end, we
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fused the EGFP cDNA to a Handl mutant generously provided by Anthony Firulli in 
which the two residues previously shown to be phosphorylated during Rcho-1 
differentiation were mutated to alanines and, therefore, cannot be phosphorylated 
(T107;S109A) (Firulli et al., 2003). This construct was transfected into Rcho-1 stem 
cells and these were cultured in non-differentiating conditions for 24, 48 or 72 hours 
post-transfection. At these time-points, cells were immunostained with an antibody 
specific for the nucleolar protein C23. This assay revealed that Handl T107;S109A- 
EGFP was almost exclusively nucleolar at all time points (Figure 5.2). This result 
suggests that Handl phosphorylation at residues T107 and S I09 is necessary for its 
release from the nucleolus during Rcho-1 TG cell differentiation.
We also engineered a mutant Handl-EGFP protein in which the same two 
residues were mutated to aspartic acids, substitutions that are thought to mimic the 
change in amino acid charge introduced by phosphorylation (T107;S109D; Huang et 
al., 2004b). This construct was again transfected into Rcho-1 stem cells and these 
were cultured in non-differentiating conditions for 24, 48 or 72 hours post­
transfection. This assay revealed that Handl T107;S109D-EGFP was dispersed 
throughout the nucleoplasm in discrete foci at all time points (Figure 5.3). This result 
suggests that Handl phosphorylation at residues T107 and S I09 is sufficient for its 
release from the nucleolus during Rcho-1 differentiation.
We next counted cells to investigate whether the observed differences in the 
subcellular localisations of these two mutant Handl-EGFP fusion proteins were 
statistically significant (Figure 5.4a,c). This data revealed that the number of Handl- 
EGFP T107;S109A-transfected cells with nucleolar fluorescence at any time-point 
post-transfection was significantly higher than the number with nuclear-wide 
fluorescence at the same time point (also compare Figure 5.4a with Figure 4.2a for 
differences relating to wild-type Handl-EGFP). In contrast, the Handl-EGFP 
T107;S109D mutant was predominantly nucleoplasmic throughout the time course 
of the experiment and <5% of cells exhibited nucleolar fluorescence at any given 
time point (also compare Figure 5.4c with Figure 4.2a). Thus the observed 
differences in the sub-cellular locations of these two mutant Handl-EGFP fusion 
proteins, with respect to wild-type Handl-EGFP, were statistically significant.
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T107 ;S109A-EGFP a-C23 Merge
H H
Figure 5.2. Mutation o f Handl residues T107 and S109 to alanines creates a 
Handl mutant that cannot be released from the nucleolus.
A Handl-EGFP T107;S109A mutant fusion protein remains nucleolar in transfected Rcho-1 cells 
over a 72 hour time-course post-transfection.
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Figure 5.3. Mutation of Handl residues T107 and S109 to aspartic acids creates 
a Handl phosphorylation mimic that localises to nucleoplasmic foci.
Handl-EGFP T107;S109D assumes a nuclear-wide punctate localisation in transfected Rcho-1 cells 
and this remains over a 72 hour time-course post-transfection.
Moreover the differences in the sub-cellular locations o f  the Handl mutant 
fusion proteins have a significant bearing on their ability, again relative to wild-type 
Handl-EGFP, to induce TG cell differentiation (Figure 5.4b,d). The number o f  
fluorescent TG cells in Handl-EGFP T107;S109A-transfected populations, as 
assessed by up-regulation o f PL-1 and cytoskeletal complexity, was significantly less 
than the number in wild-type Handl-EGFP-transfected populations at any given time 
point post-transfection (also compare Figure 5.4b with Figure 4.2b for differences 
relating to wild-type Handl-EGFP). Moreover, the number o f fluorescent TG cells in 
Handl-EGFP T107;S109A-EGFP mutant populations did not significantly increase 
over the 72-hour time-course. In contrast, the numbers o f  fluorescent TG cells in 
Handl-EGFP T107;S109D mutant populations at the 48- and 72-hours post­
transfection were significantly greater than the number o f  fluorescent TG cells at the
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24 hour time-point, but still significantly less than those in wild-type Handl-EGFP 
cultures at any given time-point (also compare Figure 5.4d with Figure 4.2b). These 
results collectively reveal that the Handl-EGFP T107;S109A and the Handl-EGFP 
T107;S109D proteins are significantly less efficient than wild-type Handl-EGFP at 
driving Rcho-1 differentiation.
a.
80-
60-
40
o  20-
C.
100 '
£  80 ■ Q)
~  60 ■ 
0>
S 40 •
§  20 • 
LL
S? 0 •
b.
1
□  Stem
9  ___.■G iantSQ24h 48h 72hHours post-transfection
r— i □  Nucleolar ■  Nuclear
ill
24h 48h 72h
Hours post-transfection
24h 48h 72h
Hours post-transfection
d.
8.
80
60
55 40
=  20
<S
r— I astern  * * T 
■  Giant ,----- ,i n
24h 48h 72h
Hours post-transfection
Figure 5.4. The subnuclear locations of the two H andl mutants are significantly 
different and correlate with their relative abilities to drive Rcho-1 
differentiation.
Handl T107;S109A-EGFP localises predominantly to the nucleolus throughout the 72 hour time 
course o f the experiment (a) and is unable to promote TG cell differentiation (b). In contrast Handl 
T107;S109D-EGFP is detectable throughout the nucleus at all time points during the experiment (c) 
and is able to promote TG differentiation to an extent similar to, but still significantly less than, wild- 
type Handl-EGFP (d). Measurements are mean±S.E.M.; n=400. * indicates p<0.05; ** indicates 
p<0.01; *** indicates p<0.001.
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We next carried out experiments with a view to identify the nuclear-wide foci 
to which the Handl T107;S109D-EGFP fusion protein localises. These bodies neither 
co-localise with Cajal bodies (as assessed by immunostaining with an anti-Coilin 
antibody; data not shown) nor centromeres (using an anti-CENPB antibody; data not 
shown). A cohort o f  these bodies do, however, co-localise with regions o f active gene 
transcription, so called ‘transcription factories’ (Iborra et al., 1996; Osbourne et al, 
2004), as determined by co-localisation with RNA polymerase II (RNA Pol II; Figure 
5.5). However, at present, we cannot precisely define these nuclear bodies and this 
remains an area o f future studies.
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Figure 5.5. H andl T107;S109D-EGFP localises to a subset o f ‘transcription 
factories’.
A cohort of the foci to which the Handl T107;S109D-EGFP fusion protein localises in transfected 
Rcho-1 stem cells overlap with so-called ‘transcription factories’, demarcated by RNA Pol I I .
5.2.3. B568 antagonises H a n d l-E G F P  nucleo lar  release an d  
is ‘e lim ina ted ’ d u ring  Rcho-1 differentia tion
In light o f  our results implicating phosphorylation in the release o f nucleolar 
Handl, it is interesting that a protein phosphatase 2A (PP2A) complex site- 
specifically dephosphorylates Handl at the T107 and S I09 residues in Rcho-1 stem 
cells (Firulli et al., 2003). The PP2A complex responsible for this contains the 
regulatory (B, substrate-recognising) subunit B568 and appropriately B56S 
expression is down-regulated during Rcho-1 differentiation. Thus, we next
Handl (T107;S109D) 
EGFP
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investigated whether B568 is involved in the regulation of Handl activity via 
nucleolar sequestration.
To this end, we over-expressed a construct encoding B56S in Rcho-1 stem 
cells co-transfected with Handl-EGFP under non-differentiating conditions. 
Compared with Rcho-1 stem cells transfected with Handl-EGFP alone, significantly 
more of these cells exhibited nucleolar EGFP fluorescence 72 hours post-transfection 
(compare Figure 5.6a with Figure 4.2a). Moreover, the number of fluorescent TG 
cells in co-transfected cultures, as assessed by up-regulation of PL-1 and changes in 
cytoskeletal complexity, was significantly lower than the number of fluorescent TG 
cells in cells transfected with Handl-EGFP alone (compare Figure 5.6b with Figure 
4.2b). This suggests that B568 blocks the release of Handl-EGFP from the nucleolus 
and, in so doing, inhibits Rcho-1 TG cell differentiation.
We next over-expressed B56S in Rcho-1 cells, 24 hours after a change in 
serum conditions to induce TG cell differentiation, in order to investigate whether the 
observed effect of ectopic B56S  on the localisation of Handl-EGFP also applies to 
endogenous H andl. This was observed to inhibit the differentiation of these cells into 
TG cells (Figure 5.7) as the number of Rcho-1 TG cells in transfected cultures was 
significantly lower than in untransfected cultures. Importantly, B568  over-expression 
was associated with a significant block to the nucleolar release of endogenous H andl. 
The percentage of control cells with nucleolar-endogenous Handl was 43.9±1.87 
(mean±S.E.M.; n=210) compared with the percentage of R56£-overexpressing cells 
with nucleolar-endogenous Handl 72 hours after transfection, which was 69.2±2.56 
(mean±S.E.M.; n=250) (p=<0.001). These results suggest tha tB 568  blocks the 
release of endogenous Handl from the nucleolus and this inhibits Rcho-1 
differentiation.
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Figure 5.6. B568 inhibits the nucleolar release o f H andl-EG FP and its 
promotion of Rcho-1 TG cell differentiation.
Co-expression of B568 with Handl-EGFP prevents release of the fluorescent fusion protein from the 
nucleolus (a), relative to when Handl-EGFP is expressed alone (Figure 4.2a). Ectopic expression of  
B568 blocks Handl-EGFP-induced TG cell differentiation (b), relative to when Handl-EGFP when 
expressed alone (Figure 4.2b). Measurements are mean±S.E.M.; n=330; * indicates p<0.05; ** 
indicates p<0.01; *** indicates p<0.001.
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Figure 5.7. B568 inhibits Rcho-1 TG cell differentiation induced by a change in 
serum conditions.
Ectopic expression of B568 in Rcho-1 stem cells, 24 hours after serum replacement to induce 
differentiation, inhibits TG cell differentiation. Measurements are mean±S.E.M.; n=350; * indicates 
p<0.05; ** indicates p<0.01; *** indicates p<0.001.
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Notably, immunostaining o f Rcho-1 cells over-expressing B568 using an anti- 
8565 antibody revealed that, whilst distributed throughout Rcho-1 stem cells, the 
protein is predominantly cytoplasmic and excluded from the nuclei and nucleoli o f  
TG cells (Figure 5.8). In support o f this observation, western blot analysis using the 
anti-B565 antibody on whole-cell Rcho-1 lysates subtracted for the nucleolar fraction 
confirmed that endogenous B568 predominantly localises to the nuclear/ nucleolar 
compartment o f Rcho-1 stem cells but is restricted to the cytoplasm o f TG cells 
(Figure 5.9). These results suggest that B568 is trafficked to the cytoplasm during 
Rcho-1 TG cell differentiation.
a-B568 DNA Merge
Stem
Giant
Figure 5.8. Ectopic B568 is nuclear in Rcho-1 stem cells but is exported from the 
nucleus upon their differentiation.
Ectopic B56S is localised throughout the nucleus, including the nucleoli, in Rcho-1 stem cells (a) but 
relocates to the cytoplasm upon their differentiation into trophoblast giant cells (b).
179
Chapter 5
M'(K) Stem 
116.
6 6 .
Giant 
m
'<"7
Total
B565
GAPDH
2.5 -.
<n
%Q)
C
5oI-o.
Stem TotalG iant
Figure 5.9. Relocation of endogenous B565 during Rcho-1 differentiation is 
confirmed by western blot analysis.
Western blot analysis on whole-cell Rcho-1 lysates, subtracted for the nucleolar fraction, reveals 
elevated non-nucleolar, but decreased nucleolar, B565 during Rcho-1 TG cell differentiation.
5.2.4. Plk4 is the nucleolar kinase that phosphorylates 
H andl
Our results and those o f  others (Firulli et al., 2003) implicate the site-specific 
phosphorylation o f  Handl as essential for its nucleolar release, subsequent 
heterodimer formation with E-factors and trans-activational activity in the nucleus. 
This cascade o f  events likely underlies the onset o f  Rcho-1 TG cell differentiation. 
Thus the next question we wished to address was the identity o f  the nucleolar kinase 
responsible for phospho-Handl nucleolar release. Previously, studies in HEK293 
cells implicated protein kinase C and, particularly, protein kinase A (PKC and PKA), 
as the kinases that phosphorylate Handl at T 107 and S I09 during this process (Firulli 
et al., 2003). However, since neither o f these ubiquitous kinases localise to the 
nucleolus (reviewed by Jaken, 1996; Griffioen and Thevelein, 2002), and are absent 
from the mammalian nucleolar proteome, despite their ubiquitous cell type 
expression (Scherl et al., 2002; Andersen et al., 2002; Andersen et al., 2005), it is
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unlikely that they are responsible for phosphoryating endogenous Handl in the 
context of nucleolar-nuclear relocation.
Rcho-1 stem cells exit the mitotic cell cycle and undergo endoreduplication 
concomitant with differentiation (MacAuley et al., 1998). We thus adopted a 
candidate-protein approach to identify a nucleolar serine/ threonine kinase that may 
simultaneously modify the cell cycle. A comprehensive search of the nucleolar 
proteome database (Scherl et al., 2002; Andersen et al., 2002; Andersen et al., 2005; 
www.lamondlab.com/NOPdb/) revealed a putative candidate in the non-canonical 
polo-like kinase Plk4 (Sak, Stkl 8). Plk4 belongs to a small family of eukaryotic 
serine/ threonine polo-like kinases (Plks) that function predominantly during mitosis 
(reviewed by Lowery et al., 2005; van de Weerdt and Medema, 2006). Plk4 localises 
to the nucleolus specifically at phase G2, the cell cycle stage at which both TS cells 
and Rcho-1 stem cells are thought to initiate endocycling upon their commitment to 
differentiate (MacAuley et al., 1998). Moreover, Plk4 is involved in the anaphase- 
promoting complex/ cyclosome- (APC/C)-dependent destruction of the mitotic cyclin 
B1 and exit from mitosis in the post-gastrulation embryo (Hudson et al., 2001). This 
is very relevant to our study as under certain conditions the APC/C destroys mitotic 
cyclins to promote mitotic cell cycle exit and the initiation of endoreduplication. For 
example, APC/C substrate-determining Cdhl orthologues in angiosperm plants 
(Ccs52A) and Drosophila (Fizzy-related, Fzr) are respectively required for down- 
regulating mitotic cyclins to switch the mitotic cell cycle at phase G2 to the 
endocycle during seed (Cebolla et al., 1999) and salivary gland (Sigrist and Lehner, 
1997) development. Furthermore, mutations that interfere with the activity o f the 
mitotic cyclin B-Cdkl complex induce an endoreduplication phenotype in both 
fission yeast (Hayles et al., 1994) and budding yeast (Azzam et al., 2004). Indeed 
APC/C targets, including Cyclin B l, Cdkl and Aurora A, persist beyond the 
appropriate cell cycle checkpoint in cells of a Plk4-null mouse (Hudson et al., 2001).
Semi-quantitative RT-PCR using mRNA prepared from Rcho-1 stem cells 
and cells at different stages of their differentiation into TG cells revealed that Plk4 is 
up-regulated during this process. This elevation was most marked a few hours after 
serum modification, and was subsequently maintained at high levels during a time- 
course of TG cell differentiation over eight-day time-course (Figure 5.10).
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Figure 5.10. Plk4 is up-regulated at the onset of Rcho-1 differentiation.
Semi-quantitative RT-PCR analysis reveals that Plk4 is up-regulated at the onset o f Rcho-1 
differentiation induced by 10% horse serum (from the stem cell stage to ‘day O’; 3 hours’ exposure to 
HS) and maintained at high levels during subsequent differentiation.
We subsequently sought to investigate the subcellular localisation o f  PIk4 in 
Rcho-1 stem cells. A GFP-Plk4 fusion protein localised to multiple nucleoli with 
additional peri-nuclear fluorescence in Rcho-1 stem cells synchronised at the G2/M 
checkpoint by nocodazole treatment (Figure 5.11). Furthermore, immunostaining 
with an anti-Plk4 antibody showed that endogenous Plk4 also localised to Rcho-1 
stem cell nucleoli synchronised at the G2/M checkpoint using nocodazole (Figure 
5.12). Interestingly, endogenous Plk4 occupied only a single nucleolus in each Rcho- 
1 stem cell, the significance o f which is presently unclear.
Merge
Figure 5.11. A GFP-Plk4 fusion protein is nucleolar in Rcho-1 stem cells 
synchronised at the G2/M phase checkpoint.
A GFP-Plk4 fusion protein localises to multiple nucleoli with additional peri-nuclear fluorescence in 
Rcho-1 stem cells synchronised at the G2/M phase checkpoint following nocodozole treatment.
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Figure 5.12. Endogenous Plk4 localises to a single nucleolus in Rcho-1 stem cells 
synchronised at the G2/M phase checkpoint.
Endogenous Plk4 localises to a single nucleolus in Rcho-1 stem cells synchronised at the G2/M phase 
checkpoint following nocodozole treatment.
Figure 5.13. The sub-cellular localisation of GFP-Plk4 differs markedly in 
asynchronous Rcho-1 cells.
GFP-Plk4 localises to multiple subcellular regions in addition to the G2/M phase nucleolus, localizing 
throughout the nucleus in a punctuate, nuclear-wide pattern (a), to the peri-nucleus (b) along the 
cleavage furrow (c) and throughout the cytoplasm (d) depending on the cell cycle stage.
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Notably GFP-Plk4 localised to multiple subcellular regions in asynchronous 
Rcho-1 stem cells (Figure 5.13), revealing punctate nuclear-wide (anaphase; Figure 
5.13a), peri-nuclear (interphase; Figure 5.13b), cleavage furrow (telophase; Figure 
5.13c) and cytoplasmic (prophase; Figure 5.13d) fluorescence depending on stage of 
the cell cycle. Thus the subcellular location of Plk4 in Rcho-1 cells mirrors that in 
3T3 fibroblasts, where these localisations were first reported (Hudson et al., 2001).
In light of these results, we then proceeded to investigate whether Plk4 
phosphorylates Handl during Rcho-1 TG cell differentiation. Initially, we 
investigated whether Plk4 and Handl interact in vivo. To this end, we performed co- 
immunoprecipitation analysis using lysates of either untreated and asynchronous 
Rcho-1 stem cells (control, Co) or Rcho-1 cells induced to differentiate for one hour 
by a change in culture conditions (horse serum, HS; Figure 5.14). This revealed that 
endogenous Handl can pull-down endogenous Plk4 and conversely endogenous Plk4 
can pull-down endogenous Handl. Moreover, the relative concentration of Handl 
and/ or Plk4 immunoprecipitate was greater in a co-immunoprecipitation assay using 
lysates of Rcho-1 cells induced to differentiate for one hour, in comparison to an 
assay using control lysates of untreated and asynchronous Rcho-1 stem cells. Thus 
endogenous Handl and endogenous Plk4 interact in vivo and appropriately their 
interaction is enhanced by inducing Rcho-1 cells to differentiate.
Given Plk4 interacts with Handl, we next investigated whether Plk4 
phosphorylates Handl. To do this, we carried out an in vitro kinase assay using an in 
vitro-translated Handl-GST substrate protein and in v/vo-translated wild-type Plk4 
and an activated Plk4 mutant that possesses a mutation in the T-loop region of the 
kinase (T170D-Plk4) (Swallow et al., 2005; Figure 5.15; Figure 5.23). This assay 
revealed that Plk4 is able to specifically phosphorylate Handl to greater than 1 mol 
Pimol'1 substrate and at levels comparable to its established substrate a-Casein 
(Swallow et al., 2005). Notably Plk4 could neither phosphorylate the T107;S109A 
nor the T107;S109D mutant EGFP fusion proteins in the same assay (data not 
shown). These results suggest that Plk4 acts in a site-specific manner at the predicted 
T107 and S I09 residues in helix 1 and may act as a Handl kinase in a relevant 
physiological setting.
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Figure 5.14. Endogenous H andl interacts with endogenous Plk4 in vivo.
Co-immunoprecipitation o f endogenous Handl with endogenous Plk4, or vice versa, in either 
untransfected Rcho-1 stem control cells (Co), or Rcho-1 stem cells promoted to differentiate with 10% 
HS for one hour (HS) reveals that the two factors interact in vivo. Note the stronger interaction in the 
HS-treated cells, consistent with a commitment towards a TG cell fate. NS: non-specific band.
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Figure 5.15. Plk4 phosphorylates H andl in vitro.
A GST-Handi fusion protein is specifically phosphorylated in vitro by both wild-type Plk4 and the 
activated mutant T170D-Plk4 (Swallow et al., 2005) and at levels comparable to the Plk4 positive 
control substrate a-Casein. Plk4 can neither phosphorylate GST alone nor the negative control protein 
BBS2. W T: wild-type.
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To investigate the functional significance of Handl phosphorylation by Plk4 
in vivo, we next conducted over-expression (gain-of-function) and RNAi-mediated 
knock-down (loss-of-function) assays involving Plk4 in Rcho-1 stem cells (Figure 
5.16, Figure 5.17). Over-expression of FLAG-Plk4 in conditions that favour Rcho-1 
stem cell maintenance (shown as FBS) significantly promoted Rcho-1 differentiation 
to a level equivalent to that induced by horse serum (Figure 5.16a). Only transfected 
cells were counted, and these were identified by immunostaining using an anti-FLAG 
antibody. These data suggest that gain of Plk4 function promotes TG cell 
differentiation.
Conversely, RNAi-mediated knock-down of endogenous Plk4, using two 
independent RNAi sequences (Plk4shRNAil and Plk4shRNAi2), significantly blocked 
the differentiation of Rcho-1 stem cells cultured under differentiation-inducing 
conditions (shown as HS; Figure 5.16b; sequence o f RNAi oligonucleotides and 
position within Plk4 are shown in Appendix 3). Plk4 knock-down was demonstrated 
in this assay by western blot using an anti-Plk4 antibody (Figure 5.16c). These data 
indicate that loss of Plk4 function blocks TG cell differentiation.
We next investigated the effect of Plk4 gain- or loss-of-function on Handl 
subcellular localisation. Gain in Plk4 function by the over-expression o f a FLAG- 
Plk4 fusion protein, which was associated with reduced numbers o f Rcho-1 stem 
cells, resulted in a significant increase in nuclear-wide-endogenous Handl levels, as 
assessed by counts of transfected cells. The percentage of control cells with nuclear- 
wide-endogenous Handl localisation was 28.6±2.08 (mean±S.E.M.; n=210), whilst 
the percentage of Plk4-over-expressing cells with nuclear-wide-endogenous Handl 
localisation was 54.1+2.78 72 hours after transfection (mean±S.E.M.; n=250) 
(p=<0.001). These data suggest that gain of Plk4 function promotes nucleolar release 
of endogenous Handl in Rcho-1 stem cells.
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Figure 5.16. Gain- or loss-of function of Plk4 in Rcho-1 stem cells respectively 
enhances or inhibits TG cell differentiation.
Over-expression o f Plk4 (FLAG-Plk4) in Rcho-1 cells cultured in non-differentiating conditions 
(shown as FBS) significantly promotes TG cell differentiation (a). Knock-down of endogenous Plk4 in 
Rcho-1 stem cells cultured in differentiation-inducing conditions (shown as HS), using two 
independent RNAi sequences (Plk4shRNAil (i) and Plk4shRNAi2 (ii)), significantly blocks TG cell 
differentiation (b). Plk.4 knock-down was demonstrated by western blot analysis using an anti-Plk4 
antibody and then comparing Plk4 levels between un-transfected (control, Co) and transfected cells by 
scanning densitometry (c). Measurements: n=360; *** indicates pO.OOl. o/e: over-expression.
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Conversely, knock-down o f endogenous Plk4, which as associated with 
reduced numbers o f TG cells, resulted in increased levels o f nucleolar-endogenous 
Handl. The percentage o f cells with nucleolar-endogenous Handl in control cells 
was 43.9±1.87 (mean±S.E.M.; n=210), whilst the percentage o f  cells 72 hours after 
transfection with Plk4shRNAil with nucleolar-endogenous Handl was 68.9±2.39 
(mean±S.E.M.; n=230), and those 72 hours after transfection with Plk4shRNAi2 was 
69.8±1.44 (mean±S.E.M.; n=230) (p=<0.001). These data collectively indicate that 
loss o f  Plk4 function blocks the nucleolar release o f  endogenous Handl in Rcho-1 
stem cells. Moreover, over-expression o f FLAG-Plk4 or RNAi-mediated knock-down 
o f  endogenous Plk4, using two independent RNAi sequences, in Rcho-1 cells resulted 
in enhanced or reduced phosphorylation o f  non-nucleolar Handl respectively, as 
assessed by immunostaining using an anti-phosphoserine antibody (Figure 5.17).
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Figure 5.17. Plk4 gain- or loss-of function in Rcho-1 stem cells respectively 
enhances or reduces Handl phosphorylation in vivo.
Western analysis and scanning densitometry show that over-expression o f Plk4 (FLAG-Plk4) 
significantly enhances the phosphorylation o f non-nucleolar Handl (lysates subtracted for the 
nucleolar fraction; lane 2), relative to untransfected, control Rcho-1 cells (lane 1; Co). Conversely, 
down-regulation o f Plk4 (by two RNAi sequences; lanes 3 and 4) significantly reduces Handl 
phosphorylation.
The results described so far suggest that the nucleolar phosphorylation o f  
Handl by Plk4 underlies Handl nucleolar release as a pre-requisite for TG cell 
differentiation in the Rcho-1 cell line. However this data was derived from an in vitro 
cell-based model so we subsequently sought to investigate whether it occurred in an 
in vivo setting. To this end, we obtained Plk4-null embryos from the laboratory o f
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James Dennis and Carol Swallow (SLRI, Toronto, Canada). PM^-heterozygous and 
Plk4-null E7.5 embryos were genotyped using primers and nested PCR techniques 
previously described (Hudson et a l 2001; data not shown) and the lack o f Plk4 
protein in Plk.4-null embryos was confirmed by immunostaining for anti-Plk4 (data 
not shown). Genotyped Plk4-null embryos were then investigated in terms of  
trophoblast differentiation and mis-Iocalisation o f  Handl in vivo (Figure 5.18 -  
Figure 5.21). Compared with heterozygous control embryos, E7.5 Plk4-null concepti 
were smaller (Figure 5.18a,b) and have a markedly enlarged ectoplacental cone 
(EPC) (Figure 5.18c,d). This was consistent with an expansion in the diploid source 
o f  trophoblast ‘stem cells’ and reduced TG cell differentiation.
Figure 5.18. Plk4-null embryos are smaller and have an enlarged ectoplacental 
cone and reduced SGC number compared to P!k4-heterozygotes.
Histological sections through Plk4-heterozygous and -homozygous mutants at E7.5 reveal that Plk4- 
null embryos are smaller than their heterozygous littermates (compare (a) with (b)) and have a 
significantly expanded ectoplacental cone (EPC) of diploid trophoblast cells (compare (c) with (d)). 
The / ’/^-hom ozygous mutant visceral yolk sac (b) also appears rough and disorganised in appearance.
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DNA staining of histological sections revealed that the differentiation of 
primary trophoblast giant cells (PGC), namely those that arise directly from 
trophectoderm at the blastula stage, was normal in Plk4-null mutants (Figure 
5.19a,c,e). However, the secondary trophoblast giant cell (SGC) population, which 
arises from the outer layer of the EPC, was significantly reduced with associated 
failed migration through the overlying maternal decidua (Figure 5.19b,d,f). PGC and 
SGC populations were distinguished by relative positions in relation to the maternal 
decidua (reviewed in Chapter 1, section 1.2.1) and by immunostaining for prolactin­
like protein A (PLP-A), which is expressed exclusively in a peri-nuclear pattern in 
SGCs and Rcho-1 TG cells, but not in PGCs (Hamlin et al., 1994; Ma and Linzer, 
2000; Figure 5.22). Comparable plane sections through E7.5 embryos revealed 
63±9.6 (mean±S.E.M.) SGCs in controls versus 21 ±5.2 (mean±S.E.M.) SGCs in 
Plk4-null embryos. Six replica sections for each genotype were analysed. These 
observations suggest that SGC, but not PGC, differentiation is impaired in a Plk4- 
deficient background.
The subcellular localisation of Handl was then investigated in the Plk4- 
heterozygous (Figure 5.20) and PIk4-null (Figure 5.21) backgrounds using an anti- 
Hand 1 antibody. This revealed that Handl was nuclear-wide in the majority o f SGCs 
in the control Plk4 heterozygotes (Figure 5.20). However, in the expanded diploid 
trophoblast of P/fcZ-mutants, Handl remained predominantly nucleolar, coincident 
with a rare commitment to a SGC fate (Figure 5.21). Collectively, these studies 
confirmed inappropriate in vivo subcellular localisation of endogenous Handl in a 
Plk4 loss-of-function background. This supports our in vitro analyses in Rcho-1 cells, 
which themselves are a model of SGCs (reviewed in Chapter 1, section 1.6.1), and 
strongly suggests that Plk4-dependent phosphorylation of Handl underlies its 
nucleolar release.
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Figure 5.19. PGC differentiation, but not SGC differentiation, is normal in Plk4- 
null embryos.
DNA staining of sections (the boxes in (a) are magnified in (c) and (e), and the boxes in (b) are 
magnified in (d) and (f)) reveals that P/W-homozygous mutants have equivalent levels o f  PGCs (c, d) 
but significantly reduced SGCs (e, f) compared with their P/A4-heterozygous littermates. White 
arrowheads identify PGCs in (c) and (d) and SGCs in (e) and (f).
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Figure 5.20. /YA</-heterozygous SGCs form normally and have nuclear-wide 
H andl.
Immunostaining for Handl (the box in (a) is magnified in (c), and the box in (b) is magnified in (d)) 
reveals nuclear-wide localisation of Handl in SGCs in ^/^-heterozygous control embryos. White 
asterisks in (a) and (b) reveal the relative position of the most rostral part o f the embryo in section.
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Figure 5.21. P lk4 -null trophoblast remains undifferentiated and exhibits 
nucleolar-restricted H andl.
Immunostaining for Handl (the box in (a) is magnified in (c) and (e), and the box in (b) is magnified 
in (d) and (f)) reveals nucleolar restriction of Handl in the expanded diploid trophoblast population o f  
the Plk4-m\\ embryos (a, c). This was confirmed by counterstaining for the nucleolar-specific maker 
Nucleostemin (NS; e, f). White asterisks in (a) and (b) reveal the relative position o f the most rostral 
part o f the embryo in section. White arrowheads in (c) highlight mutant cells with exclusively 
nucleolar Handl.
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Figure 5.22. PLP-A is a specific marker of secondary giant cells and Rcho-1 
giant cells. Secondary giant cells (SGCs) emerging from the ectoplacental cone (EPC) at E7.5 
express PLP-A, as determined by immunofluorescence, whereas primary giant cells (PGCs), derived 
from the polar trophectoderm, are negative for PLP-A (a; white arrowheads highlight SGCs and 
PGCs). Rcho-1 giant cells cultured for 72 hours express PLP-A (b), consistent with the observation 
that they represent a model for SGCs.
5.3. DISCUSSION
A previous study showed that the phosphorylation o f  Handl at T107 and 
S I09 during Rcho-1 TG cell differentiation enhances the affinity o f  the transcription 
factor for its E-factor binding partners and thus its biological activity (Firulli et al., 
2003). In this chapter, we reveal that this phosphorylation event also underlies its 
nucleolar release at the onset o f Rcho-1 differentiation. Moreover, we have revealed 
that the polo-like kinase Plk4 is responsible for Handl phosphorylation in this 
context. Plk4-nu\\ embryos appropriately have impaired SGC differentiation and this 
is underpinned by a failure o f Handl nucleolar release. Additionally, nuclear export 
o f  B568 during Rcho-1 differentiation counteracts PP2A-mediated Handl 
dephosphorylation and aids the increase in Handl phosphorylation. Taken together, 
our results show that Plk4-mediated Handl phosphorylation drives its nucleolar- 
nuclear release as a pre-requisite for TG cell differentiation during placentation.
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5.3.1. Site-specific phosphorylation of Handl underpins its 
nucleolar release
Our results uniquely show that only nuclear-wide phospho-Handl, but not 
unphosphorylated Handl sequestered in the nucleolus, is able to promote Rcho-1 
differentiation. Firstly, we demonstrated that a Handl T107;S109A-EGFP fusion 
protein, which cannot be phosphorylated at these two residues, remained almost 
exclusively nucleolar during a 72-hour time-course of Rcho-1 differentiation. In these 
cultures, the number of fluorescent TG cells 72 hours post-transfection was not 
significantly different to the number of fluorescent TG cells 24 hours post­
transfection. These observations suggest that the change in charge conferred by 
phosphorylation of these two helix 1 residues is necessary for promoting Handl 
nucleolar release. The few TG cells observed in the Handl T107;S109A-EGFP 
mutant cultures 72 hours post-transfection were likely attributable to endogenous 
wild-type Handl activity.
In contrast, substitution of both T107 and S I09 for aspartic acid residues 
yielded the opposite result. The Handl T107;S109D-EGFP mutant fusion protein 
adopted a nuclear-wide distribution immediately after its expression, due to either a 
failure of nucleolar sequestration or retention. It is of note that aspartate substitutions 
serve as substitutes of phosphorylation, mimicking the change in charge that 
phosphorylation confers. For example, mutation of a serine residue to an aspartate in 
helix 1 of c-Myc renders the bHLH transcription factor constitutively active (Huang 
et al., 2004b). Thus the Handl T107;S109D-EGFP mutant fusion protein acts as a 
useful positive control in this study. It suggests that the change in protein charge 
conferred by phosphorylation of these two helix 1 residues is sufficient for Handl 
nucleolar release. The fact that this mutant is not as potent as wild-type Handl in 
driving TG cell differentiation is in agreement with previous observations that this 
mutant has a reduced affinity for nucleoplasmic E-factors and a predisposition to 
homodimerise (Firulli et al., 2003). In conclusion, the phosphorylation of Handl at 
T107 and/ or S I09 is required for its release from the nucleolus in Rcho-1 stem cells 
at the onset of TG cell differentiation. It will be interesting in this regard to analyse 
the trophoblast phenotype of Handl T107;S109A and Handl T107;S109D knock-in
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mice, which are currently being generated (A. Firulli, personal communication).
Interestingly, the Handl T107;S109D mutant fusion protein localised to 
discrete, as-yet unidentified nucleoplasmic foci. Why wild-type Handl-EGFP does 
not occupy such foci is curious. Perhaps its association with these unidentified bodies 
occurs at a very early stage of differentiation or is only transient, whilst the Handl 
phosphorylation mimic constitutively resides within these foci. Preliminary data 
excluded co-localisation of these foci with centrosomes or Cajal bodies by 
immunostaining for markers specific for these organelles. However, a degree of co­
localisation of the Handl phosphorylation mimic was demonstrated with so-called 
transcription factories (Iborra et al., 1996; Osbourne et al., 2004), specific nuclear 
sites of gene activation and nascent RNA synthesis. Immunostaining for RNA 
polymerase II, a marker for such foci, demonstrated a weak overlap with Handl 
T107;S109D. Since there was not a complete overlap in localisation of the 
T107;S109D mutant with transcription factories, it was hypothesised that this fusion 
protein may also in part become a component of site-specific multi-protein 
complexes involved in chromatin remodelling and gene expression. Indeed, during 
terminal differentiation of C2C12 myoblasts the nucleolar ZPF106 protein is released 
and localises to very similar nucleoplasmic foci that coincide with the TSPYL 
protein, a putative chromatin-remodelling factor (Grasberger and Bell, 2005). 
Interestingly, another of the Handl interactors identified in the Y2H screen was the 
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily E member 1 (Smarcel; Appendix 8). This is involved in transcriptional 
activation and repression of select genes by chromatin remodeling (Belandia et al.,
2002). Thus activated, nucleoplasmic Handl may localise to these site-specific 
chromatin-remodelling complexes to regulate genes required for TG cell 
differentiation. In conclusion, despite some overlap with transcription factories and a 
strong possibility of co-localisation with a subset of chromatin remodeling 
complexes, the identity of the nuclear-wide foci to which the Handl T107;S109D 
mutant localises are currently unknown.
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5.3.2. Nuclear export of B568 complements Handl nucleolar 
release
The regulatory subunit B568 of protein phosphatase 2 A (PP2A) targets Handl 
for dephosphorylation at T107 and S I09 (Firulli et al., 2003). Appropriately, this 
previous study also showed that B56S is down-regulated during Rcho-1 
differentiation. As final confirmation that Handl nucleolar release is reliant on site- 
specific phosphorylation, we over-expressed B568 in Rcho-1 stem cells co­
transfected with Handl-EGFP. This resulted in both a significant failure of the 
fluorescent fusion protein to exit the nucleolus and a significant reduction of TG cell 
differentiation compared to Rcho-1 stem cells transfected with Handl-EGFP alone. 
Moreover, ectopic expression of B565 in Rcho-1 stem cells cultured in 
differentiation-inducing conditions antagonised their differentiation as compared with 
untransfected Rcho-1 stem cells cultured under the same conditions. Importantly, this 
B568-induced block to differentiation was associated with a failure of endogenous 
Handl to exit the nucleolus.
We also demonstrated that the PP2A B568 subunit is distributed throughout 
Rcho-1 stem cells but is predominantly cytoplasmic and excluded from the nuclei and 
nucleoli of TG cells. This observation is consistent with a relevant role for B568 in 
Rcho-1 stem cell maintenance. As part of a PP2A complex, B568 is possibly present 
in and/ or around the nucleoli of Rcho-1 stem cells. Here it may target any Handl that 
has been inappropriately phosphorylated and released from the nucleolus prior to cell 
commitment to differentiation. After the onset of TG cell differentiation, exclusion of 
B568 from the nucleus, in combination with the down-regulation o f the B56S gene 
(Firulli et al., 2003), may prevent PP2A8566 site-specifically dephosphorylating 
Handl in the nucleoplasm. Nuclear exclusion of B565 is reminiscent of the 
cytoplasmic sequestration and negative regulation of the myogenic and Mash2 bHLH 
factors by I-mfa (Chen et al., 1996; Kraut et al., 1998) and of the p50 subunit of NF- 
k B  by Ik B  (Beg et al., 1992). In conclusion, the down-regulation (Firulli et al., 2003) 
and nuclear export (data presented in this study) of B565 prevents PP2AB568-mediated 
dephosphorylation of Handl during Rcho-1 differentiation.
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5.3.3. Plk4 is the kinase responsible for nucleolar Handl 
phosphorylation
The data presented in this chapter are consistent with a requirement for the 
polo-like kinase Plk4 in the phosphorylation of nucleolar Handl as a pre-requisite for 
its release into the nucleus and concomitant TG cell differentiation. Appropriately, 
Plk4 mRNA levels increase during this process, immediately after serum withdrawal. 
This is consistent with our interpretation that the kinase triggers the onset of 
endoreduplication at the point of Rcho-1 stem cell commitment to differentiate. Plk4 
mRNA levels are known to be cell cycle regulated, being low in G1 phase but 
reaching a peak at the G2/M transition (Swallow et al., 2005). However, our 
observations in TG cells are in contrast with the findings of previous studies that have 
been unable to detect Plk4 expression in other distinct quiescent and differentiated 
cells (Fode et al., 1994). However, the differences in Plk4 expression in TG cells 
versus other cell types may reflect the unique requirement for TS cells to enter the 
endocycle in order to differentiate into TG cells.
Despite the transient interaction between kinases and their substrates, we were 
able to demonstrate interaction and reaction between endogenous Handl and Plk4 in 
vitro. Moreover, over-expression and RNAi-mediated knock-down of Plk4 had 
appropriate effects on Handl phosphorylation and sub-cellular localisation, as well as 
Rcho-1 stem cell fate. This confirms that Plk4 gain- or loss-of-function has effects on 
TG cell differentiation via the modulation of Handl subcellular localisation. It is 
interesting in this regard that transient over-expression of Plk4 has previously been 
shown to suppress mitotic cell cycling and promote multi-nucleation (Fode et al., 
1994; Fode et al., 1996). A non-canonical target consensus phosphorylation motif for 
Plk4 has only recently been determined via in vitro kinase assays on peptide spots 
arrays (Z-[Ile/Leu/Val]-Ser/Thr-Y-Y-X-Z/Pro; Leung et al., 2007). In this degenerate 
consensus sequence, Y is a large, hydrophobic residue, Z is a charged residue, whose 
charge specifically depends on the context of the surrounding sequence, and residues 
in brackets are unfavoured. However, Plk4 cannot phosphorylate several peptides 
containing this theoretically-optimal motif, suggesting the existence of other 
sequences outside of the core motif that influence the reaction. Thus the consensus
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phosphorylation motif of Plk4 is highly context-dependent. In peptides that have a net 
positive charge, Plk4 favours basic residues in the -2 and +4 positions. Conversely, in 
peptides with a net negative charge, Plk4 favours acidic residues in the -2 and +4 
positions (Leung et al., 2007). This may explain why the region of Handl containing 
the T107 and S I09 residues does not strictly match this consensus sequence. Notably 
the study by Leung and co-workers also showed that Plk4 can phosphorylate peptides 
when they are free in solution, and that it cannot phosphorylate GST alone and 
requires a high substrate yield for in vitro kinase assays. These observations are in 
agreement with our findings.
Plk4-null mouse embryos arrest at E7.5 and are embryonic lethal at E8.0 due 
to widespread apoptosis caused by inappropriate anaphase arrest (Hudson et al., 
2001). However, the mutant extra-embryonic tissues were not analysed in detail 
(Hudson et al., 2001). Consequently, our study is the first to investigate the 
phenotype of Plk4-null embryos in terms of trophoblast differentiation in vivo. We 
revealed that embryos deficient for Plk4 have a markedly-enlarged ectoplacental cone 
(EPC) compared with Plk4-heterozygous controls. This is consistent with an 
expansion of the diploid source of trophoblast cells and reduced SGC differentiation 
from the outer layer of the EPC. Our data reveal that the inability of Handl to exit the 
nucleolus in Plk4-null diploid trophoblast underlies the enlarged EPC of these 
concepti, namely because the diploid TG cell precursors cannot exit the mitotic cell 
cycle and so continue to proliferate. At first, this finding does not appear to agree 
with the initial analyses of Plk4-null embryos, namely the defects in mitotic 
progression and thus impaired cell proliferation. However, the fact that Plk4-null 
embryos proceed through many cell divisions before arresting at E7.5 was proposed 
to be either due to a persistence of maternal Plk4 mRNA or protein, functional 
redundancy with another polo-like kinase or due to unique features of the mitotic exit 
network during early embryogenesis (Hudson et al., 2001; Swallow et al., 2005). 
These factors may also underlie the proliferation of diploid trophoblast until 
embryonic arrest at E7.5. That is, the larger EPC of Plk4-null concepti reflects not 
hyper-proliferation of diploid trophoblast, but rather a lack of SGC differentiation.
The observation of reduced SGC differentiation in Plk4-mx\\ embryos is also 
consistent with the phenotype previously described for Handl-null embryos. Handl-
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null embryos develop until around E7.5 and begin to gastrulate and establish an 
implantation chamber through PGC migration. However, they have significantly 
reduced numbers of SGCs (Riley et al., 1998). Despite the lack of SGCs being a 
common feature of both Handl-rm\\ and Plk4-null concepti, Plk4-null mutants do not 
exactly phenocopy Handl-null mutants. This is consistent with the fact that not all of 
Handl function during early embryogenesis is mediated through Plk4 and vice versa. 
Indeed, whilst Plk4 is required for mitotic cell cycle exit in rodent trophoblast, Handl 
is required for the proliferation and maintenance of diploid trophoblast in the EPC, by 
an as-yet unknown mechanism (Riley et al., 1998). This may be dependent on its 
binding E-factors, which are present in SGC precursors but are down-regulated 
during TG cell differentiation (Scott et al., 2000). In fact, in the absence o f Handl, 
the EPC is reduced to approximately 20% of its normal size due to reduced 
trophoblast cell number (Riley et al., 1998). How these findings can be reconciled 
with the more recent finding that Handl -null TS cells do not have proliferation 
defects in culture (Hemberger et al., 2004) is currently unclear. Thus the crucial 
finding in the context of this study is that, in both genetic backgrounds, commitment 
o f diploid trophoblast precursors to a SGC fate is impaired.
Importantly, whilst Handl was nuclear-wide in a significant number of SGCs 
in control embryos, the transcription factor remained predominantly nucleolar in the 
expanded diploid trophoblast of Plk4-null mutants. This was coincident with a 
restricted and rare commitment to a SGC fate in the mutant placentae and is 
consistent with our in vitro studies. Thus, the observed effects of Plk4 knock-down in 
Rcho-1 cells, namely a block to TG cell differentiation and retention of nucleolar 
Handl, mimics the in vivo situation following Plk4 loss-of-function. It is important to 
acknowledge that some SGCs arise in Plk4-nu\\ concepti, and furthermore 
endogenous Handl was detected outside of the nucleolus in some of these cells. This 
is not hugely surprising, as other factors are known to drive TG cell differentiation 
(Chapter 1, Table 1.2b), and these would likely be able to still do so in the absence of 
Plk4. Moreover, Handl is phosphorylated at other residues in addition to T107 and 
S I09 during TG cell differentiation (for example, the basic domain residue serine-98; 
Firulli et al., 2003). Although we did not investigate whether Plk4 phosphorylates 
this residue and others, we acknowledge that other nucleolar kinases in addition to 
Plk4 target Handl for phosphorylation during this differentiation process and may
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contribute to its nucleolar release.
Our data suggest a differential requirement for Plk4 and nuclear-localised 
Handl during the differentiation of PGCs and SGCs. DNA staining of histological 
sections revealed that the differentiation of PGCs, which arise directly from the 
trophectoderm at the blastocyst stage, was normal in Plk4-null mutants. Despite their 
morphological similarity, the mechanisms underlying the differentiation of PGCs and 
SGCs are different. This is supported by the fact that the glycoprotein mCGMl and 
certain hormones, such as PL-II and PLP-A, are confined to SGCs (Rebstock et al., 
1993; Ma and Linzer, 2000; reviewed in Chapter 1, section 1.2.4.2). Indeed Handl, 
or at least zygotic Handl, does not appear to be required for primary TG cell 
differentiation as Handl-null blastocysts form trophectoderm and hatch and outgrow 
in vitro (Cross et al., 1995; Riley et al., 1998). Thus, by inference, Plk4-mediated 
nucleolar release of pre-existing Handl is not required for PGC differentiation. This 
differential effect on SGC versus PGC differentiation in P/&4-deficient embryos is in 
agreement with the in vitro studies, in that Rcho-1 differentiation is thought to most 
closely resemble SGC differentiation (Hamlin et al., 1994). This is an observation 
supported by our demonstration of the expression of the SGC-specific marker PLP-A 
(prolactin-like protein A) in Rcho-1 TG cells, in agreement with previous studies 
(Hamlin et al., 1994; Ma and Linzer, 2000). It is also worth mentioning that Handl is 
required for the normal differentiation of all four subtypes of SGCs in the recent 
study by Simmons and colleagues, which importantly includes the so-called ‘parietal 
SGCs’ that form the interface with the maternal decidua (Simmons et al., 2007).
The cellular functions of Plk4 include regulating centriole duplication during 
prophase and spindle organisation during cytokenesis (Bettencourt-Dias et al., 2005; 
Habedanck et al., 2005; Kleylein-Sohn et al., 2007). Down-regulation of Plk4 is also 
thought to play a part in the DNA damage response at the‘G2/M checkpoint by 
promoting p53-dependent apoptosis, which possibly relies on an observed interaction 
between Plk4 and p53 (Li et al., 2005; Swallow et al., 2005). Plk4 is the most 
divergent member of the polo-like kinase family and, unlike other Plk members, does 
not exhibit functional redundancy (Swallow et al., 2005; Figure 5.23a). The basis of 
this lack of conservation may be underpinned by the fact that Plk4 possesses only one 
so-called polo-box (pb), a protein-protein interaction domain that is thought to
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localise the enzyme to subcellular structures, whilst all other Plks possess two (Leung 
et al., 2002; Swallow et al., 2005; Figure 5.23b). The single polo box of Plk4 is 
moreover thought to interact with an upstream Plk4-specific ‘cryptic’ polo-box, 
which forms a novel intra-molecular dimer that may play a part in the unique 
localisation of Plk4, amongst Plk family members, to the nucleolus (Hudson et al., 
2001; Leung et al., 2002; Figure 5.23b).
Our findings provide insight into the functional basis for Plk4 nucleolar 
localisation during G2 phase in TS cells. Plk4 localises to the nucleolus specifically 
at phase G2, the cell cycle stage at which Rcho-1 cells are thought to initiate 
endocycling upon their commitment to differentiate (MacAuley et al., 1998). We also 
provide evidence that Plk4 localises to a single nucleolus in each Rcho-1 stem cell. 
This raises the possibility that each nucleolus has a discrete identity in terms of 
protein content and putative function(s). Our in vivo data show that Plk4 
phosphorylates nucleolar Handl during G2 as a prerequisite for Handl nucleolar 
release and the onset of endoreduplication and concomitant TG cell differentiation. 
The consequence of this is that Plk4 restricts the potency of TS cells by promoting 
mitotic cell cycle exit and the onset of endoreduplication with concomitant TG cell 
differentiation. This is the first role proposed for Plk4 in the nucleolus. Of relevance 
for our study, Plk4 is known to contribute to the activation of the anaphase-promoting 
complex/ cyclosome- (APC/C) ubiquitin ligase. This targets mitotic cyclins for 
proteasomal destruction as a pre-requisite for endocycle entry (Hudson et al., 2001). 
Thus our data show that Plk4 plays a part in promoting mitotic cell cycle exit and 
entry into the endocycle, at least in rodent trophoblast. This is in addition to its role in 
promoting exit from mitosis during normal mitotic cell cycling.
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Figure 5.23. Comparison of the basic structure o f murine PIk4 with that o f P lkl 
(a) and the evolutionary divergence of Plk4 from other members o f the Plk 
family (b).
In (a), phylogenic relationship of polo-like kinases was determined by the CLUSTALX program, and 
the scale represents 0.1 amino acid replacement per site. In (b), the position o f the threonine-170 
residue, whose mutation to an aspartic acid generates a gain-of-function Plk4 allele (Swallow et al., 
2005), is shown, pb: polo box, cry-pb: cryptic polo-box, blue boxes: PEST destruction motifs., d: 
Drosophila, m: mouse, h: human. Adapted from Hudson et al., 2001.
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5.3.4. Summary and concluding remarks
We conclude that the site-specific phosphorylation of Handl at two key 
residues in helix 1 is essential for its nucleolar release in rodent trophoblast. A 
previous study illustrated that site-specific phosphorylation of Handl is enhanced 
during the differentiation of Rcho-1 cells and that this alters Handl dimerisation 
affinities and thus its biological function (Firulli et al., 2003). Our study is entirely 
consistent with these findings but defines the phosphorylation and resultant nucleolar 
release of Handl as the earliest event in the cascade towards the commitment of 
Rcho-1 stem cells to a TG cell fate. Phosphorylation of Handl at T107 and S I09 at 
the onset of Rcho-1 differentiation is enhanced by the polo-like kinase Plk4 and the 
down-regulation and nuclear export of the Handl-targeting PP2A subunit, B568. 
That the protein kinases A and C were previously shown to phosphorylate Handl 
may also still be biologically-relevant and occur in the nucleoplasm, but only after 
Handl has been phosphorylated in the nucleolus by Plk4 as a pre-requisite for its 
release (Firulli et al., 2003). We propose that, in the hypo-phosphorylated state, 
Handl is sequestered in the nucleolus and is thus unable to physically interact with E- 
proteins. However, Handl phosphorylation likely changes the charge and/ or 
conformation of the transcription factor and so abrogates its affinity for its nucleolar 
repressor, HICp40. This is particularly likely in view of the finding that the HLH 
domain of Handl, within which region T107 and S I09 reside, is known to bind 
several other proteins, possibly including HICp40. Nuclear-wide Handl is then able 
to heterodimerise with E-proteins and thus activate its target genes and/ or trigger 
mitotic cell cycle exit, an event which commits Rcho-1 stem cells towards a 
differentiated TG cell fate.
The processes that underlie the nucleolar-nucleoplasmic/ cytoplasmic 
shuttling of mammalian factors are largely unknown, but several studies, mainly in 
budding yeast, have shown that phosphorylation is responsible for such trafficking 
(Table 5.1). In this study we present the first example of phosphorylation 
underpinning the release of a nucleolar factor during interphase in a mammalian cell. 
Site-specific phosphorylation of nucleolar Handl by Plk4 identifies not only the first 
physiological substrate for this non-canonical polo-like kinase but also underpins the
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functional release of Handl into the nucleoplasm. In the context of this study, the 
alteration of protein charge or steric hindrance introduced by phosphorylation or 
other post-translational modifications likely abrogates the interaction between the 
sequestered factor and its ribosomal-machinery-bound nucleolar anchor, namely 
HICp40, to permit its escape from the nucleolus. Otherwise, Handl phosphorylation 
may promote its interaction with a nuclear anchor or perhaps activate a putative 
nucleolar export signal. By whichever mechanism, this covalent modification may 
thus act as a ‘molecular switch’, implying that nucleoplasmic-nucleolar shuttling can 
be regulated and is responsive to extracellular stimuli via intracellular signalling 
pathways.
In conclusion, the findings presented in this chapter reveal a novel mode of 
Handl regulation during TG cell differentiation. This provides insight into the 
molecular mechanism underlying rodent trophoblast invasion and placentation. In the 
following chapter, we discuss the wider implications of these findings, the 
unanswered questions that remain and the aims of ongoing studies.
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Chapter 6
General discussion
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6.1. Nucleolar release of Handl acts as a molecular 
switch to determine trophoblast stem cell fate
The interaction of Handl with other factors is important for controlling its 
activity (Firulli et al., 2000). Given the promiscuous dimerisation properties of 
Handl with both class A and class B bHLH factors (Chapter 1, Table 1.1), we 
hypothesised that the transcription factor may functionally interact with non-bHLH 
factors and that these co-factors may regulate Handl activity.
In our current study, we demonstrated that the activity o f Handl is regulated 
by the rodent orthologue of the human I-mfa domain-containing protein (HICp40). 
HICp40-dependent nucleolar sequestration negatively-regulates Handl activity in a 
faithful model of TS cells, the Rcho-1 cell line (reviewed in Chapter 1, section 1.6). 
Specifically, the nucleolar localisation of Handl is associated with its transcriptional 
inactivity and TS cell renewal. Rcho-1 TS cells can be induced to undergo TG cell 
differentiation by modifying the culture conditions, namely by replacing fetal bovine 
serum with horse serum. We found that Handl disperses throughout Rcho-1 stem cell 
nuclei coincident with their differentiation into TG cells. As confirmation of this, 
HICp40 gain- and loss-of function assays modulate Rcho-1 TG cell differentiation by 
affecting Handl subcellular localisation. Thus the release of Handl from the 
nucleolus is necessary and sufficient for TG cell differentiation and this mechanism 
may underlie the first differentiation event during embryogenesis.
A previous study showed that Handl is phosphorylated at two residues in 
helix I during TG cell differentiation (Firulli et al., 2003). This enhances the affinity 
o f Handl for its bHLH binding partners as a crucial step in the TG cell differentiation 
program. We demonstrated that an increase in Handl phosphorylation at these two 
residues underpins its nucleolar release at the onset of TG cell differentiation. 
Crucially, our findings are entirely consistent with the earlier study (Firulli et al.,
2003), but place the phosphorylation and nucleolar release of Handl as the earliest 
event during TG cell differentiation. We speculate that this post-translational 
modification modifies the charge and/ or conformation of Handl, so diminishing its 
affinity for nucleolar HICp40 and thus triggering its nucleolar release.
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We then investigated which nucleolar kinase phosphorylates Handl. This was 
shown to be Plk4 (Sak), a non-canonical member of the serine/ threonine polo-like 
kinase family whose members commonly modify the subcellular localisation of their 
substrates (Toyoshima-Morimoto et al., 2001; 2002; Kim et al., 2005). 
Haploinsufficiency for Plk4 results in mitotic infidelity, chromosomal instability and 
carcinogenesis, particularly old age-onset liver tumourigenesis (Ko et al., 2005). The 
basis of this is likely to be the crucial role for Plk4 in centriole duplication and 
spindle organisation during mitosis (Bettencourt-Dias et al., 2005; Habedanck et al., 
2005; Kleylein-Sohn et al., 2007). Indeed, PLK4 expression is aberrant in some 
colorectal cancers and hepatomas (MacMillan et al., 2001; Ko et al., 2005). Plk4-mi\\ 
mice are embryonic lethal at E9.5-El0.0 due to widespread apoptosis caused by 
inappropriate anaphase arrest (Hudson et al., 2001). However, the trophoblast lineage 
was not analysed in this study.
Plk4 is unique in the mammalian Plk family in that it localises to the 
nucleolus during the second gap phase (G2) of the mitotic cell cycle (Hudson et al., 
2001). Interestingly this is the stage at which TG cell differentiation is thought to be 
initiated (MacAuley et al., 1998). Therefore, Plk4 is in the right place at the right 
time to activate Handl and so initiate endoreduplication. Our current study 
demonstrated that Plk4 can interact and react with Handl in vitro and in vivo. 
Moreover gain- and loss-of-function Plk4 assays modify Handl subcellular 
localisation with appropriate effects on TG cell differentiation. Importantly, Handl is 
unable to exit the nucleoli of Plk4-null diploid trophoblast and this is associated with 
their impaired ability to undergo SGC differentiation.
O f note, the site-specific phosphorylation of Handl by Plk4 is complemented 
by the ‘elimination’ of a Handl phosphatase. During TG cell differentiation the 
Handl-targeting regulatory subunit B568 of protein phosphatase 2A (PP2A) is both 
exported from the nucleus (data presented in this study) and down-regulated (Firulli 
et al., 2003). Thus a positive-feedback loop is likely to ensue, whereby the 
elimination of PP2A3568 from the nuclear compartment allows phosphorylated Handl 
to persist. Phosphorylated Handl is in turn able to accomplish its nuclear functions 
and this further drives the process of TG cell differentiation (Figure 6.1).
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Figure 6.1. The molecular mechanism underlying mitotic cell cycle exit in rodent 
trophoblast.
During TS cell renewal, pre-existing Handl is sequestered in an inactive state in the nucleolus by the 
rat orthologue of HICp40. Should nucleolar Handl be inappropriately phosphorylated by Plk4 and 
released, nuclear PP2A8565 targets it for dephosphorylation and nucleolar re-entry. It is unknown 
whether Handl nucleolar sequestration is active or passive (a). A change in serum conditions results in 
the phosphorylation o f nucleolar Handl by Plk4 during phase G2 o f the final mitotic cell cycle. 
Concurrently, B565 is exported to the cytoplasm and down-regulated. These events enhance the 
phosphorylation of Handl, resulting in its nucleolar release (b). P: phosphoserine/ phosphothreonine.
209
Chapter 6
In conclusion, our current study implicates the bHLH factor Handl in 
governing the onset of endoreduplication and thus cell fate in rodent trophoblast. The 
release of Handl from the nucleolus represents the molecular switch between 
proliferative self-renewal of Rcho-1 stem cells and their differentiation into TG cells. 
It is also worth mentioning that the role of bHLH transcription factors in promoting 
mitotic cell cycle exit is not without precedent. An Arabidopsis strain (gl3) that 
undergoes reduced trichome endocycles has a mutation in a gene encoding a bHLH 
factor (Payne et al., 2000). Similarly, the bHLH factor dMyc and the Notch-induced 
HLH factor Extra macrochaetae (Emc) are necessary for Drosophila ovarian somatic 
cells to enter the endocycle and differentiate into follicular epithelial cells (Maines et 
al., 2004; Adam and Montell, 2004). In light of these studies and our current work we 
propose that bHLH factors, which are often involved in determining cell fate, play an 
evolutionarily-conserved role in promoting the onset of endoreduplication and 
accompanying terminal differentiation.
6.2. A conserved eukaryotic cascade that modifies the 
cell cycle relies on the nucleolus
The commitment of TS cells to a TG cell fate coincides with their terminal 
mitotic cell cycle exit and concomitant entry into the endocycle (Cross et al., 1995; 
MacAuley et al., 1998; Hughes et al., 2004). In this study, we have shown that the 
release of Handl from the nucleolus underlies the onset of endoreduplication in the 
rodent trophoblast lineage. Notably, for a rodent TS cell to exit the mitotic cell cycle, 
mitotic cyclins must also be ubiquitinated for proteasomal degradation by the 
anaphase-promoting complex/ cyclosome (APC/C) (MacAuley et al., 1998). 
Otherwise their activity must be inactivated (Palazon et al., 1998). The APC/C 
complex is also required for exit from mitosis during the mitotic cell cycle, which in 
turn is dependent again on its targeting of mitotic cyclins for degradation (reviewed 
by Cerutti and Simanis, 2000).
APC/C substrate specificity is governed by its interaction with WD-repeat 
family proteins including budding yeast Cdc20 {Drosophila Fizzy, human p55CDC)
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and Cdhl (Drosophila Fizzy-related (Fzr), human hCDHl) (Sigrist and Lehner, 
1997; Lorca et al., 1998; Kramer et al., 2000). APC/Ccdc20 appears during metaphase 
and is required for the destruction of the Separase inhibitor Securin as a crucial step 
towards sister chromatid separation and the trigger for anaphase entry. In contrast, 
APC/Ccdhl predominates in late anaphase and promotes mitotic exit by targeting 
mitotic cyclins and other mitotic inducers for proteasomal degradation (reviewed by 
Sullivan and Morgan, 2007).
That the APC/CCdhl targets mitotic cyclins for proteasomal degradation to 
trigger mitotic exit is very relevant in light of the findings of our study. APC/C 
substrate-determining yeast Cdhl orthologues in Arabidopsis (Ccs52A) and 
Drosophila (Fzr) are respectively required for down-regulating mitotic cyclins to 
switch the mitotic cell cycle at phase G2 to the endocycle during seed (Cebolla et al., 
1999) and salivary gland (Sigrist and Lehner, 1997) development. Furthermore, 
mutations that reduce mitotic Cyclin B-Cdkl activity induce an endoreduplication 
phenotype in both fission (Hayles et al., 1994) and budding (Azzam et al., 2004) 
yeast. Thus in terms of mitotic cell cycle exit in TS cells, the release of Handl from 
the nucleolus underlies the onset of the endocycle. How Handl achieves this is as yet 
unknown, but possible mechanisms are discussed later in this chapter (section 6.3.2).
6.2.1. Release of a factor sequestered in the nucleolus 
underlies mitotic (cell cycle) exit and genomic hyper­
amplification
In this study, we show that the release of a nucleolar factor, Handl, underpins 
the onset of endoreduplication and concomitant TG cell differentiation in the Rcho-1 
trophoblast stem cell line. Interestingly, studies in S. cerevisiae have also identified 
an APC/CCdhl activator that is sequestered in the pre-mitotic nucleolus, the 
phosphatase Cdcl4 (Shou et al., 1999; 2002; Visintin et al., 1999; 2003; Yoshida and 
Toh-e, 2002). During interphase and early mitosis, Cdcl4 is bound in an inactive 
state to the nucleolar, multi-functional regulator of nucleolar silencing and telophase 
(RENT) complex (reviewed by Cockell and Gasser, 1999). This complex comprises 
several nucleolar proteins including Cfil (Netl), Nani and Sir2. However, at the
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onset of anaphase, Cdcl4 is released from the nucleolus to dephosphorylate its 
nuclear targets (reviewed by Cockell and Gasser, 1999). These include a cyclin- 
dependent kinase inhibitor (Sicl), which is stabilised by dephosphorylation, and a 
Sicl transcription factor (Swi5), whose dephosphorylation induces its nuclear entry. 
Another of its targets is the APC/C substrate-determining subunit Cdhl, whose 
dephosphorylation promotes its nuclear export and integration into an APC/Ccdhl 
complex that ubiquitinates and marks mitotic cyclins for proteasomal degradation 
(Jaquenoud et al., 2002; Bembenek et al., 2005; reviewed by Morgan and Sullivan, 
2007). Collectively, these events underlie exit from mitosis in budding yeast and the 
onset o f the next mitotic cell cycle.
Cdcl4 inactivation by nucleolar sequestration during interphase also serves a 
second cellular function in budding yeast. This negative regulatory mechanism 
prevents inappropriate Cdc 14-dependent dephosphorylation and inactivation o f DNA 
replication factors during S-phase (Bloom and Cross, 2007). In this regard, it is 
interesting that Handl is sequestered in the nucleolus in an inactive state until cells 
begin to hyper-amplify the genome during endoreduplication (data presented in this 
study). In conclusion, the nucleolar sequestration of a cell fate determinant, Cdc 14 in 
budding yeast or Handl in rodent trophoblast, is a key cellular event that regulates 
exit from mitosis and genomic replication.
6.2.2. A polo-like kinase is recruited to the nucleolus to 
phosphorylate and release a factor involved in mitotic (cell 
cycle) exit
The mechanistic similarities between the budding yeast mitotic exit network 
and the entry of TS cells into the endocycle extend beyond the analogous function of 
the APC/C. We have shown that nucleolar release of Handl is dependent on its 
phosphorylation by the polo-like kinase, Plk4. Interestingly, the sole polo-like kinase 
in budding yeast, Cdc5, phosphorylates Cdc 14 to initiate its nucleolar release (Shou 
et al., 1999; Shou et al., 2002; Visintin et al., 1999; Visintin et al., 2003; Yoshida and 
Toh-e, 2002).
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Cdc5 phosphorylates Cdc 14 at the end of the Cdc fourteen early anaphase 
release (FEAR) network, a poorly-understood cascade that releases a small amount of 
Cdc 14 from the nucleolus (Stegmeier et al., 2002). Cdc5 also phosphorylates Cdc 14, 
amongst other targets, during the mitotic exit network (MEN). This cascade is 
initiated by the first wave of nucleolar-released Cdc 14, which triggers a G protein- 
(Teml-) initiated signalling cascade and the dephosphorylation of the Cdcl5 kinase 
(Shou et al., 2002). Ultimately, this results in a positive-feedback loop that releases 
Cdcl4 from the nucleolus in bulk (Jaspersen et al., 1998; Shou et al., 1999; 2002; 
Visintin et al., 1999; 2003; Yoshida and Toh-e, 2002).
Plk4 is a component of the analogous mammalian mitotic exit network that 
relies on the same premise of APC/CCdhl-dependent destruction of mitotic cyclins 
(Hudson et al., 2001). Although Plk4-nu\\ embryos exhibit high levels of cyclin B 
and Cdkl, indicative of defective APC/CCdhl activation, it is unclear whether Plk4 
directly phosphorylates and activates components of the APC/CCdhl. It is notable, 
however, that the sole polo-like kinase in fission yeast (Plol; May et al., 1998), and 
the related mammalian Plk family member, Plkl (Kotani et al., 1998; Feng et al., 
2001; Golan et al., 2002; Moshe et al., 2004), modulate APC/C activity by 
phosphorylating its subunits, inhibitors and even its proteasome effector.
Alternatively, the process may be analogous to the MEN in budding yeast in 
that Plk4 could activate an as-yet unidentified phosphatase that then 
dephosphorylates and activates an APC/C component. Indeed, one human CDC 14 
isoform, CDC 14A, is centrosomal and dephosphorylates and activates the human 
CDH1 component of the APC/C as a pre-requisite for exit from mitosis (Bembenek 
and Yu, 2001). Another human CDC 14 isoform, CDC14B, is nucleolar during 
interphase, but its function has been more elusive (Kaiser et al., 2002; Mailand et al.,
2002). It will in this regard be interesting to see whether Plk4 can phosphorylate 
CDC14B in the G2 phase nucleolus and furthermore investigate the functional basis 
of such an event. However, it is worth mentioning that the S. pombe homologue of 
Cdc 14 (Flplp/ Clplp) is not required for mitotic exit, but is instead involved in 
septum formation and cytokinesis (Cueille et al., 2001; Trautmann et al., 2001). Thus 
it would not be surprising to find that the mechanism governing mitotic cell cycle exit 
in rodent trophoblast does not involve CDC 14 isoforms.
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Notably other aspects of Cdc5 and Plk4 regulation are also conserved between 
yeast and mammals. For example, both Cdc5 and Plk4 are rapidly ubiquitinated for 
proteasomal degradation as part of a negative feedback loop during G1 by the 
APC/C, which they in part activated at the end of the previous mitotic cell cycle 
(Fode et al., 1996; Shirayama et al., 1998). In the case of Plk4, a low protein half-life 
is conferred by three so-called PEST sequences at its C-terminus (Fode et al., 1996; 
Yamashita et al., 2001; Figure 5.23b). In conclusion, whilst both Cdc5 and Plk4 are 
required at anaphase for exit from mitosis, we have shown in this study that Plk4 can 
additionally initiate endoreduplication during phase G2 under certain conditions. It 
achieves this by phosphorylating nucleolar Handl, whose release into the 
nucleoplasm underlies the transition from the mitotic cell cycle to the endocycle.
6.2.3. A PP2A complex antagonises the nucleolar release of a 
factor involved in mitotic exit
The down-regulation (Firulli et al., 2003) and nuclear export (data presented 
in this study) of the regulatory (B, substrate-recognising) subunit B566 of the protein 
phosphatase 2A (PP2A) serine/ threonine phosphatase contributes to Rcho-1 TG cell 
differentiation. This exclusion of PP2A8565 from the nucleolus and nucleus likely 
facilitates Plk4-dependent Handl phosphorylation at the onset of TG cell 
differentiation. This is yet another conserved aspect of the cascade governing cell 
cycle regulation between yeast and mammals: the PP2A B-subunit Cdc55 plays a 
critical role in blocking the onset of the budding yeast MEN (Queralt et al., 2006).
Budding yeast Netl, the nucleolar anchor for Cdc 14, is kept hypo- 
phosphorylated prior to anaphase by a PP2A complex containing Cdc55 (Queralt et 
al., 2006). This has the effect of suppressing ectopic Cdc 14 nucleolar release and thus 
inappropriate mitotic exit outside of anaphase. At anaphase the sister chromatid- 
separating protease Separase, released at the onset of anaphase from its Securin 
inhibitor, interacts with and inactivates PP2ACdc55 (Queralt et al., 2006). Thus, a 
PP2A complex containing Cdc55 (budding yeast) or B568 (rat trophoblast; Firulli et 
al., 2003; data presented in this study) antagonises exit from mitosis until the onset of 
anaphase or exit from the mitotic cell cycle until the onset of endoreduplication
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respectively. However, the PP2A complexes achieve this effect by different means. 
PP2ACdc55 dephosphorylates the nucleolar sequesteror of Cdc 14, Netl (Queralt et al.,
2006), whereas PP2A8565 maintains the sequestered factor, Handl, in a 
dephosphorylated state during TS cell renewal (data presented in this study).
6.2.4. Speculative extrapolations of our model
In conclusion, there are numerous similarities between a mechanism 
governing mitotic exit in budding yeast and mitotic cell cycle exit in rodent 
trophoblast. In light of these, it is possible that other aspects of the S. cerevisiae 
FEAR and MEN pathways also serve to modulate the onset of TG cell differentiation. 
Cdc55 is degraded by Separase at the onset of anaphase in budding yeast and this 
allows Cdc5-dependent phosphorylation of Cdc 14 to persist (Queralt et al., 2006). In 
this regard, it will be interesting to investigate whether mammalian Separase is partly 
responsible for B565 ‘elimination’ at the onset of TG cell differentiation. 
Additionally, at anaphase, Cdc5 is also thought to phosphorylate the nucleolar 
sequesteror of Cdcl4, Netl (Yoshida and Toh-e, 2002). PP2ACdc55 conversely keeps 
Netl hypo-phosphorylated prior to anaphase (Queralt et al., 2006). Thus it is possible 
that Plk4 and PP2A8566 similarly modulate the phosphorylation of the Handl 
sequesteror, HICp40. Indeed another kinase, the pTEFb component Cdk9, 
phosphorylates HICp40 at conserved sites in its I-mfa domain (Wang et al., 2007). 
Related to this, it would be interesting to investigate whether, like other bHLH 
proteins, Handl recruits the pTEFb complex to its target gene transcripts for the 
purpose of transcriptional elongation (Simone et al., 2002). Should this be the case, 
the observed inhibitory effect of HICp40 on the pTEFb complex (Young et al.,
2003), possibly via nucleolar sequestration, may represent another mode by which 
HICp40 negatively-regulates Handl transcriptional activity. Further investigation is 
required to confirm these hypotheses.
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6.3. Unanswered questions
There are, however, some aspects of our model that remain unclear and 
require further investigation. For example, the bHLH or non-bHLH transcription 
factor partners to which nucleolar-released Handl binds in TG cells remain to be 
definitively determined. A few studies have suggested that the bHLH factors Stral3 
and/ or Hrtl-3, and the HMG-box factor Soxl5, bind Handl during TG cell 
differentiation and that this makes Handl transcriptionally-competent (Firulli et al., 
2000; Hughes et al., 2004; Yamada et al., 2006). However, no in vivo evidence was 
provided by these studies. Another study suggested that Handl may act as a 
homodimer to drive the process of TG cell differentiation in vivo (Hu et al., 2006). 
The identity of the pro-endoreduplicative signals and how they affect Plk4 and 
PP2A8565 activity upstream of Handl are also currently unknown. Finally, at present, 
we can only speculate as to how the nucleolar release of Handl triggers mitotic cell 
cycle exit. The following section discusses some of the putative underlying cellular 
and molecular mechanisms which could shed light on these key questions.
6.3.1. What precedes the release of Handl from the 
nucleolus?
The nucleolar release of Handl is by no means at the pinnacle of the cascade 
that promotes TG cell differentiation. However, precisely how the transition from the 
normal mitotic cycle to endocycle is regulated remains poorly understood, 
particularly in the rodent trophoblast lineage. In Drosophila, one study identified an 
insulin receptor/ phospho-inositol-3-kinase-reliant link between the abundance of 
dietary amino acids and mitotic cell cycle exit (Britton and Edgar, 1998; Britton et 
al., 2002). There also appears to be a relationship between the onset of 
endoreduplication in Drosophila and oxygen concentration, dependent on cyclin 
D/Cdk4 (Frei and Edgar, 2004). This is interesting in light of the results of previous 
studies and ours that report that low oxygen concentration blocks aspects of invasive 
trophoblast differentiation (Gultice et al., 2006; Lash et al., 2007; Takeda et al.,
2007). However, whether such mechanisms induce rodent TS cells entry into the 
endocycle is currently unknown.
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In light of our recent work we can assume that as-yet unidentified factors in 
horse serum (HS), or alternatively a lack of inhibitory factors present in fetal bovine 
serum (FBS), are responsible for driving TS cells into the endocycle. These 
extracellular factors are likely to initiate an intracellular signalling cascade that 
modulates Handl phosphorylation, via the adjustment of Plk4 and/ or B568 levels, 
subcellular localisation and/ or activity. Such a mechanism would not be without 
precedent: a previous study showed that Fgf2 binds to Casein kinase II, and that this 
event promotes nucleolar serine/ threonine phosphorylation o f Nucleolin (Bonnet et 
al., 1996). More recently, the GTP-dependent shuttling of Nucleostemin between the 
nucleolar and nucleoplasmic compartments has been proposed to link extracellular 
signalling cascades to protein subcellular localisation (Tsai and McKay, 2002). 
Indeed, nucleoli are known to respond to changes in cellular growth rate and 
metabolic activity, suggesting that they constantly receive and respond to signalling 
events. At the onset of endoreduplication, Plk4 expression increases (data presented 
in this study) whilst that of B568 is down-regulated (Firulli et al., 2003). This occurs 
in parallel with the export of the B568 protein from the nucleus. Further investigation 
is therefore needed to identify the factors that regulate the transcription of these two 
genes in rodent trophoblast.
In proliferating diploid trophoblast, Plk4 plays a part in regulating centriole 
duplication during prophase and spindle organisation during cytokenesis 
(Bettencourt-Dias et al., 2005; Habedanck et al., 2005; Kleylein-Sohn et al., 2007) 
and localises to the nucleoli at every G2 phase (Hudson et al., 2001). However, it is 
clear from our data that Plk4 does not react with nucleolar Handl during each mitotic 
cell cycle in proliferating TS cells. How, then, is the nucleolar Plk4-Handl reaction 
confined to diploid trophoblast about to undergo TG cell differentiation? One 
possibility is that the PP2A3568 complex, present in TS cell nuclei, antagonistically 
counteracts Plk4-dependent Handl phosphorylation. Only when the TS cell is 
triggered to differentiate is B568 protein exported to the cytoplasm and B568 down- 
regulated, which allows phosphorylated Handl to persist in the nucleus. However, 
this cyclic phosphorylation-dephosphorylation mechanism strikes us as inefficient. 
Other mechanisms may thus restrict the reaction of Plk4 with Handl to an 
appropriate time.
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Another possibility is that levels of Plk4 protein need to cross a critical 
threshold to phosphorylate nucleolar Handl. Crucially, this level would be higher 
than that required for its other cellular functions. This hypothesis is supported by our 
observation of Plk4 up-regulation at the onset of TG cell differentiation. 
Nevertheless, this up-regulation of Plk4 is coincident with the nucleolar release of 
Handl, which suggests that other mechanisms must also play a part. Perhaps in order 
to phosphorylate Handl, Plk4 must bind a nucleolar co-activator, itself activated by a 
change in serum conditions. Yet another possibility is that Plk4 only recognises 
Handl after the transcription factor has first been phosphorylated by a nucleolar 
‘priming kinase’. This would be reminiscent of the mechanism of action of its related 
mammalian family member, Plkl (Elia et al., 2003). The polo-box domain (PBD) of 
Plkl, which comprises both of its polo-boxes and some flanking sequence, can only 
dock onto its substrates after their modification by enzymes including Cdks, MAP 
kinases and other mitotic kinases (reviewed by Lowery et al., 2003). This mechanism 
of action may also apply to the S. pombe polo-like kinase Plol (Grallert and Hagan, 
2002). Further investigation would be required to investigate whether kinase(s) act 
upstream of Plk4 on H andl.
Alternatively it is possible that the signalling cascades upstream of nucleolar 
and non-nucleolar Plk4 may be independent. This was recently suggested by others 
(Tanenbaum and Medemao, 2007) and would entail the activation of nucleolar Plk4, 
but not non-nucleolar Plk4, in response to a change in serum conditions. Finally, we 
have assumed that Handl phosphorylation reduces its affinity for HICp40 and that 
this underlies its nucleolar release. An alternative possibility is that, in proliferating 
TS cells, HICp40 conceals the Handl phosphorylation sites targeted by Plk4. HICp40 
modification in response to a change in serum conditions may subsequently expose 
these residues to the kinase.
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6.3.2. What follows the release of Handl from the 
nucleolus?
Perhaps the principal question still remaining is just how the nucleolar release 
of Handl triggers mitotic cell cycle exit. The most obvious hypothesis is that nuclear- 
wide Handl commits TS cells to differentiation via transcriptional effects. However, 
very few target genes and protein-protein interactions have been identified for Handl 
in trophoblast. Furthermore, where interactions have been identified, such as occurs 
between Handl and the HMG-box transcription factor Soxl5 (Yamada et al., 2006), 
the functional significance remains unclear.
A pre-requisite for endoreduplication in all organisms is the down-regulation 
of genes whose products promote entry into mitosis (Grafi and Larkins, 1995; Sauer 
et al., 1995; MacAuley et al., 1998). Indeed, an inappropriate endocycle can be 
induced in diploid cells simply by inhibiting mitotic cyclin activity (Sigrist and 
Lehner, 1997). Conversely, ectopic expression of mitotic cyclins shunts endocycling 
plant cells into a mitotic cell cycle (Schnittger et al., 2002). Handl can function as a 
transcriptional repressor but no evidence to date implicates it in the down-regulation 
of mitotic activators in trophoblast. It is interesting, however, that Plk4-null embryos 
exhibit high levels of cyclin B and Cdkl (Hudson et al., 2001), indicative o f a loss of 
APC/C function. It is possible, then, that Plk4 may directly phosphorylate 
components, regulators or downstream effectors of the APC/C. Indeed, this is a 
function attributed to Plol, the sole polo-like kinase in S. pombe (May et al., 2002), 
and the highly-related mammalian polo-like kinase Plkl (Kotani et al., 1998; Feng et 
al., 2001; Golan et al., 2002; Moshe et al., 2004). Otherwise nuclear-wide Handl, or 
the products of its target genes, may block mitotic cyclin synthesis or activity. Indeed 
Handl is released during G2, just prior to what would normally be the start of mitosis 
and which is coincident with mitotic cyclin synthesis (MacAuley et al., 1998).
A role for Handl in cell cycle control has been suggested previously, on the 
basis of the down-regulation of the transcription factor in gastric and pancreatic 
cancers (Kaneda et al., 2002; Hagihara et al., 2004). Two studies focusing on the 
cardiac lineage have implicated Handl in the regulation of genes encoding cell cycle
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modifiers, including cyclin D l (Smart et al., 2002; Risebro et al., 2006). It is 
plausible, therefore, that the dramatic switch upon TG cell differentiation from cyclin 
D3 to D l expression (MacAuley et al., 1998; Palazon et al., 1998), and the up- 
regulation of two associated cyclin-dependent kinase inhibitors (Bates et al., 1998; 
Hattori et al., 2000), may be instigated by Handl. Notably Smart and co-workers 
identified Wnt2 as a putative target gene of Handl, albeit in a cardiac cell model 
(Smart et al., 2002). Notably, deletion of the Wnt2 gene in mice is associated with 
defective placentation characterised by ectopic TG cells (Monkley et al., 1996). This 
suggests that Wnt2 is involved in blocking TG cell differentiation and moreover 
implicates Handl in its repression in trophoblast.
In the current study, we reveal that a constitutively-nucleoplasmic Handl 
phosphorylation mimic (Handl T107;S109D) localises to discrete subnuclear foci. 
These may represent a subset of so-called ‘transcription factories’, based on co­
localisation of RNA polymerase II. These sites, which may be transiently occupied 
by wild-type Handl, are hotspots of gene activation in the nucleus (Osbourne et al.,
2004). Additionally these subnuclear bodies resemble chromatin-remodelling 
complexes, which are involved in altering DNA-nucleosome topology, to which other 
transcription factors localise upon their release from the nucleolus (Grasberger and 
Bell, 2005). Chromatin-remodelling complexes have additionally been shown to bind 
and sequester the mitotic cyclins whose inactivation is necessary for mitotic cell 
cycle exit (Kellogg et al., 1995). Interestingly, another of the Handl interactors 
identified in the Y2H screen was the SWI/SNF-related matrix-associated actin- 
dependent regulator of chromatin subfamily E member 1 (Smarcel; Appendix 8). 
This is involved in transcriptional activation and repression of select genes by 
chromatin remodeling (Belandia et al., 2002). Further investigation is required to 
corroborate this interaction and to investigate whether it has functional significance in 
rodent TG cell differentiation.
Does nuclear-wide Handl alternatively promote mitotic cell cycle exit more 
directly, in a mechanism independent of transcription? One way in which Handl 
could achieve this is by promoting TS cells to endoreduplicate by default. Handl has 
been shown to promote TG cell differentiation by competing for the E-factor binding 
partners and promoters of Mash2, a bHLH factor required for TS cell maintenance
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(Guillemot et al., 1994; Scott et al., 2000). However the role of Handl in promoting 
TG cell differentiation is not restricted to inhibiting Mash2-dependent transcription 
(Scott et al., 2000). Moreover, Rcho-1 TS cells proliferate independently of Mash2 
(Cross et al., 1995).
Another possibility is that nuclear-wide Handl, or the products of putative 
Handl target genes, interfere with fibroblast growth factor (Fgf)-dependent 
signalling. Fgfs, in particular Fgf4, have been shown previously to play a part in TS 
cell maintenance (Tanaka et al., 1998; Zhong et al., 2006). Such a role for Handl has 
been suggested previously, in view of the fact that ectopic Handl expression in TS 
cells can override Fgf4-dependent mitotic cell cycling and force endocycle entry 
(Hughes et al., 2004). However, the mechanistic basis for this was not investigated. 
In this regard, it is also interesting that another of the Handl interactors identified in 
our Y2H screen was the receptor for Fgf4-dependent signaling in trophoblast stem 
cells (Fgf receptor-2 (Fgfr2); Appendix 8; Auman et al., 1998). However, further 
investigation is needed to corroborate this interaction and assess its functional 
significance.
Retinoic acid (RA)-dependent signalling also promotes TG cell differentiation 
(Yan et al., 2001), possibly via the transcription factors Stra2 (AP-2y) and Stral3, 
which themselves drive TG cell differentiation (Auman et al., 2002; Hughes et al.,
2004). However an involvement of Handl in this pathway has yet to be determined. 
It is also interesting that Notch-dependent signalling has been implicated in the 
transition from the mitotic cell cycle to the endocycle, at least in Drosophila 
follicular epithelial cells (Deng et al., 2001; Schaeffer et al., 2004; Sun and Deng,
2005). In one study Notch-dependent signalling was shown to down-regulate the 
homeodomain gene Cut, whose product is a negative regulator of the APC/C 
activator Fzr (Sun and Deng, 2005). Handl can bind Mastermind-like 2 (Maml2), a 
placenta-expressed trans-activator of the Notch signalling pathway (P. Riley, 
unpublished data). However, whether this interaction occurs in rodent trophoblast 
with functional significance is unknown.
221
Chapter 6
An alternative possibility is that Handl modifies the function of the APC/C. A 
modified APC/C may target Snail and Geminin, factors that inhibit the onset of 
endoreduplication in diploid trophoblast (Nakayama et al., 1998; Gonzalez et al.,
2006), for proteasomal degradation. Thus in Plk4-null trophoblast Handl would be 
unable to achieve this because it remains sequestered in the nucleolus. It is interesting 
in this regard that several of the Handl interactors identified in our Y2H screen are 
E3 ubiquitin ligases or proteins with RING-finger domains, which are motifs that 
mediate the transfer of ubiquitin from conjugating enzymes to substrates to be 
degraded. Whether a relationship exists between Handl and APC/C activity is 
unknown, however, and would require further investigation. The possible events 
downstream of the release of Handl from the nucleolus during TG cell differentiation 
are listed in Figure 6.2.
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Figure 6.2. How does nuclear H andl promote mitotic cell cycle exit and the 
onset of endoreduplication in trophoblast stem cells?
Handl may promote endoreduplication in a transcription-dependent or transcription-independent 
fashion. This may antagonise Fgf-dependent signalling pathways, which sustain TS cell proliferation, 
or may promote RA- and Notch-dependent signalling pathways, which promote TG cell 
differentiation. Otherwise APC/C activity may be modified to target mitotic cyclins and 
endoreduplication inhibitors for destruction.
CRC: chromatin remodelling complex, APC/C: anaphase-promoting complex/ cyclosome, FGF: 
fibroblast growth factor, RA: retinoic acid, P: phosphoserine/ phosphothreonine.
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6.4. Integrating our findings with established views 
on the nucleolus
The nucleolus belongs to a group of nuclear bodies (NBs), subnuclear entities 
that also include splicing speckles, Cajal bodies, PML bodies and transcription, 
replication and repair factories (reviewed by Handwerger and Gall, 2006). The 
nucleolus is the most prominent of these NBs and is visible by phase contrast light 
microscopy by virtue of its large size (5-10pm) and high refractile index relative to 
the surrounding nucleoplasm, which reflects its dense protein content. As such, 
Wagner, Valentin and Schleiden first identified the nucleolus in three independent 
reports between 1835 and 1838 (reviewed by Franke, 1988). Nucleoli are eukaryote- 
specific, but the size and number of nucleoli vary between eukaryotes. Higher 
eukaryotic cells possess several, spherical nucleoli per cell, whilst budding yeast cells 
usually possess only one nucleolus, which is crescent-shaped and occupies up to a 
third of the nucleus (reviewed by Melese and Xue, 1995).
Traditionally the nucleolus has been viewed as a ‘ribosome factory’, a 
eukaryotic subnuclear organelle dedicated to ribosome subunit biogenesis (Perry, 
1966). Ribosome biogenesis is a complex process and is incompletely understood, 
particularly in higher eukaryotes (reviewed by Fatica and Tollervey, 2002). Briefly, it 
involves the synthesis and assembly of four mature rRNA molecules. Three of these 
(28S, 18S and 5.8S) are generated from a 47S precursor transcribed from tandemly- 
repeated ribosomal DNA (rDNA), namely the so-called nucleolar organizer regions 
(NORs) or clusters of ‘ribosomal genes’. In humans, the NORs reside on the five 
acrocentric chromosomes and nucleoli form around these loci. The organelle contains 
both RNA polymerase I, responsible for the transcription of rDNA into pre-rRNA 
(the 47S precursor). They also contain the machinery for subsequent pre-rRNA 
processing, for example the small nucleolar ribonucleoproteins (snoRNPs). Finally, 
protein components that are later complexed with the mature rRNA species to form 
the 40S and 60S ribosome subunits are also concentrated in the nucleolus. These 
subunits ultimately leave the nucleolus and nucleus and bind to cytoplasmic mRNA 
to form a functional (80S) ribosome.
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More recently, several studies have characterised the ultrastructure (reviewed 
in this chapter, section 6.4.1), biogenesis (section 6.4.2) and roles beyond ribosomal 
biogenesis (section 6.4.3) of the nucleolus. Additionally, motifs found in nucleolar 
proteins have been arranged into phylogenies and this has given an insight into its 
evolutionary history (Staub et al., 2004). Although nucleoli are eukaryote-specific, 
many of their constituent proteins, particularly those related to ribosome biogenesis, 
are of prokaryotic, particularly archaebacterial, origin. An interesting observation is 
that most of the higher eukaryote-specific nucleolar protein domains are involved in 
protein-protein interaction, protein folding (chaperone) and chromatin remodelling. 
This suggests an increasing tendency during evolution towards compaction of 
material, perhaps to ensure efficient ribosome biogenesis and/ or to tightly sequester 
factors away from the rest of the cell. The nucleolus likely arose because it provided 
a selective advantage in terms of an enhanced efficiency of ribosomal biogenesis and 
thus proliferation rate. However, once evolved, cells probably exploited the presence 
of the nucleolus to incorporate additional functions. We show, for example, that the 
role of the nucleolus as a sequestration centre for proteins involved in cell cycle 
regulation is conserved between evolutionarily-distinct eukaryotes (discussed 
previously in this chapter (section 6.2)).
6.4.1. Theories of nucleolar ultrastructure
The amniote nucleolus is subdivided into three components (reviewed by 
Scheer and Hock, 1999; Dundr and Misteli, 2001; Raska et al., 2006; Sirri et al.,
2008). The transcription of rDNA occurs at the border between the fibrillar centers 
(FC), which are rich in RNA Pol I subunits and surround the NORs, and the dense 
fibrillar component (DFC), which surrounds the FC and is characterised by an 
abundance of Fibrillarin. Although the number and size of the FC foci vary, a typical 
nucleolus contains about thirty, each accommodating about four rRNA genes 
(reviewed by Dundr and Misteli, 2001). Subsequent pre-rRNA processing occurs in 
the DFC, which is rich in snoRNPs, and then processed rRNA molecules are 
transported to the granular component (GC), for association with ribosomal proteins. 
The GC is the largest intra-nucleolar domain and is rich in B23. Thus the process of 
ribosomal biogenesis is vectorial. It occurs in discrete stages as the rRNA transcripts
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move outwards through the concentric layers surrounding the ribosomal genes (Thiry 
et al., 2000). There is, however, considerable diversity in the arrangement of the three 
nucleolar components between species. For example, only amniotes possess the FC, 
the nucleoli of lower eukaryotes such as Drosophila and yeast instead being bipartite 
(reviewed by Thiry and Lafontaine, 2005). Plant cell nucleoli also have a fourth 
nucleolar structure, the nucleolar vacuole or cavity, whose role is unknown (reviewed 
by Shaw and Brown, 2004). Additionally, the plant DFC and FC are integrated into a 
unique nucleolar structure called the nucleonema (Sato et al., 2005).
The GC, the largest and most permeable nucleolar sub-domain, has been 
described as a ‘non-ribosomal landscape’ (Handwerger et al., 2005; Politz et al.,
2005). This region lacks rDNA and ribosome biogenesis machinery and as such is 
unlikely to play any major role in ribosome biogenesis. The GC may therefore 
represent the ‘sequestration centre’, whose existence is strongly supported by the 
findings of our work and other studies. Indeed, the nucleolar proteins p l9 ARF and 
Nucleostemin specifically occupy this sub-domain (Lindstrom et al., 2001; Politz et 
al., 2005). Interestingly, we showed that Handl appears to co-localise with NS in this 
region (Figure 5.22), but further investigation using subnucleolar fractionation 
techniques would be required to definitively localise Handl to this domain. Notably, 
Politz and colleagues also noted that the GC is heterogeneous at a molecular level 
(Politz et al., 2005). It is further subdivided into compartments, within which a 
certain factor or group of factors may be enriched.
Our results reveal that endogenous Plk4 resides in only a single H andl- 
positive nucleolus in each Rcho-1 stem cell, being absent from the others. This 
appears to be a unique finding as, to our knowledge, no literature to date has reported 
such a protein sub-nucleolar localisation. This raises the possibility that different 
nucleoli within the same nucleus may possess different proteomes, which is implicit 
o f heterogeneity between nucleoli within the same cell. Indeed, mammalian nuclei 
can possess nucleoli with considerable heterogeneity in size and morphology 
(reviewed by Hernandez-Verdun, 2006), which is implicit of differences in 
composition. If confirmed, such an observation impacts on the current theories 
regarding nucleolar biogenesis and structure. Nevertheless, we cannot rule out 
antibody-specific artifacts giving rise to these observations, especially in light of the
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fact that an over-expressed GFP-Plk4 fusion protein localised to multiple nucleoli per 
cell.
6.4.2. The dynamic nucleolus theory
The formation of the nucleolus and the maintenance of its architecture are 
thought to be dependent on ribosomal biogenesis (reviewed by Scheer and Hock, 
1999; Dundr and Misteli, 2001; Raska et al., 2006). Early studies showed that ectopic 
rDNA transcription is sufficient for the genesis of a nucleolus in budding yeast and 
Drosophila cells (Karpen et al., 1988; Oakes et al., 1998). In humans, nucleolar size 
can be used to gauge the rapidity of cell proliferation in tumour cells (Derenzini et 
al., 2000). Moreover, inhibition of ribosomal biogenesis, via the inactivation of RNA 
Pol I using actinomycin-D (Act-D), inactivation of upstream-binding factor (Ubf) 
using anti-Ubf antibodies, or upon infection by certain viruses, leads to a loss of 
nucleolar integrity and its breakdown (Dundr et al., 1996; Rubbi and Milner, 2003; 
reviewed by Hiscox, 2007). These data have led to the now widely-believed theory 
that the nucleolus is self-organised, that is, ‘the nucleolus is an organelle formed by 
the act of building a ribosome’ (Melese and Xue, 1995). By this mechanism, nucleoli 
form passively as a result of local accumulation of factors around the rDNA genes.
However, a more recent study has uncoupled the maintenance o f nucleolar 
morphology from RNA Pol I-driven transcription in Xenopus (Gonda et al., 2003). In 
this study, two proteins (FRGY2a and FRGY2b) were shown to reversibly 
disassemble the nucleolus in vitro and in vivo, independently of transcriptional 
inhibition. It is interesting, also, that inhibition of proteasome activity can affect 
nucleolar morphology independently of RNA Pol I activity (Mattsson et al., 2001). 
Furthermore, as discussed in the next section, the fact that several proteins 
accumulate in nucleoli after inhibition of RNA Pol I-dependent transcription suggests 
that neither resident nucleolar proteins, nor nucleolar structure, are dependent upon 
rDNA transcription.
In addition to the formation of the nucleolus, the maintenance of nucleolar 
architecture is also dependent on ongoing ribosomal biogenesis. As such, nucleoli
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disassemble at the onset of mitosis, when rDNA transcription and pre-rRNA 
processing terminate (reviewed by Dundr and Misteli, 2000; Dundr et al., 2000; 
Hernandez-Verdun et al., 2002; Leung et al., 2004). This is likely due to the 
phosphorylation and inactivation of components of the rDNA-transcription 
machinery by the increasing levels of Cyclin B l-Cdkl during prophase (Sirri et al., 
2002). Although some components of the rDNA-transcription machinery remain 
attached to the NORs during mitosis, most nucleolar proteins, particularly those 
involved in pre-rRNA processing, are released from the NORs and disperse 
throughout the cell (Leung et al., 2004). By metaphase these have either bound the 
peri-chromosomal region (PR) (Gautier et al., 1992), or have clustered into 
cytoplasmic aggregates, so-called nucleolus-derived foci (NDF) (Dundr et al., 1996; 
Dundr and Olson, 1998). Proteins may adopt the former localisation to maintain the 
integrity of chromosomes during mitotic segregation, or otherwise ensure an equal 
protein distribution between daughter cells.
RNA polymerase I transcription reinitiates at late telophase when Cyclin B 1 - 
Cdkl activity reduces, and this, in combination with chromosomal decondensation, 
induces PR- and NDF-associated proteins to travel to the NORs (Dousset et al.,
2001). Here they form pre-nucleolar bodies (PNBs), which ultimately coalesce during 
early G1 phase into nucleoli in a step-wise process in which the FC and DFC form 
before the GC (Bell et al., 1992; Jimenez-Garcia et al., 1994; Savino et al., 2001; 
reviewed by Dimario, 2004; Angelier, 2005; reviewed by Boisvert et al., 2007). 
Notably, only higher eukaryotic nucleoli undergo these cycles of disassembly and 
reassembly prior to and after mitosis. Yeast nucleoli remain intact during cell division 
and rDNA transcription continues during yeast mitosis (Oakes et al., 1998; reviewed 
by Fatica and Tollervey, 2002; Tschochner and Hurt, 2003). This is interesting in 
light of the fact that the mechanism governing mitotic exit in budding yeast is not 
conserved in higher eukaryotes (Kaiser et al., 2002; Mailand et al., 2002).
Several proteins have also been demonstrated via time-lapse video­
microscopy with photo-bleaching (FLIP and FRAP) experiments to be in a state of 
continuous flux between the nucleolus and nucleoplasm during interphase (Phair and 
Misteli, 2000). The residence times of most nucleolar proteins are thought to be on 
the order of tens of seconds; thus a micrograph image of the nucleolus is just a
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‘snapshot of multiple nucleolar components in rapid motion’ (reviewed by Olson and 
Dundr, 2005). These observations support the previously-described ‘hit and run’ 
model, namely that proteins enter the nucleolus by passive diffusion rather than by 
active targeting, and only those proteins with a high affinity for nucleolar components 
are retained. These observations have important implications for our model, namely 
that this rapid nucleolar-nucleoplasmic diffusion may also apply to Handl.
On first consideration, these observations would suggest that mitotic Handl 
would trigger precocious TG cell differentiation. However this is clearly not the case, 
possibly because mitotic Handl is kept inactive in NDFs or at peri-chromosomal loci. 
Nevertheless, to date, only nucleolar proteins involved in ribosomal biogenesis have 
been localised to NDFs or to the PR during mitosis. It is interesting in this regard that 
we have demonstrated that the trans-activational activity of Handl is negatively- 
regulated by cytoplasmic HICp32. Although the functional basis and biological 
relevance of this interaction is not known, HICp32 may act in the same fashion as 
non-nucleolar I-mfa to inhibit Handl activity. That is, it may sequester mitotic Handl 
in the cytoplasm, away from its nuclear target genes, and/ or interfere with its DNA- 
binding activity (Chen et al., 1996; Kraut et al., 1998). Alternatively, of course, the 
Handl -HICp40 interaction may remain intact during mitosis. In this case, non- 
nucleolar HICp40 may continue to block Handl activity by an as-yet uncharacterised 
mechanism. It should also be noted that the commitment o f Rcho-1 stem cells to a 
TG cell fate is induced by Handl nucleolar release, specifically during G2. In this 
regard, mitotic Handl release from the nucleolus does not coincide with the pre­
mitotic cellular conditions (at prophase) required to induce mitotic cell cycle exit. 
Nevertheless, these previous studies would explain why some Rcho-1 stem cells 
exhibit non-nucleolar Handl, namely because they are mitotic.
6.4.3. The pluri-functional nucleolus theory
Traditionally the nucleolus has been thought of as a ‘ribosome factory’, a 
eukaryotic subnuclear organelle dedicated to ribosome subunit biogenesis. Recently, 
however, it has become clear that the nucleolus is actually more ‘plurifunctional’ than 
once thought, particularly in higher eukaryotes (reviewed by Pederson, 1998; Table
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6.1). Yet further functions for the nucleolus have been inferred by the physical 
association and protein trafficking between nucleoli and other nuclear bodies such as 
splicing speckles, paraspeckles and Cajal (coiled) bodies (Sleeman et al., 1998; Fox 
et al., 2002; Leung and Lamond, 2002).
Table 6.1. The putative, wide-ranging roles of the nucleolus.
Role Reference(s)
Translation and/ or export o f certain mRNAs
Processing of tRNA precursors
Control of ageing
Regulation of RNA editing
Schneiter et a l,  1995.
Ideue et al., 2004.
Bertrand et al., 1998. 
Pederson and Politz, 2000. 
Thompson et al., 2003.
Sinclair and Guar ante, 1997. 
Johnson et ah, 1998.
Desterro et al., 2003.
Sansam et al., 2003.
Regulation of the meiotic pachytene checkpoint San-Segundo and Roeder, 1999.
Biogenesis of ribonucleoprotein machines 
(signal recognition particle (SRP), spliceosomal 
U5 and U6 snoRNAs, and telomerase)
Small interfering RNA (siRNA) pathways
Jacobson and Pederson, 1998. 
Politz et al., 2000.
Jady and Kiss, 2001.
Wong et al., 2002.
Pontes et a t ,  2006.
One major role for the nucleolus is as a cellular ‘stress sensor’ (reviewed by 
Olson, 2004), which is not surprising given the link between cell proliferation rate 
and ribosome biogenesis. The organelle importantly contributes to the control of 
apoptosis. This was first suggested by the DNA damage-dependent nucleolar- 
nucleoplasmic shuttling of the pro-apoptotic factors Dedd, Ingl and Daxx (Stegh et 
al., 1998; Scott et al., 2001; Lin and Shih, 2002). The nucleolus has also been 
implicated in the cellular p53-dependent (Tao and Levine, 1999; Weber et al., 1999; 
Tsai and McKay, 2002) and -independent (Mayer et al., 2005) responses to DNA 
damage and other stresses. Notably, several nucleolar proteins are released into the 
nucleoplasm in response to DNA damage. These are thought to interact with
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nucleoplasmic p53 to inhibit its proteasomal degradation, so stabilising the tumour- 
suppressor (Tao and Levine, 1999; Weber et al., 1999; Colombo et al., 2002; Daniely 
et al., 2002; Kurki et al., 2004). In this respect, chemical or immunological disruption 
of the nucleolus is sufficient to stabilise p53, even in the absence of DNA damage 
(Rubbi and Milner, 2003). The ability of the nucleolus to act as a ‘stress sensor’ is in 
part dependent on its compartmentalisation of proteins away from the rest of the cell 
(Table 6.2).
By the end of 2001, 121 human proteins had been localised to the nucleolus. 
In most cases, these were individually shown to adopt a nucleolar localisation by way 
of antibody staining and fluorescent tagging. Owing to their high density, nucleoli 
can be isolated from disrupted nuclei by centrifugation through a sucrose gradient. In 
this regard, large-scale nucleolar protein identification, by mass spectrometry, has 
been carried out and the human nucleolar proteome has recently been published 
(Scherl et al., 2002; Andersen et al., 2002; Andersen et al., 2005; reviewed by Leung 
et al., 2003). These proteomic analyses have provided a more detailed insight into the 
composition of the organelle.
The first two published proteomic analyses of nucleoli purified from HeLa 
(human cervical carcinoma) cells identified 271 proteins (Andersen et al., 2002) and 
210 proteins (Scherl et al., 2002), where the combination of these results revealed a 
collection of approximately 350 different nucleolar proteins. Recently another study 
increased this number and also analysed the composition of HeLa cell nucleoli under 
differing metabolic conditions, for example chemical-induced inhibition of RNA Pol 
I transcription or proteasome-dependent proteolysis (Andersen et al., 2005; Figure
6.3). This particular study allowed the examination of the behaviour and dynamics of 
certain sets of proteins. One interesting observation was that, whilst some proteins 
exit the nucleolus in response to metabolic inhibition, some actually accumulate in 
the organelle (Fox et al., 2002; Andersen et al., 2005). Thus there appears to be no 
unique, complete proteome for the nucleolus, but rather different proteomes that are 
dependent on the metabolic state of the cell. This is in agreement with our 
observations relating to the release of Handl from the nucleolus to the nucleoplasm 
during TG cell differentiation.
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Currently, the nucleolar proteome database (NOPdb), listed at 
www.lamondlab.com/NOPdb/, comprises more than 700 proteins (Leung et al.,
2006). This represents about 2.5% of the predicted human proteome, and also details 
the quantitative changes in protein levels for 498 of these proteins after transcription 
is inhibited by treating cells with actinomycin-D. Of note, the Arabidopsis thaliana 
proteome has also been recently characterised (Pendle et al., 2005). Approximately 
70% of the 217 identified proteins were homologues of human nucleolar proteins. It 
is also of note that, whilst the budding yeast nucleolar proteome has not been 
definitely characterised, one study carried out large-scale protein localisation studies 
using GFP fusion proteins to illustrate the nucleolar localisation of numerous proteins 
(Huh et al., 2003). Andersen and colleagues later compared the findings of this study 
with those of the human nucleolar proteome and showed that approximately 90% of 
the yeast nucleolar proteins with human homologues are also nucleolar in HeLa cells 
(Andersen et al., 2005). These studies suggest that the contents of the nucleolus have 
been highly conserved throughout eukaryotic evolution.
Despite it becoming increasingly clear that the nucleolus is more 
plurifunctional than once thought, the findings of the nucleolar proteome analyses 
were still relatively surprising. An unexpectedly high percentage (88%) o f the 
proteins identified in the original human nucleolar proteome screen were not 
previously thought to exist in this organelle. Furthermore, about 30% of proteins co­
purified with isolated human nucleoli are of unknown function, being encoded by 
novel ORFs (Scherl et al., 2002; Andersen et al., 2002; Andersen et al., 2005; 
reviewed by Leung et al., 2003; Figure 6.3). A couple of studies have attempted to 
assign a function to these factors following literature searches and bioinformatics but 
with limited success (Coute et al., 2006; Hinsby et al., 2006). These two studies 
suggested potential functions for about 150 previously-uncharacterised human 
proteins, o f which only 30% were projected to function in ribosomal biogenesis.
Further insight into the roles of the novel proteins that reside in the nucleolus 
was gained by an analysis of the domains they possess (Andersen et al., 2002; Scherl 
et al., 2002). The most abundant motifs in the nucleolar proteome, which include 
RRMs (RNA-recognition motifs), DEAD/DEAH (Asp-Glu-Ala-Asp/His)-box 
helicase domains and WD- (Trp-Asp)-repeat motifs (reviewed by Leung et al., 2003),
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are present in neither HICp40 nor in Handl, however. Certain amino acid residues 
are also over- or under-represented in nucleolar proteins, in comparison with the total 
cell proteome. Charged amino acids (e.g. glutamate, aspartate, lysine and arginine) 
are favoured in nucleolar proteins compared to total cellular proteins. This is in 
accordance with the fact that several nucleolar-localised proteins possess basic NoLS 
motifs. In contrast, neutral residues (e.g. proline and cysteine), are disfavoured. This 
residue bias is true for both HICp40 and Handl. Furthermore the protein 
phosphatase-1 (PPl)-binding motif, (Lys/Arg)-Val-X-Phe, and the tetra-peptides 
FGGR and RGGF are enriched in nucleolar proteins, compared with either total- 
cellular or nuclear-specific proteins (reviewed by Leung et al., 2003). However, 
neither HICp40 nor Handl possess these tetrapeptides.
The unexpected protein content of the HeLa nucleolus is in agreement with 
our finding of Handl in the nucleolus of rodent diploid trophoblast cells, a protein 
with no known role in the traditional functions of the organelle. It is, however, 
unlikely that all proteins that localise to the nucleoli were identified in the nucleolar 
proteome analyses (Scherl et al., 2002; Andersen et al., 2002; Andersen et al., 2005). 
Nucleolar samples for analysis were not obtained from cells exposed to certain 
metabolic conditions and, moreover, these cells were unsynchronised. Since several 
proteins undergo bi-directional shuttling between the nucleolus and nucleoplasm, 
depending on the cell cycle stage or in response to certain stimuli, many factors were 
also likely of a too low a concentration to be detected in these analyses. More 
importantly in light of the findings of our study, only nucleoli purified from HeLa 
cells were analysed. Thus tissue-specific factors, for example trophoblast-expressed 
Handl, would not have been present. These are thus excluded from the current 
nucleolar proteome list and this was acknowledged by the authors (Andersen et al.,
2002). This is supported by the absence of other tissue-specific proteins in the 
published nucleolar proteome, which are nonetheless known to associate with the 
organelle, for example, the testes determinant Maestro (Smith et al., 2003).
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Uncharacterised/ novel proteins
Others 
Ribosomal proteins 
RNA-modifying enzymes 
Splicing-related factors 
DNA-binding proteins 
RNA helicases 
Transcription factors 
RNA-binding proteins 
Cell cycle proteins 
Other translation factors 
hnRNP 
Contaminants 
Chaperones 
DNA-replication proteins 
Chromatin-related factors 
Kinases/ phosphatases 
Cytoskeleton proteins 
Ubiquitin-related proteins 
RNA polymerases 
DNA repair proteins
0 20 40 60 80 100 120
Figure 6.3. The findings of recent human nucleolar proteome analyses.
Adapted from www.lamondlab.com/NOPdb/NPDdatabase.htm. (January 2008). hnRNP: 
heterogeneous nuclear ribonucleoprotein.
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One of the first studies to suggest a role for the nucleolus as a ‘sequestration 
centre’ was by Munro and colleagues (Munro and Pelham, 1984). In this study, the 
Drosophila chaperone Hsp70 was shown to conditionally localise to the nucleolus as 
part of the cellular response to temperature-induced stress. Since then, several 
mitogenic growth factors, such as PTHrP, Fgf2 and Fgf3 (Henderson et al., 1995; 
Antoine et al., 1997; reviewed by Pederson, 1998b; Sheng et al., 2004), enzymes, for 
instance protein phosphatase 1-gamma (PPly; Trinkle-Mulcahy et al., 2001) and cell 
cycle regulators, for example Cdc2 (Ino et al., 1993), have been shown to adopt a 
nucleolar localisation. Indeed, at least 3.5% of the proteins identified in the recent 
nucleolar proteome screens have established roles in cell cycle control (Andersen et 
al., 2005; Figure 6.3). Also nucleolar are specific tumour suppressors, such as pRB 
(Takemura et al., 2002) and other transcription factors, for example the Hox 
homeoproteins (Corsetti et al., 1995). Although the basis for their nucleolar 
localisation was not characterised, these factors are unlikely to serve any function in 
ribosomal biogenesis. This suggests that nucleolar sequestration of proteins is a 
relatively common mechanism of post-translational gene control.
The findings of our study and the observations of others (A. Firulli, personal 
communication) showed that bHLH factors closely-related to Handl, namely Hand2, 
Twist 1 and MyoD, do not localise to the nucleolus. However, regulation by nucleolar 
sequestration may apply to other members of the bHLH superfamily. Indeed, Wang 
and colleagues showed that zebrafish Myf5 localises to the nucleolus, although the 
functional significance of this was not investigated (Wang et al., 2005). It will be 
interesting to investigate whether this mechanism regulates not only bHLH 
transcription factors but also a wider range of factors involved in modulating 
transcription, some of which have been identified in the nucleolar proteome (Figure
6.3). Examples of protein regulation utilising nucleolar sequestration are described in 
Table 6.2.
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Table 6.2. Well-characterised examples of proteins whose sequestration in the nucleolus regulates their activity.
Sequestered Nucleolar
factor(s) sequesteror(s) Bask for nucleolar sequestration References
Cdcl4
(S. cerevisiae)
Cdcl4 is nucleolar during interphase and early mitosis. At anaphase onset Cdcl4 enters the 
nucleoplasm to dephosphorylate its targets and trigger mitotic exit.
Visintin et al., 1999; 2003. 
Shou et al., 2001; 2002. 
Yoshida and Toh-e, 2002.
Rnr2, Rnr4 
(S. cerevisiae)
Wtml Rnr2 and Rnr4, subunits of ribonucleotide reductase (Rnr), are only released from the 
nucleolus to bind the cytoplasmic third subunit, Rnrl, at the advent of S-phase.
Lee and E Hedge, 2006.
Mdm2
(Mouse)
Pml, p!9ARF The ubiquitin ligase Mdm2 is nucleoplasmic in resting cells and targets p53 for proteolysis. 
Upon DNA damage, Mdm2 is recruited to the nucleolus to permit p53 stabilisation.
Tao and Levine, 1999. 
Weber et al., 1999. 
Bemardi et al., 2004.
HIF-la
(Mouse)
pl9ARF In normoxic cells the a-subunit of HIF-1 is sequestered in the nucleolus. Upon hypoxic 
stress it is released to bind its [3-subunit binding partner to form HIF-1.
Fatyol and Szalay, 2001.
VHL
(Human)
Unknown The ubiquitin ligase VHL is nucleoplasmic in resting ceils and targets the alpha subunit of 
hypoxia-inducible factor-1 (HIF-la) for proteolysis. However under hypoxic conditions, 
VHL is sequestered in the nucleolus and HIF-1 is stabilised.
Mekhail et al., 2004.
Hsp70
(Mouse)
Unknown Hsp70, an inhibitory chaperone of Hsfl, is nucleoplasmic in resting cells and prevents Hsfl 
from binding Hsf2. Upon heat shock, Hsp70 is recruited to the nucleolus to allow Hsfl-Hs£2 
interaction, stress granule formation and the heat shock response.
Alastalo et al., 2003.
RelA
(Mouse)
pl9ARF, B23, Nfbp DNA damage recruits RelA, a component of NFkB, to the nucleolus. This prevents its 
binding cytoplasmic p50 to form NFkB and results in apoptosis. In response to mitogenic 
cytokines, RelA is released from nucleoli to form NFkB and this promotes cell proliferation.
Stark and Dunlop, 2005.
Telomerase
(Human)
Nucleolin Telomerase is sequestered in an inactive state in the nucleolus during most of the cell cycle, 
but is released at the onset of telomere replication in late S-phase. Interestingly, the nucleolar 
localisation of telomerase is neither detected in transformed cells nor in cells that have 
experienced DNA damage.
Wong et al., 2002. 
Khurts et al., 2004.
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Once considered a simple ribosome biosynthesis factory, the eukaryotic 
nucleolus is now recognised as a major orchestrator of numerous cellular functions 
(reviewed by Pederson, 1998; Boisvert et al., 2007). This is supported by the 
surprisingly wide range of factors recently discovered in the nucleolus by proteomic 
analysis (Andersen et al., 2002; Scherl et al., 2002; Andersen et al., 2005). Our 
study supports previous studies that implicate the organelle as a molecular ‘safe’ or 
‘sink’ that temporarily stores factors in an inactive state until a specific cell cycle 
stage or the occurrence of a certain metabolic state. Compartmentalisation of 
proteins within the cytoplasm (Beg et al., 1992; Chen et al., 1996; Kraut et al., 
1998), or within PML bodies (Goodson et al., 2001) has also been reported. The 
nuclear lamina has also emerged as a major site for the sequestration of transcription 
factors, including c-Fos, Oct-1 and pRb, whose release into the nucleoplasm from 
the nuclear periphery coincides with an up-regulation of their target genes (Imai et 
al., 1997; Johnson et al., 2004; Ivorra et al., 2006).
However, despite these studies, the nucleolus stands out as likely being the 
organelle most suited for use as a sequestration centre for transcription factors. This 
organelle is the largest in the nuclear matrix, is highly-permeable and furthermore 
lacks a membrane (reviewed by Dundr and Misteli, 2001; Handwerger et al., 2005). 
These features would permit the storage of a stockpile of pre-existing protein that 
could be released, in response to cellular cues at a specific cell cycle stage or at a 
certain developmental time-point, without the need for transcriptional up-regulation 
or even nuclear import. That nucleoli are usually located at or near the nuclear 
envelope in higher eukaryotes, or otherwise connected to the nuclear envelope by a 
so-called ‘nucleolar canal’; reviewed by Hemandez-Verdun, 2006b), suggests that 
nucleolar sequestration may also regulate the activity of cytoplasmic proteins. In 
conclusion, our current study represent the most compelling evidence to-date that the 
nucleolus can act in this fashion as a subnuclear ‘sequestration centre’ in the 
physiological setting of cell fate determination.
Several studies have reported a flux of cell fate determinants between the 
nucleolus and nucleoplasm. In many cases the subcellular localisation of these 
factors correlates with the status of the cell, namely whether it continues to 
proliferate or commits to differentiate (Galcheva-Gargova et al., 1998; Gao and
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Scott, 2002; Tsai and McKay, 2002; Kuroda et al., 2004). For example, the nucleolar 
Rbml9 RNA-binding factor is expressed throughout the undifferentiated murine 
embryonic gut tube but restricted in the adult to stem cells residing in the duodenal 
crypts of Lieberkiihn. This assumes a cell-wide distribution to promote intestinal 
epithelial differentiation (Lorenzen et al., 2005). Another example concerns the 
bHLH-Zip transcription factor c-Myc, which has been localised to the nucleolus in 
several studies (Schlosser et al., 2003; Datta et al., 2004; Arabi et al., 2005; Sanders 
and Gruppuso, 2005). This is only released from p l9 ARF-dependent nucleolar 
anchorage to reach its nucleoplasmic heterodimerisation partner Max if  quiescent 
adult hepatocytes are induced to re-enter the cell cycle during liver regeneration after 
partial hepatectomy (Sanders and Gruppuso, 2005). Similarly the testis-specific 
transcription factor ZPF106 is released from the nucleolus during terminal 
differentiation of C2C12 myoblasts as levels of its sequesteror TSG118 diminish 
(Grasberger and Bell, 2005). Translocation from the nucleolus to the nucleoplasm of 
CTCF is also accompanied by differentiation of human myeloid cells and rat 
neuroblasts into neurones (Torrano et al., 2006). Finally, Nucleostemin, a putative 
p53 regulator that resides in the nucleolus of several stem cell types, is similarly 
down-regulated and/ or released into the nucleoplasm during their terminal 
differentiation (Tsai and Mackay, 2002).
Despite these examples, we are nevertheless the first to report that the 
nucleolar sequestration and release of a protein can control the commitment o f stem 
cells by effects outside of the nucleolus. That is, the change in subcellular 
localisation of many of the aforementioned nucleolar cell fate determinants affects 
the process of ribosome biogenesis with ultimate effects on cell fate. For example, 
nucleolar CTCF silences rDNA transcription (Torrano et al., 2006) and nucleolar 
p l9 ARF targets the rRNA processing factor B23 for degradation through 
ubiquitination (Itahana et al., 2003; Sugimoto et al., 2003; Bertwistle et al., 2004). 
In both cases, this coincides with cell cycle arrest, entry into the quiescent state and 
concomitant differentiation. Conversely, c-Myc promotes cell proliferation by 
facilitating rDNA transcription and rRNA processing (Schlosser et al., 2003; Arabi 
et al., 2005). Furthermore, even proteins whose localisation in the nucleolus has 
been attributed to their negative regulation by nucleolar sequestration have 
secondary, traditionally-nucleolar roles. For example, Cdcl4 contributes to the
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organisation of nucleolar chromatin and aids nucleolar segregation at mitosis (de 
Almeida et al., 1999). Similarly, Pch2, whose sequestration in the nucleolus is 
thought to play a role in the meiotic pachytene checkpoint, represses rDNA 
recombination (San-Segundo and Roeder, 1999). Additionally, the growth factor 
Fgf2 regulates ribosomal biogenesis (Sheng et al., 2005). We believe, however, that 
Handl is unlikely to have a role in ribosome biogenesis. Handl is tissue-specific and 
the components required for ribosomal biogenesis are thought to be uniform across 
cell types (reviewed by Fatica and Tollervey, 2002; Tschochner and Hurt, 2003). 
Thus, Handl nucleolar residence is likely solely explained by its negative regulation 
by HICp40. Its nucleolar localisation is thus the strongest evidence yet that the 
organelle can, in some cases, act solely as a subnuclear ‘sequestration centre’.
6.5. Extrapolating our findings to human 
placentation
So what are the implications of our findings for the understanding of human 
placentation? Unfortunately it is unlikely that the role we propose for Handl in 
determining rodent TS cell fate is conserved in humans. As discussed in Chapter 1 
(section 1.2), the placenta is evolutionary a young organ. As such, the process of 
decidual invasion and the molecular mechanisms underlying it are in many cases 
very different between mammalian species (reviewed by Georgiades et al., 2002 
and Malassine et al., 2003). Moreover, HAND1 is not thought to be essential for the 
differentiation of the human counterpart of rodent TG cells, the extravillous 
trophoblast (EVT) (Knofler et al., 1998; Janatpour et al., 1999; Loregger et al., 
2003; Meinhardt et al., 2005). Strikingly, human EVT cells, the equivalent invasive 
trophoblast subtype to rodent TG cells, do not undergo endoreduplication. This 
notably represents circumstantial evidence that murine Handl is required for mitotic 
cell cycle exit at the onset of TG cell differentiation. Finally, many examples of 
protein regulation dependent on nucleolar sequestration are poorly conserved, even 
between mammals (Zhang and Xiong, 1999).
Our results do, however, confirm the findings of previous studies in
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demonstrating that hypoxia has a negative effect on Rcho-1 TG cell differentiation 
(Gultice et al., 2006; Lash et al., 2007; Takeda et al., 2007). This has implications 
for the understanding of the molecular basis of pre-eclampsia. Pre-eclampsia occurs 
in up to 10% of all human pregnancies and is characterised by inadequate invasion 
of trophoblast into the maternal decidua (reviewed by Redman and Sargeant, 2005; 
Sibai et al., 2005; reviewed in Chapter 1, section 1.2.2.4). Our data, in combination 
with the work of others, strongly support the hypothesis that hypoxia inhibits the 
activation of critical factor(s) involved in the differentiation of invasive rodent 
trophoblast (Gultice et al., 2006; Lash et al., 2006; Takeda et al., 2007). This may 
include Handl, but appears to be independent of its nucleolar release. In any case, 
our data support the idea that pathologically-prolonged hypoxic conditions during 
placentation could give rise to pre-eclampsia or other defects.
6.6. Ongoing and future studies
It remains to be determined whether the nucleolar sequestration of Handl by 
HICp40 and its release upon Plk4-dependent phosphorylation regulates its 
biological activity in other key lineages in which a requirement for Handl function 
has been demonstrated, most notably the developing heart. Investigating how the 
cardiac function of Handl is controlled has proven difficult in vivo, due to early 
embryonic lethality following Handl loss-of-function. Furthermore, few cardiac 
cell lines exist, precluding in vitro analysis of Handl function. In this section we 
address ongoing studies in the cardiomyocyte lineage to determine whether 
nucleolar sequestration and/ or release of Handl is a more widespread mechanism 
o f regulating its activity during embryogenesis.
6.6.1. Ongoing and future in vitro studies
As described in Chapter 3 (section 3.2.2), Handl-EGFP localises to the 
nucleoli o f H9c2 cells, a rat ventricular cardiomyocyte cell line. This suggests that 
the underlying molecular mechanisms responsible for Handl nucleolar anchorage 
are retained in at least one cardiac cell model. However, this cell line is terminally-
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differentiated and so the potential o f its use in vitro to assess the functional 
significance o f  Handl nucleolar sequestration during cardiomyocyte differentiation 
is limited. We have, in this regard, also observed Handl-EGFP nucleolar 
localisation in subtypes o f  embryonic carcinoma (EC) and embryonic stem (ES) cell 
lines, cells that can be induced to differentiate into derivatives o f all three primary 
germ layers, including cardiomyocytes (Figure 6.4).
^■9mm
Figure 6.4. Handl-EGFP localises to the nucleoli o f embryonic carcinoma (EC) 
and embryonic stem (ES) cell lines.
Handl-EGFP localises to the nucleoli o f P19-CL6 cells, an EC cell line whose differentiation is 
modestly skewed towards the cardiomyocyte lineage (Habara-Ohkubo, 1996; a). Handl-EGFP also 
localises to the nucleoli o f an ES cell line that endogenously expresses EGFP upon their 
differentiation into Nkx2.5-expressing cardiomyocytes (Wu et al., 2006; b).
Studies suggest that the process o f  ES cell differentiation into EBs in vitro 
faithfully models the molecular changes that accompany fetal cardiomyocyte 
differentiation in the developing heart in vivo (Maltsev et al., 1993; Doevendans et 
al., 2000). Despite this, a study in the HM1 ES cell line suggests that 
cardiomyocytes that differentiate in vitro are not mature cardiomyocytes, but 
instead, in terms o f electrophysiological characteristics and gene expression, more 
closely resemble those o f  the early primary myocardium o f  the embryonic heart 
tube (Fijnvandraat et al., 2003). Despite the results o f  this study, it is likely that 
different ES cell lines exhibit variation in behaviour and gene expression patterns. 
ES cells in culture are derived from the inner cell mass (ICM) o f  developing 
blastocysts. When maintained in an undifferentiated state by culturing in the 
presence o f  leukemia inhibitory factor (LIF), they are able to undergo proliferative 
self-renewal. However, by removing LIF from the culture medium, ES cells in
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suspension spontaneously differentiate into embryoid bodies (EBs), three- 
dimensional floating cell aggregates. EBs comprise many different specialised cell 
types derived from the three germ layers of the developing embryo, namely the 
endoderm, ectoderm and mesoderm. Importantly for our study, EBs can contain 
beating cardiomyocytes, located between an epithelial layer and a basal layer of 
mesenchymal cells (Risebro et al., 2006).
ES cells provide the best available model system in which to study the 
molecular basis of cardiomyocyte differentiation in vitro (reviewed by Boheler, 
2002). Indeed, they have previously been employed to interrogate aspects of Handl 
regulation and function in vivo (Riley et al., 2000; Smart et al., 2002; Risebro et al., 
2006). However, the percentage of ES cells that differentiate into cardiomyocytes in 
culture is generally very low (reviewed by Boheler et al., 2002). A transgenic ES 
cell line, generously provided by Sean Wu, was in this regard chosen for further 
study. Wu and colleagues introduced a 2.1 kb enhancer fragment o f the early cardiac 
differentiation marker Nkx2.5, as well as 500bp of Nkx2.5 basal promoter, upstream 
of the EGFP cDNA into CJ7 ES cells (Wu et al., 2006). Using this transgenic ES 
cell line, differentiated cardiomyocytes, which express Nkx2.5, can therefore be 
distinguished and isolated by virtue of EGFP fluorescence (Movie 6.1, Appendix 
10).
Initially, we sought to investigate at which time-point the Handl protein 
became detectable during the differentiation of these transgenic ES cells into 
cardiomyocytes. In agreement with previous studies (Riley et al., 2000; Risebro et 
al., 2006), western blot analysis using an anti-Hand 1 antibody revealed that Handl 
was absent in ES cells (data not shown) and was low in cells differentiated for 4 
days (Figure 6.5). Handl protein levels had increased by 6 days after the onset of 
differentiation and persisted at high levels until day 10. After this period, the 
amount o f Handl protein reduced (Figure 6.5). Consistent with these observations, 
we could neither detect Handl via immunostaining in stem cells nor in cells 
differentiated for 4 days (data not shown).
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Figure 6.5. Handl is endogenously expressed in transgenic in vitro- 
differentiated cardiomyocytes.
Western blot analysis using an anti-Handl antibody and whole-cell transgenic ES cell lysates shows 
that, during a time-course o f differentiation over 14 days, Handl appears in EGFP-cxpresslng 
cardiomyocytes at the day 4-6 period (post-LIF removal) and persists until day 10, after which 
period its levels decline.
We then carried out immunostaining o f  cardiomyocytes, dissociated from 
EBs differentiated for 6 and 8 days, namely the time-points at which Handl levels 
are maximal. However, this has so far given spurious results. A peri-nuclear signal, 
seemingly for endogenous Handl, was observed in fluorescent cardiomyocytes 
(Figure 6.6). Although this pattern was seen in some Rcho-1 TG cells (Chapter 4, 
Figure 4.5a), suggesting its reliability, cells in these cultures that lacked detectable 
EGFP expression also exhibited this pattern. Since these cells were unlikely to be 
Handl-positive cardiomyocytes, this signal is likely non-specific. This result was 
independent o f  fixation method, antibody concentration and source. Currently, we 
are attempting to perform in situ hybridisation analyses with the anti-Handl 
antibody. This will allow us to analyse the subcellular localisation o f  Handl during
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cardiomyocyte differentiation o f  these transgenic ES cells without the need for 
immunofluorescence and may eliminate non-specific signals.
Figure 6.6. A non-specific peri-nuclear pattern for H andl in EGFP-expressing 
cardiomyocytes differentiated for 8 days.
Populations o f transgenic ES cells were differentiated for 8 days by removing LIF from the culture 
medium and EBs were dissociated to isolate individual cardiomyocytes. After fixing, 
immunostaining with an anti-Handl antibody revealed a peri-nuclear pattern in cells with (a), but 
also in cells without (b), EGFP fluorescence.
In light o f  our inability to detect a specific signal for Handl by 
immunostaining EGFP-expressing cardiomyocytes, we harvested EBs differentiated 
over a 12 day time-course and performed western blot analysis on whole-cell 
lysates subtracted for the nucleolar fraction. Although FACS sorting was considered 
in order to isolate fluorescent cardiomyocytes, Handl expression is likely restricted 
to only those ES-derived cells that differentiate along the cardiomyocyte lineage. 
Thus whole EBs were harvested for use in this assay. In contrast to the results we 
obtained using Rcho-1 cell lysates subtracted for the nucleolar fraction (Chapter 4, 
Figure 4.6), the relative amounts o f Handl we observed in the non-nucleolar ES cell 
lysates at each time-point mirrors those observed in the whole-cell ES cell lysates at 
each time-point in Figure 6.5 (data not shown). This suggests that following an up- 
regulation in Handl at approximately day 6 post-differentiation induction, Handl is 
immediately, or very soon after becomes, nuclear-wide.
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This result suggests that Handl may be released almost immediately after its 
nucleolar sequestration during cardiomyocyte differentiation. Ongoing studies seek 
to investigate this by analysing a more detailed time-course of differentiation, 
particularly between the fourth and sixth days post-differentiation induction, during 
which period we observe the most dramatic increase in Handl levels. However, 
overall, the results described in this chapter suggest that Handl is not regulated via 
nucleolar sequestration during cardiomyocyte differentiation in vitro. Unlike the 
onset of differentiation of TG cells, which is marked by immediate mitotic cell 
cycle exit and endocycle entry, cardiomyocyte differentiation is not thought to 
initiate so abruptly and is a more gradual multi-step process. Taking this into 
account, Handl protein may not need to be stored in an inactive state in ES cells 
with a view to being instantaneously activated at a specific developmental time- 
point. Thus Handl up-regulation may be sufficient to regulate Handl activity 
during cardiomyocyte differentiation in vitro. In any case, we are currently 
modifying the transgenic ES cells used in the assays described in this chapter to 
stably express a Handl-dsRed fusion protein. This will enable us to analyse changes 
in the subcellular location of Handl during ES cell differentiation into EGFP- 
expressing cardiomyocytes.
6.6.2. Ongoing and future in vivo studies
As illustrated in Chapter 3 (Figure 3.7), whole-mount in situ hybridisation 
using a probe for full-length HICp40 demonstrated that the murine orthologue is 
expressed in the left ventricle and outflow tract. These are regions of the developing 
heart in which Handl is endogenously co-expressed, as reviewed in Chapter 1 
(section 1.3.2.2). Thus HICp40 is expressed in the right place and at the right time 
to negatively-regulate Handl activity by nucleolar sequestration during murine 
cardiac morphogenesis.
In light of the MICp40 expression pattern, it would be interesting to generate 
a mouse model lacking MICp40 expression in cardiac tissues. This has been 
considered, and would be carried out by electroporating a construct with similarity 
to the RNAi vector used in this study, namely based on the described HI
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polymerase III shRNAi (Kunath et al., 2003). In this vector, the 5T termination 
sequence, preceding the relevant RNAi hairpin sequence, is flanked by loxP 
sequences. Using this approach, it would not be necessary to target the endogenous 
locus; the construct would be present but inactive in all cells, but RNAi knock­
down of HICp40 would only occur upon cre-recombination of the 5T termination 
sequence. Furthermore, an EGFP reporter gene has been incorporated between the 
loxP sequences, which would mark cells transfected with the conditional vector. 
Initially the construct would be extensively tested in vitro, namely by inducing cre- 
recombination in stably-transfected cells and assessing EGFP expression. Floxed 
MICp40 shRNA mice would be crossed with two knock-in strains of cardiac- 
specific ere recombinase-QXpressing mice already in house, namely Mlc2v-creKI 
mice (provided by Ken Chien) and Mx2.5-creKI mice (provided by Robert 
Schwartz). Hearts of embryos derived from such matings would then be analysed 
between E8.0-E10.5 and cardiomyocytes immunostained to assess the subcellular 
localisation of Handl.
On the basis of our findings in the trophoblast lineage, and assuming 
MICp40 plays a similar role in negatively-regulating Handl activity during cardiac 
morphogenesis, conditional MICp40-nu\\ mice would be predicted to exhibit a gain- 
of-function Handl cardiac phenotype. This would likely result in OFT extension 
and LV abnormalities, as recently reported in a mouse over-expressing Handl in its 
‘native’ (endogenously-expressed) tissues (Risebro et al., 2006). Interestingly, the 
study by Risebro and co-workers implicated Handl in governing the balance 
between cardiac precursor cell (CPC) proliferation and differentiation. Specifically, 
whilst down-regulation of Handl during normal cardiac morphogenesis permits 
CPC cell cycle exit and differentiation, CPCs over-expressing Handl are hyper- 
proliferative, which results in distal OFT hyperplasia and thus extension (Risebro et 
al., 2006; reviewed in Chapter 1, section 1.3.2.2). In view o f the function for Handl 
in governing TS cell fate, it may be the case that excess Handl protein in these 
CPCs is responsible for their hyper-proliferation and the mechanism for this may be 
retention of Handl in the nucleolus. This hypothesis is supported by the fact that 
Handl, presumably nucleolar, is required for proliferation of diploid trophoblast in 
the EPC (Riley et al., 1998). To address this question we have prepared 
cryosections of H andl-overexpressing E9.5 mouse hearts. We hope to conduct
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immunostaining and/ or in situ hybridisation analysis to investigate the subcellular 
localisation of Handl in cells of the presumptive OFT and LV, and analyse whether 
the relative proportions of nucleolar versus nuclear-wide Handl differ with respect 
to wild-type hearts at the same developmental stage.
In light of the findings of this study in the rodent trophoblast lineage, a non­
conditional MICp40-nu\\ mouse model would be equally interesting. On first 
consideration, and in light of the role we demonstrate for the rat orthologue of 
HICp40 in rodent trophoblast, we would predict that this mouse would phenocopy 
certain aspects of the Mash2-deficient mouse (Guillemot et al., 1994). As discussed 
in Chapter 1 (section 1.2.4.2), Mash2 plays a complementary role to Handl during 
trophoblast differentiation in that it maintains TS cell diploidy through an as-yet 
uncharacterised mechanism. Mash2-null mice are appropriately embryonic lethal at 
E7.0 as a consequence of precocious TG cell differentiation (Guillemot et al., 
1994). This phenotype would be predicted to apply also to a loss-of-function 
MICp40 (that is, gain-of-function Handl) mouse. In the absence of its nucleolar 
sequesteror, Handl, which promotes TG cell differentiation, would likely be 
ectopically nuclear-wide and could thus promote mitotic cell cycle exit. That said, a 
simple lack of Handl nucleolar sequestration may not precede its normal, nuclear 
function. One possible reason for this is that Plk4-dependent phosphorylation of 
Handl, which not only promotes Handl nucleolar release but also enhances the 
affinity of Handl for its nuclear E-factor binding partners (Firulli et al., 2003), only 
occurs during a narrow developmental window during placentation.
In conclusion, further work is needed to investigate whether nucleolar 
sequestration modulates the activity of Handl in the cardiomyocyte lineage. 
Although our preliminary data suggest that nucleolar sequestration is unlikely to 
control Handl activity during cardiomyocyte differentiation in vitro, further 
experiments will be needed to rule this out in vivo. Additional studies are also 
required to investigate whether Handl activity is regulated by nucleolar 
sequestration in other lineages in which it is expressed during development, namely 
the developing limb, gut and autonomic nervous system. It is entirely possible, 
however, that Handl regulation via nucleolar sequestration is a tissue-specific 
mechanism and restricted exclusively to the rodent trophoblast lineage.
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APPENDICES 
APPENDIX 1. Reagents
All reagents were of AnalaR grade and were obtained from Sigma Aldrich or 
Gibco (Invitrogen) unless otherwise stated. Solutions were made using Milli-Q- 
purified dl-bO and autoclaved where appropriate. The reagents are listed below.
1. Construction of plasmids
•  1% agarose gel: lg  agarose, 1ml lOxTBE running buffer (25mM EDTA 
pH8.0 (186.lg  EDTA, 20g NaOH, 1.01 dH20)), 0.9M Tris/ HC1 pH 8.0 
(121.lg TRIZMA™ base (Tris), 42ml c.HCl, 1.01 dH20), 0.9mM Boric 
Acid), 9ml dH20, 0.5pg/ml ethidium bromide.
• lOx TE: lOOmM Tris-HCl (pH 8.0), lOmM EDTA.
•  Ampicillin: Ampicillin (200mg) was dissolved in 4ml dH20 (final 
concentration 50mg/ml), filtered (using a 0.22pm Millipore filter (Waters, 
Harrow, Middx, U.K)) using a 5ml syringe, before being stored at -20°C.
• Annealing Buffer: 0.25mM TE pH8.0 (lOmM Tris/ HC1 pH 8.0, ImM 
EDTApH8.0), lOOmM NaCl.
• Gel loading solution: 0.5% bromophenol blue, 0.5% xylene cyanol, 50% 
FicolUoo-
•  Kanamycin: Kanamycin (150mg) was dissolved in 10ml dH20 (final 
concentration 15mg/ml) filtered (using a 0.22pm Millipore filter (Waters, 
Harrow, Middx, U.K)) using a 5ml syringe, before being stored at -20°C.
•  LB/ agar plates: 15g bacto-agar (Difco) was added to 1 litre LB and this 
was autoclaved. After setting, the LB-Agar mix was heated in a microwave 
to melt, allowed to cool and supplemented with either 50pg/ml ampicillin or 
15pg/ml kanamycin (1:1000), poured into bacteriological plates and allowed 
to set at room temperature. Plates were then stored at 4°C.
•  Luria broth (LB): lOg NaCl, lOg Bacto-Tryptone (Difco) and 5g Bacto- 
Yeast Extract (Difco) were dissolved in 1 litre dH20 and this was autoclaved.
•  Pfu  polymerase PCR reaction mixtures: solution A (lOOmM dNTP mix,
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15mM Pfu Buffer, 50% glycerol, lOpmol of each primer, lOng template); 
solution B (20mM Pfu buffer, 10 units Pfu DNA polymerase).
•  TELT plasmid preparation solution A: 500pl 50mM Tris pH 8.0, 400^1 
4% Triton X-100, 5ml 2.5M LiCl, 1.25ml 62.5mM EDTA, 2.85ml dH20.
2. Cell culture
• 0.1% gelatin: lg  gelatin in 1.01 dH20, autoclaved.
• Cell culture (3-galactosidase assay buffer: 2xp-gal assay buffer (0.2M 
sodium phosphate (pH 7.4), 2mM magnesium chloride, 0.1M p- 
mercaptoethanol, 1.5mg/ml ONPG).
• H9c2/ MEF medium: DMEM + GlutaMAX, 10% Foetal Bovine Serum, 
1% (lOOmg/ml) Penicillin-Streptomycin Mix.
• NIH-3T3 medium: DMEM + GlutaMAX, 10% Bovine Calf Serum, 1% 
(lOOmg/ml) Penicillin-Streptomycin Mix.
• NP-40 lysis buffer: 25mM Tris-HCl (pH 8.0), 120mM NaCl, 0.5% NP-40, 
4mM NaF, lOOpM NasV0 4 , ImM PMSF, lOOpg/ml aprotinin, 10p.g/ml 
leupeptin.
• P19-CL6 medium, maintains P19-CL6 stem cell proliferation: MEM
Alpha + GlutaMAX, 10% Foetal Bovine Serum, 1% (lOOmg/ml) Penicillin- 
Streptomycin Mix.
• P19-CL6 medium, promotes P19-CL6 EC cell differentiation: MEM
Alpha + GlutaMAX, 10% Foetal Bovine Serum, 1% (lOOmg/ml) Penicillin- 
Streptomycin Mix, 1% dimethyl sulphoxide (DMSO).
• Rcho-1 medium, maintains stem cell proliferation: NCTC-135, 20% 
Foetal Bovine Serum, 1% (lOOmg/ml) Penicillin-Streptomycin Mix, 1% 
Sodium Pyruvate, lOOpM P-mercaptoethanol solution.
• Rcho-1 medium, promotes TG cell differentiation: NCTC-135, 10% 
Horse Serum, 1% (lOOmg/ml) Penicillin-Streptomycin Mix, 1% Sodium 
Pyruvate, lOOpM (3-mercaptoethano 1 solution.
•  RIPA buffer: 50mM Tris-HCl (pH7.6), 150mM NaCl, 1% NP-40, 0.5% 
DOC, 0.1% SDS, 0.0ImM PMSF (in isopropanol), ImM DTT, lx  protease 
inhibitors (added fresh).
• Transgenic ES stem cell medium, maintains stem cell proliferation:
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DMEM + GlutaMAX, 15% ES-qualified FCS, 1% (lOOmg/ml) Penicillin- 
Streptomycin Mix, 1% non-essential amino acids, ImM sodium pyruvate, 
lOOpM p-mercaptoethanol solution, 103 units/ml ESGRO™ {Chemicon).
•  Transgenic ES stem cell medium, promotes differentiation: DMEM + 
GlutaMAX, 15% ES-qualified FCS {Chemicon), 1% (lOOmg/ml) Penicillin- 
Streptomycin Mix, 1% non-essential amino acids, ImM sodium pyruvate, 
lOOpM p-mercaptoethanol solution.
• Trophoblast stem cell medium: RPMI1640 (pH 7.2), 20% Foetal Bovine 
Serum, 1% L-glutamine, 1% Sodium Pyruvate, 25ng/ml Fgf4 (.Peprotech), 
lpg/ml heparin, 1% (lOOmg/ml) Penicillin-Streptomycin Mix, lOOpM p- 
mercaptoethanol.
3. Yeast two-hybrid assay
• Yeast complete medium (1.01): 20g bacto-peptone, lOg yeast extract, 50ml 
40% glucose, 10ml 0.2% adenine.
• Yeast lysis buffer: lOmM Tris-HCl (pH 8.0), 2% Triton X-100, 1% SDS, 
lOOmM NaCl, ImM EDTA.
•  Yeast minimal medium (1.01): 6.7g nitrogen base, 50ml 40%glucose, 10ml 
0.2% adenine, 10ml 0.2% uracil, 3m 1% lysine.
• Yeast plates: appropriate medium containing 20g agar.
4. In vitro-translation and GST pull-down assay
• Binding buffer: 20mM Tris-HCl pH8.0, lOOmM NaCl, ImM EDTA, 0.5% 
NP-40, protease inhibitor cocktail {Roche’, added fresh).
5. Whole mount in situ hybridisation
•  Hybridisation buffer: 50% formaldehyde, 1.3x SSC (pH5.3 with citric 
acid), 5mM EDTA pH8.0, 50pg/ml yeast RNA, 0.002% Tween-20, 0.005% 
CHAPS, lOOmg/ml heparin in dH20.
•  NTMT: lOOmM Tris-HCl pH9.5, lOOmM NaCl, 50mM MgCl2, 0.05% 
Tween-20.
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6. Luciferase assay
• 2xp~Gal assay buffer: 0.2M Sodium Phosphate, 2mM Magnesium 
Chloride, 0.1M p-mercaptoethano 1, 1.5mg/ml O-Nitrophenyl-p-D- 
galactopyrano side.
• Luciferase cell culture lysis buffer: 25mM Tris (pH7.8), 2mM DTT, 2mM 
l,2-diaminocyclohexane-N,N,N’,N’-tetraacetic acid, 10% glycerol, 1% 
Triton X-100.
7. RNA extraction and RT-PCR
Reagents were provided in the Micro-FastTrack™ 2.0 kit from Invitrogen.
•  Binding buffer: 500mM NaCl, lOmM Tris-HCl pH7.5 in dH2 0 .
• Elution Buffer: lOmM Tris-HCl pH7.5 in dH2 0 .
• M icro-FastTrack™  2.0 Lysis Buffer: 1ml Stock Buffer + 20pl Protein/ 
RNase degrader (proprietary mix of proteases; added fresh).
• Stock buffer: 200mM NaCl, 200mM Tris-HCl pH7.5, 1.5mM MgCl2, 2% 
SDS.
8. Northern blot analysis
Reagents were provided in the NorthemMax™ Formaldehyde based system kit
from Ambion.
•  High stringency wash solution: O.lxSSC (2 0 x: 3xNaCl, 0.3M sodium
citrate pH7.0), 0.1% SDS.
• Low stringency wash solution: lxSSC, 0.1% SDS.
• MOPS gel running buffer (lOx): 200mM MOPS (3-[N-
Morpholino]propanesulphonic acid), 50mM sodium acetate, lOmM EDTA.
9. Western blot analysis
• lxR unning Buffer: 25mM Tris-HCl, 192mM Glycine, 0.4% SDS
• lxT ransfer Buffer: 25mM Tris-HCl, 192mM Glycine, 0.4% SDS, 20% 
Methanol.
• lOxTBS: 250mM Tris-HCl pH 8.0, 50mM KC1, 25mM NaCl.
• 2xLaemelli Buffer for SDS-PAGE (5% P-mercaptoethanol added fresh):
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250mM Tris-HCl pH6 .8 , 4% SDS, 25% glycerol, 0.1% bromophenol blue
• Blocking buffer: 5% non-fat milk {Marvel) in TBS with 0.05%Tween-20.
• Gel loading solution: 250mM Tris-HCl pH 6 .8 , 4% SDS, 25% glycerol, 
0.1% bromophenol blue, 5% P-mercaptoethanol (added fresh).
•  SDS-PAGE Resolving Gel (10%; component volumes per 10ml gel): 
3.33ml 30% acrylamide {National Diagnostics), 50 j l x 1 20% SDS, 3.75ml 1M 
Tris pH8 .8 , 2.82ml dH2 0 , 3.3pl Temed, 50pl 20% ammonium persulphate 
(Amps). Once the resolving gel was poured, a layer of dH2 0 -saturated 
isobutanol was placed on top to prevent air from blocking the 
polymerisation process.
• SDS-PAGE Stacking Gel (8 %; component volumes per 5ml gel): 1.33ml 
30% acrylamide, 25pl 20% SDS, 0.625ml 1M Tris pH6 .8 , 3ml dH2 0 , 5pl 
Temed, 25pi 20% ammonium persulphate (Amps)
• Stripping buffer: 70mM Tris-HCl pH 6 .8 , 2% SDS, lOOmM p- 
mercaptoethanol
• TEST: 0.05% Tween-20 in 1 xTBS.
• Wash buffer: 0.5% Tween-20 in lxTBS
10. Im mu noprecipitation
Reagents were provided in the a-FLAG M2 antibody kit from Sigma.
•  Lysis buffer: 50mM Tris HC1 (pH7.4), 150mM NaCl, ImM EDTA, 1% 
Triton X, 0.1MPMSF,
11 .In vitro phosphorylation (kinase) assay
• Kinase Buffer: 50mM Hepes pH7.5, 5mM MgCH, ImM DTT
\2.Plk4-null embryo analysis
• lOxPBS: 1.37M NaCl, 27mM KC1, 43mM Na2 H P0 4 .7H2 0 , 14mM 
KH2 PO4 , treated with DEPC.
•  Eosin stain: 0.2% eosin Y in 95% ethanol.
•  Mayer’s Haematoxylin: 50g potassium alum, 0.2g sodium iodate, l.Og 
citric acid, 50.0g chloral hydrate, 1.0g haematoxylin, made to 1.01 with dH2 0
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13.Embryoid body dissociation
• Enzyme medium: Low calcium medium supplemented with 1 mg/ml 
collagenase B {Roche) and 30pM CaCl2
• KB medium: 85mM KC1, 30mM K2 HPO4 , 5mM MgS0 4 , ImM EGTA, 
5mM sodium pyruvate, 5mM creatine, 20mM taurine, 20mM glucose, 2mM 
Na2ATP in dH2 0.
•  Low calcium medium: 120mM NaCl, 5.4mM KC1, 5mM MgS0 4 , 5mM 
sodium pyruvate, 20mM Taurine, lOmM Hepes/NaOH pH6.9 in dH2 0.
APPENDIX 2. PCR Primers
The melting temperature (Tm) of an oligonucleotide primer can be 
determined from the equation Tm=2AT+4GC, where AT is the number of AT base 
pairs and GC the number of GC base pairs. The annealing temperature in a PCR is 
set at 5°C less than the Tm of the primers. All primers were ordered from Sigma 
Aldrich (www.Sigma-Aldrich.com). were received as lyophilised powder and were 
re-suspended in dH20 to 10jag/pl and then to a working concentration of O.lpg/pl.
•  Colony PCR {HICshRNAl). forward (5 ’- ATCCTTCAGCTGGTGAACT-3 ’); 
reverse (5’- ATTCGCGCTAGGTTGATTC -3’).
• Colony PCR (HICshRNA2): forward (5 ’ -AGTCCAGCTTGTCTGTAAA-3 9); 
reverse (5’- ATT CGCGCT AGGTT GATT C -3’).
• Colony PCR (Plk4shRNAl): forward (5 ’ - AC AGAG ATTT CC AGG ACT A-3 ’); 
reverse (5’- ATT CGCGCT AGGTT GATT C -3’).
• Colony PCR (Plk4shRNAl): forward (5 9- ATACTGGCGGAAAATATCA-3 ’); 
reverse (5’- ATT CGCGCT AGGTT GATT C -3’).
• HICshRNAl: 5 9 - AAT CCTT C AGCT GGT G AACTT-3 9.
• HICshRNA2. 5 9 -C AGT CC AGCTT GT CT GT AAAC A-3 9.
•  MICp32 IMAGE clone amplification: forward (5’-
T AT GCGAT CGAT AGCT AGG A-3 ’); reverse (5 ’-
GAT AGCGCT AGGCGG AT CG-3 ’).
• MICp32 RT-PCR: forward (5 9 -GAGCAGCAGTGCCCGGTCGA-3 ’); reverse 
(59 -CT GAT GT CT GGAGTT G AGGC-3 ’)•
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• MICp40 BAC amplification: forward (5’-
CGGGGT ACCGCTT CCCT GGGGC ATT CCT-3 ’); reverse (5’-
CTT GGC AT CCCCCCGT GGGCT GT-3 ’).
• MICp40 RT-PCR: forward (5 ’ -GG AGT GGT C AGGCT GCC AGG-3 ’); reverse 
(5 ’ - AGCGAGGGCTT C ACCCGCGC-3 ’).
• Murine H andl (wild-type and mutant) amplification for cloning: forward 
(5 ’ -CCGG A ATT CT GT CCA AC AT GA ACCT CGT GGGC-3 ’); reverse (5’- 
CGGGGT ACCGT CT GGTTT AGCT CC AGCGCCC A-3 ’).
• Murine H andl bHLH domain amplification for cloning: forward (5’- 
CCGG AATT CT GT CCA AC AT GCG AA AAGGCT C A-3 ’); reverse (5 ’ - 
CGGGGT ACCGTT CCTT GGCC AGC ACGT CC AT C-3 ’).
• Murine H andl histidine-rich stretch (and flanking sequence) amplification 
for cloning: forward (5 ’ -CCGG AATT CT GT CC AAC AT G AGCT ACGC AC AT - 
3’); reverse (5’-CGGGGTACCGTTGCGGCGGGTGTGAGTGGTGA-3’).
• Murine Hand2 amplification for cloning: forward (5’-
CCGG A ATT CT GT CC AAC AT GAGT CT GGT GGGG-3 ’); reverse (5 ’ -
CGGGGT ACCCT GCTT G AGCT CC AGGGCCC AG A-3 ’).
• Murine Plk4 RT-PCR: forward (5 ’ -GTT GGTT GGGCT AC AC AGCT -3 ’); 
reverse (5 ’ -CT GAT GG AAG AT ACT CCT GC-3 ’)•
• Murine Tubulin RT-PCR: forward (5 ’ -T C ACT GT GCCT GAACTT ACC-3 ’); 
reverse (5 ’ -GG AAC AT AGCCGT A AACT GC-3 ’).
• Plk4- null embryo genotyping round 1 (mutant): forward (5’-
TTT AAAAGT GCCCGCT AGC-3 ’); reverse (5
AT CGCTT CTT G ACG AGTT C-3 ’).
• Plk4- null embryo genotyping round 1 (wild-type): forward (5’-
GCCCCC ACT AAG ACG AC-3 ’); reverse (5 ’ - AGCT GGGGCT CG ACT AG-3 ’) •
• Plk4- null embryo genotyping round 2 (mutant): forward (5*-
TTT AAAAGT GCCCGCT AGC-3 ’); (5 ’ - AAGCCT GGGG AT GT ACC-3 ’).
• Plk4-n\s\\ embryo genotyping round 2 (wild-type): forward (5*-
GCCCCCACTAAGACGAC-3’); reverse (5’-
TGCTAGT AAAT AATCCGAC AGG-3 ’).
• Plk4shR N A l: 5 ’ - AAC AG AG ATTTCC AGG ACT AT-3 ’.
• Plk4shRNA2: 5 ’ - AAT ACT GGCGG AAA AT AT C AGT-3 ’.
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A PP E N D IX  3. Position of  RNAi sequences
The oligonucleotides designed for RNAi analysis (listed in Appendix 2) are 
shown below to illustrate the dsRNA, comprising a 9-nucleotide hairpin loop, that 
is expected to form in vivo. Also shown are the positions within HICp40 and Plk4 
to which the RNAi oligonucleotides were designed. Please refer to Figures 3.1 and 
5.23b for further information regarding HICp40 and Plk4 protein structure.
HICshRNAH
Sense Antisense
ggtaccAATCCTTCAGCTGGTGAACTTttcaagagaAAGTTCACCAGCTGAAGGATTtttttggaaat
gTTAGGAAGTCGACCACTTGAA aagttcfctTTCAAGTGGTCGACTTCCTAAaaaaacctttagatc
GTG
ATG
(109) 173 179
II___
273 355
l-mfa domain HICp40
45 63 
NoLS
T T
246 252
HICshRNAi2
Sense Antisense
ggtaccCAGTCCAGCTTGTCTGTAAACAttcaagagaTGTTTACAGACAAGCTGGACTGtttttggaaat
gGTCAGGTCGAACAGACATTTGT aagtfctt ACAAATGTCTGTTCGACCTGACaaaaacctttagatc
Plk4shRNAi1
Sense Antisense
ggtaccAACAGAGATTTCCAGGACTATttcaagagaATAGTCCTGGAAATCTCTGTTtttttggaaat
gTT GTCGCT AAAGGTCC T GAT A aagttetct T ATC AGGACCTTT AGAGAC AAaaaaacctttagatc
12
I
265
I
Kinase domain
528 534 596 836 911
cry-pb l j [ jpb2 Plk4
705 711 847
Plk4shRNAi2
Sense Antisense
ggtaccAATACTGGCGGAAATATCAGTtteaagagaACTGATATTTCCGCCAGTATTtttttggaaat
gTTATGACCGCCTTTATAGTCA aag tfc tt TGACTATAAAGGCGGTCATAAaaaaacctttagatc
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APPENDIX 4. Handl fragment constructs
The two Handl fragment constructs were constructed as described in 
Chapter 2 (section 2.1), and are as follows. Please refer to Figure 1.1b for further 
information regarding Handl protein structure.
• bHLHnandi-EGFP: the isolated bHLH domain o f Handl fused to EGFP (Handl 
residues 93-147).
• Handlnis-EGFP: a fragment of Handl containing the N-terminal histidine-rich 
domain and the residues that immediately flank it (Handl residues 6-21).
APPENDIX 5: PCR Programs
All reactions used a PE Applied Biosystems GeneAmp® PCR System 9700.
1. RT-PCR 
1 cycle
• 10 minute incubation at 25 °C
• 50 minute incubation at 42°C
• 15 minute incubation at 70°C
2. 77/r/genom 
30 cycles
• Template denaturation: 30 second incubation at 94°C
• Primer annealing: 30 second incubation at 58°C
• PCR product extension: 45 second incubation at 72°C
3. Pjwgenom 
30 cycles
•  Template denaturation: 30 second incubation at 97.5°C
•  Primer annealing: 30 second incubation at 58°C
•  PCR product extension: 45 second incubation at 72°C
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APPENDIX 6. Antibodies
Primary antibodies are listed below with the employed respective
fluorescent-tagged (for immunostaining) or horse radish peroxidase-conjugated (for
immunoblotting) secondary antibody. Rhodamine-phalloidin (Molecular Probes)
was used at a final concentration of 5 units (165nM).
• a-B568 (/Strategene): used at a concentration of 1/500 for immunostaining 
(mouse-TRITC (Dako) at a concentration o f 1/50 used as the secondary 
antibody) and 1/2000 for immunoblotting (mouse-HRP (Amersham) at a 
concentration of 1/5000 used as the secondary antibody).
• a-C23 (a-Nucleolin; Santa Cruz): used at a concentration of 1/100 for 
immunostaining (rabbit-TRITC (Dako) at a concentration of 1/50 used as the 
secondary antibody) and 1/100 for immunoblotting (rabbit-HRP (Amersham) at 
a concentration of 1/5000 used as the secondary antibody).
• a-EGFP (Clontech): used at a concentration of 1/1000 for immunoblotting 
(mouse-HRP (Amersham) at a concentration of 1/5000 used as the secondary 
antibody).
• a-FLAG M2 (Sigma): used at a concentration of 1/700 for immunoblotting 
(mouse-HRP (Amersham) at a concentration of 1/5000 used as the secondary 
antibody).
• a-GAPDH (Chemicon): used at a concentration of 1/1000 for immunoblotting 
(mouse-HRP (Amersham) at a concentration of 1/5000 used as the secondary 
antibody).
• a-Handl (Abeam): used at a concentration of 1/300 for immunostaining 
(rabbit-FITC (Santa Cruz) at a concentration of 1/100 used as the secondary 
antibody) and 1/500 for immunoblotting (rabbit-HRP (Amersham) at a 
concentration of 1/5000 used as the secondary antibody).
• a-Handl C-terminus (Santa Cruz): used at a concentration of 1/100 for 
immunostaining (goat-FITC (Dako) at a concentration of 1/50 used as the 
secondary antibody) and 1/200 for immunoblotting (goat-HRP (Santa Cruz) at a 
concentration of 1/5000 used as the secondary antibody).
• a-HIC (a kind gift from Jean-Paul Mesnard): used at a concentration of 1/500
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for immunoblotting (mouse-HRP (Amersham) at a concentration of 1/5000 used 
as the secondary antibody).
• a-HIF (Sigma): used at a concentration of 1/250 for immunoblotting (mouse- 
HRP (Amersham) at a concentration of 1/5000 used as the secondary antibody).
• a-HIS (Abeam): used at a concentration of 1/1000 for immunoblotting (mouse- 
HRP (Amersham) at a concentration of 1/5000 used as the secondary antibody).
• a-phosphoserine (Abeam): used at a concentration of 1/150 for immunoblotting 
(mouse-HRP (Amersham) at a concentration of 1/5000 used as the secondary 
antibody).
• a-PLl (Chemicon): used at a concentration of 1/200 for immunostaining 
(rabbit-FITC (Santa Cruz) at a concentration of 1/100 used as the secondary 
antibody).
• a-Plk4 (Abeam): used at a concentration of 1/200 for immunostaining (goat- 
FITC (Dako) at a concentration of 1/50 used as the secondary antibody) and 
1/200 for immunoblotting (goat-HRP (Santa Cruz) at a concentration of 1/5000 
used as the secondary antibody).
• a-PLP-A (Chemicon): used at a concentration of 1/200 for immunostaining 
(mouse-TRITC (Dako) at a concentration of 1/50 used as the secondary 
antibody).
•  a-PolII (Upstate): used at a concentration of 1/100 for immunostaining (mouse- 
TRITC (Dako) at a concentration of 1/50 used as the secondary antibody).
APPENDIX 7. In situ hybridisation riboprobes
•  Handl (pcDNA3-Handl): cDNA expression driven by T7 RNA polymerase, 
probe linearised with Notl.
• HICp40 (pKS+-HICp40): cDNA expression driven by T3 RNA polymerase, 
probe linearised with Hindlll. Cross-reacts with MICp40.
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APPENDIX 8. Y2H screen data
Appendices
The table below lists details of clones with homology to known proteins that 
were identified in the Y2H screen. False positives are excluded.
Clone Size (bp) Protein
A10 411 Checkpoint with forkhead and RING finger domains 
protein (Chff); RING finger protein 196 (Rfpl96)
B12 536 Zinc finger protein 313 (Zfp313)
B15 570 Mastermind-like protein-2 (Maml2)
C23 397 Hypothetical RING finger domain-containing protein
D18 Fibrillarin-2 (Fib2)
E17 467 RING finger protein 26 (Rnf26)
G18 607 Bromodomain and PHD finger containing-protein 1 
(Brpfl; Peregrin)
J24 547 SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily E member 1 
(Smarcel)
J31 515 Nicotinamide nucleotide transhydrogenase (Nm)
LI Tubulin
L18 593 Exportin-T (tRNA exportin) (Xpot)
N27 613 Fibroblast growth factor receptor-2 (Fgfr2)
Q8 512 Thrombospondin-1 precursor (Thbs-1)
Q27 324 Human I-mfa domain-containing protein (HIC)
R19 307 Human I-mfa domain-containing protein (HIC)
Alfl ‘i - ■’=-4;
S31 611 RING finger protein 31 (Zinc in-between RING finger 
ubiquitin A protein; Zibra)
289
APPENDIX 9. Quantitative data
The following tables list the quantitative data obtained during the course of this study, 
a. Luciferase assay
Transfected constructs Luciferase activity (RLU) P-Gal activity RLU/ ft-Gal activity
R1 R2 R3 Mean R1 R2 R3 Mean
Reporter alone 0.27 0.04 0.55 0.29 1.26 0.80 0.90 0.99 0.29
H andl + reporter 1.44 1.88 1.17 1.50 0.66 1.02 0.75 0.81 1.85
E12 + reporter 0.51 0.58 0.89 0.66 0.75 0.61 0.70 0.69 0.95
HICp40 + reporter 0.23 0.40 0.20 0.28 0.99 1.48 0.95 1.14 0.24
HICAC + reporter 0.12 0.20 0.67 0.50 0.72 0.70 0.84 0.75 0.67
HICp32 + reporter 0.43 0.81 1.02 0.75 0.28 0.50 0.61 0.57 1.32
H andl + E12 + reporter 15.69 20.91 17.11 17.90 0.93 0.91 1.39 1.08 16.57
H andl + E12+ HICp40 + reporter 8.21 6.10 5.10 6.47 1.29 1.92 1.60 1.60 4.04
H andl + E l 2+ HICAC + reporter 13.19 19.04 11.22 14.48 0.89 1.09 0.76 0.91 15.91
H andl + E12+ HICp32 + reporter 13.29 12.56 10.00 11.95 0.72 0.98 1.19 0.96 12.44
Rl: reading 1; R2: reading 2; R3: reading 3; RLU: relative light units
291
b. Handl-EGFP immuno-Iocalisation assays in NIH-3T3 and H9c2 cells
Cell population Nucleolar Handl-EGFP (%) S.E.M.
NIH-3T3, Handl-EGFP o/e 15.0 1.55
NIH-3T3, Handl-EGFP & HICp40 o/e 85.4 1.24
H9c2, Handl-EGFP o/e 98.6 2.70
o/e: over-expression.
c. Handl-EGFP immuno-Iocalisation assays in Rcho-1 cells
Cells were cultured in normoxic conditions in medium supplemented with fetal bovine serum (FBS) unless otherwise stated.
Cell population Nucleolar Handl-EGFP (%) S.E.M.
| 24hr 48hr 72hr 24hr 48hr | 72hr
Handl-EGFP o/e 68.4 46.4 33.4 1.32 0.95 1.80
Handl-EGFP T107;S109A o/e 70.2 64.2 60.5 1.79 0.95 3.17
Handl-EGFP T107;S109D o/e 5.10 2.50 1.20 0.82 0.44 1.30
Handl-EGFP & B56S o/e 69.4 65.4 61.1 1.05 1.54 6.48
o/e: over-expression.
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d. Endogenous Handl immuno-Iocalisation assays in Rcho-1 cells
Cells were cultured in normoxic conditions in medium supplemented with fetal bovine serum (FBS) unless otherwise stated.
Cell population Handl-EGFP (%) S.E.M.
Untransfected, HS 28.6 (Nu), 43.9 (No) 2.08 (Nu), 1.87 (No)
Untransfected, HS, HxC 44.6 (No) 2.01 (No)
Untransfected, HS, C0 CI2 45,6 (No) 1.51 (No)
B568 o/e, HS 69.2 (No) 2.56 (No)
HICp40-EGFP o/e, HS 77.6 (No) 2.67 (No)
FLAG-Sako/e 54.1 (Nu) 2.78 (Nu)
B IC sh W A il  o/e 47.1 (Nu) 1.93 (Nu)
HICshRNAi2 o/e 46.4 (Nu) 2.39 (Nu)
P M shR N A il o/e 68.9 (No) 2.39 (No)
Plk4shRNAi2 o/e 69.8 (No) 1.44 (No)
Nu: nuclear-wide; No: nucleolar; o/e: over-expression; HS: cultured in medium supplemented with horse serum; CoCl2: cultured in medium supplemented with 250pM
cobalt chloride; HxC: cultured in a hypoxic chamber.
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e. Rcho-1 TG cell differentiation assays
Cells were cultured in normoxic conditions in medium supplemented with fetal bovine serum (FBS) unless otherwise stated. All cell counts 
have been corrected for the spontaneous differentiation rate of Rcho-1 stem cells (5.9±0.5% per 24 hours), which represents the percentage 
of Rcho-1 cells cultured in FBS-supplemented medium that initiate TG cell differentiation over a 24 hour period (Nakayama et al., 1998; 
Scott et al., 2000). All cell counts have also been corrected for an observed increase in differentiation rate due to the transfection with a 
construct encoding EGFP alone (10.3% per 24-hour period; mean±S.E.M.; n=250; p<0.01).
R<:ho-l TS cells (<Vo) S.E.M.
24hr 48hr 72hr 24hr 48hr 72hr
Cell Dooulation
Untransfected 81.2 70.9 65.2 1.32 0.95 1.8
Untransfected, HS 56.1 35.5 29.2 1.79 0.95 3.17
Untransfected, HS, HxC - - 40.1 - - 1.60
Untransfected, HS, CoCl2 38.0 - 2.16
Handl-EGFP o/e 59.1 35.7 24.8 0.82 0.44 1.30
Handl-EGFP o/e, HxC 61.4 34.5 25.0 1.40 2.30 1.08
Handl-EGFP, o/e, CoCl2 60.1 37.5 23.4 1.35 1.03 2.09
Handl- EGFP T107;S109A o/e 64.4 64.1 56.5 1.05 0.45 1.59
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Cell population Rcho-1 TS cells (%) S.E.M._____________
^ ___________48hr___________ 72hr 24hr 48hr 72hr
Handl-EGFP T107;S109D o/e 71.8 52.7 31.4 3.77 1.54 6.48
B568 o/e 67.2 64.8 61.4 1.17 0.44 1.22
B568 o/e, HS 54.8 49.4 45.8 1.68 1.22 1.48
Handl-EGFP (wt) & B568 o/e 68.2 62.0 56.8 1.44 3.10 1.50
HICp40-EGFP o/e, HS 68.6 63.2 54.5 2.22 1.07 0.57
FLAG-Plk4 o/e 60.2 49.5 37.1 1.68 0.50 1.17
HICshRNAil o/e 58.0 40.5 39.8 0.71 1.21 1.93
HICshRNAi2 o/e 61.8 51.9 40.6 0.60 0.61 0.64
Plk4shKNAil o/e, HS 72.3 57.9 54.8 0.36 0.44 1.21
Plk4shSNAi2 o/e, HS 73.0 58.8 54.1 1.68 1.36 1.30
o/e: over-expression; HS: cultured in medium supplemented with horse serum; CoCl2: cultured in medium supplemented with 250 pM cobalt chloride; HxC: cultured in a 
hypoxic chamber.
Appendices
APPENDIX 10. Time-lapse movies
QuickTime time-lapse movies (.mov format) are provided on the attached CD.
• Movie 4.1. Handl-EGFP is released from the nucleolus over a 12-hour period 
as individual transfected Rcho-1 stem cells commit to differentiate, which is 
coincident with decreased motility and an expansion in size. Time-lapse was 
initiated 24 hours after transfection and images captured every 20 minutes over 
a period of 12 hours.
• Movie 6.1. After differentiation, £GFP-expressing transgenic ES cells produce 
embryoid bodies (EBs) containing contractile, fluorescent cardiomyocytes.
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University of Kyoto, Japan. May 17th-18th 2007 (oral and poster presentation).
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